0001437749-22-007930.txt : 20220401 0001437749-22-007930.hdr.sgml : 20220401 20220331204945 ACCESSION NUMBER: 0001437749-22-007930 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 109 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220401 DATE AS OF CHANGE: 20220331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO KEY INTERNATIONAL INC CENTRAL INDEX KEY: 0001019034 STANDARD INDUSTRIAL CLASSIFICATION: COMPUTER COMMUNICATIONS EQUIPMENT [3576] IRS NUMBER: 411761861 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-13463 FILM NUMBER: 22795330 BUSINESS ADDRESS: STREET 1: 3349 HIGHWAY 138 STREET 2: BUIDING A, SUITE E CITY: WALL STATE: NJ ZIP: 07719 BUSINESS PHONE: 7323591100 MAIL ADDRESS: STREET 1: 3349 HIGHWAY 138 STREET 2: BUIDING A, SUITE E CITY: WALL STATE: NJ ZIP: 07719 FORMER COMPANY: FORMER CONFORMED NAME: SAC TECHNOLOGIES INC DATE OF NAME CHANGE: 19961115 10-K 1 bkyi20211231_10k.htm FORM 10-K bkyi20211231_10k.htm
0001019034 BIO KEY INTERNATIONAL INC false --12-31 FY 2021 170,000,000 170,000,000 7,853,759 7,853,759 7,814,572 7,814,572 0.0001 0.0001 1,250 5,114 24 7.8 1 4 633 702 0 3 4 500 4 4 1 1 1 5 5 5 1 18 5 0 0 3 0 0 0 5 10 10 0 0 0 0 0 0 0 0 3 EMEA - Europe, Middle East, Africa 00010190342021-01-012021-12-31 iso4217:USD 00010190342021-06-30 xbrli:shares 00010190342022-03-29 thunderdome:item 00010190342021-12-31 00010190342020-12-31 iso4217:USDxbrli:shares 0001019034us-gaap:ServiceMember2021-01-012021-12-31 0001019034us-gaap:ServiceMember2020-01-012020-12-31 0001019034us-gaap:LicenseMember2021-01-012021-12-31 0001019034us-gaap:LicenseMember2020-01-012020-12-31 0001019034bkyi:HardwareMember2021-01-012021-12-31 0001019034bkyi:HardwareMember2020-01-012020-12-31 00010190342020-01-012020-12-31 0001019034us-gaap:CommonStockMember2019-12-31 0001019034us-gaap:AdditionalPaidInCapitalMember2019-12-31 0001019034us-gaap:RetainedEarningsMember2019-12-31 00010190342019-12-31 0001019034us-gaap:CommonStockMember2020-01-012020-12-31 0001019034us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-31 0001019034us-gaap:RetainedEarningsMember2020-01-012020-12-31 0001019034us-gaap:CommonStockMemberbkyi:PublicOfferingMember2020-01-012020-12-31 0001019034us-gaap:AdditionalPaidInCapitalMemberbkyi:PublicOfferingMember2020-01-012020-12-31 0001019034us-gaap:RetainedEarningsMemberbkyi:PublicOfferingMember2020-01-012020-12-31 0001019034bkyi:PublicOfferingMember2020-01-012020-12-31 0001019034bkyi:WarrantsIssuedInConnectionWithConvertibleNotesMemberus-gaap:CommonStockMember2020-01-012020-12-31 0001019034bkyi:WarrantsIssuedInConnectionWithConvertibleNotesMemberus-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-31 0001019034bkyi:WarrantsIssuedInConnectionWithConvertibleNotesMemberus-gaap:RetainedEarningsMember2020-01-012020-12-31 0001019034bkyi:WarrantsIssuedInConnectionWithConvertibleNotesMember2020-01-012020-12-31 0001019034us-gaap:CommonStockMember2020-12-31 0001019034us-gaap:AdditionalPaidInCapitalMember2020-12-31 0001019034us-gaap:RetainedEarningsMember2020-12-31 0001019034us-gaap:CommonStockMember2021-01-012021-12-31 0001019034us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-31 0001019034us-gaap:RetainedEarningsMember2021-01-012021-12-31 0001019034us-gaap:CommonStockMember2021-12-31 0001019034us-gaap:AdditionalPaidInCapitalMember2021-12-31 0001019034us-gaap:RetainedEarningsMember2021-12-31 0001019034us-gaap:AccountingStandardsUpdate201602Member2021-01-012021-12-31 0001019034us-gaap:AccountingStandardsUpdate201602Member2020-01-012020-12-31 xbrli:pure 0001019034bkyi:ReverseStockSplitMember2020-11-202020-11-20 utr:Y 0001019034us-gaap:EquipmentMembersrt:MinimumMember2021-01-012021-12-31 0001019034us-gaap:EquipmentMembersrt:MaximumMember2021-01-012021-12-31 0001019034us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2021-01-012021-12-31 0001019034us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2021-01-012021-12-31 0001019034us-gaap:SoftwareDevelopmentMember2021-01-012021-12-31 0001019034srt:MinimumMember2021-01-012021-12-31 0001019034srt:MaximumMember2021-01-012021-12-31 0001019034us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-31 0001019034us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-31 0001019034us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-31 0001019034us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-31 0001019034us-gaap:LicenseMembersrt:NorthAmericaMember2021-01-012021-12-31 0001019034us-gaap:LicenseMembersrt:SouthAmericaMember2021-01-012021-12-31 0001019034us-gaap:LicenseMemberus-gaap:EMEAMember2021-01-012021-12-31 0001019034us-gaap:LicenseMembersrt:AsiaMember2021-01-012021-12-31 0001019034bkyi:HardwareMembersrt:NorthAmericaMember2021-01-012021-12-31 0001019034bkyi:HardwareMembersrt:SouthAmericaMember2021-01-012021-12-31 0001019034bkyi:HardwareMemberus-gaap:EMEAMember2021-01-012021-12-31 0001019034bkyi:HardwareMembersrt:AsiaMember2021-01-012021-12-31 0001019034us-gaap:ServiceMembersrt:NorthAmericaMember2021-01-012021-12-31 0001019034us-gaap:ServiceMembersrt:SouthAmericaMember2021-01-012021-12-31 0001019034us-gaap:ServiceMemberus-gaap:EMEAMember2021-01-012021-12-31 0001019034us-gaap:ServiceMembersrt:AsiaMember2021-01-012021-12-31 0001019034srt:NorthAmericaMember2021-01-012021-12-31 0001019034srt:SouthAmericaMember2021-01-012021-12-31 0001019034us-gaap:EMEAMember2021-01-012021-12-31 0001019034srt:AsiaMember2021-01-012021-12-31 0001019034us-gaap:LicenseMembersrt:NorthAmericaMember2020-01-012020-12-31 0001019034us-gaap:LicenseMembersrt:SouthAmericaMember2020-01-012020-12-31 0001019034us-gaap:LicenseMemberus-gaap:EMEAMember2020-01-012020-12-31 0001019034us-gaap:LicenseMembersrt:AsiaMember2020-01-012020-12-31 0001019034bkyi:HardwareMembersrt:NorthAmericaMember2020-01-012020-12-31 0001019034bkyi:HardwareMembersrt:SouthAmericaMember2020-01-012020-12-31 0001019034bkyi:HardwareMemberus-gaap:EMEAMember2020-01-012020-12-31 0001019034bkyi:HardwareMembersrt:AsiaMember2020-01-012020-12-31 0001019034us-gaap:ServiceMembersrt:NorthAmericaMember2020-01-012020-12-31 0001019034us-gaap:ServiceMembersrt:SouthAmericaMember2020-01-012020-12-31 0001019034us-gaap:ServiceMemberus-gaap:EMEAMember2020-01-012020-12-31 0001019034us-gaap:ServiceMembersrt:AsiaMember2020-01-012020-12-31 0001019034srt:NorthAmericaMember2020-01-012020-12-31 0001019034srt:SouthAmericaMember2020-01-012020-12-31 0001019034us-gaap:EMEAMember2020-01-012020-12-31 0001019034srt:AsiaMember2020-01-012020-12-31 0001019034bkyi:PistolstarMember2020-06-302020-06-30 0001019034bkyi:PistolstarMemberbkyi:PromissoryNoteMember2020-06-30 0001019034bkyi:PistolstarMember2020-06-30 utr:M 0001019034bkyi:PistolstarMemberbkyi:PromissoryNoteMember2020-06-302020-06-30 0001019034bkyi:PistolstarMemberbkyi:PromissoryNoteMember2020-12-31 0001019034bkyi:PistolstarMemberbkyi:PromissoryNoteMember2021-01-212021-01-21 0001019034bkyi:PistolstarMemberus-gaap:TradeNamesMember2020-06-302020-06-30 0001019034bkyi:PistolstarMemberbkyi:ProprietarySoftwareMember2020-06-302020-06-30 0001019034bkyi:PistolstarMemberus-gaap:CustomerRelationshipsMember2020-06-302020-06-30 0001019034bkyi:PistolstarMemberus-gaap:CustomerRelationshipsMembersrt:MinimumMember2020-06-302020-06-30 0001019034bkyi:PistolstarMemberus-gaap:CustomerRelationshipsMembersrt:MaximumMember2020-06-302020-06-30 0001019034us-gaap:GeographicDistributionForeignMember2021-12-31 0001019034us-gaap:GeographicDistributionDomesticMember2021-12-31 0001019034srt:MinimumMember2021-12-31 0001019034srt:MaximumMember2021-12-31 0001019034us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-31 0001019034us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberbkyi:OneCustomerMember2021-01-012021-12-31 0001019034us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberbkyi:OneCustomerMember2020-01-012020-12-31 0001019034us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberbkyi:ThreeCustomersMember2021-01-012021-12-31 0001019034us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberbkyi:OneCustomerMember2020-01-012020-12-31 00010190342020-09-30 00010190342021-01-012021-09-30 0001019034bkyi:SoftwareLicenseRightsMember2015-12-312015-12-31 0001019034bkyi:SoftwareLicenseRightsMember2017-01-012017-03-31 0001019034bkyi:SoftwareLicenseRightsMember2021-01-012021-12-31 0001019034bkyi:SoftwareLicenseRightsMember2020-01-012020-12-31 0001019034bkyi:The2015SoftwareLicenseMember2021-01-012021-12-31 0001019034bkyi:The2015SoftwareLicenseMember2021-12-31 0001019034bkyi:The2015SoftwareLicenseMember2020-12-31 0001019034bkyi:SoftwareLicenseRightsMember2021-12-31 iso4217:HKD 0001019034us-gaap:ForeignCorporateDebtSecuritiesMember2019-12-31 0001019034us-gaap:ForeignCorporateDebtSecuritiesMember2019-01-012019-12-31 0001019034us-gaap:ForeignCorporateDebtSecuritiesMember2020-06-30 0001019034us-gaap:ForeignCorporateDebtSecuritiesMember2021-09-30 0001019034us-gaap:EquipmentMember2021-12-31 0001019034us-gaap:EquipmentMember2020-12-31 0001019034us-gaap:FurnitureAndFixturesMember2021-12-31 0001019034us-gaap:FurnitureAndFixturesMember2020-12-31 0001019034us-gaap:SoftwareDevelopmentMember2021-12-31 0001019034us-gaap:SoftwareDevelopmentMember2020-12-31 0001019034us-gaap:LeaseholdImprovementsMember2021-12-31 0001019034us-gaap:LeaseholdImprovementsMember2020-12-31 0001019034us-gaap:TradeNamesMember2021-12-31 0001019034us-gaap:TradeNamesMember2020-12-31 0001019034bkyi:ProprietarySoftwareMember2021-12-31 0001019034bkyi:ProprietarySoftwareMember2020-12-31 0001019034us-gaap:CustomerRelationshipsMember2021-12-31 0001019034us-gaap:CustomerRelationshipsMember2020-12-31 0001019034us-gaap:PatentsMember2021-12-31 0001019034us-gaap:PatentsMember2020-12-31 0001019034bkyi:ResearchDevelopmentAndEngineeringExpenseMember2021-01-012021-12-31 0001019034bkyi:ResearchDevelopmentAndEngineeringExpenseMember2020-01-012020-12-31 0001019034us-gaap:LicensingAgreementsMember2021-12-31 0001019034us-gaap:AccountsPayableMemberbkyi:MrWongKwokFongMember2019-12-31 0001019034bkyi:AccruedLiabilitiesOtherMemberbkyi:MrMichaelDepasqualeMember2019-12-31 0001019034bkyi:TheNoteMemberbkyi:SeniorSecuredConvertibleNoteMember2019-07-10 0001019034bkyi:TheNoteMemberbkyi:SeniorSecuredConvertibleNoteMember2019-07-102019-07-10 0001019034bkyi:InvestorWarrantMember2019-07-10 00010190342019-07-102019-07-10 00010190342019-07-10 0001019034bkyi:AmendedNoteMemberbkyi:SeniorSecuredConvertibleNoteMember2020-03-12 0001019034bkyi:AmendedNoteMemberbkyi:SeniorSecuredConvertibleNoteMember2020-03-122020-03-12 00010190342020-03-12 00010190342020-06-12 0001019034bkyi:AmendedNoteMemberbkyi:SeniorSecuredConvertibleNoteMember2020-06-10 0001019034bkyi:ConversionOfSeniorSecuredConvertibleNoteToCommonStockMember2020-06-102020-06-10 0001019034bkyi:January2020NoteMemberbkyi:SecuredRedeemableConvertibleNoteMember2020-01-13 0001019034bkyi:January2020NoteMemberbkyi:SecuredRedeemableConvertibleNoteMember2020-01-132020-01-13 0001019034bkyi:January2020NoteMemberbkyi:SecuredRedeemableConvertibleNoteMember2020-06-122020-06-12 0001019034bkyi:February2020NoteMemberbkyi:SecuredRedeemableConvertibleNoteMember2020-02-13 0001019034bkyi:February2020NoteMemberbkyi:SecuredRedeemableConvertibleNoteMember2020-02-13 0001019034bkyi:February2020NoteMemberbkyi:SecuredRedeemableConvertibleNoteMember2020-03-12 0001019034bkyi:February2020NoteMemberbkyi:SecuredRedeemableConvertibleNoteMember2020-03-122020-03-12 0001019034bkyi:February2020NoteMembersrt:MinimumMemberbkyi:SecuredRedeemableConvertibleNoteMember2020-02-13 0001019034bkyi:February2020NoteMembersrt:MaximumMemberbkyi:SecuredRedeemableConvertibleNoteMember2020-02-13 0001019034bkyi:February2020NoteMemberbkyi:SecuredRedeemableConvertibleNoteMember2020-02-132020-02-13 0001019034bkyi:February2020NoteMemberbkyi:SecuredRedeemableConvertibleNoteMember2020-07-102020-07-10 0001019034bkyi:May2020NoteMemberbkyi:SecuredRedeemableConvertibleNoteMember2020-05-06 0001019034bkyi:May2020NoteMemberbkyi:SecuredRedeemableConvertibleNoteMember2020-05-062020-05-06 00010190342020-05-062020-05-06 00010190342020-05-06 0001019034bkyi:InvestorWarrantMember2020-05-06 0001019034bkyi:InvestorWarrantMember2020-07-012020-07-31 0001019034bkyi:June2020NoteMemberbkyi:SecuredRedeemableConvertibleNoteMember2020-06-29 0001019034bkyi:June2020NoteMemberbkyi:SecuredRedeemableConvertibleNoteMember2020-06-292020-06-29 00010190342020-06-292020-06-29 00010190342020-06-29 0001019034bkyi:InvestorWarrantMember2020-06-29 0001019034bkyi:June2020NoteMemberbkyi:SecuredRedeemableConvertibleNoteMember2020-07-012020-09-30 0001019034bkyi:June2020NoteMemberbkyi:SecuredRedeemableConvertibleNoteMember2020-07-012020-07-31 0001019034bkyi:SalesIncentiveAgreementWithTTIMemberbkyi:TechnologyTransferInstituteMember2020-03-252020-03-25 0001019034bkyi:SalesIncentiveAgreementWithTTIMemberbkyi:TechnologyTransferInstituteMember2020-03-25 0001019034srt:MaximumMemberbkyi:SalesIncentiveAgreementWithTTIMemberbkyi:TechnologyTransferInstituteMember2020-03-25 0001019034bkyi:WarrantsIssuableForEach1MillionRevenueInExcessOf20MilllionMemberbkyi:SalesIncentiveAgreementWithTTIMemberbkyi:TechnologyTransferInstituteMember2020-03-25 0001019034srt:MaximumMemberbkyi:SalesIncentiveAgreementWithTTIMemberbkyi:TechnologyTransferInstituteMember2020-03-252020-03-25 0001019034bkyi:SalesIncentiveAgreementWithTTIMemberbkyi:TechnologyTransferInstituteMember2021-01-012021-12-31 0001019034bkyi:SalesIncentiveAgreementWithTTIMemberbkyi:TechnologyTransferInstituteMember2020-01-012020-12-31 0001019034bkyi:EmployeeStockPurchasePlanMember2021-06-18 0001019034bkyi:EmployeeStockPurchasePlanMember2021-06-182021-06-18 0001019034bkyi:PublicOfferingMember2020-07-232020-07-23 0001019034bkyi:PrefundedWarrantsMember2020-07-232020-07-23 0001019034bkyi:EquityWarrantsMember2020-07-232020-07-23 00010190342020-03-302020-03-30 00010190342020-03-30 0001019034us-gaap:RestrictedStockMember2021-01-012021-12-31 0001019034us-gaap:RestrictedStockMember2020-08-312020-08-31 0001019034us-gaap:RestrictedStockMember2020-11-302020-11-30 0001019034us-gaap:RestrictedStockMember2020-01-012020-12-31 0001019034us-gaap:CommonStockMembersrt:DirectorMember2021-01-012021-12-31 0001019034us-gaap:CommonStockMembersrt:DirectorMember2020-01-012020-12-31 0001019034bkyi:ReferralFeeWarrantsMemberus-gaap:InvestorMember2020-06-30 0001019034bkyi:ReferralFeeWarrantsMemberus-gaap:InvestorMember2020-01-012020-06-30 0001019034bkyi:ReferralFeeWarrantsMemberbkyi:EmployeeMember2020-09-30 0001019034bkyi:ReferralFeeWarrantsMemberbkyi:EmployeeMember2020-01-012020-09-30 0001019034bkyi:ReferralFeeWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-12-31 0001019034bkyi:ReferralFeeWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2020-12-31 0001019034bkyi:ReferralFeeWarrantsMemberus-gaap:MeasurementInputSharePriceMember2021-12-31 0001019034bkyi:ReferralFeeWarrantsMemberus-gaap:MeasurementInputSharePriceMember2020-12-31 0001019034bkyi:ReferralFeeWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2021-12-31 0001019034bkyi:ReferralFeeWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2020-12-31 0001019034bkyi:ReferralFeeWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2021-12-31 0001019034bkyi:ReferralFeeWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2020-12-31 00010190342019-01-012019-12-31 0001019034bkyi:PublicOfferingWarrantsMember2020-01-012020-12-31 0001019034bkyi:PrefundedWarrantsMember2020-01-012020-12-31 0001019034bkyi:OtherWarrantsMember2020-01-012020-12-31 0001019034bkyi:InTheMoneyOptionsMember2021-12-31 0001019034bkyi:InTheMoneyOptionsMember2020-12-31 00010190342015-09-23 0001019034bkyi:September2015WarrantsMember2015-09-23 00010190342015-09-232015-09-23 0001019034bkyi:The2004StockOptionPlanMember2004-10-12 0001019034bkyi:The2004StockOptionPlanMembersrt:MinimumMember2004-10-122004-10-12 0001019034bkyi:NonstatutoryStockMemberbkyi:The2004StockOptionPlanMember2004-10-122004-10-12 0001019034bkyi:The2015EquityIncentivePlanMember2020-12-31 0001019034bkyi:The2015EquityIncentivePlanMember2016-01-27 0001019034bkyi:The2015EquityIncentivePlanMember2019-12-31 0001019034bkyi:The2015EquityIncentivePlanMember2021-12-31 0001019034bkyi:The2015EquityIncentivePlanMember2016-01-272016-01-27 0001019034bkyi:The2015EquityIncentivePlanMembersrt:MinimumMember2021-01-012021-12-31 0001019034bkyi:The2015EquityIncentivePlanMembersrt:MaximumMember2021-01-012021-12-31 0001019034bkyi:The2004StockOptionPlanMember2019-12-31 0001019034bkyi:NonPlanMember2019-12-31 0001019034bkyi:The2004StockOptionPlanMember2020-01-012020-12-31 0001019034bkyi:The2015EquityIncentivePlanMember2020-01-012020-12-31 0001019034bkyi:NonPlanMember2020-01-012020-12-31 0001019034bkyi:The2004StockOptionPlanMember2020-12-31 0001019034bkyi:NonPlanMember2020-12-31 0001019034bkyi:The2004StockOptionPlanMember2021-01-012021-12-31 0001019034bkyi:The2015EquityIncentivePlanMember2021-01-012021-12-31 0001019034bkyi:NonPlanMember2021-01-012021-12-31 0001019034bkyi:The2004StockOptionPlanMember2021-12-31 0001019034bkyi:NonPlanMember2021-12-31 0001019034bkyi:ExercisePriceRange1Member2021-01-012021-12-31 0001019034bkyi:ExercisePriceRange1Member2021-12-31 0001019034bkyi:ExercisePriceRange2Member2021-01-012021-12-31 0001019034bkyi:ExercisePriceRange2Member2021-12-31 0001019034bkyi:ExercisePriceRange3Member2021-01-012021-12-31 0001019034bkyi:ExercisePriceRange3Member2021-12-31 0001019034us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMember2021-12-31 0001019034us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMember2021-01-012021-12-31 0001019034us-gaap:EmployeeStockOptionMemberbkyi:ExercisePriceLessThanAverageMarketPriceOfCommonSharesMember2021-01-012021-12-31 0001019034us-gaap:EmployeeStockOptionMemberbkyi:ExercisePriceLessThanAverageMarketPriceOfCommonSharesMember2020-01-012020-12-31 0001019034us-gaap:RestrictedStockMemberbkyi:ExercisePriceLessThanAverageMarketPriceOfCommonSharesMember2021-01-012021-12-31 0001019034us-gaap:RestrictedStockMemberbkyi:ExercisePriceLessThanAverageMarketPriceOfCommonSharesMember2020-01-012020-12-31 0001019034bkyi:ExercisePriceLessThanAverageMarketPriceOfCommonSharesMember2021-01-012021-12-31 0001019034bkyi:ExercisePriceLessThanAverageMarketPriceOfCommonSharesMember2020-01-012020-12-31 0001019034us-gaap:EmployeeStockOptionMemberbkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2021-01-012021-12-31 0001019034us-gaap:EmployeeStockOptionMemberbkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2020-01-012020-12-31 0001019034us-gaap:WarrantMemberbkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2021-01-012021-12-31 0001019034us-gaap:WarrantMemberbkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2020-01-012020-12-31 0001019034bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2021-01-012021-12-31 0001019034bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2020-01-012020-12-31 0001019034bkyi:SwivelSecureEuropeMemberus-gaap:SubsequentEventMember2022-03-08 0001019034bkyi:SwivelSecureEuropeMemberus-gaap:SubsequentEventMember2022-03-082022-03-08 0001019034us-gaap:CommonStockMemberus-gaap:SubsequentEventMemberbkyi:StockIssuedInLieuOfBoardFeesMembersrt:DirectorMember2022-03-102022-03-10 0001019034us-gaap:CommonStockMemberus-gaap:SubsequentEventMemberbkyi:StockIssuedInLieuOfBoardCommitteeFeesMembersrt:DirectorMember2022-03-102022-03-10 0001019034us-gaap:CommonStockMemberus-gaap:SubsequentEventMemberbkyi:StockIssuedInLieuOfBoardCommitteeFeesMembersrt:DirectorMember2022-03-112022-03-11 0001019034us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:SubsequentEventMember2022-03-112022-03-11 0001019034bkyi:FactoredAccountsReceivableMember2021-01-012021-12-31 0001019034us-gaap:NotesReceivableMember2021-01-012021-12-31
 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

 

 

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021

 

OR

 

 

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM ___ TO ___

 

COMMISSION FILE NUMBER: 1-13463

 

BIO-KEY INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

41-1741861

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification Number)

 

3349 HIGHWAY 138, BUILDING A, SUITE E, WALL, NJ 07719

(Address of principal executive offices) (Zip Code)

(732) 359-1100

Registrant’s telephone number, including area code.

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

 
 

Common Stock, $0.0001 par value per share

 

BKYI

 

Nasdaq Capital Market

 

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.   Yes  ☐    No  ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.   Yes  ☐    No  ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  ☒   No  ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒   No  ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer  ☐

 

Accelerated filer  ☐

   

Non-accelerated filer   ☒

 

Smaller reporting company  ☒

   
  

Emerging growth company  ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 
 

 

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒

 

As of June 30, 2021 (the last business day of the registrant’s most recently completed second fiscal quarter), the aggregate market value of the registrant’s common stock held by non-affiliates was approximately $27.6 million based upon the closing price for shares of the registrant’s post-split common stock of $3.80 as reported by the Nasdaq Stock Market on that date.

 

As of March 29, 2022, the registrant had 8,405,209 shares of common stock outstanding.

 

 

 
 

 

 

TABLE OF CONTENTS

 

 

PART I

 1
     

Item 1.

Business

1

Item 1A

Risk Factors

9
Item 1B Unresolved Staff Comments 16

Item 2

Property

16

Item 3

Legal Proceedings

16

Item 4

Mine Safety Disclosures

16
     
 

PART II

 17
     

Item 5

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

17

Item 6

Reserved

17

Item 7

Management’s Discussion and Analysis of Financial Condition and Results of Operations

17

Item 7A

Quantitative And Qualitative Disclosures About Market Risk

23

Item 8

Financial Statements and Supplementary Data

23

Item 9

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

23

Item 9A

Controls and Procedures

24

Item 9B

Other Information

24

Item 9C

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

25
     
 

PART III

 25
     

Item 10

Directors, Executive Officers and Corporate Governance

25

Item 11

Executive Compensation

29

Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

32

Item 13

Certain Relationships and Related Transactions, and Director Independence

35

Item 14

Principal Accounting Fees and Services

36
     
 

PART IV

 36
     

Item 15

Exhibits and Financial Statement Schedules

36

Item 16

Form 10-K Summary

38
 

Signatures

69

 

 

 
 

 

 

 

PRIVATE SECURITIES LITIGATION REFORM ACT

 

All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “anticipate,” “believe,” “should,” “estimate,” “will,” “may,” “future,” “plan,” “intend” and “expect” and similar expressions generally identify forward-looking statements. Although we believe our plans, intentions, assumptions and expectations reflected in the forward-looking statements are reasonable, we cannot be sure they will be achieved. Additionally, the duration and severity of the current COVID-19 pandemic and the conflict between Ukraine and Russia and their effects on our business operations, sales cycles, personnel, and the geographic markets in which we operate, and numerous other matters of national, regional and global scale, including those of a political, economic, business and competitive nature could cause our actual results to be materially different than those expressed in our forward looking statements. We caution that it is very difficult to predict the impact of known factors, it is impossible for us to anticipate all factors that could affect our actual results, and that actual results may differ materially and adversely from the forward-looking statements contained herein due to a number of factors, including but not limited to those factors set forth under the caption “Risk Factors” in Item 1A of this Annual Report and other filings with the Securities and Exchange Commission. These factors are not intended to represent a complete list of the general or specific factors that may affect us. It should be recognized that other factors, including general economic factors and business strategies, may be significant, presently or in the future. Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

 

 
 

 

 

PART I

 

ITEM 1. BUSINESS

 

Solely for convenience, trademarks and tradenames referred to in this Annual Report on Form 10-K appear (after the first usage) without the ® and ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames.

 

Overview

 

BIO-key International, Inc. (the “Company,” “BIO-key,” “we,” or “us”) is a leading identity and access management (IAM) platform provider enabling secure work-from-anywhere for enterprise, education, and government customers.  Our vision is to enable any organization to secure streamlined and passwordless workforce, customer, citizen and student access to any online service, workstation, or mobile application, without a requirement to use tokens or phones.  Our products include PortalGuard® and PortalGuard Identity-as-a-Service (IDaaS) enterprise IAM, WEB-key® biometric civil and large-scale ID infrastructure, and high-quality, low-cost accessory hardware to provide a full and complete solution for identity-innovating customers.

 

BIO-key PortalGuard empowers organizations to maximize the power of cloud, mobile and web technologies by securing users’ identities and connecting them with the applications they rely on, while keeping cyber-intruders and unauthorized delegates (proxy) out.

 

Millions of users trust BIO-key® to secure access to a variety of cloud, mobile and web applications, on-premise and cloud-based hypervisor servers from all of their devices. Employees and contractors sign into BIO-key PortalGuard to seamlessly and securely access the applications of need to do their work, and customers sign into BIO-key PortalGuard to access online services.  Organizations use PortalGuard to securely collaborate and communicate with their partners and to provide their customers with flexible, resilient user experiences online and while using mobile devices.

 

BIO-key’s WEB-key is a scalable biometric service management platform, incorporating key functions for regulatory compliance, enrollment, authentication or identification, and integrity in a multi-tenant private or public cloud delivery platform.  Government agencies use BIO-key for their large-scale civil ID projects, because WEB-key underpins a biometric identity ecosystem, is cloud-ready, and provides a scalable, high-integrity trust platform which can be operated anywhere and supports over 30 fingerprint scanners interchangeably.

 

We also deliver biometric software integration application programming interfaces, or APIs, allowing software developers to leverage our platform to securely and efficiently embed biometric multi-factor authentication, or MFA, into their own products.  This allows software developers to focus on their core functionality while BIO-key ensures users enter the application without requiring they carry their phone or any token.

 

Even the most security-focused organizations are suffering breaches as a result of human error or improper conduct. As enterprises scale the number of software as a service, or SaaS applications, and multi-cloud services they rely on and the interconnections between them increase, assured identity has emerged as a critical component of an organization’s security framework, directly affecting each triad of cybersecurity – confidentiality, integrity, and availability.  As access perimeters dissolve, organizations must evolve from network-based security models to Zero Trust and Continuous Authentication and Risk Trust Assessment (CARTA) security models, focusing on adaptive and context-aware controls.  True server-secured biometric verification removes the human nature vulnerability at the root of many security compromises creating a more reliable means to manage user access and protect digital assets against rogue users willing to hand over their credentials to a proxy.  Our global identity as a service, or IDaaS, hosting capability allows our customers to simplify and efficiently scale their security infrastructures across internal IT systems and external customer facing applications without installation overhead, security or uptime management efforts.

 

We designed BIO-key PortalGuard IDaaS and WEB-key to provide organizations an integrated approach to managing and securing all of their identities using the technologies they already use while providing capacity for future needs through the strategic use of biometrics to limit vulnerability and contain authentication costs.  Our platform allows users to authenticate their customers, employees, contractors, and partners. It enables any user to connect to any device, cloud or application, all with a simple, customizable, intuitive and consumer-friendly user experience.  We utilize server-secured biometrics to support roving users without requiring them to carry their phone or a token. As of December 31, 2021, more than 300 customers across multiple industries use BIO-key to secure and manage access for users around the world.

 

 

1
 

 

Development of Business

 

We were founded in 1993 to develop and market advanced fingerprint biometric technology and related security software solutions. First incorporated as BBG Engineering, the company was renamed SAC Technologies in 1994 and renamed BIO-key International, Inc. in 2002. Our principal executive office is located at 3349 Highway 138, Building A, Suite E, Wall, New Jersey 07719.   

 

We were pioneers in developing automated, finger identification technology that supplements or compliments other methods of identification and verification, such as personal inspection identification, passwords, tokens, smart cards, ID cards, credit card, passports, driver’s licenses, or other form of possession or knowledge-based credentialing. Our advanced technology has been, and is, used to improve both the accuracy and speed of competing fingerprint biometrics in some of the largest biometric systems in the world.

 

On June 30, 2020, we enhanced our product offering by acquiring PistolStar, Inc. (“PistolStar”) for $2.5 million.  PistolStar provides enterprise-ready identity access management solutions to commercial, government and education customers throughout the United States and internationally.  PistolStar develops and markets our PortalGuard line of software and services.  

 

On March 8, 2022, we expanded our sales and support operation into Europe, Africa and the Middle East (“EMEA”) by acquiring Swivel Secure Europe, SA for up to $2.25 million. Swivel Secure Europe is a Madrid, Spain based provider of IAM solutions serving  over 300 customers through a network of  dozens of channel partners throughout EMEA. Swivel Secure Europe is the exclusive distributer of AuthControl® Sentry, AuthControl Enterprise and AuthControl MSP product line in Europe, Middle East, and Africa, excluding the United Kingdom. Swivel Secure maintains a direct sales force with offices in Madrid, Spain and Lisbon, Portugal.

 

Our Products

 

BIO-key PortalGuard and PortalGuard IDaaS

 

BIO-key PortalGuard is an independent, customer-controlled and neutral-by-design cloud-based identity platform that allows our customers to integrate with any cloud or on-premise SaaS application, service or cloud host, as well as Windows device authentication through a single secure, reliable and scalable IAM platform.  It provides identical capabilities in both a SaaS (PortalGuard IDaaS) or on-premise (PortalGuard) delivery model. PortalGuard integrates BIO-key’s Identity Bound Biometric biometric (IBB) authentication as a first-class authentication options that are not tied to a device or “what you have” authentication, allowing relying parties to positively identify who is accessing their systems, not the device they might have handed off.   Our three-way IAM neutrality consists of:

 

 

●

seventeen MFA authentication factor choices, including our server-secured IBB, via fingerprint scanners, or using a palm scan, facial selfie, or voice biometric via a mobile phone.
 

●

open user directory choices including on premise, hybrid or full-Azure Active Directory, LDAP, IBM Domino, or custom SQL user directory; and  
 

●

multiple single sign on, or SSO, federation options, including SAML, OIDC, CAS and WS-Fed.

 

The forgoing allows our customers to combine and authenticate legacy and future technologies and to securely connect users to the technology that they choose. We design transparent compatibility of the BIO-key PortalGuard IDaaS with on-premise infrastructures and public and hybrid clouds.

 

Our customers use the BIO-key PortalGuard IDaaS to secure their workforces and student populations and make their partner networks more collaborative. PortalGuard IDaaS provides more and secure experiences for their customers and end users, which enables our customers to future-proof their environments. PortalGuard IDaaS can be used as the central system for an organization’s connectivity, access, authentication and identity lifecycle management needs across all of its users, technology and applications. We enable our customers to easily deploy, manage and secure applications and devices, and offer provisioning services using open source tools.

 

Developers can leverage an extensive suite of API and modular SDK tools to build custom cloud, mobile and web application enrollment and authentication experiences that leverage BIO-key PortalGuard and WEB-key as the underlying identity management platform. Once deployed, PortalGuard allows administrators to enforce contextual access management decisions based on conditions such as user identity, device, geolocation, application destination identity, IP range, and time of day.

 

Our customers use BIO-key to (i) manage and secure work-related IT access of their employees, contractors and supply chain partners, which we call workforce identity; and (ii) manage and secure the identities of users of their web properties, which we call customer identity.

 

BIO-key PortalGuard and PortalGuard IDaaS for Workforce Identity.  PortalGuard streamlines the way an organization’s employees, contractors and supply chain partners connect to its applications and data from any device, while increasing user efficiency, preventing unauthorized delegation, credential sharing, and keeping digital environments secure through our MFA capabilities. We enable organizations to provide their workforces with immediate and secure access to every application from any device they use, without maintaining multiple credentials.  Our multi-directory support interfaces with the directories in place at an organization, while allowing SQL-based custom directories where none presently exist.  BIO-key PortalGuard Desktop allows customers to extend the BIO-key PortalGuard IDaaS to their existing on-premises and remote workstation Windows sign in.  

 

2
 

 

BIO-key PortalGuard and PortalGuard IDaaS for Customer Identity.  BIO-key PortalGuard allows organizations to secure access to their online properties, while upgrading their customers’ user experience by delivering self-enrollment and management for customer-facing cloud, mobile or web applications. We enable an organization’s product team to layer BIO-key’s MFA, SSO and self-service password reset, or SSPR, functionality into their cloud, web and mobile applications through federation standards or using our APIs.  Our customers are able to centrally manage policies, audit and log access across their properties, leading to more seamless customer experiences.

 

BIO-key VST and WEB-key; Products; Civil and Large-Scale ID Infrastructure

 

We have developed what we believe is the most discriminating and effective commercially available finger-based biometric technology. This technology is embedded in our PortalGuard product for enterprise security, providing customers with a unique capability to authenticate users without a phone or token, where appropriate, such as manufacturing, retail, call centers, and health care workers.  Other markets for scalable biometric engines include government markets, large scale identity projects such as voter’s registration, driver’s license, national ID programs, and SIM card registration.

 

We also offer a full line of easy to use finger scanners for both enterprise and consumer markets.  Our SideSwipe®, EcoID® and SidePass® finger readers can be used on any laptop, tablet or other device which contains a USB A or C port.  We market and sell these fingerprint scanners through distributors and directly to end users via Amazon.

 

Impact of COVID-19

 

The COVID-19 outbreak has led us to migrate to a remote business model for our sales, marketing, administrative and executive teams.  Research and development and production have adjusting to the situation to maintain production as best as possible considering the conditions and regulations.  Our transition to remote work was highly successful, and our teams operated efficiently using our own IAM software to authenticate video conferencing applications and other collaboration tools.  The COVID-19 pandemic has extended sales cycles and delayed deployments in most markets in which we operate, particularly in Africa.  We continue to conduct business daily, some still from home, and others in office occasionally, as we are actively closing transactions throughout the continuing climate, with no changes to personnel.

 

Markets

 

Identity and Access Management, User Multi-Factor Authentication, Single Sign On, Privilege Entitlement and Access Control

 

Our products simplify the authentication process for enterprise users and consumers, while raising security levels. This allows our customers to meet new, stronger authentication requirements and security best practices across many industries, while delivering a superior end-user experience. Customers use our products to reduce risk of theft, fraud, loss, account takeover attacks, and unauthorized account sharing by limiting access to valuable assets, privileges, data, services, networks and places to only authorized individuals. Our products provide stronger identity binding and a superior user experience versus traditional credentialing systems, which utilize a physical or knowledge-based electronic credential to authenticate the holder but fail to authenticate the actual user in addition to the token. Both commercial enterprises and the public sector have seen a shift in the requirement for stronger authentication, and the FBI, NIST and industry thought leaders such as SalesForce and Microsoft have encouraged entities to enhance their security posture by implementing stronger 2-factor authentication (2FA) or MFA. We believe the market for advanced user MFA, including fingerprint biometrics, extends to nearly every industry segment and the market opportunity for our products is massive, global and growing. 

 

Historically, our largest market has been identity and access management for highly regulated industries like government and healthcare. However, we are witnessing a change in the landscape as organizations within all industries and of all sizes are embracing biometric technology and MFA as a security and workflow solution. Championed by the millions of users that have been successfully introduced to biometrics by companies such as Apple and Samsung, today’s users have witnessed the security and convenience benefits of biometric technology in their phones and welcome the same user experience to access applications without passwords.

 

More recently, in connection with the acquisition of PistolStar we have developed a large customer base in the higher education vertical. Colleges and universities throughout the United States use our PortalGuard single sign on platform. As colleges and universities continue to operate in remote environments, we have seen additional demand for our solutions.

 

Upon introducing a series of compact fingerprint readers, we saw an immediate increase in inquiries from both commercial companies seeking an alternative to passwords, and from consumers recognizing that they could use SidePass, SideSwipe or EcoID to replace their Windows passwords and enable Windows Hello without replacing or upgrading laptops or tablets.

 

3
 

 

In October 2015, we established BIO-key Hong Kong for purposes of establishing relationships and conducting business is the Asia Pacific Region. Through our Hong Kong subsidiary, we support the growing demand for secure identification and authentication in the region.

 

We believe there is potential for significant market growth in the following key areas:

 

 

●

Corporate network access control, corporate campuses, computer networks, and applications.
     
 

●

Large scale identification projects, especially in Africa and the surrounding regions.
     
 

●

Government funded initiatives, including the state board of elections.
   

 
 

●

International law enforcement use case applications as prospects see us as a global leader in the biometric technology space as witnessed by our agreement with the Israeli Defense Force, and the Singapore and Dubai Police departments.
   

 
 

●

Consumer mobile credentialing, including mobile payments, credit and payment card programs, data and application access, and commercial loyalty programs. 
   

 
 

●

Demand for BIO-key hardware products from Windows 10 users and Fortune 500 companies.
   

 
 

●

Government services and highly regulated industries including, Medicare, Medicaid, Social Security, drivers' licenses, campus and school ID, passports/visas.
   

 
 

●

New remote authentication challenges, including those created by the COVID-19 pandemic.

 

 

Business Model

 

Our business model is focused on the following key areas:

 

Market

Drivers

Frequent announcements of supply chain breaches, ransomware attacks, and administrative access compromises highlight the shortcomings of mainstream MFA and security approaches, which leave far too much responsibility on end-users to comply with cyber-hygiene policies. BIO-key’s biometric authentication process prevents human error and human nature from undermining secure authentication, while making the end user’s access easier than ever. The current climate of broad enterprise adoption of MFA to replace passwords presents opportunities for us to leverage our unique differentiators and exploit the gaps in existing IAM technology approaches. One of those gaps is the challenge of authenticating users that “rove” among workstations. A second gap is preventing unauthorized account sharing and delegation.

 

OEM

Customers

We will continue to prioritize securing agreements with OEM customers. The history of success supporting NCR, McKesson, Omnicell, and LexisNexis provides an established footprint that we intend to build upon. As OEM customers embed our solutions within their products, the customer benefits from the enhanced security and workflow, and frees them from investing in R&D to manage an IAM infrastructure of their own. OEM customers’ ordering patterns are more predictable and OEM customers generally require lower service and support resourcing.

 

Highly

Regulated

Industries

Government ID projects and healthcare organizations, including hospitals, clinics, and small private practices present a strong opportunity for us. Additionally, the financial services industry, including banks and credit unions has grown substantially.

 

Partner

Model

In 2021, we continued to grow our Channel Alliance Partner program (CAP) focused on partnering with select value added resellers, integrators, and resellers. We added Intellisys and other master agent distributors to our partners.  We partner with leading application, managed service and infrastructure vendors, such as Insight, NGEN, Amazon Web Services, UCROO Campus, Software House International (SHI), Virtual Graffiti, Atlassian, and ProCirrus. 

 

Microsoft

Partnership

We are a Microsoft Partner and our line of compact fingerprint scanners has been tested and qualified by Microsoft to support Windows Hello and Windows Hello for Business.

 

4
 

 

Hardware

Hardware products generated 25% of our revenue in 2021. EcoID has emerged as our most popular scanner for enterprise deployments. For customers that require the highest level of security, PIV-Pro is a FIPS compliant fingerprint scanner, suitable for highly regulated industries and organizations that want a best-in-class solution.

 

We have grown our business through a combination of organic growth and the strategic acquisitions of PistolStar and Swivel Secure Europe. We expect to continue to pursue strategic acquisitions of select businesses and assets in the IAM space.  In furtherance of this strategy, we are active in the industry and regularly evaluate businesses that we believe will either provide an entry into new market verticals or be synergistic with our existing operations and in either case, be accretive to earnings.  We cannot provide any assurance as to whether we will be able to complete any acquisition and if completed, successfully integrate any business we acquire into our operations. Please see the section captioned “RISK FACTORS” for additional information regarding acquisition risks.

 

 

 

Marketing and Distribution

 

We sell our products directly through our field and inside sales teams, as well as indirectly through our network of channel partners. Through our Channel Alliance Program, we have partnered with more than 40 resellers, system integrators and other distribution partners.  We are committed to continue to aggressively grow this program in 2022.

 

We partner with leading application, managed service and infrastructure vendors, such as Insight, NGEN, Amazon Web Services, Pathify (formerly Ucroo Campus), Software House International (SHI), Virtual Graffiti, Atlassian, and ProCirrus.

 

We offer our software under a SaaS term license and generate annual recurring revenue (ARR) primarily by selling multi-year subscriptions to our software. We employ a customer success team, focused on customer satisfaction and early remediation. 

 

In 2020, we announced two contracts with our partner Technology Transfer Institute for large-scale identification projects in Nigeria. We received our first purchase, related to this project, which we shipped in the first quarter of 2021. The COVID-19 pandemic has and may continue to delay the rollout of these programs. 

 

Intellectual Property Rights

 

We develop and own significant intellectual property and believe that our intellectual property is fundamental to our biometric and IAM product operation:

 

Patents

 

We own patented technologies and trade secrets developed or acquired by us.

 

In May 2005, the U.S. Patent & Trademark Office issued patent 6,895,104 for our Vector Segment fingerprint technology (VST), our core biometric analysis and identification technology. With the payment of all maintenance fees, this patent will expire on March 4, 2023.

 

On October 3, 2006, we announced that our patent for a biometric authentication security framework had been granted by the U.S. Patent & Trademark Office. The patent No. 7,117,356 was issued to us for a biometric authentication security framework that enhances commercial and civil biometric use. Our authentication security framework protects privacy and security of cloud or network-based authentications while also facilitates ease of use of biometric systems. The technology that this patent is based on is the foundation for the authentication security incorporated in our WEB-key product line. WEB-key is a mature enterprise authentication solution that functions in a wide variety of application environments. The solution supports a variety of implementation alternatives including card technologies for “two-factor” authentication and also supports “single-factor” authentication. Partners and customers implementing our WEB-key software to provide convenient and secure user identity include a number of institutions including the Allscripts Healthcare Solutions, Computer Associates Site Minder, Oracle Access Manager and many other enterprise and solutions-based systems. With the payment of all maintenance fees, this patent will expire on May 20, 2023.

 

On December 26, 2006, we were issued US patent No. 7,155,040 covering our unique image processing technology, which is critical for enhancing information used in the extraction of biometric minutiae. The issued patent protects a critical part of an innovative four-phase image enhancement process developed by us. With the payment of all maintenance fees, this patent will expire on January 29, 2025.

 

5
 

 

On April 15, 2008, we were issued US patent No. 7,359,553 covering our image enhancement and data extraction core algorithm components. The solution protected under this patent provides the capability to quickly and accurately transform a fingerprint image into a computer image that can be analyzed to determine the critical data elements. With the payment of all maintenance fees, this patent will expire on January 3, 2025.

 

On August 19, 2008, we were issued US patent No. 7,415,605 for our “Biometric Identification Network Security” method. The solution protected under this patent provides a defense against hackers and system attacks, while leveraging the industry standard Trusted Platform Module (TPM) specification for encryption key management. With the payment of all maintenance fees, this patent will expire on May 20, 2023.

 

On November 18, 2008, we were issued US patent No. 7,454,624 for our “Match Template Protection within a Biometric Security System” method. The solution protected under this patent limits the scope of enrollment templates usage and also eliminates the need for revocation or encryption processes, which can be expensive and time consuming. With the payment of all maintenance fees, this patent will expire on May 17, 2025.

 

On March 10, 2009, we were issued US patent No. 7,502,938 for our “Trusted Biometric Device” which covers a simple, yet secure method of protecting a user’s biometric information. It covers the transmission of information from the point the information is collected at the biometric reader until the data reaches the computer or device that is authenticating the user’s identity. With the payment of all maintenance fees, this patent will expire on October 25, 2025.

 

On May 26, 2009, we were issued US patent No. 7,539,331 for our “Image Identification System” method for improving the performance and reliability of image analysis within an image identification system. With the payment of all maintenance fees, this patent will expire on March 22, 2022.

 

On November 8, 2011, we were issued US Patent No. 8,055,027 for our “Generation of Directional Information in the Context of Image Processing” method for image enhancement and processing. With the payment of all maintenance fees, this patent will expire on October 10, 2027.

 

On June 5, 2012, PistolStar was issued US Patent No. 8,196,193 for “Method For Retrofitting Password Enabled Computer Software with a Redirectional User Authentication Method”, where a device, method, and system may be used to integrate and control authentication and passwords among various applications and platforms. With the payment of all maintenance fees, this patent will expire on November 1, 2030. 

 

On July 3, 2012, we were issued US Patent No. 8,214,652 for our “Biometric Identification Network Security”, an expanded method of network and related network authentication security systems utilizing hardware-based support for encryption and key management for authentication purposes. With the payment of all maintenance fees, this patent will expire on April 24, 2024.

 

On March 12, 2013, PistolStar was issued US Patent No. 8,397,077 for “Client Side Authentication Redirection”, where user specific attributes may be accessed and used to produce a generated password, using an algorithm and the user attributes. With the payment of all maintenance fees, this patent will expire on August 7, 2030.

 

On May 3, 2017, we were issued US Patent No. 9,646,146 for our “Utilization of Biometric Data”, a method enables existing small area sensors to capture substantially more fingerprint surface area, leading to a higher degree of accuracy when performing a match. With the payment of all maintenance fees, this patent will expire on March 6, 2035.   

 

On June 19, 2018 we were issued U.S. Patent No. 10,002,244 for our “Utilization of Biometric Data” to allow continuous, passive user authentication on a mobile device. With the payment of all maintenance fees, this patent will expire on March 6, 2035.

 

On July 27, 2018 we were issued U.S. Patent No. 10,025,831 for “Adaptive Short Lists and Acceleration of Biometric Database Search”, a method to quickly and iteratively search a database of biometric data. With the payment of all maintenance fees, this patent will expire on August 10, 2036.

 

On September 3, 2019 we were issued U.S. Patent No. 10,400,481 for “Fingerprint Lock”, a lock design method of the shackle and spring integration to electronics. With the payment of all maintenance fees, this patent will expire on June 27, 2037.

 

On September 10, 2019 we were issued U.S Patent No. 10,410,040 for “Fingerprint Lock Control method and Fingerprint Lock System”, a lock design method of the control process of scanning, and server communications for user profile management. With the payment of all maintenance fees, this patent will expire on July 26, 2037.

 

6
 

 

On April 20, 2021 we were issued U.S. Patent No. 10,984,085 for “Biometric Recognition for Uncontrolled Acquisition Environments”, expected to be deployed in mobile devices, the patent provides a method of continuous capture of the users biometric data before the need of the authentication or enrollment, as well as during an active session with a user, to assure the user has not changed. 

 

We have also been granted parallel patents to the US Patent portfolio to certain of our patents in many foreign countries offering protection of our intellectual property rights around the world.

 

Trademarks

 

We have registered our trademarks “BIO-key”, “True User Identification”, “Intelligent Image Indexing”, “WEB-key”, “SideSwipe”, “SidePass”, “EcoID”, “PistolStar®”, “PortalGuard”, “MobileAuth”, and “PASSIVEKEY®” with the U.S. Patent & Trademark Office, as well as many foreign countries, protecting our companies name and key technology offering names.

 

Through our subsidiary PistolStar, we own the following additional registered trademarks: “PortalGuard®”, “PASSIVEKEY®”, and “PISTOLSTAR®”. We also acquired the following unregistered trademarks: “PortalGuard NebulaTM”, “Password PowerTM” and “ScoochTM”.

 

Copyrights and trade secrets

 

We take measures to ensure copyright and license protection for our software releases prior to distribution. When possible, the software is licensed in an attempt to ensure that only licensed and activated software functions to its full potential. We also take measures to protect the confidentiality of our trade secrets.

 

Research and Development

 

Our PortalGuard IAM product line is mature, with hundreds of active customers, and we are adding additional factors and capabilities to the product, as well as enhancing the self-management for the functionally equivalent PortalGuard IDaaS offering. A significant new authentication factor set will come via our MobileAuth application for users to experience multiple biometric secure authentication via their mobile phone devices. Our VST and WEB-key biometric platforms are mature, stable, and widely-deployed. We concentrate our research and development efforts on enhancing the functionality, reliability and integration of our current products as well as acquiring and developing new and innovative products and solutions for providing broader access to the BIO-key user experience. 

 

Although we believe that our identification technology is one of the most advanced and discriminating fingerprint technologies available today, the markets in which we compete are characterized by rapid technological change and evolving standards and use-cases. In order to maintain our position in the market, we will need to continue to upgrade and refine our existing technologies as new standards become relevant to our customers and markets.

 

During the years ended December 31, 2021 and 2020, we incurred expenses of $2,355,056 and $1,396,436, respectively, for research and development.

 

In future periods our R&D efforts will remain focused on updating and advancing our core software products including PortalGuard and PortalGuard IDaaS, MobileAuth, WEB-key and VST. These products are critical to support the anticipated growth in enterprise IAM and large-scale ID projects.

 

Competition

 

The IAM MFA and SSO market has many providers of solutions in either standalone or IAM suite delivery models. We believe that our unique differentiator in this market is the incorporation of an unparalleled server-secured biometric authentication capability among our 17 authentication factors. There are numerous companies involved in the development, manufacturing and marketing of fingerprint biometrics products to commercial, government, law enforcement and prison markets. These companies include, but are not limited to, IDEMIA, Thales, NEC, Neurotechnology, and Innovatrics.

 

The majority of sales for automated fingerprint identification products in the market to date have been deployed for government agencies, healthcare facilities, and law enforcement applications. The consumer and commercial markets represent areas of growth potential for biometrics, led by the use of mobile devices.

 

The epidemic of security and data breaches reported over the past few years is one of the driving factors for identifying new methods of protecting valuable data. After attempting to create a more sophisticated password, or more efficient token or PIN, it has become apparent that each of these methods are easily compromised, and the downside risks are significant.

 

7
 

 

We have also seen FIDO-compliant keys enter the market, led by Yubico’s YubiKey, a USB key that acts as a credential for access.  Keys alone do not meet the needs of large organizations for which key sharing and lost keys are concerns.  We have introduced a line of low-cost USB keys and they do not offer the security benefits of biometric technology as they can be easily lost or stolen and replacement costs / managing the product becomes a growing expense.

 

With respect to competing biometrics technologies, each has its strengths and weaknesses and none has emerged as a market leader:

 

 

●

Fingerprint identification is generally viewed as very accurate, inexpensive and non-intrusive and is the dominant biometric in use today and will be for the foreseeable future;

 

 

●

Palm Vein scanning is expensive, technique-sensitive, and offers mobility challenges;

 

 

●

Iris scanning is viewed as accurate, but the hardware is significantly more expensive; and

 

 

●

Facial recognition can have privacy concerns with work-from-home use, and is typically highly dependent on ambient lighting conditions, angle of view, and other factors.

 

Government Regulations

 

Various state, federal and EU privacy laws govern the collection, storage, use and any sale of biometric-related data.  To the extent that BIO-key’s IDaaS offerings include the collection and storage of customer users’ personal or biometric data, we operate as a processor of such data.  Our WEB-key platform includes compliance features to ensure automated compliance with these laws including collection of informed written consent during enrollment workflows and robust auditing to control and report on the retention of biometric data and removal requests.  Additionally, our customers have access to these tools to maintain their own compliance, including deletion of user data when business relationships terminate.

 

We believe in biometric privacy rights, and that both users and their organizations benefit from a responsibly operated biometric identity infrastructure.  We actively participate in industry privacy workgroups as recognized biometric subject matter experts in order to influence and keep abreast of any proposed changes to these regulations. Beyond these regulations, we are not currently subject to direct regulation by any government agency, other than regulations generally applicable to businesses or related to specific project requirements. In the event of any international sales, we would be subject to various domestic and foreign laws regulating such exports and export activities.

 

Environmental Regulations

 

As of the date of this report, we have not incurred any material expenses relating to our compliance with federal, state, or local environmental laws and do not expect to incur any material expenses in the foreseeable future.

 

Seasonality

 

Generally, our revenues do not exhibit a seasonal pattern, however, revenue is affected by customer budgeting, government fiscal year planning, and capital budgets.

 

Human Capital Resources

 

As of the date of this report, we employed fifty-one individuals on a full-time basis as follows: (i) twenty-two in engineering, customer support, and research and development; (ii) nine in finance and administration; and (iii) twenty in sales and marketing. We also have one employee who provides engineering services and one employee who provides administrative services, both on a part-time basis, and two part-time factory contractors in China. None of our employees are represented by a labor union and we believe that our relationship with our employees is good.

 

Available Information

 

We maintain a website with the address www.BIO-key.com. Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports are available on our website, without charge, as soon as reasonably practicable after they are filed electronically with the SEC. The SEC also maintains a website that contains reports, proxy and information statements and other information statements and other information regarding issuers who file electronically with the SEC. The SEC’s website address is www.sec.gov.

 

8
 

 

ITEM 1A. RISK FACTORS

 

Set forth below are the risks that we believe are material to our investors. This section contains forward-looking statements. You should refer to the explanation of the qualifications and limitations on forward-looking statements appearing just before the section captioned “BUSINESS” in Item 1 above. Effective November 20, 2020, we implemented a reverse stock split of our outstanding common stock at a ratio of 1-for-8. All share figures are reflected on a post-split basis.

 

BUSINESS AND FINANCIAL RISKS

 

We have historically not generated significant revenue and have sustained substantial operating losses.

 

In order to increase revenue, we have developed a direct sales force and anticipate the need to retain additional sales, marketing and technical support personnel and may need to incur substantial expenses. We cannot assure you that we will be able to secure these necessary resources, that a significant market for our technologies will develop, or that we will be able to achieve our targeted revenue. If we are unable to achieve revenue or raise capital sufficient to cover our ongoing operating expenses, we will be required to scale back operations, including marketing and research initiatives, or in the extreme case, discontinue operations. As of December 31, 2021, we had an accumulated deficit of approximately $105 million.

 

Our biometric technology has yet to gain widespread market acceptance and we do not know how large of a market will develop for our technology.

 

Biometric technology has received only limited market acceptance, particularly in the private sector. Our technology represents a novel security solution and we have not yet generated significant sales. Although recent security concerns relating to identification of individuals and appearance of biometric readers on popular consumer products, including the Apple iPhone, have increased interest in biometrics generally, it remains an undeveloped, evolving market. Biometric based solutions compete with more traditional security methods including keys, cards, personal identification numbers and security personnel. Acceptance of biometrics as an alternative to such traditional methods depends upon a number of factors including:

 

 

●

national or international events which may affect the need for or interest in biometric solutions;

 

 

●

the performance and reliability of biometric solutions;

 

 

●

marketing efforts and publicity regarding these solutions;

 

 

●

public perception regarding privacy concerns;

 

 

●

costs involved in adopting and integrating biometric solutions;

 

 

●

proposed or enacted legislation related to privacy of information; and

 

 

●

competition from non-biometric technologies that provide more affordable, but less robust, authentication (such as tokens and smart cards).

 

For these reasons, we are uncertain whether our biometric technology will gain widespread acceptance in any commercial markets or that demand will be sufficient to create a market large enough to produce significant revenue or earnings. Our future success depends, in part, upon business customers adopting biometrics generally, and our solution specifically.

 

Biometric technology is a new approach to Internet security, which must be accepted in order for our WEB-key solution to generate significant revenue.

 

Our WEB-key authentication initiative represents a new approach to Internet security, which has been adopted on a limited basis by companies that distribute goods, content or software applications over the Internet. The implementation of our WEB-key solution requires the distribution and use of a finger scanning device and integration of database and server side software. Although we believe our solutions provide a higher level of security for information transmitted over the Internet than existing traditional methods, unless business and consumer markets embrace the use of a scanning device and believe the benefits of increased accuracy outweigh implementation costs, our solution will not gain market acceptance.

 

9
 

 

The market for our solutions is still developing and if the biometrics industry adopts standards or a platform different from our standards or platform, our competitive position would be negatively affected.

 

The market for identity solutions is still developing. The evolution of this market may result in the development of different technologies and industry standards that are not compatible with our current solutions, products or technologies. Several organizations set standards for biometrics to be used in identification and documentation. Although we believe that our biometric technologies comply with existing standards, these standards may change and any standards adopted could prove disadvantageous to or incompatible with our business model and current or future solutions, products and services.

 

Our software products may contain defects which will make it more difficult for us to establish and maintain customers.

 

Although we have completed the development of our core biometric technology, it has only been used by a limited number of business customers. Despite extensive testing during development, our software may contain undetected design faults and software errors, or “bugs” that are discovered only after it has been installed and used by a greater number of customers. Any such defect or error in new or existing software or applications could cause delays in delivering our technology or require design modifications. These could adversely affect our competitive position and cause us to lose potential customers or opportunities. Since our technologies are intended to be utilized to secure physical and electronic access, the effect of any such bugs or delays will likely have a detrimental impact on us. In addition, given that biometric technology generally, and our biometric technology specifically, has yet to gain widespread acceptance in the market, any delays would likely have a more detrimental impact on our business than if we were a more established company.  

 

In order to generate revenue from our biometric products, we are dependent upon independent original equipment manufacturers, system integrators and application developers, which we do not control. As a result, it may be more difficult to generate sales.

 

We market our technology through licensing arrangements with:

 

 

●

original equipment manufacturers (OEMs), system integrators and application developers which develop and market products and applications which can then be sold to end users; and
   

 
 

●

companies which distribute goods, services or software applications over the Internet.

 

As a technology licensing company, our success will depend upon the ability of these manufacturers and developers to effectively integrate our technology into products and services which they market and sell. We have no control over these licensees and cannot assure you that they have the financial, marketing or technical resources to successfully develop and distribute products or applications acceptable to end users or generate any meaningful revenue for us. These third parties may also offer the products of our competitors to end users. While we have commenced a significant sales and marketing effort, we have only begun to develop a significant distribution channel and may not have the resources or ability to sustain these efforts or generate any meaningful sales.

 

We face intense competition and may not have the financial and human resources necessary to keep up with rapid technological changes, which may result in our technology becoming obsolete.

 

The Internet, facility access control, and information security markets are subject to rapid technological change and intense competition. We compete with both established biometric companies and a significant number of startup enterprises as well as providers of more traditional methods of access control. Most of our competitors have substantially greater financial and marketing resources than we do and may independently develop superior technologies, which may result in our technology becoming less competitive or obsolete. We may not be able to keep pace with this change. If we are unable to develop new applications or enhance our existing technology in a timely manner in response to technological changes, we will be unable to compete in our chosen markets. In addition, if one or more other biometric technologies such as voice, face, iris, hand geometry or blood vessel recognition are widely adopted, it would significantly reduce the potential market for our fingerprint identification technology. 

 

We recognized revenues from Africa in 2021 and expect continued revenues from Africa and the European Union in future periods. Our financial performance will be subject to risks associated with changes in the value of the U.S. dollar versus local currencies.

 

Owing to the international scope of our operations, including our recent acquisition of Swivel Secure Europe, SA, we are exposed to foreign exchange risk. Our primary exposure to movements in foreign currency exchange rates relates to non-U.S. dollar-denominated sales and operating expenses worldwide. Weakening of foreign currencies relative to the U.S. dollar will adversely affect the U.S. dollar value of our foreign currency-denominated sales and earnings, if any, and could lead to us raising international pricing, potentially reducing the demand for our products. In addition, margins on sales of our products in foreign countries and on sales of products that include components obtained from foreign suppliers could be materially adversely affected by foreign currency exchange rate fluctuations. As a result, our business and the price of our common stock may be affected by fluctuations in foreign exchange rates, which may have a significant impact on our results of operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place.

 

10
 

 

Although we have made significant sales of our products throughout Asia and Africa in prior years, we have not been able to consistently enforce our contract rights and collect all receivables which has resulted in material write-offs.

 

Our ability to enforce our international contracts is contingent on our relationships with foreign resellers, and their financial viability. Although we are making efforts to better enforce our contract rights, there can be no assurance that we will be able to fully collect all receivables originating in Asia and Africa or that will not have to write-off future receivables which may be material in amount.  Any such write-offs have in the past and will negatively impact our financial position and results of operation.

 

We depend on key employees and members of our management team, including our Chairman of the Board and Chief Executive Officer, Chief Financial Officer, and our Chief Legal Officer, in order to achieve our goals. We cannot assure you that we will be able to retain or attract such persons.

 

Our employment contracts with Michael W. DePasquale, our Chairman of the Board and Chief Executive Officer, Cecilia C. Welch, our Chief Financial Officer, and James D. Sullivan, our Chief Legal Officer, expire annually, and renew automatically for successive one year periods unless notice of non-renewal is provided by the Company. Although the contracts do not prevent them from resigning, they do contain confidentiality and non-compete clauses, which are intended to prevent them from working for a competitor within one year after leaving our Company. Our success depends on our ability to attract, train and retain employees with expertise in developing, marketing and selling software solutions. In order to successfully market our technology, we will need to retain additional engineering, technical support and marketing personnel. The market for such persons remains highly competitive and our limited financial resources will make it more difficult for us to recruit and retain qualified persons.

 

We cannot assure you that the intellectual property protection for our core technology provides a sustainable competitive advantage or barrier to entry against our competitors.

 

Our success and ability to compete is dependent in part upon proprietary rights to our technology. We rely primarily on a combination of patent, copyright and trademark laws, trade secrets and technical measures to protect our propriety rights. We have filed a patent application relating to both the optic technology and biometrics solution components of our technology wherein several claims have been allowed. The U.S. Patent and Trademark Office has issued us a series of patents for our Vector Segment fingerprint technology (VST), and our other core biometric analysis and identification technologies. However, we cannot assure you that we will be able to adequately protect our technology or other intellectual property from misappropriation in the U.S. and abroad. Any patent issued to us could be challenged, invalidated or circumvented or rights granted thereunder may not provide a competitive advantage to us. Furthermore, patent applications that we file may not result in issuance of a patent or, if a patent is issued, the patent may not be issued in a form that is advantageous to us. Despite our efforts to protect our intellectual property rights, others may independently develop similar products, duplicate our products or design around our patents and other rights. In addition, it is difficult to monitor compliance with, and enforce, our intellectual property rights on a worldwide basis in a cost-effective manner. In jurisdictions where foreign laws provide less intellectual property protection than afforded in the U.S. and abroad, our technology or other intellectual property may be compromised, and our business would be materially adversely affected. If any of our proprietary rights are misappropriated or we are forced to defend our intellectual property rights, we will have to incur substantial costs. Such litigation could result in substantial costs and diversion of our resources, including diverting the time and effort of our senior management, and could disrupt our business, as well as have a material adverse effect on our business, prospects, financial condition and results of operations. We can provide no assurance that we will have the financial resources to oppose any actual or threatened infringement by any third party. Furthermore, any patent or copyrights that we may be granted may be held by a court to infringe on the intellectual property rights of others and subject us to the payment of damage awards. 

 

We may be subject to claims with respect to the infringement of intellectual property rights of others, which could result in substantial costs and diversion of our financial and management resources.

 

Third parties may claim that we are infringing on their intellectual property rights. We may violate the rights of others without our knowledge. We may expose ourselves to additional liability if we agree to indemnify our customers against third party infringement claims. While we know of no basis for any claims of this type, the existence of and ownership of intellectual property can be difficult to verify, and we have not made an exhaustive search of all patent filings. Additionally, most patent applications are kept confidential for twelve to eighteen months, or longer, and we would not be aware of potentially conflicting claims that they make. We may become subject to legal proceedings and claims from time to time relating to the intellectual property of others in the ordinary course of our business. If we are found to have violated the intellectual property rights of others, we may be enjoined from using such intellectual property, and we may incur licensing fees or be forced to develop alternative technology or obtain other licenses. In addition, we may incur substantial expenses in defending against these third party infringement claims and be diverted from devoting time to our business and operational issues, regardless of the merits of any such claim.

 

11
 

 

In addition, in the event that we recruit employees from other technology companies, including certain potential competitors, and these employees are engaged in the development of portions of products which are similar to the development in which they were involved at their former employers, we may become subject to claims that such employees have improperly used or disclosed trade secrets or other proprietary information. If any such claims were to arise in the future, litigation or other dispute resolution procedures might be necessary to retain our ability to offer our current and future services, which could result in substantial costs and diversion of our financial and management resources. Successful infringement or licensing claims against us may result in substantial monetary damages, which may materially disrupt the conduct of our business and have a material adverse effect on our reputation, business, financial condition and results of operations. Even if intellectual property claims brought against us are without merit, they could result in costly and time consuming litigation, and may divert our management and key personnel from operating our business.

 

If we are unable to effectively protect our intellectual property rights on a worldwide basis, we may not be successful in the international expansion of our business.

 

Access to worldwide markets depends in part on the strength of our intellectual property portfolio. There can be no assurance that, as our business expands into new areas, we will be able to independently develop the technology, software or know-how necessary to conduct our business or that we can do so without infringing the intellectual property rights of others. To the extent that we have to rely on licensed technology from others, there can be no assurance that we will be able to obtain licenses at all or on terms we consider reasonable. The lack of a necessary license could expose us to claims for damages and/or injunction from third parties, as well as claims for indemnification by our customers in instances where we have a contractual or other legal obligation to indemnify them against damages resulting from infringement claims. With regard to our own intellectual property, we actively enforce and protect our rights. However, there can be no assurance that our efforts will be adequate to prevent the misappropriation or improper use of our protected technology in international markets.

 

We face inherent product liability or other liability risks that could result in large claims against us. 

 

We have inherent risk of exposure to product liability and other liability claims resulting from the use of our products, especially to the extent customers may depend on our products in public safety situations that may involve physical harm or even death to individuals, as well as exposure to potential loss or damage to property. Despite quality control systems and inspection, there remains an ever-present risk of an accident resulting from a faulty manufacture or maintenance of products, or an act of an agent outside of our or our supplier’s control. Even if our products perform properly, we may become subject to claims and costly litigation due to the catastrophic nature of the potential injury and loss. A product liability claim, or other legal claims based on theories including personal injury or wrongful death, made against us could adversely affect operations and financial condition. Although we may have insurance to cover product liability claims, the amount of coverage may not be sufficient. 

 

We may need to obtain additional financing to execute our business plan over the long-term, which may not be available. If we are unable to raise additional capital or generate significant revenue, we may not be able to continue operations.

 

We have historically financed our operations through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. We currently require approximately $735,000 per month to conduct our operations, a monthly amount that we have been unable to consistently achieve through revenue generation. During 2021, we generated approximately $5.1 million of revenue, which is below our average monthly requirements. If we are unable to generate sufficient revenue to cover operating expenses and fund our business plan, we will need to obtain additional third-party financing. We may, therefore, need to obtain additional financing through the issuance of debt or equity securities. We cannot assure you that we will be able to secure any such additional financing on terms acceptable to us or at all. If we cannot obtain such financing, we will not be able to execute our business plan, will be required to reduce operating expenses, and in the extreme case, discontinue operations. 

 

We may not achieve profitability if we are unable to maintain, improve our offerings.

 

We believe that our future business prospects depend in part on our ability to maintain and improve our current services and to develop new ones on a timely basis. Our services will have to achieve market acceptance, maintain technological competitiveness, and meet an expanding range of customer requirements. As a result of the complexities inherent in our service offerings, major new wireless data services and service enhancements require long development and testing periods. We may experience difficulties that could delay or prevent the successful development, introduction or marketing of new services and service enhancements. Additionally, our new services and service enhancements may not achieve market acceptance. If we cannot effectively develop and improve services, we may not be able to recover our fixed costs or otherwise become profitable.

 

12
 

 

If we fail to adequately manage our resources, it could have a severe negative impact on our financial results or stock price.

 

We could be subject to fluctuations in technology spending by existing and potential customers. Accordingly, we will have to actively manage expenses in a rapidly changing economic environment. This could require reducing costs during economic downturns and selectively growing in periods of economic expansion. If we do not properly manage our resources in response to these conditions, our results of operations could be negatively impacted.

 

We are subject to risks and uncertainties associated with the continued growth of our international operations, which may harm our business.

 

We have international operation, recently expanded our international operations when we acquired Swivel Secure Europe SA, and plan to continue expanding abroad. Accordingly, our business is subject to risks and uncertainties associated with doing business outside of the United States and could be adversely affected by a variety of factors, including:

 

 

●

multiple, conflicting and changing laws and regulations such as privacy, security, and data use regulations, tax laws, export and import restrictions, economic and trade sanctions and embargoes, employment laws, anticorruption laws, regulatory requirements, reimbursement or payer regimes and other governmental approvals, permits and licenses;
 

●

failure by us, our collaborators or our distributors to obtain regulatory clearance, authorization or approval for the use of our product candidates in various countries;
 

●

additional potentially relevant third-party patent rights;
 

●

complexities and difficulties in obtaining intellectual property protection and enforcing our intellectual property;
 

●

difficulties in staffing and managing foreign operations;
 

●

financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our product candidates and exposure to foreign currency exchange rate fluctuations;
 

●

natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions;
 

●

regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributors’ activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act (FCPA), its books and records provisions, or its anti-bribery provisions, or laws similar to the FCPA in other jurisdictions in which we may now or in the future operate; and
 

●

anti-bribery requirements of several Member States in the European Union and other countries that may change and require disclosure of information to which U.S. legal privilege may not extend.

 

Any of these factors could significantly harm our business, operating results, financial condition or prospects.

 

The outbreak of COVID-19 has and may continue to have a negative impact on our business, sales, results of operations and financial condition.

 

The global outbreak of COVID-19 has led to severe disruptions in general economic activities, particularly retail operations and travel, as businesses and federal, state, and local governments take increasingly broad actions to mitigate this public health crisis. Individually and collectively, the consequences of the COVID-19 outbreak have and could continue to have a material adverse effect on our business, sales, results of operations and financial condition.  Although our employees have been accustomed to working remotely prior to the COVID-19 pandemic, the uncertainty has extended sales cycles, extended payment terms, impacted access to inventory overseas, and delayed the start of planned deployments.

 

The extent to which the COVID-19 outbreak ultimately impacts our business, sales, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of new variants, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. Even after the COVID-19 outbreak has subsided, we may continue to experience significant impacts to our business as a result of its global economic impact, including any economic downturn or recession that has occurred or may occur in the future. 

 

We have taken measures to minimize the health risks of COVID-19 to our employees, as their safety and well-being are a top priority. Our U.S. employees are working from both the office and remotely. The extent to which COVID-19 impacts our business, sales and results of operations will depend on future developments, which are highly uncertain and cannot be predicted.

 

Our business could be negatively impacted by security threats, including cybersecurity threats, ransomware, and other disruptions.

 

As a technology company, we face various security threats, including cybersecurity threats to gain unauthorized access to sensitive information. Although we utilize various procedures and controls to monitor these threats and mitigate our exposure to such threats, there can be no assurance that these procedures and controls will be sufficient in preventing security threats from materializing. If any of these events were to materialize, they could lead to losses of sensitive information, critical infrastructure, personnel or capabilities, essential to our operations and could have a material adverse effect on our reputation, financial position, results of operations, or cash flows.

 

13
 

 

Cybersecurity attacks in particular are evolving and include but are not limited to, malicious software, attempts to gain unauthorized access to data, and other electronic security breaches that could lead to disruptions in critical systems, unauthorized release of confidential or otherwise protected information and corruption of data. Although we have implemented systems and procedures that are designed to protect customer, employee, vendor and Company information, prevent data loss and other security breaches, and otherwise identify, assess, and analyze cybersecurity risks, these measures may not be effective. Development and maintenance of these systems is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures increase and become more sophisticated. We face an evolving threat landscape in which cybercriminals, among others, employ a complex array of techniques designed to access personal data and other information, including, for example, the use of fraudulent or stolen access credentials, malware, ransomware, phishing, denial of service and other types of attacks. While, to the best of our knowledge, we have not experienced any material misappropriation, loss or other unauthorized disclosure of confidential or personally identifiable information as a result of a security breach or cyberattack that could materially increase financial risk to the Company or our customers, such a security breach or cyberattack could adversely affect our business and operations, including by damaging our reputation and our relationships with our customers, employees and investors, exposing us to litigation, fines, penalties or remediation costs.

 

Our failure to maintain appropriate environmental, social, and governance ("ESG") practices and disclosures could result in reputational harm, a loss of customer and investor confidence, and adverse business and financial results.

 

There is an increasing focus from certain investors, employees, customers and other stakeholders concerning corporate responsibility, specifically related to environmental, social and governance matters (“ESG”). Some investors may use these non-financial performance factors to guide their investment strategies and, in some cases, may choose not to invest in us if they believe our policies and actions relating to corporate responsibility are inadequate. The growing investor demand for measurement of non-financial performance is addressed by third-party providers of sustainability assessment and ratings on companies. The criteria by which our corporate responsibility practices are assessed may change due to the constant evolution of the sustainability landscape, which could result in greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. If we elect not to or are unable to satisfy such new criteria, investors may conclude that our policies and/or actions with respect to corporate social responsibility are inadequate. We may face reputational damage in the event that we do not meet the ESG standards set by various constituencies.

 

Furthermore, if our competitors’ corporate social responsibility performance is perceived to be better than ours, potential or current investors may elect to invest with our competitors instead. In addition, in the event that we communicate certain initiatives and goals regarding environmental, social and governance matters, we could fail, or be perceived to fail, in our achievement of such initiatives or goals, or we could be criticized for the scope of such initiatives or goals. If we fail to satisfy the expectations of investors, employees and other stakeholders or our initiatives are not executed as planned, our reputation and business, operating results and financial condition could be adversely impacted.

 

Russia’s recent military intervention in Ukraine and the international community’s response have created substantial political and economic disruption, uncertainty, and risk.

 

Russia’s military intervention in Ukraine in late February 2022, Ukraine’s widespread resistance, and the NATO led and United States coordinated economic, financial, communications, and other sanctions imposed by other countries have created significant political and economic world uncertainty. There is significant risk of expanded military confrontation between Russia and other countries.  It is not possible to predict the broader consequences of the conflict, including related geopolitical tensions, and the measures and retaliatory actions taken by the U.S. and other countries in respect thereof, as well as any counter measures or retaliatory actions by Russia in response. At a minimum, the continuing conflict is likely to cause regional instability, geopolitical shifts and could materially adversely affect global trade, currency exchange rates, regional economies and the global economy, which could materially adversely affect our financial condition or results of operations.  Current and likely additional international sanctions against Russia may contribute to higher costs, particularly for petroleum-based products.  These and related actions, responses, and consequences that cannot now be predicted or controlled may contribute to world-wide economic reversals.

 

There is a scarcity of and competition for acquisition opportunities.

 

There are a limited number of operating companies available for acquisition that we deem to be desirable targets. In addition, there is a very high level of competition among companies seeking to acquire these operating companies. Many established and well-financed entities are active in acquiring interests in companies that we may find to be desirable acquisition candidates. Many of these entities have significantly greater financial resources, technical expertise and managerial capabilities than us. Consequently, we will be at a competitive disadvantage in negotiating and executing possible acquisitions of these businesses. Even if we are able to successfully compete with these entities, this competition may affect the terms of completed transactions and, as a result, we may pay more or receive less favorable terms than we expected for potential acquisitions. We may not be able to identify operating companies that complement our strategy, and even if we identify a company that complements our strategy, we may be unable to complete an acquisition of such a company for many reasons, including:

 

 

●

failure to agree on the terms necessary for a transaction, such as the purchase price;

 

 

●

incompatibility between our operational strategies or management philosophies with those of the potential acquiree;

 

 

●

competition from other acquirers of operating companies;

 

 

●

lack of sufficient capital to acquire a profitable distribution company; and

 

 

●

unwillingness of a potential acquiree to work with our management.

 

14
 

 

Risks related to acquisition financing.

 

We have a limited amount of financial resources and our ability to make additional acquisitions without securing additional financing from outside sources is limited. In order to continue to pursue our acquisition strategy, we may be required to obtain additional financing. We may obtain such financing through a combination of traditional debt financing or the placement of debt and equity securities. We may finance some portion of our future acquisitions by either issuing equity or by using shares of our common stock for all or a portion of the purchase price for such businesses. In the event that our common stock does not attain or maintain a sufficient market value, or potential acquisition candidates are otherwise unwilling to accept our common stock as part of the purchase price for the sale of their businesses, we may be required to use more of our cash resources, if available, in order to maintain our acquisition program. If we do not have sufficient cash resources, we will not be able to complete acquisitions and our growth could be limited unless we are able to obtain additional capital through debt or equity financings.

 

We may experience difficulties in integrating the operations, personnel and assets of any business we acquire which may disrupt our business, dilute stockholder value, and adversely affect our operating results.

 

A component of our business plan is to acquire businesses and assets in the biometric and identity access management industry. There can be no assurance that we will be able to identify, acquire or profitably manage businesses or successfully integrate acquired businesses into the Company without substantial costs, delays or other operational or financial problems. Such acquisitions also involve numerous operational risks, including:

 

 

●

difficulties in integrating operations, technologies, services and personnel;

 

 

●

the diversion of financial and management resources from existing operations;

 

 

●

the risk of entering new markets;

 

 

●

            difficulties in retaining the existing customers;

 

 

●

the potential loss of existing or acquired strategic operating partners following an acquisition;

 

 

●

the potential loss of key employees following an acquisition and the associated risk of competitive efforts from such departed personnel;

 

 

●

assumed or unforeseen liabilities that arise in connection with the acquired business

 

 

●

possible legal disputes with the acquired company following an acquisition; and

 

 

●

the inability to generate sufficient revenue to offset acquisition or investment costs.

 

As a result, if we fail to properly evaluate and execute any acquisitions or investments, our business and prospects may be seriously harmed.

 

To the extent we make any material acquisitions, our earnings may adversely affected by non-cash charges relating to the amortization of intangible assets.

 

Under applicable accounting standards, purchasers are required to allocate the total consideration paid in a business combination to the identified acquired assets and liabilities based on their fair values at the time of acquisition. The excess of the consideration paid to acquire a business over the fair value of the identifiable tangible assets acquired must be allocated among identifiable intangible assets including goodwill. The amount allocated to goodwill is not subject to amortization. However, it is tested at least annually for impairment. The amount allocated to identifiable intangible assets, such as customer relationships and the like, is amortized over the life of these intangible assets. We expect that this will subject us to periodic charges against our earnings to the extent of the amortization incurred for that period. Because our business strategy focuses, in part, on growth through acquisitions, our future earnings may be subject to greater non-cash amortization charges than a company whose earnings are derived solely from organic growth. As a result, we may experience an increase in non-cash charges related to the amortization of intangible assets acquired in our acquisitions. Our financial statements will show that our intangible assets are diminishing in value, even if the acquired businesses are increasing (or not diminishing) in value.

 

RISKS RELATED TO OUR COMMON STOCK

 

We have issued a substantial number of options and warrants exercisable into shares of our common stock which could result in substantial dilution to the ownership interests of our existing stockholders.

 

As of the date of this report, approximately 4,902,000 shares of our common stock were reserved for issuance upon exercise or conversion of outstanding stock options and warrants. The exercise or conversion of these securities will result in a significant increase in the number of outstanding shares and substantially dilute the ownership interests of our existing stockholders. 

 

An active trading market for our common stock may not be sustained.

 

Although our common stock is listed on the Nasdaq Capital Market, an active trading market for our shares may not be developed and if developed, sustained. If an active market for our common stock is not developed or sustained, it may be difficult for you to sell your shares without depressing the market price for the shares or sell your shares at all. Any inactive trading market for our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration. 

 

15
 

 

If we fail to comply with the continued minimum closing bid requirements of the Nasdaq or other requirements for continued listing, our Common Stock may be delisted and the price of our Common Stock and our ability to access the capital markets could be negatively impacted.

 

Our common stock is listed for trading on Nasdaq. We must satisfy Nasdaq’s continued listing requirements, including, among other things, a minimum closing bid price requirement of $1.00 per share and minimum stockholders’ agreement. A delisting of our common stock from Nasdaq could materially reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our Common Stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, employees and fewer business development opportunities.

 

We may need to raise additional funds in the future through issuances of securities and such additional funding may be dilutive to stockholders or impose operational restrictions.

 

We may need to raise additional capital in the future to help fund our operations through sales of shares of our common stock or securities convertible into shares of our common stock, as well as issuances of debt. Such additional financing may be dilutive to our stockholders, and debt financing, if available, and may involve restrictive covenants which may limit our operating flexibility. If additional capital is raised through the issuance of shares of our common stock or securities convertible into shares of our common stock, the percentage ownership of existing stockholders will be reduced. These stockholders may experience additional dilution in net book value per share and any additional equity securities may have rights, preferences and privileges senior to those of the holders of our common stock.

 

Because we do not expect to pay dividends for the foreseeable future, investors seeking cash dividends should not purchase our shares of common stock.

 

We have never declared or paid any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our common stock in the foreseeable future. Payment of any future dividends will be at the discretion of our board of directors after taking into account various factors, including but not limited to our financial condition, operating results, cash needs, growth plans and the terms of any credit agreements that we may be a party to at the time. Accordingly, investors seeking cash dividends should not purchase shares of our common stock. 

 

Provisions of our certificate of incorporation, bylaws and Delaware law may make a contested takeover of our Company more difficult.

 

Certain provisions of our certificate of incorporation, bylaws and the General Corporation Law of the State of Delaware (“DGCL”) could deter a change in our management or render more difficult an attempt to obtain control of us, even if such a proposal is favored by a majority of our stockholders. For example, we are subject to the provisions of the DGCL that prohibit a public Delaware corporation from engaging in a broad range of business combinations with a person who, together with affiliates and associates, owns 15% or more of the corporation’s outstanding voting shares (an “interested stockholder”) for three years after the person became an interested stockholder, unless the business combination is approved in a prescribed manner. Our certificate of incorporation also includes undesignated preferred stock, which may enable our board of directors to discourage an attempt to obtain control of us by means of a tender offer, proxy contest, merger or otherwise. Finally, our bylaws include an advance notice procedure for stockholders to nominate directors or submit proposals at a stockholders meeting. Delaware law and our charter may, therefore, inhibit a takeover. 

 

The trading price of our common stock may be volatile.

 

The trading price of our shares has from time to time fluctuated widely and in the future may be subject to similar fluctuations. The trading price may be affected by a number of factors including the risk factors set forth in this Annual Report on Form 10-K as well as our operating results, financial condition, announcements of innovations or new products by us or our competitors, general conditions in the biometrics and access control industries, and other events or factors. We cannot assure you that any of the broker-dealers that currently make a market in our common stock will continue to serve as market makers or have the financial capability to stabilize or support our common stock. A reduction in the number of market makers or the financial capability of any of these market makers could also result in a decrease in the trading volume of and price of our shares. In recent years broad stock market indices, in general, and the securities of technology companies, in particular, have experienced substantial price fluctuations. Such broad market fluctuations may adversely affect the future-trading price of our common stock.  

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

Not applicable.

 

ITEM 2. PROPERTY

 

We do not own any real estate. We conduct operations from leased premises in Eagan, Minnesota (5,544 square feet), Bedford, New Hampshire (3,364 square feet), and Wall, New Jersey (4,517 square feet). Internationally, we conduct operations from leased premises in Tsuen Wan, Hong Kong (1,098 square feet), in Jiangmen, China (3,267 square feet) and in Madrid, Spain (459 square feet). Our Eagan, Minnesota and Bedford, New Hampshire offices provide research and development, and customer support, for BIO-key software and PistolStar software, respectively. Our Wall, New Jersey location serves as our corporate headquarters. Our Hong Kong location is a small warehouse for finished goods as well as administrative and sales support. Our Jiangmen, China facility provides our hardware research and development, contract manufacturing and warehousing of raw materials, work-in-process, and finished goods. Our Madrid, Spain office serves as our sales organization for Europe, the Middle East, and parts Africa.

 

ITEM 3. LEGAL PROCEEDINGS

 

From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of the date of this report, we are not a party to any pending lawsuit.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

16
 

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Our common stock currently trades on the Nasdaq Capital Market under the symbol “BKYI”.

 

Holders

 

As of March 29, 2022, the number of stockholders of record of our common stock was 126.

 

Dividends

 

We have not paid any cash dividends on our common stock to-date and have no intention of paying any cash dividends on our common stock in the foreseeable future. The declaration and payment of dividends on our common stock is also subject to the discretion of our Board of Directors and certain limitations imposed under the Delaware General Corporation Law.  The timing, amount, and form of dividends, if any, will depend on, among other things, our results of operations, financial condition, cash requirements and other factors deemed relevant by our Board of Directors.

 

Securities Authorized for Issuance under Equity Compensation Plans

 

For information on securities authorized for issuance under the Company’s equity compensation plans, see “Item 12 - Security Ownership of Certain Beneficial Owners and Related Stockholder Matters.”

 

Unregistered Sales of Equity Securities

 

There were no unregistered sales of the Company’s equity securities during 2021 that were not previously disclosed in a Quarterly Report on Form 10-Q or in a Current Report on Form 8-K.

 

Rule 10b-18 Transactions

 

None.

 

ITEM 6. RESERVED

 

Not Applicable.

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

This Management’s Discussion and Analysis of Financial Condition and Results of Operations, and other parts of this Report contain forward-looking statements that involve risks and uncertainties. All forward-looking statements included in this Report are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth in the section captioned “RISK FACTORS” in Item 1A and elsewhere in this Report.

 

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations is intended to help you understand our Company. This discussion is provided as a supplement to and should be read in conjunction with our consolidated financial statements for the years ended December 31, 2021 and 2020 and the accompanying notes included elsewhere in this Report.

 

Effective November 20, 2020, we implemented a reverse stock split of our outstanding common stock at a ratio of 1-for-8. All share figures are reflected on a post-split basis.

 

Overview

 

We are a leading identity access management (IAM) platform provider for the enterprise and large-scale customer and civil ID solutions.  Built to leverage BIO-key’s world-class biometric core platform among 16 other strong authentication factors, BIO-key PortalGuard and hosted PortalGuard IDaaS are platforms that enable our customers to securely and easily assure that only the right people can access the right systems.  PortalGuard goes beyond traditional multifactor authentication (MFA) solutions by addressing sizeable gaps, such as allowing roving users to biometrically authenticate at any workstation without using their phones or tokens, eliminating unauthorized account delegation, detecting duplicate users, and accommodating in-person identification. 

 

17
 

 

Millions of people use BIO-key every day to securely access a variety of cloud, mobile and web applications, on-premise and cloud-based servers from all of their devices. Employees, contractors, students and faculty sign in through PortalGuard to seamlessly and securely access the applications they need to do their important work, without relying on personal phone use or per-user tokens. Organizations use our platform to securely collaborate with their supply chain and partners, and to provide their customers with flexible, resilient user experiences online or in-person.

 

Large-scale customer and civil ID customers use our scalable biometric management platform and FBI-certified scanner hardware to manage enrollment, de-duplication and authentication for millions of users. One large bank has enrolled and identifies over 19 million of their customers in branches on a daily basis. 

 

We sell our branded biometric and FIDO authentication hardware as accessories to our IAM platforms, so that customers can have a single vendor providing all components of their IAM solution. We do not mandate the use of BIO-key hardware with our software and services. Our NIST-certified fingerprint biometric platform is unique in that it supports interoperable mixing and matching combinations of different manufactures’ fingerprint scanners in a deployment, so that the right scanner can be selected for the right use case, without mandating the user of a particular scanner.

 

Security-conscious software developers leverage our platform APIs and federation interfaces to securely and efficiently embed biometric and MFA identity capabilities into their software.   Our approach to IDaaS allows our customers to efficiently scale their security and identity infrastructures to protect both internal cloud workforce- and external customer-facing applications.

 

We operate a SaaS business model with customers subscribing to term use of our software for annual recurring revenue. We sell our products directly through our field and inside sales teams, as well as indirectly through our network of channel partners including resellers, system integrators, master agents and other distribution partners. Our subscription fees include a term license of hosted or on-premise product and technical support and maintenance of our platform. We base subscription fees primarily on the products used and the number of users enrolled in our platform. We generate subscription fees pursuant to noncancelable contracts with a weighted average duration of approximately one year. 

 

PortalGuard is used by our customers to manage and secure IT access by their employees, contractors and partners, which we call workforce identity. PortalGuard is also used to manage and secure the identities of an organization’s customers through integration of APIs we have developed and industry-standard federation standards, which we call customer identity. We invoice customers in advance in annual and multi-year prepaid installments for subscriptions to our platforms.

 

Strategic Outlook

 

Historically, our largest market has been access control within highly regulated industries such as government, financial services, and healthcare.  In 2019 we became the go-to biometric authentication provider for board of election offices which continue to deploy our hardware and software to secure internal access to the voter registration database. We have and expect to continue  to extend this footprint in 2022 and beyond.

 

In 2020, we announced that we had secured two contracts with our partner Technology Transfer Institute. The contracts are for large-scale identification projects in Africa and Nigeria. Under the first contract, we will provide biometric authentication to support the infrastructure of a new e-commerce project developed with the expectation to generate more than one million jobs in Nigeria. The second contract provides for BIO-key hardware and software to be used by a leading African telecommunications company to secure internal access to customer data. Currently Africa and the surrounding regions are receiving government funding to expand the use of biometric authentication solutions to help establish trustworthy government programs and reduce fraud. We received our first purchase order related to these contracts in the fourth quarter of 2020 which we shipped in the first quarter of 2021. The COVID-19 pandemic has and may continue to delay the rollout of these programs.

 

We plan to have a more significant role in the IAM market which continues to expand. We plan to offer customers a suite of authentication options that complement our biometric solutions. The more well-rounded offerings of authentication options will allow customers to customize their approach to authentication all under one umbrella.

 

We expect to grow our business within government services and highly-regulated industries in which we have historically had a strong presence including financial services, higher education, and healthcare.  We believe that continued heightened security and privacy requirements in these industries, and as colleges and universities continue operating in remote environments, we will generate increased demand for security solutions, including biometrics. In addition, we expect that the compatible, yet superior portable biometric user experience offered by our technology for Windows 10 users will accelerate the demand for our computer network log-on solutions and fingerprint readers.  Through value add-offerings via direct sales, resellers, and strategic partnerships with leading higher education platform providers, we will continue to grow our installed base. 

 

18
 

 

Our primary sales strategies are focused on (i) increased marketing efforts into the IAM market, (ii) dedicated pursuit of large-scale identification projects across the globe and (iii) growing our channel alliance program which we have grown to more than one hundred and fifty participants and continues to generate incremental revenues.

 

A second component of our growth strategy is to pursue strategic acquisitions of select businesses and assets in the IAM space.  In furtherance of this strategy, we are active in the industry and regularly evaluate businesses that we believe will either provide an entry into new market verticals or be synergistic with our existing operations and in either case, be accretive to earnings.  We cannot provide any assurance as to whether we will be able to complete any acquisition and if completed, successfully integrate any business we acquire into our operations. 

 

Recent Developments

 

As discussed under “Item 1A. Risk Factors” given the uncertainty of the duration and severity of the current COVID-19 pandemic and the conflict between Ukraine and Russia and their effects on our business operations, sales cycles, personnel, and the geographic markets in which we operate, and numerous other matters of national, regional and global scale, including those of a political, economic, business and competitive nature, the related financial impact cannot be reasonably estimated at this time.

 

The complications caused by COVID-19 has forced organizations to quickly adapt to a work from home remote business model. This increases the risk of unauthorized users, phishing attacks, and hackers who are eager to take advantage of the challenges of securing remote workers. We believe that biometrics should continue to play a key role in remote user authentication.

 

On March 8, 2022, we expanded our sales and support operation into Europe, Africa and the Middle East (“EMEA”) by acquiring Swivel Secure Europe, SA for up to $2.25 million. Swivel Secure Europe is a Madrid, Spain based provider of IAM solutions serving  over 300 customers through a network of  channel partners throughout EMEA. Swivel Secure the exclusive distributer of AuthControl Sentry, AuthControl Enterprise and AuthControl MSP product line in Europe, Middle East, and Africa, excluding the United Kingdom. Swivel Secure maintains a direct sales force with offices in Madrid, Spain and Lisbon, Portugal. There can be no assurance that we will be able to manage Swivel Secure Europe, SA’s business or successfully integrate the business with our historic operations without substantial costs, delays or other operational or financial problems. 

 

 

RESULTS OF OPERATIONS

 

Consolidated Results of Operations

 

Two Year % trend

 

   

Years ended

December 31,

  
   

2021

    

2020

  

Revenues

                

Services

     25

%

     50

%

License fees

     50

%

     34

%

Hardware

     25

%

     16

%
      100

%

     100

%

Costs and other expenses

                

Cost of services

     13

%

     18

%

Cost of license fees

     4

%

     2

%

Cost of hardware

     16

%

     9

%
      33

%

     29

%

Gross Profit

     67

%

     71

%
                 

Operating expenses

                

Selling, general and administrative

     118

%

     206

%

Research, development and engineering

     46

%

     49

%

Total operating expenses

     164

%

     255

%

Operating loss

     -97

%

     -184

%
                 

Other income (expense)

                

Total other income (expense)

     -2

%

     -158

%

Net loss

     -99

%

     -342

%

 

19
 

 

Revenues and Costs and other expenses

 

                   

2021 - 2020

  
   

2021

    

2020

    

$ Chg

    

% Chg

  
                                 

Revenues

                                

Services

   $ 1,273,354     $ 1,432,228     $ (158,874

)

     -11

%

License fees

     2,555,809       962,038       1,593,771       166

%

Hardware

     1,285,326       442,516       842,810       190

%

Total Revenue

   $ 5,114,489     $ 2,836,782     $ 2,277,707       80

%
                                 

Costs and other expenses

                                

Services

   $ 686,175     $ 502,214     $ 183,961       37

%

License fees

     183,199       49,891       133,308       267

%

Hardware

     803,555       242,721       560,834       231

%

Total Costs and other expenses

   $ 1,672,929     $ 794,826     $ 878,103       117

%

 

 

Revenues

 

Revenue increased $2,277,707 or 80% to $5,114,489 in 2021 as compared to $2,836,782 in 2020 due to the factors stated below. 

 

For the years ended December 31, 2021, and 2020, service revenues included approximately $1,100,000 and $1,383,000, respectively, of recurring maintenance and support revenue, and approximately $173,000 and $49,000, respectively, of non-recurring custom services revenue.  Recurring service revenue decreased 20% from 2020 to 2021  due largely to the decreased maintenance as PistolStar acquired customer maintenance agreements expired by June 30, 2021. Non-recurring custom services increased 252% due to increased new customer installations and conversion to the cloud platform. As our customer base continues to grow, we expect the service revenue to increase in future periods.

 

For the years ended December 31, 2021 and 2020, license revenue increased approximately $1,594,000 or 166% to $2,555,809, due primarily to  new customer orders and cloud conversion customers, in addition to existing recurring revenue contracts.

 

Hardware sales increased by approximately $843,000, or 190%, to $1,285,326 in 2021 from $442,516 in 2020. The increase was attributable largely to sales in Nigeria for an international government agency during the first quarter of 2021.

 

Costs of goods sold

 

For the year ended December 31, 2021, cost of service increased approximately 37% to $686,175, due to the increased revenue and the direct support for the PortalGuard installations.

 

License costs for the year ended December 31, 2021 increased $133,308, or approximately 267%, to $183,199 related to increased license revenue and the resale of associated third party software.

 

Hardware costs for the year ended December 31, 2021 increased $560,834, or approximately 231%, to $803,555. The increase was associated with the increased hardware sales and hardware mix.

 

 

Selling, general and administrative

 

               

2021 - 2020

  

2021

    

2020

    

$ Chg

    

% Chg

 
                             
$ 6,028,360     $ 5,848,687     $ 179,673

 

     3

%

 

Selling, general and administrative costs for year ended December 31, 2021 were $6,028,360 representing 3% increase from 2020. The increase included higher administrative personnel expenses, marketing expenses, Delaware franchise taxes, and bad debt expense related to the reserve on the note receivable of $100,000 and an allowance for doubtful accounts of $200,000. These were  offset by lower factoring fees, contract and temporary labor, non-cash compensation, the absence of one-time expenses incurred in 2020 for integration costs incurred in connection the acquisition of Pistol Star, as well as accounting and legal fees. 

 

20
 

 

Research, development and engineering

 

 

               

2021 - 2020

  

2021

    

2020

    

$ Chg

    

% Chg

 
                             
$ 2,355,056     $ 1,396,436     $ 958,620       69

%

 

For the year ended December 31, 2021, research, development and engineering costs were $2,355,056 representing a 69% increase over 2020. Included in the increase were personnel costs associated with PistolStar, new hires and recruiting fees, increased professional fees, and increased amortization of intangible assets acquired from PistolStar. These amounts were offset by a decrease and non-cash compensation.

 

Other income (expense)

 

                    2021 - 2020  
    2021     2020     $ Chg     % Chg  
                                 

Interest income

     4,075       30,649       (26,574 )     -87 %

Foreign currency loss

     (50,000 )     -       50,000       N/A  

Investment-debt security reserve

     (60,000 )     -       60,000       N/A  

Government grant – Paycheck Protection Program

     -       340,819       (340,819 )     -100 %

Interest expense

     (18,000 )     (4,343,212 )     4,325,212       -100 %

Loss of extinguishment of debt

     -       (499,076 )     499,076       -100 %
    $ (123,925 )   $ (4,470,820 )   $ 4,346,895       -97 %

 

Other expense for 2021 consisted of interest expense from the amortization of debt discounts of $18,000, a reserve on the investment-debt security as adjustment for collections of such security of $60,000, and a foreign currency adjustment to an accounts receivable invoice of $50,000, offset by interest income of $4,075. Interest expense for 2020 related to the amortization of debt discounts and debt issuance costs relating to convertible notes of approximately $3,574,000, as well as the amortization of a beneficial conversion feature of approximately $641,000. Also included in other income (expense) for 2020 was a loss on the extinguishment of a convertible note in the approximate amount of $500,000 resulting from the issuance of an amended and restated convertible note, for which the issuer did not grant a concession. These amounts were partially offset by amounts received under the Payment Protection Program (the “Program”) the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) administered by the U.S. Small Business Administration of approximately $341,000 and interest income of approximately $31,000.

 

LIQUIDITY AND CAPITAL RESOURCES

 

Operating activities overview

 

Net cash used for operations during the year ended December 31, 2021 was approximately $8,942,000. Items of note included:

 

 

●

Net positive cash flows related to non-cash expenses of approximately $1,367,000.
 

●

Net negative cash flows related to changes in accounts receivable, prepayments, inventory, accruals, lease liabilities, and deferred revenue in the aggregate amount of approximately $5,601,000 and our net loss for the period.

 

Investing activities overview

 

Approximately $42,000 was used for investing in capital expenditures during the year ended December 31, 2021.

 

Financing activities overview

 

Approximately $219,000 was used in financing activities during the year ended December 31, 2021 consisting of repayment of notes payable, and costs associated with the issuance of our securities, net of proceeds from common stock sold to employees under the Company's employee stock purchase plan.

 

21
 

 

Sources of Liquidity

 

Since our inception, our capital needs have been principally met through proceeds from the sale of equity and debt securities. We expect capital expenditures to be less than $100,000 during the next twelve months.

 

The following sets forth our primary sources of capital during the previous two years:

 

We entered into an accounts receivable factoring arrangement with a financial institution (the “Factor”) which has been extended to October 31, 2022 and may be discontinued at that time. Pursuant to the terms of the arrangement, from time to time, we sell to the Factor a minimum of $150,000 per quarter of certain of our accounts receivable balances on a non-recourse basis for credit approved accounts. The Factor remits 35% of the foreign and 75% of the domestic accounts receivable balance to us (the “Advance Amount”), with the remaining balance, less fees, forwarded to us once the Factor collects the full accounts receivable balance from the customer. In addition, from time to time, we receive over advances from the Factor. Factoring fees range from 2.75% to 15% of the face value of the invoice factored and are determined by the number of days required for collection of the invoice. We expect to continue to use this factoring arrangement periodically to assist with our general working capital requirements due to contractual requirements.   

 

On April 20, 2020, we entered into a Paycheck Protection Program Term Note (the “SVB Note”) with Silicon Valley Bank (“SVB”) pursuant to the Program. We received total proceeds of approximately $341,000 which was used in accordance with the requirements of the CARES Act. The full amount of the SVB Note was forgiven.

 

On July 23, 2020, we completed an underwritten public offering of shares of common stock and warrants resulting in net proceeds of approximately $22.7 million, inclusive of the over-allotment and after deducting underwriting discounts and commissions and estimated offering expenses. We used approximately $4.2 million of the net proceeds to repay all outstanding amounts due under outstanding convertible promissory notes at that time.

 

Liquidity Outlook

 

At December 31, 2021, our total cash and cash equivalents were approximately $7,800,000, as compared to $16,993,096 at December 31, 2020.  At December 31, 2021, we had working capital of approximately $12,013,000. 

 

As discussed above, we have historically financed our operations through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. We currently require approximately $735,000 per month to conduct our operations, a monthly amount that we have been unable to consistently achieve through revenue generation.  During 2021, we generated approximately $5,114,000 of revenue, which is below our average monthly requirements. We expect that Swivel Secure Europe will generate positive cash flow in 2022. If we are unable to generate sufficient revenue to fund current operations and execute our business plan, we may need to obtain additional third-party financing. As of the date of this report, we do not expect that we will need to obtain additional financing during the next twelve months.

 

22
 

 

Our long-term viability and growth will depend upon the successful commercialization of our technologies and our ability to obtain adequate financing. To the extent that we require such additional financing, no assurance can be given that any form of additional financing will be available on terms acceptable to us, that adequate financing will be obtained to meet our needs, or that such financing would not be dilutive to existing stockholders. If available financing is insufficient or unavailable or we fail to continue to generate sufficient revenue, we may be required to further reduce operating expenses, delay the expansion of operations, be unable to pursue merger or acquisition candidates, or in the extreme case, not continue as a going concern.

 

OFF-BALANCE SHEET ARRANGEMENTS

 

We do not have any off-balance sheet arrangements that have or, are in the opinion of management reasonably likely to have, a current or future effect on our financial condition or results of operations.

 

CRITICAL ACCOUNTING POLICIES

 

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ significantly from these estimates under different assumptions or conditions. There have been no material changes to these estimates for the periods presented in this Annual Report on Form 10-K.

 

We believe that of our significant accounting policies, which are described in Note A of the notes to our consolidated financial statements included in this Annual Report on Form 10-K, the following accounting policies involve a greater degree of judgment and complexity. Accordingly, these are the policies we believe are the most critical to aid in fully understanding and evaluating our financial condition and results of operations, as listed below:

 

1. Revenue Recognition

 

2. Business Combinations 

 

3. Goodwill and acquired intangible assets

 

4. Impairment or Disposal of Long Lived Assets, including Intangible Assets

 

5. Research and Development Expenditures

 

6. Income Taxes

 

7. Accounting for Stock-Based Compensation

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Not Applicable.

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

See financial statements appearing at pages 37-64 of this Annual Report on Form 10-K.

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None.

 

23
 

 

ITEM 9A. CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2021. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and procedures as of December 31, 2021, our CEO and CFO concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

 

Management’s Annual Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, the risk. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Under the supervision and with the participation of our management, including our CEO and CFO, we have conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2021, based upon the framework in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management has concluded that our internal control over financial reporting was effective as of December 31, 2021.

 

As we are a smaller reporting company, this annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to rules of the Securities and Exchange Commission that permit the Company to provide only management’s report in this Annual Report on Form 10-K.

 

Changes in Internal Control Over Financial Reporting

 

No change in our internal control over financial reporting occurred during the quarter ended December 31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

ITEM 9B. OTHER INFORMATION

 

None.

 

24
 

 

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 

Not Applicable.

 

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

The following sets forth certain information about each director and executive officer of the Company.

 

NAME

  

AGE

  

POSITIONS HELD

Michael W. DePasquale

    

67

  

Chairman of the Board of Directors and Chief Executive Officer

Thomas E. Bush, III (a)* (c)

    

69

  

Director

Robert J. Michel (a) (b)*

    

65

  

Director

Thomas Gilley (c)*

    

62

  

Director

Wong Kwok Fong (Kelvin)

    

58

  

Director and Vice-Chairman of the Board of Directors

Pieter Knook (b)

    

61

  

Director

Emmanual Alia (Manny) (b)

    

54

  

Director

Cecilia C. Welch

    

62

  

Chief Financial Officer

Mira K. LaCous

    

59

  

Chief Technology Officer

James D. Sullivan

    

54

  

Vice President of Strategy and Compliance, Chief Legal Officer

 

 

(a)

Compensation Committee Member

 

 

(b)

Audit Committee Member

 

 

(c)

Nominating Committee Member

 

 

*

Indicates chair of committee

 

Set forth below is a brief description of the background and business experience of our directors and executive officers for the past five years. 

 

25
 

 

Directors

 

Michael W. DePasquale has served as our Chief Executive Officer and a Director since January 3, 2003, and Chairman of the Board since January 29, 2014. He served as Co-Chief Executive Officer of the Company from July 2005 to August 2006. Mr. DePasquale brings more than 30 years of executive management, sales and marketing experience to the Company. Prior to joining us, Mr. DePasquale served as the President and Chief Executive Officer of Prism eSolutions, Inc., a Pennsylvania-based provider of professional consulting services and online solutions for ISO-9001/14000 certification for customers in manufacturing, healthcare and government markets, since February 2001. From December 1999 through December 2000, Mr. DePasquale served as Group Vice President for WRC Media, a New York-based distributor of supplemental education products and software. From January 1996 until December 1999, Mr. DePasquale served as Senior Vice President of Jostens Learning Corp., a California-based provider of multimedia curriculum. Prior to Jostens, Mr. DePasquale held sales and marketing management positions with McGraw-Hill and Digital Equipment Corporation. Mr. DePasquale earned a Bachelor of Science degree from the New Jersey Institute of Technology. He serves as the Vice Chairman on the Board of Directors of the International Biometrics and Identification Industry Association. We believe Mr. DePasquale’s qualifications to sit on the board of directors include his extensive executive management experience in the technology sector and biometric industry expertise which strengthen the board’s collective qualifications, skills and experience.   

 

Thomas E. Bush, III has served as a Director of the Company since January 29, 2014. Since 2009, Mr. Bush has provided business consulting services through his firm, Tom Bush Consulting. Prior to that, Mr. Bush served with the Federal Bureau of Investigation for over 33 years. Mr. Bush joined the FBI in September 1975, ultimately becoming the Director of the CJIS division, with over 2,500 employees and a budget of approximately one billion dollars. Mr. Bush is known for providing critical services in support of the criminal justice community, including two significant IT projects, Next Generation Identification and N-Dex, which were awarded by CJIS during his tenure at the FBI. Mr. Bush has received many awards during his career, most notably a Presidential Rank Award for Meritorious Service in 2007. We believe Mr. Bush’s qualifications to sit on the board of directors include his extensive experience in law enforcement, security matters, and the use of biometric technologies in the government sector, which provide the board with a unique perspective on security and public sector matters. 

 

Robert J. Michel has served as a Director of the Company since April 10, 2017. He has over 30 years of accounting and financial management experience. Since September, 2018, he has served as the Chief Financial Officer of Daxor Corporation (Nasdaq: DXR), a medical device manufacturing company specializing in blood volume analysis. Prior to Daxor, from November, 2017 until September 2018, Mr. Michel served as the CFO of Roadway Moving, Inc., a transportation, moving and storage company located in New York City. Immediately prior to Roadway Moving, Inc., Mr. Michel served as a consultant with Feuer & Orlando, LLP, a New York City based CPA firm, from May, 2016 until November 2017. From 2009 until March, 2016, Mr. Michel was the Chief Financial Officer of Asta Funding, Inc. (Nasdaq: ASFI), a diversified financial services company where he was responsible for all financial matters and SEC reporting. From 2004 until 2009, Mr. Michel served as the Controller and the Director of Financial Reporting and Compliance for Asta Funding. Mr. Michel is a certified public accountant, earned a MBA in Taxation from St. John’s University, and a BS in Business Administration from Villanova University. Mr. Michel gained his public accounting experience at PricewaterhouseCoopers in New York.  We believe Mr. Michel’s qualifications to sit on the board of directors include his substantial experience in accounting and financial management for public companies which provide the board with a deep knowledge of financial and SEC reporting and strengthen the board’s collective qualifications, skills, and experience.

 

Thomas Gilley has served as a Director of the Company since January 29, 2014. Mr. Gilley is an entrepreneur, investor and advisor in the connected product Internet of Things (IoT) industry with 37 patents. Since founding his Enterprise Software IoT company in 2012 and selling it in 2016, Mr. Gilley invests in technology companies, serves as growth strategy advisor, and independent board member to companies in the connected industry. Mr. Gilley was previously employed at Apple Computer, in the Advance Technology Group, Portable Products Group and Strategy Advisor. Before and after Apple, Mr. Gilley founded several successful companies including PicoStar, a Silicon Valley incubator-technology investment company, and an on-demand web media company he sold to Vignette. Mr. Gilley acted as CTO throughout the transaction until the company’s ultimate acquisition by OpenText. We believe Mr. Gilley’s qualifications to sit on the board of directors include his substantial experience in starting, operating and financing technology companies which provides the board with a deep knowledge of the sales and development cycles applicable to growth businesses in the technology industry.

 

Wong Kwok Fong (Kelvin) has served as a Director of the Company since December 4, 2015, as Managing Director of our Hong Kong Subsidiary since August 2016, and as Vice-Chairman of the Board of Directors since March 2019. He is the co-founder of China Goldjoy Group (previously World Wide Touch Technology Holdings Limited), a company listed on The Stock Exchange of Hong Kong. From 1997 until August, 2015, Mr. Wong served as the Chairman of China Goldjoy Group and served as its Chief Technology Officer through October 2016. During this time, Kelvin played a significant role in the substantial growth of the business. Kelvin brings over 20 years of senior management experience in manufacturing, supply chain, and marketing functions in the electronics and technology industries, including establishing manufacturing plants in Hong Kong and China, and building an extensive network in the electronics and technology industries. We believe Kelvin’s qualifications to sit on the board of directors include his substantial experience in the technology industry, including biometrics and payment systems, and serving the Asian markets, which broaden and strengthen the board’s collective qualifications, skills, and experience.

 

26
 

 

Pieter Knook, has served as a Director of the Company since May 2, 2016. Mr. Knook has over 30 years of experience in mobility and software technology in Europe, Asia and the United States. Since 2010, Mr. Knook has served on the boards of a number of private equity backed and publicly traded early stage technology companies, including Altitude Angel in Reading, the London Internet Exchange, BroadHorizon in the Netherlands and Telenor in Norway. Mr. Knook served as the Director of Internet Services at Vodafone Group in London from March 2008 through October 2010. Prior to joining Vodafone, Mr. Knook spent 18 years at Microsoft. As President of Microsoft Asia from 1997 to 2001, Mr. Knook led the company’s efforts in opening and expanding Asian markets. He subsequently served as Senior Vice President of Microsoft’s mobile communication business from 2001 through 2008. We believe Mr. Knook’s qualifications to sit on the board of directors include his extensive technology industry experience, which further broaden and strengthen the board’s collective qualifications, skills, and experience.

 

Emmanual Alia (Manny), was appointed Director of the Company on April 3, 2020. Since 2018 Mr. Alia has been providing management consulting services as an advisor to businesses seeking market entry strategies to emerging markets such as Africa and the Caribbean. From 2011 to 2018, Mr. Alia served as an Executive Director at the Corporate and Investment division of JPMorgan, and as a Senior Vice-President at CHASE Bank’s Consumer and Community Banking specializing in the financial and banking services industry and opportunities in Africa. During Mr. Alia’s tenure with JPMorgan, he served as head of WholeSale Operations in the Receivables Operations of the Global banking operations in the US and Canada, head of Retail Banking in the Greater Detroit area, and head of branches in the New York and New Jersey areas. For two years Mr. Alia was co-chair of the Black Organizational Leadership Development, an employee networking group in JPMorgan that works with firm’s leadership to strengthen the firm’s message, strategies and community outreach globally. Mr. Alia received a Bachelor of Arts in Accounting from SouthEastern University and a Master’s of Business Administration (MBA) from Cornell University. We believe Mr. Alia’s qualifications to sit on the board of directors include his extensive industry experience and connection and networking abilities in the African communities and markets which further broaden and strengthen the board’s collective qualifications, skills, and experience.

 

Non-director Executive Officers

 

Cecilia C. Welch has served as the Chief Financial Officer of the Company since December 21, 2009. Ms. Welch joined the Company in 2007 as Corporate Controller. Prior to joining the Company, from January 2006 to December 2006, she was the Controller for Savaje Technologies (acquired by Sun Microsystems), a developer of advanced mobile telephone software. From October 2004 to January 2006, she was Controller for Crystal Systems, a manufacturer of sapphire crystals used for industrial, semiconductor, defense, and medical applications. From December 1988 to July 2004, she was the Controller for ATN Microwave (acquired by Agilent Technologies), a manufacturer of automated test equipment. Ms. Welch has a Bachelor’s degree in Accounting from Franklin Pierce University.

 

Mira K. LaCous has served as Chief Technology Officer of the Company since March 13, 2014. Prior to her appointment as Chief Technology Officer, she served as Senior Vice President of Technology & Development since 2012, and as our Vice President of Technology and Development since 2000. Ms. LaCous has over 35 years of product/project management, solution architecture, software development, team leadership and customer relations experience, with a background that includes successfully bringing numerous innovative products and technologies to market, including automated voice response systems, automated building control systems, software piracy protection, internet training materials and testing, page layout and design software, image scanning software and systems, biometric security systems, automated national ID systems using biometrics, and biometric algorithms.  Ms. LaCous has been a speaker at multiple events/conferences and has worked with teams around the globe bringing biometric technology deployments to life.  Ms. LaCous is the author of eight (8) US patented technologies, multiple international patents and lead the engineering team in developing other patents and inventive technologies.  Ms. LaCous has a Bachelor’s in Computer Science, with mathematics and physics from North Dakota State University.

 

James D. Sullivan has served as BIO-key’s Senior Vice President of Strategy and Compliance and BIO-key’s Chief Legal Officer since February 2020, as Senior Vice President of Strategy and Business Development from April 2012 through December 2018, and the dual role as Senior Vice President of Global Sales from August 2015 through December of 2016. Mr. Sullivan is a recognized expert in biometric authentication, cyberlaw and privacy for consumer and mobile applications. During over 18 years with the Company, Mr. Sullivan has directly worked with dozens of the Company’s customers, including AT&T, Israel Defense Forces, LexisNexis, NCR and Omnicell, as well as large-scale biometric-centered identity management projects that interface daily with millions of corporate and consumer users. Mr. Sullivan earned a Juris Doctor cum laude from Georgia State University College of Law, is a member of the Georgia Bar, and enrolled to practice before the IRS. Mr. Sullivan has an undergraduate degree in Computer Science from Brown University and has over 25 years of experience in IT projects and implementation, including directly working with security and identity management solutions at the Company, Computer Associates, Platinum Technology, and Memco Software.

 

27
 

 

Committees of the Board of Directors

 

Audit Committee

 

Our audit committee is comprised of Robert J. Michel (Chair), Pieter Knook, and Emmanual Alia, all of whom meet the independence standards for purposes of serving on an audit committee established by NASDAQ and under the Exchange Act. Our audit committee (i) assists the board of directors in its oversight of the integrity of our financial statements, compliance with legal and regulatory requirements, and corporate policies and controls, (ii) has the sole authority to retain and terminate our independent registered public accounting firm, approve all auditing services and related fees and the terms thereof, and pre-approve any non-audit services to be rendered by our independent registered public accounting firm, and (iii) is responsible for confirming the independence and objectivity of our independent registered public accounting firm. Our independent registered public accounting firm has unrestricted access to our audit committee. Our board of directors has determined that Robert J. Michel qualifies as an “audit committee financial expert,” as such term is defined in Item 407 of Regulation S-K.

 

Our audit committee operates under a written charter that is reviewed annually. The charter is available on our website at www.bio-key.com.

 

Compensation Committee

 

Our compensation committee is comprised of Thomas Bush, III (Chair) and Robert Michel, both of whom meet the independence standards established by NASDAQ and under the Exchange Act. The compensation committee’s duties include overseeing our overall compensation philosophy, policies and programs. This includes reviewing and analyzing the design and function of our various compensation components, establishing salaries, incentives and other forms of compensation for officers and non-employee directors, and administering our equity incentive plan. In fulfilling its responsibilities, the compensation committee has the authority to delegate any or all of its responsibilities to a subcommittee of the compensation committee.

 

Our compensation committee operates under a written charter that is reviewed annually. The charter is available on our website at www.bio-key.com.

 

Code of Ethics

 

We have adopted a Code of Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions. Our Code of Ethics is designed to deter wrongdoing and promote: (i) honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; (ii) full, fair, accurate, timely and understandable disclosure in reports and documents that we file with, or submit to, the SEC and in our other public communications; (iii) compliance with applicable governmental laws, rules, and regulations; (iv) the prompt internal reporting of violations of the code to an appropriate person or persons identified in the code; and (v) accountability for adherence to the code.  We intend to disclose amendments or waivers of the Code of Ethics on our website within four business days.  Any person may obtain a copy of our Code of Ethics free of charge by sending a written request for such to the attention of the Chief Financial Officer of the Company, 3349 Highway 138, Building A Suite E, Wall, NJ 07719.  

 

Term of Office

 

Our directors are elected at the annual meeting of stockholders and hold office until the annual meeting of the stockholders next succeeding his or her election, or until his or her prior death, resignation or removal in accordance with our bylaws. Our officers are appointed by the Board and hold office until the annual meeting of the Board next succeeding his or her election, and until his or her successor shall have been duly elected and qualified, subject to earlier termination by his or her death, resignation or removal.

 

Delinquent Section 16(a) Reports

 

Reports of all transactions in our common stock by officers, directors and ten percent (10%) stockholders are required to be filed with the SEC pursuant to Section 16(a) of the Exchange Act. Based solely on our review of copies of the reports received, or representations of such reporting persons, we believe that during the year ended December 31, 2021, all Section 16(a) filing requirements applicable to our officers, directors and ten percent (10%) stockholders were satisfied in a timely fashion, except for one late Form 4 filing by Mr. Sullivan reporting an open market purchase.

 

28
 

 

ITEM 11. EXECUTIVE COMPENSATION

 

The following table sets forth a summary of the compensation paid to or accrued by our chief executive officer and the two most highly compensated executive officers other than our chief executive officer, for the fiscal years ended December 31, 2021 and 2020:

 

SUMMARY COMPENSATION TABLE

Name and Principal

Position

Fiscal

Year

  

Salary

($)

    

Bonus

($)

   

Stock

Awards

($) (1)

   

All Other

Compensation

($) (2)

    

Total

($)

  
                                           

Michael W. DePasquale

2021

     275,000       -       -       1,944       276,944  

Chief Executive Officer

2020

     275,000       50,000       21,450       2,219       348,669  
                                           

Mira K. LaCous

2021

     216,333       -       -       3,092       219,425  

Chief Technology Officer

2020

     213,000       -       21,450       2,493       236,943  
                                           

James Sullivan

2021

     225,000       -       -       10,241  (3)     235,241  

Chief Legal Officer

2020

     150,000       35,000       21,450       137,238  (4)     343,688  

 

(1)

The aggregate grant date fair value of the restricted shares is calculated by the multiplying the quantity of shares issued by the closing trading price of the shares on the date of issuance calculated under FASB ASC 718.

(2)

Consists of life insurance premiums paid by the Company except as otherwise noted.

(3)

(4)

Consists of $8,987 of sales commissions and $1,254 of life insurance premiums paid by the Company.

Consists of $135,383 of sales commissions and $1,855 of life insurance premiums paid by the Company.

 

Narrative Disclosure to Summary Compensation Table

 

Compensation for our executives is comprised of three main components: base salary, annual performance-based cash bonus, and long-term equity awards. We do not target a specific weighting of these three components or use a prescribed formula to establish pay levels. Rather, the board of directors and compensation committee considers changes in the business, external market factors and our financial position each year when determining pay levels and allocating between long-term and current compensation for the named executive officers.

 

Cash compensation is comprised of base salary and an annual performance-based cash bonus opportunity. The compensation committee generally seeks to set a named executive officer’s targeted total cash compensation opportunity within a range that is the average of the applicable peer company and/or general industry compensation survey data, adjusted as appropriate for individual performance and internal pay equity and labor market conditions.

 

In setting cash compensation levels, we favor a balance in which base salaries are generally targeted at slightly below the peer average and a bonus opportunity that is targeted at slightly above the average. The base salary of our CEO has not been increased since 2018. Effective January 1, 2021, we increased the base salary of Mr. Sullivan to $225,000 to compensate for the fact that in connection with his promotion to Chief Legal Officer, he would be limited to sales commissions on only three of his existing long term accounts.  

 

Performance-based bonuses have historically been based upon the achievement of certain revenue milestones established by the compensation committee. The committee believes that this higher emphasis on performance-based cash bonuses places an appropriate linkage between a named executive officer’s pay, his or her individual performance, and the achievement of specific business goals by placing a higher proportion of annual cash compensation at risk, thereby aligning executive opportunity with the interests of stockholders.

 

In 2020, due to extraordinary efforts in maintaining operations during the pandemic, acquiring PistolStar, and the completing an underwritten public offering, Mr. DePasquale and Mr. Sullivan were awarded cash bonuses of $50,000 and $35,000, respectively.

 

We also include an equity component as part of our compensation package because we believe that equity-based compensation aligns the long-term interests of our named executive officers with those of stockholders. In August 2020, we issued 4,125 shares of restricted stock to Mr. DePasquale, Mr. Sullivan, and Ms. LaCous. These shares vest in equal annual installments over a three-year period from the date of grant. We did not issue any stock options or restricted shares to our named executive officers in 2021.

 

These cash and equity compensation components of pay are supplemented by various benefit plans that provide health, life, accident, disability and severance benefits, most of which are the same as the benefits provided to all of our US based employees.

 

Employment Agreements

 

On March 26, 2010, we entered into an employment agreement, effective as of March 25, 2010, with Michael W. DePasquale to serve as our Chief Executive Officer until March 24, 2011. The agreement automatically renews for subsequent one-year terms, unless the employment relationship is terminated by either party, or modified in accordance with the terms and conditions of the agreement. Since 2018, Mr. DePasquale’s annual base salary has been $275,000, subject to adjustment by the compensation committee. In addition to the base salary, a “Performance Bonus” may be awarded to Mr. DePasquale on the basis of the Company achieving certain corporate and strategic performance goals, as determined by the compensation committee in its sole discretion. The employment agreement contains standard and customary confidentiality, non-solicitation and “work made for hire” provisions as well as a covenant not to compete which prohibits Mr. DePasquale from doing business with any current or prospective customer of the Company or engaging in a business competitive with that of the Company during the term of his employment and for the one-year period thereafter. This agreement also contains a number of termination and change in control provisions as described under the captions “Termination Arrangements” and “Change in Control Arrangements” below.

 

29
 

 

On April 5, 2017, we entered into an employment agreement with James Sullivan. The agreement automatically renews for subsequent one-year terms, unless terminated by the Company upon at least two months prior written notice which is treated as termination without cause. Since 2021, Mr. Sullivan’s annual base salary has been $225,000, subject to adjustment by the compensation committee. The agreement contains standard and customary confidentiality, technical invention provisions as well as non-competition and non-solicitation covenants which prohibit Mr. Sullivan from doing business with any current or prospective customer of the Company or engaging in any business competitive with that of the Company during the term or his employment and for the one-year period thereafter. The agreement also contains a number of termination provisions as described under the caption “Termination Agreements” below.

 

On November 20, 2001, we entered into an employment agreement with Mira LaCous. The agreement automatically renews for subsequent one-year terms, unless terminated by the Company upon at least one-month prior written notice which is treated as termination without cause and provides for a discretionary bonus which shall not exceed 50% of base salary. The agreement contains standard and customary confidentiality, technical invention provisions as well as non-competition and non-solicitation covenants which prohibit Ms. LaCous from doing business with any current or prospective customer of the Company or engaging in any business competitive with that of the Company during the term or her employment and for the one-year period thereafter. The agreement also contains a number of termination provisions as described under the caption “Termination Agreements” below.

 

Stock Option Grants and Restricted Stock Awards

 

In the event of any change in the outstanding shares of our common stock by reason of a stock dividend, stock split, combination of shares, recapitalization, merger, consolidation, transfer of assets, reorganization, conversion or what the board deems to be similar circumstances, the number and kind of shares subject to outstanding options and restricted stock awards, and the exercise price of such options shall be appropriately adjusted. Restricted Furthermore, option agreements and restricted stock award agreements contain change of control provisions as described under the caption “Change in Control Provisions” below. 

 

30
 

 

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR END

 

DECEMBER 31, 2021

 

The following table sets forth for each named executive officer, information regarding outstanding equity awards as at December 31, 2021. The option awards and per share amounts for all periods reflect our 1-for-8 reverse stock split, which was effective November 20, 2020.

 

   

Option Awards

  

Stock Awards

  

Name

  

Number of

securities

underlying

unexercised

options

exercisable

(#)

    

Number of

securities

underlying

unexercised

options

unexercisable

(#)

    

Option

exercise

price

($)

  

Option

expiration

date

  

Number of

shares or

units

of stock that

have not

vested

(#)

    

Market value

of

shares of

units of

stock that

have not

vested

($)(1)

  
                                           

Michael W. DePasquale

     2,605               17.27  

8/13/2022

     2,750       6,078  
      31,250               21.20  

3/16/2024

                
      4,167               15.68  

3/23/2025

                
      2,778       1,389 (2)     9.44  

3/21/2026

                
                                           

Mira LaCous

     1,042               17.27  

8/13/2022

     2,750       6,078  
      12,500               21.20  

3/16/2024

                
      1,563               15.68  

3/23/2025

                
      1,042       521 (2)     9.44  

3/21/2026

                
                                           

James Sullivan

     2,084               17.27  

8/13/2022

     2,750       6,078  
      12,500               21.20  

3/16/2024

                
      3,125               15.68  

3/23/2025

                
      2,084       1,041 (2)     9.44  

3/21/2026

                

 

 

(1)

Calculated based on the closing market price of the Company’s common stock on December 31, 2021 of $2.21 per share.
 

(2)

The options vest equally in three annual installments commencing March 21, 2020.

 

Narrative Disclosure to Outstanding Equity Awards at Fiscal Year End Table

 

The following are the material terms of each agreement, contract, plan or arrangement that provide for payments to one or more of our named executive officers at, following or pursuant to their resignation, retirement or termination, or in connection with a change in control of the Company.

 

Termination Arrangements

 

We may terminate our employment agreement with Mr. DePasquale at any time with or without cause. In the event of termination by us without cause, we will continue to pay Mr. DePasquale his then current base salary for the greater of nine months from the date of such termination or the number of months remaining until the end of the term of the agreement.

 

We may terminate our employment agreement with Mr. Sullivan at any time with or without cause. In the event of termination by us without cause, we will continue to pay Mr. Sullivan his then current base salary, plus earned commissions, for the greater of six months from the date of such termination or the number of months remaining until the end of the term of the agreement.

 

We may terminate our employment agreement with Ms. LaCous at any time with or without cause. In the event of termination by us without cause, we will continue to pay Ms. LaCous her then current base salary for nine months from the date of such termination.

 

31
 

 

Change in Control Provisions

 

Our 2015 Equity Incentive Plan (the “Plan”) provides for the acceleration of vesting of unvested options and termination of any restriction or forfeiture provisions applicable to restricted stock awards upon a “Change in Control” of the Company. A Change in Control is defined in the Plans to include (i) a sale or transfer of substantially all of the Company’s assets; (ii) the dissolution or liquidation of the Company; (iii) a merger or consolidation to which the Company is a party and after which the prior stockholders of the Company hold less than 50% of the combined voting power of the surviving corporation’s outstanding securities; (iv) the incumbent directors cease to constitute at least a majority of the Board of Directors; or (v) a change in control of the Company which would otherwise be reportable under Section 13 or 15(d) of the Exchange Act. In the event of a “Change In Control” the Plan provides for the immediate vesting of all options issued thereunder and termination of all forfeiture provisions applicable to restricted stock award issued thereunder. Options issued to executive officers outside of the Plans contain change in control provisions substantially similar to those contained in the Plans.

 

Our employment agreement with Mr. DePasquale contains a change in control provision that is triggered if Mr. DePasquale is not offered continued employment with us or any successor, or within five years following such Change of Control, we or any successor terminate Mr. DePasquale’s employment without cause. If this occurs, then we will pay Mr. DePasquale his base salary and benefits earned but unpaid through the date of termination, and any prorated bonus earned during the then current bonus year, plus two times his then current base salary.

 

 

DIRECTOR COMPENSATION FOR THE FISCAL YEAR ENDED

DECEMBER 31, 2021

 

The following table sets forth for each director, information regarding their compensation for the year ended December 31, 2021:

 

Name (1)

  

Stock Awards

($) (2)

    

Total

($)

  

Thomas E. Bush, III (3)

     4,505       4,505  

Thomas Gilley (3)

     3,505       3,505  

Pieter Knook (4)

     6,009       6,009  

Robert J Michel (4)

     6,009       6,009  

Emmanual Alia (5)

     5,508       5,508  

 

 

(1)

Mr. DePasquale and Kelvin Wong have been omitted from the above table because they do not receive any additional compensation for serving on our Board of Directors.
 

(2)

The aggregate fair value of the common stock issued was calculated based on the closing price of our common stock on the date of issuance in accordance with FASB ASC 718.
 

(3)

At December 31, 2021, Messrs. Bush and Gilley each held options to purchase 2,325 shares of common stock.
 

(4)

At December 31, 2021, Messrs. Knook and Michel each held options to purchase 2,064 shares of common stock.
 

(5)

At December 31, 2021, Mr. Alia held options to purchase 313 shares of common stock.

 

Narrative Disclosure to Director Compensation Table

 

During 2021, we had a policy to pay to each non-employee director $3,000 per board meeting, $1,000 per telephonic board meeting, and $500 per board committee meeting attended. Fees for attendance at regular quarterly board meetings held during the first three quarters of each fiscal year are paid through the issuance of common stock and payments for the last meeting of the year are paid in cash or, at the option of the director, in shares of common stock. All of our directors elected to receive payment in common stock for the last board meeting in 2021. We recently revised our policy regarding non-employee director fees to provide for payment of $3,000 per board meeting and $1,000 per board committee meeting attended payable in the manner described above. All directors will be indemnified by us for actions associated with being a director to the fullest extent permitted under Delaware law. We reimburse each of our non-employee directors for their reasonable expenses incurred in connection with attending meetings of the board of directors and related committees. 

 

ITEM 12.   SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

The following table sets forth, as of March 29, 2022, information with respect to the securities holdings of all persons that we, pursuant to filings with the SEC and our stock transfer records, have reason to believe may be deemed the beneficial owner of more than 5% of our common stock. The following table also sets forth, as of such date, the beneficial ownership of our common stock by all of our current officers and directors, both individually and as a group.

 

32
 

 

The beneficial owners and amount of securities beneficially owned have been determined in accordance with Rule 13d-3 under the Exchange Act and, in accordance therewith, include all shares of our common stock that may be acquired by such beneficial owners within 60 days of March 29, 2022 upon the exercise or conversion of any options, warrants or other convertible securities. This table has been prepared based on 8,405,209 shares of common stock outstanding on March 28, 2022.

 

Name and Address of Beneficial Owner (1)

  

Amount and Nature

of Beneficial

Ownership

    

Percentage

of

Class

  
                 

Michael W. DePasquale

     103,258 (2)      1.2

%

Cecilia Welch

     56,626 (3)     *  

Mira LaCous

     30,272 (4)     *  

James Sullivan

     79,293 (5)     *  

Thomas Gilley

     13,283 (6)     *  

Robert J. Michel

     14,110 (7)     *  

Thomas E. Bush, III

     13,591 (8)     *  

Pieter Knook

     13,122 (9)     *  

Emmanual Alia

     8,793 (10)     *  

Wong Kwok Fong (Kelvin)

     583,659 (11)     6.9

%

All officers and directors as a group ten (10) persons

     916,007       10.9

%
                 

Lind Global Micro Fund, LP

     833,125 (12)     9.9

%

 

*

Less than 1%
 

(1)

Unless otherwise indicated, the address of each person listed below is c/o BIO-key International, Inc., 3349 Highway 138, Building A, Suite E, Wall, NJ 07719.
 

(2)

Includes 40,800 shares issuable on exercise of options and 39,125 shares of restricted stock of which 37,750 remain subject to vesting. Does not include 1,389 shares issuable upon exercise of options subject to vesting.
 

(3)

Includes 22,501 of shares issuable upon exercise of options and 34,125 shares of restricted stock of which 32,750 remain subject to vesting. Does not include 1,041 shares issuable upon exercise of options subject to vesting.
 

(4)

Includes 16,147 of shares issuable upon exercise of options and 11,625 shares of restricted stock of which 10,250 remain subject to vesting. Does not include 521 shares issuable upon exercise of options subject to vesting.
 

(5)

Includes 19,793 of shares issuable on exercise of options and 34,125 shares of restricted stock of which 32,750 remain subject to vesting. Does not include 1,041 shares issuable upon exercise of options subject to vesting.
 

(6)

Includes 2,013 of shares issuable on exercise of options and 5,000 shares of restricted stock which  remain subject to vesting. Does not include 312 shares issuable upon exercise of options subject to vesting.
 

(7)

Includes 1,752 of shares issuable on exercise of options and 5,000 shares of restricted stock which  remain subject to vesting. Does not include 312 shares issuable upon exercise of options subject to vesting.
 

(8)

Includes 2,013 of shares issuable on exercise of options and 5,000 shares of restricted stock which remain subject to vesting. Does not include 312 shares issuable upon exercise of options subject to vesting.
 

(9)

Includes 1,752 of shares issuable on exercise of options and 5,000 shares of restricted stock which 5, remain subject to vesting. Does not include 312 shares issuable upon exercise of options subject to vesting.
 

(10)

Includes 105 of shares issuable on exercise of options and 5,000 shares of restricted stock  which  remain subject to vesting. Does not include 208 shares issuable upon exercise of options subject to vesting.
 

(11)

Includes 25,695 of shares issuable on exercise of options and 9,125 shares of restricted stock of which 7,750 remain subject to vesting. Does not include 1,389 shares issuable upon exercise of options subject to vesting.The address of Kelvin is Flat C, 27/F, Block 5, Grand Pacific Views, Siu Lam, Hong Kong N7.
 

(12)

Consists of shares issuable upon exercise of warrants. The address of Lind Global Capital Micro Fund, LP is 444 Madison Ave, Floor 41, New York, NY 10022

 

33
 

 

EQUITY COMPENSATION PLAN INFORMATION

 

The following table sets forth, as of December 31, 2021, information with respect to securities authorized for issuance under equity compensation plans. The shares and per share amounts reflect BIO-key’s 1-for-8 reverse stock split, which was effective November 20, 2020.

 

On January 27, 2016, the stockholders approved the 2015 Equity Incentive Plan, which was amended on June 13, 2019 by vote of stockholders, and amended and restated by vote of stockholders on June 18, 2021 (as amended and restated, the “2015 Plan”). The 2015 Plan reserves 789,000 shares of common stock for issuance of options, restricted stock, and other equity based awards to employees, officers, directors, and consultants of the Company. Options are issued at exercise prices which may not be below 100-110% of fair market value and have terms not to exceed ten years. Options issued under the 2015 Plan vest pursuant to the terms of stock option agreements with the recipients. In the event of a change in control, certain stock awards issued under this plan may be subject to additional acceleration of vesting as may be provided in the participants’ written agreement. The 2015 Plan expires in December 2025.

 

In addition to options issued under the 2015 Plan, we have issued options to purchase common stock to employees, officers, directors and consultants outside of the plan. As of December 31, 2021, there were outstanding non-plan options to purchase 121,653 shares of common stock. The terms of these outstanding options are substantially similar to the provisions of the 2015 Plan and options issued thereunder.  In the event of change in control, as defined, certain of the non-plan options outstanding vest immediately.

 

On June 18, 2021, the stockholders approved the 2021 Employee Stock Purchase Plan (“ESPP”). Under the terms of this plan, 789,000 shares of common stock are reserved for issuance and sale to employees and officers of the Company at a purchase price equal to 85% of the lower of the closing price of our common stock as reported on the Nasdaq Capital Market on the first day or the last day of the offering period. Eligible employees are granted an option to purchase shares of common stock funded by payroll deductions. The Board may suspend or terminate the plan at any time, otherwise the plan expires June 17, 2031.

 

Plan Category  

Number of

securities to be

issued

upon exercise

of outstanding

options,

warrants and

rights

(a)

    

Weighted-

average

exercise price

of outstanding

options,

warrants and

rights

(b)

    

Number

of securities

remaining

available for

future issuance

under equity

compensation

plans

(excluding

securities

reflected in

column (a))

(c)

  

Equity compensation plans approved by security holders

     90,808 (1)(2)      11.01       1,391,260 (3) 

Equity compensation plans not approved by security holders

     121,653     $ 18.44       —  

Total

     212,461 (1)(2)    $ 16.65       1,391,260 (3) 

 

(1)

Consists of shares of common stock issuable upon the exercise of options outstanding as of December 31, 2021 under the 2015 Plan.

 

(2)

Excludes employee stock purchase rights accruing under the ESPP.

 

(3)

Amount includes 621,744 shares of common stock available as of December 31, 2021 for future issuance under the 2015 Plan and 769,516 shares of common stock available as of December 31, 2021 for future issuance under the ESPP.

 

34
 

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

Standstill Agreement with Principal Stockholder

 

Pursuant to separate securities purchase agreements dated October 29, 2015 and November 11, 2015 with each of Wong Kwok Fong (Kelvin), Micron, and Giant Leap we issued and sold shares of series A-1 stock to Kelvin and shares of series B-1 stock to Micron and Giant Leap, which were subsequently converted into shares of our common stock. The forgoing agreements contain a standstill provision (the “Standstill”) which prohibits each of these investors either alone or together with any other person, from acquiring additional shares of our common stock or any of our assets, soliciting proxies, or seeking representation on our board of directors. Kelvin is the Co-Chairman of the board of directors, and an executive officer.

 

Loans from Wong Kwok Fong (Kelvin) 

 

Between March 2019 and February 2020, we received a series of non-interest-bearing advances from Mr. Wong Kwok Fong (Kelvin) in the aggregate amount of $217,360 to pay current liabilities. The amounts were repaid in their entirety during the 2020 fiscal year. Mr. Wong is the Vice-Chairman of the Board, an executive officer, and a principal stockholder of the Company.

 

Loans from Michael W. DePasquale

 

In December 2019, we received two non-interest-bearing advances from Michael DePasquale in the aggregate amount of $114,000 to pay current liabilities. The amounts were repaid in their entirety during the 2020 fiscal year. Mr. DePasquale serves as the Chairman of the Board and Chief Executive Officer of the Company.

 

 

Sales Incentive Agreement with Technology Transfer Institute (“TTI”)

 

On March 25, 2020, we entered into a sales incentive agreement TTI. The agreement provides that for each $5,000,000 in revenue (up to a maximum of $20,000,000), TTI generates for the Company during the first year that generate net income (calculated under U.S. generally accepted accounting principles) of at least 20%, we will pay TTI a sales incentive fee of $500,000 payable by the issuance of 62,500 shares of common stock. In the event that TTI generates revenue for the Company in excess of $20,000,000 during first year, we will issue TTI a five-year warrant to purchase 12,500 shares of Common Stock at an exercise price of $12.00 per share for each $1,000,000 of revenue in excess of $20,000,000 (up to a maximum of $25,000,000). In no event will we be obligated to issue more than 250,000 shares of common stock or warrants to purchase more than 62,500 shares of common stock pursuant to this agreement. Emmanual Alia, a member of our board of directors, served as the Chief Executive Officer of TTI until August 12, 2020.

 

Director Independence

 

As required under the NASDAQ Marketplace Rules, a majority of the members of a listed company’s board of directors must qualify as “independent,” as affirmatively determined by the board of directors. Our board considered certain relationships between our directors and us when determining each director’s status as an “independent director” under Rule 5605(a)(2) of the NASDAQ Marketplace Rules. Based upon such definition and SEC regulations, we have determined that Robert Michel, Pieter Knook, Emmanual Alia, Thomas Bush, III, and Thomas Gilley are “independent” under NASDAQ standards. 

 

35
 

 

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

The following table shows fees for professional services and quarterly audit fees billed to us by Rotenberg Meril Solomon Bertiger & Guttilla, P.C. (“RMSBG”) for the audit of our annual consolidated financial statements for the years ended December 31, 2021 and 2020:

 

 

   

2021

    

2020

  
                 

Audit Fees

   $ 123,900     $ 151,584  

Audit-Related Fees

     9,795       76,925  

Tax Fees

     17,000       20,053  
                 

Total Fees

   $ 150,695     $ 248,562  

 

Audit Fees consist of fees billed for professional services rendered for the audit of our financial statements and review of the interim financial statements included in quarterly reports and services that are normally provided by our auditors in connection with statutory and regulatory filings or engagements.

 

Audit-Related Fees consist of fees billed for assurance and related services that are reasonably related to the performance of the audit or review of our financial statements and which are not reported under audit fees. These fees relate primarily to services provided in connection with registration of securities and review of documents filed with the SEC.

 

Tax Fees consist of fees billed for professional services for tax compliance assistance rendered during the fiscal year.

 

Audit Committee Pre-Approval Procedures

 

The audit committee of our board of directors consists of Robert J. Michel (Chairman), Pieter Knook, and Emmanual Alia. The audit committee approves the engagement of our independent auditors to render audit and non-audit services before they are engaged. All of the fees for 2021 and 2020 shown above were pre-approved by the audit committee.

 

The audit committee pre-approves all audit and other permitted non-audit services provided by our independent auditors. Pre-approval is generally provided for up to one year, is detailed as to the particular category of services and is subject to a monetary limit. Our independent auditors and senior management periodically report to the audit committee the extent of services provided by the independent auditors in accordance with the pre-approval, and the fees for the services performed to date. The audit committee may also pre-approve particular services on a case-by-case basis.

 

Our audit committee will not approve engagements of our independent registered public accounting firm to perform non-audit services for us if doing so will cause our independent registered public accounting firm to cease to be independent within the meaning of applicable SEC rules. In addition, our audit committee considers, among other things, whether our independent registered public accounting firm is able to provide the required services in a more or less effective and efficient manner than other available service providers.

 

PART IV

 

ITEM 15. – EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

(a)       The following documents are filed as part of this Report. Portions of Item 15 are submitted as separate sections of this Report:

 

 

(1)  Financial statements filed as part of this Report:
   
 

Report of Independent Registered Public Accounting Firm (Rotenberg Meril Solomon Bertiger & Guttilla, P.C., Saddle Brook, NJ, PCAOB ID:361
   
 

Consolidated Balance Sheets as at December 31, 2021 and 2020
   
 

Consolidated Statements of Operations—Years ended December 31, 2021 and 2020
   

 

36
 

 

 

Consolidated Statements of Stockholders’ Equity (Deficit)—Years ended December 31, 2021 and 2020
   
 

Consolidated Statements of Cash Flows—Years ended December 31, 2021 and 2020
   
 

Notes to Consolidated Financial Statements—December 31, 2021 and 2020

 

(b)       The exhibits listed in the Exhibits Index immediately preceding such exhibits are filed as part of this Report

 

37
 

 

ITEM 16. – FORM 10-K SUMMARY

 

None.

 

FINANCIAL STATEMENTS

 

The following financial statements of BIO-key International, Inc. are included herein at the indicated page numbers:
 

Report of Independent Registered Public Accounting Firm (Rotenberg Meril Solomon Bertiger & Guttilla, P.C., Saddle Brook, NJ, PCAOB ID:361

39

Consolidated Balance Sheets as at December 31, 2021 and 2020

41

Consolidated Statements of Operations—Years ended December 31, 2021 and 2020

42

Consolidated Statements of Stockholders’ Equity (Deficit) —Years ended December 31, 2021 and 2020

43

Consolidated Statements of Cash Flows—Years ended December 31, 2021 and 2020

44
  45

Notes to the Consolidated Financial Statements—December 31, 2021 and 2020

46

 

38
 

 

Report of Independent Registered Public Accounting Firm

 

To the Shareholders and Board of Directors of
BIO-key International, Inc.
Wall, NJ

 

Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of BIO-key International, Inc. and Subsidiaries (the “Company”) as of December 31, 2021 and 2020, and the related consolidated statements of operations, stockholders’ equity (deficit) and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) are especially challenging, subjective, or complex judgements. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

Revenue Recognition – Refer to Notes A and B of the consolidated financial statements

 

Description of the Matter

 

The Company’s revenues are generated pursuant to written contractual arrangements to provide software licenses and/or hardware and to provide related maintenance and support services or professional services. The Company’s performance obligations are either satisfied at a point in time when the customer obtains control of the hardware or is granted the software license or satisfied over time for maintenance revenue over the contractual period. Software licenses may be sold as perpetual licenses or subscription licenses. Contracts may include multiple performance obligations.

 

39
 

 

Significant judgment is exercised by the Company in determining revenue recognition for these contractual arrangements, and includes the following: 

 

 

●

Determination of whether products and services are considered distinct performance obligations that should be accounted for separately versus together, such as software licenses and related services that are sold with cloud-based services.
 

●

The pattern of delivery (i.e., timing of when revenue is recognized) for each distinct performance obligation.
 

●

Identification and treatment of contract terms that may impact the timing and amount of revenue recognized (e.g., variable consideration and/or optional purchases).
 

●

Determination of stand-alone selling prices for each distinct performance obligation and for products and services that are not sold separately.

 

How the Critical Audit Matter Was Addressed in the Audit

 

Our audit procedures included:

 

●

We obtained an understanding of the Company’s revenue recognition process including the various product and service offerings;
 

●

We reviewed management’s assessment of the terms and conditions of contracts with customers which included an analysis of the distinct performance obligations and a review of the conclusion as to whether revenue from such performance obligations should be recognized over time or at a point in time;
 

●

We selected a sample of contracts with customers and performed the following:
  o 

Obtained and read customer sales orders and/or sales invoices and other documents that are part of the agreement;
  o 

Tested management’s process for identifying distinct performance obligation(s) in the contract;
  o 

Tested the allocation between software revenue and maintenance revenue including testing any carve out of maintenance from subscription based software and maintenance sales.

 

The outcome of the audit procedures resulted in determining the amounts of revenue and the application of ASC 606 is reasonable.

 

 

/s/ ROTENBERG MERIL SOLOMON BERTIGER & GUTTILLA, P.C.

 

ROTENBERG MERIL SOLOMON BERTIGER & GUTTILLA, P.C.

 

We have served as the Company's auditor since 2010.

 

Saddle Brook, New Jersey
March 31, 2022       

 

40
 

 

 

BIO-key International, Inc. and Subsidiaries

CONSOLIDATED BALANCE SHEETS

 

  

December 31,

 
  

2021

  

2020

 

ASSETS

        

Cash and cash equivalents

 $7,754,046  $16,993,096 

Accounts receivable, net

  970,626   548,049 

Due from factor

  49,500   60,453 

Note receivable, net of allowance

  82,000   295,000 

Inventory

  4,940,660   330,947 

Prepaid expenses and other

  216,041   201,507 

Investment – debt security

  -   512,821 

Total current assets

  14,012,873   18,941,873 

Resalable software license rights

  48,752   58,882 

Investment – debt security, net

  452,821   - 

Equipment and leasehold improvements, net

  69,168   81,793 

Capitalized contract costs, net

  249,012   165,315 

Deposits and other assets

  8,712   8,712 

Note receivable, net of allowance

  113,000   - 

Operating lease right-of-use assets

  254,100   487,325 

Intangible assets, net

  1,298,077   1,514,146 

Goodwill

  1,262,526   1,262,526 

Total non-current assets

  3,756,168   3,578,699 

TOTAL ASSETS

 $17,769,041  $22,520,572 
         

LIABILITIES

        

Accounts payable

 $427,772  $244,158 

Accrued liabilities

  828,997   508,487 

Note payable – PistolStar acquisition, net of debt discount

  -   232,000 

Deferred revenue - current

  565,355   657,349 

Operating lease liabilities, current portion

  177,188   234,309 

Total current liabilities

  1,999,312   1,876,303 

Deferred revenue, net of current portion

  67,300   44,987 

Operating lease liabilities, net of current portion

  86,974   264,163 

Total non-current liabilities

  154,274   309,150 

TOTAL LIABILITIES

  2,153,586   2,185,453 
         

Commitments

          
         

STOCKHOLDERS’ EQUITY

        

Common stock — authorized, 170,000,000 shares; issued and outstanding; 7,853,759 and 7,814,572 of $.0001 par value at December 31, 2021 and December 31, 2020, respectively

  786   782 

Additional paid-in capital

  120,190,139   119,844,026 

Accumulated deficit

  (104,575,470

)

  (99,509,689

)

TOTAL STOCKHOLDERS’ EQUITY

  15,615,455   20,335,119 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

 $17,769,041  $22,520,572 

 

All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-8 reverse stock split, which was effective November 20, 2020.

 

The accompanying notes are an integral part of these statements.

 

41
 

 

 

BIO-key International, Inc. and Subsidiaries

CONSOLIDATED STATEMENTS OF OPERATIONS

 

   

Years ended December 31,

  
   

2021

    

2020

  
                 

Revenues

                

Services

   $ 1,273,354     $ 1,432,228  

License fees

     2,555,809       962,038  

Hardware

     1,285,326       442,516  

Total revenues

     5,114,489       2,836,782  
                 

Costs and other expenses

                

Cost of services

     686,175       502,214  

Cost of license fees

     183,199       49,891  

Cost of hardware

     803,555       242,721  

Total costs and other expenses

     1,672,929       794,826  

Gross Profit

     3,441,560       2,041,956  
                 

Operating expenses

                

Selling, general and administrative

     6,028,360       5,848,687  

Research, development and engineering

     2,355,056       1,396,436  

Total operating expenses

     8,383,416       7,245,123  

Operating loss

    (4,941,856

)

     (5,203,167

)
                 

Other income (expense)

                

Interest income

     4,075       30,649  

Foreign currency loss

     (50,000 )     -  

Investment-debt security reserve

     (60,000 )     -  

Government grant – Paycheck Protection Program

     -       340,819  

Interest expense

     (18,000

)

     (4,343,212

)

Loss on extinguishment of debt

     -       (499,076

)

Total other income (expense)

     (123,925

)

     (4,470,820

)

Net loss

     (5,065,781

)

     (9,673,987

)

Deemed dividend from trigger of anti-dilution provision feature

     -       (112,686

)

Net loss available to common stockholders

     (5,065,781

)

     (9,786,673

)
                 

Basic and Diluted Loss per Common Share

   $ (0.65

)

   $ (2.08

)
                 

Weighted Average Shares Outstanding:

                

Basic and Diluted

     7,791,741       4,700,787  

 

All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-8 reverse stock split, which was effective November 20, 2020.

 

The accompanying notes are an integral part of these statements.

 

42
 

 

 

BIO-key International, Inc. and Subsidiaries

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

 

   

Common Stock

    

Additional

Paid-in

     Accumulated          
   

Shares

    

Amount

    

Capital

    

Deficit

     Total  

Balance as of December 31, 2019

     1,812,483     $ 182     $ 87,437,661     $ (89,723,016

)

   $ (2,285,173

)

Issuance of common stock for directors’ fees

     5,270       -       28,511       -       28,511  

Issuance of common stock pursuant to securities purchase agreements

     43,939       5       277,828       -       277,833  

Issuance of common stock pursuant to public offering

     4,264,313       426       22,173,999       -       22,174,425  

Issuance of common stock pursuant to warrant exercises

     918,538       92       5,602,503       -       5,602,595  

Issuance of common stock for conversion of convertible note payable

     728,654       73       3,788,927       -       3,789,000  

Issuance of restricted common stock to employees

     41,375       4       (4

)

     -       -  

Warrants issued with convertible notes

     -       -       1,388,339       -       1,388,339  

Warrant issued for consulting fees

     -       -       107,576       -       107,576  

Legal and commitment fees

     -       -       (2,371,223

)

     -       (2,371,223

)

Beneficial conversion feature

     -       -       641,215       -       641,215  

Deemed dividends related to down-round features

     -       -       112,686       (112,686

)

     -  

Share-based compensation

     -       -       656,008       -       656,008  

Net loss

     -       -       -       (9,673,987

)

     (9,673,987

)

Balance as of December, 2020

     7,814,572     $ 782     $ 119,844,026     $ (99,509,689

)

   $ 20,335,119  

Issuance of common stock for directors’ fees

     7,828       1       25,535       -       25,536  

Issuance of restricted common stock to employees

     13,125       1       (1 )     -       -  

Forfeiture of restricted stock

      (1,250)       -       -       -       -  

Legal fees

     -       -       (5,228

)

     -       (5,228

)

Issuance of common stock for Employee stock purchase plan

     19,484       2       36,628       -       36,630  
Share based compensation for employee stock purchase plan     -       -       10,680       -       10,680  

Share-based compensation

     -       -       278,499       -       278,499  

Net loss

     -       -       -       (5,065,781

)

     (5,065,781

)

Balance as of December, 2021

     7,853,759     $ 786     $ 120,190,139     $ (104,575,470

)

   $ 15,615,455  

 

All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-8 reverse stock split, which was effective November 20, 2020.

 

The accompanying notes are an integral part of these statements.

 

43
 

 

 

BIO-key International, Inc. and Subsidiaries

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   

Years ended December 31,

  
   

2021

    

2020

  
                 

CASH FLOW FROM OPERATING ACTIVITIES:

                

Net loss

   $ (5,065,781

)

   $ (9,673,987

)

Adjustments to reconcile net loss to cash used for operating activities:

                

Depreciation

     54,649       85,751  

Amortization of intangible assets and write-off

     216,069       120,240  

Amortization of resalable software license rights

     10,130       -  

Loss on foreign currency

     50,000       -  

Reserve for investment security

     60,000       -  

Allowance for note receivable

     100,000       -  
Allowance for doubtful account     200,000       -  

Amortization of debt discount

     18,000       1,425,040  

Amortization of capitalized contract costs

     110,681       152,714  

Amortization of debt issuance costs

     -       2,166,650  

Loss on extinguishment of debt

     -       499,076  

Amortization of beneficial conversion feature

     -       641,215  

Share based and warrant compensation for employees and consultants

     289,179       763,584  

Stock based fees to directors

     25,536       28,511  

Amortization of operating lease right-of-use assets

     233,225       220,915  

Change in assets and liabilities:

                

Accounts receivable

     (672,577

)

     (237,257

)

Due from factor

     10,953       50,488  

Capitalized contract costs

     (194,378

)

     (86,510

)

Inventory

     (4,609,713

)

     98,172  

Resalable software license rights

     -       14,920  

Prepaid expenses and other

     (14,534

)

     (83,625

)

Accounts payable

     183,614       (600,399

)

Accrued liabilities

     320,510       (84,415

)

Deferred revenue

     (69,681

)

     (246,876

)

Operating lease liabilities

     (234,310

)

     (204,315

)

Net cash used for operating activities

     (8,978,428

)

     (4,950,108

)

CASH FLOWS FROM INVESTING ACTIVITIES:

                

Capital expenditures

     (42,024

)

     (35,568 )

Issuance of note receivable

     -       (295,000

)

Purchase of PistolStar

     -       (2,000,000

)

Cash acquired from purchase of PistolStar

     -       100,747  

Proceeds from maturity of debt security

     -       512,821  

Purchase of debt security

     -       (512,821

)

Net cash used for investing activities

     (42,024

)

     (2,229,821

)

CASH FLOWS FROM FINANCING ACTIVITIES:

                

Proceeds from public offering

     -       22,174,425  

Proceeds from issuance of convertible notes

     -       3,958,000  
Proceeds from Employee Stock Purchase Plan     36,630       -  

Repayment of convertible notes

     -       (4,509,250

)

Proceeds from the exercise of warrants

     -       5,602,595  

Costs to issue notes and common stock

     -       (2,693,021

)

Repayment of note payable - PistolStar

     (250,000

)

     (250,000

)

Legal fees

     (5,228

)

     -  

Net repayments of loans payable to related parties

     -       (188,737

)

Net cash (used in) provided by financing activities

     (218,598

)

     24,094,012  

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

     (9,239,050

)

     16,914,083  

CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR

     16,993,096       79,013  

CASH AND CASH EQUIVALENTS, END OF YEAR

   $ 7,754,046     $ 16,993,096  

 

The accompanying notes are an integral part of these statements.

 

44
 

 

SUPPLEMENTARY DISCLOSURES OF CASH FLOW INFORMATION

 

   

Years ended December 31,

  
   

2021

    

2020

  
                 

Cash paid for:

                

Interest

   $ 18,000     $ 109,426  

Income taxes

   $ -     $ -  
                 

Noncash investing and financing activities:

                
                 

Accounts receivable acquired from PistolStar

   $ -     $ 184,792  

Prepaid expenses acquired from PistolStar

   $ -     $ 9,485  

Equipment acquired from PistolStar

   $ -     $ 36,467  

Intangible assets acquired from PistolStar

   $ -     $ 1,480,000  

Goodwill related to PistolStar acquisition

   $ -     $ 1,262,526  

Issuance of note payable for PistolStar acquisition, net of discount

   $ -     $ 464,000  

Accrued expenses acquired from PistolStar

   $ -     $ 20,017  

Deferred revenue acquired from PistolStar

   $ -     $ 590,000  

Right-of-use asset addition under ASC 842

   $ -     $ 141,761  

Operating lease liabilities under ASC 842

   $ -     $ 141,761  

Issuance of common stock for conversion of note payable

   $ -     $ 3,789,000  

Issuance of common stock pursuant to securities purchase agreements

   $ -     $ 277,833  

Warrants issued with convertible notes

   $ -     $ 1,388,339  

Beneficial conversion feature

   $ -     $ 641,215  

Deemed dividends related to down-round features

   $ -     $ 112,686  

 

The accompanying notes are an integral part of these statements.

 

45
 

 

BIO-key International, Inc. and Subsidiaries

NOTES TO THE FINANCIAL STATEMENTS

December 31, 2021 and 2020

 

 

 

 

 

NOTE A —THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Nature of Business

 

The Company, founded in 1993, develops and markets proprietary fingerprint identification biometric technology and software solutions enterprise-ready identity access management solutions to commercial, government and education customers throughout the United States and internationally. The Company was a pioneer in developing automated, finger identification technology that supplements or compliments other methods of identification and verification, such as personal inspection identification, passwords, tokens, smart cards, ID cards, PKI, credit cards, passports, driver’s licenses, OTP or other form of possession or knowledge-based credentialing. Additionally, advanced BIO-key® technology has been, and is, used to improve both the accuracy and speed of competing finger-based biometrics.

 

Going Concern and Basis of Presentation

 

The Company has historically financed our operations through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. The Company currently requires approximately $735,000 per month to conduct operations, a monthly amount that it has been unable to consistently achieve through revenue generation. During 2021, the Company generated approximately $5,114,000 of revenue, which is below its average monthly requirements. During 2020, the Company raised approximately $24,000,000 from financing activities and at December 31, 2021 had approximately $7,800,000 in cash. With the addition of the Swivel Secure Europe, SA (see Note W), the Company expects $1,000,000 of additional cash flow, based on Swivel Secure’s current recurring revenue and expenses, to provide additional operating income. As of the date of this report, the Company has enough cash and receivables for twelve months of operations.

 

Effective November 20, 2020, the Company implemented a reverse stock split of its outstanding common stock at a ratio of 1-for-8. All share figures and results are reflected on a post-split basis.

 

Foreign Currency

 

The Company accounts for foreign currency transactions pursuant to ASC 830, Foreign Currency Matters ("ASC 830”). The functional currency of the Company is the U.S. dollar, which is the currency of the primary economic environment in which it operates. In accordance with ASC 830, monetary balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing at the applicable balance sheet date.  For foreign currency transactions included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates used in the translation of such transactions and from the remeasurement of the monetary balance sheet items are recorded as gain (loss) on foreign currency transactions.

 

 

Summary of Significant Accounting Policies

 

A summary of the significant accounting policies consistently applied in the preparation of the accompanying consolidated financial statements follows:

 

1.  Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of BIO-key International, Inc. and its wholly-owned subsidiaries (collectively, the “Company”). Intercompany accounts and transactions have been eliminated in consolidation. 

 

2. Use of Estimates

 

Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) as set forth in the Financial Accounting Standards Board’s (FASB) Accounting Standards Codification (ASC) and consider the various staff accounting bulletins and other applicable guidance issued by the U.S. Securities and Exchange Commission (SEC). These accounting principles require us to make certain estimates, judgments and assumptions. The Company believes that the estimates, judgments and assumptions upon which it relies are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Certain significant accounting policies that contain subjective management estimates and assumptions include those related to revenue recognition, accounts receivable, inventory, intangible assets and long-lived assets, and income taxes. To the extent there are material differences between these estimates, judgments or assumptions and actual results, its consolidated financial statements will be affected. In many cases, the accounting treatment of a particular transaction is specifically dictated by GAAP and does not require management’s judgment in its application. There are also areas in which management’s judgment in selecting among available alternatives would not produce a materially different result.

 

46
 
 

3. Revenue Recognition

 

In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. To achieve this core principle, the Company applies the following five steps: 

 

 

●

Identify the contract with a customer

 

●

Identify the performance obligations in the contract

 

●

Determine the transaction price

 

●

Allocate the transaction price to performance obligations in the contract

 

●

Recognize revenue when or as the Company satisfies a performance obligation

 

All of the Company's performance obligations, and associated revenues, are generally transferred to customers at a point in time, with the exception of support and maintenance, and professional services, which are generally transferred to the customer over time.

 

Software licenses

Software license revenue consist of fees for perpetual and subscription licenses for one or more of the Company’s biometric fingerprint solutions or identity access management solutions. Revenue is recognized at a point in time once the software is available to the customer for download. Software license contracts are generally invoiced in full on execution of the arrangement.

 

Hardware

Hardware revenue consists of fees for associated equipment sold with or without a software license arrangement, such as servers, locks and fingerprint readers. Customers are not obligated to buy third party hardware from the Company, and may procure these items from a number of suppliers. Revenue is recognized at a point in time once the hardware is shipped to the customer. Hardware items are generally invoiced in full on execution of the arrangement.

 

Support and Maintenance

Support and maintenance revenue consists of fees for unspecified upgrades, telephone assistance and bug fixes. The Company satisfies its support and maintenance performance obligation by providing “stand-ready” assistance as required over the contract period. The Company records deferred revenue (contract liability) at time of prepayment until the contracts term occurs. Revenue is recognized over time on a ratable basis over the contract term. Support and maintenance contracts are one to five years in length and are generally invoiced in advance at the beginning of the term. Support and Maintenance revenue for subscription licenses is carved out of the total license cost at 18% and recognized on a ratable basis over the license term.

 

Professional Services

Professional services revenues consist primarily of fees for deployment and optimization services, as well as training. The majority of the Company’s consulting contracts are billed on a time and materials basis, and revenue is recognized based on the amount billable to the customer in accordance with practical expedient ASC 606-10-55-18. For other professional services contracts, the Company utilizes an input method and recognizes revenue based on labor hours expended to date relative to the total labor hours expected to be required to satisfy its performance obligation.

 

Contracts with Multiple Performance Obligations

Some contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The standalone selling prices are determined based on overall pricing objectives, taking into consideration market conditions and other factors, including the value of the contracts, the cloud applications sold, customer demographics, geographic locations, and the number and types of users within the contracts.

 

The Company considered several factors in determining that control transfers to the customer upon shipment of hardware and availability of download of software.  These factors include that legal title transfers to the customer, the Company has a present right to payment, and the customer has assumed the risks and rewards of ownership.

 

Accounts receivable from customers are typically due within 30 days of invoicing.  The Company does not record a reserve for product returns or warranties as amounts are deemed immaterial based on historical experience.

 

Costs to Obtain and Fulfill a Contract

Costs to obtain and fulfill a contract are predominantly sales commissions earned by the sales force and are considered incremental and recoverable costs of obtaining a contract with a customer. These costs are deferred and then amortized over a period of benefit determined to be four years. These costs are included as capitalized contract costs on the balance sheet. The period of benefit was determined by taking into consideration customer contracts, technology, and other factors based on historical evidence. Amortization expense is included in selling, general and administrative expenses in the accompanying consolidated statements of operations.

 

47
 
 

Deferred Revenue 

Deferred revenue includes customer advances and amounts that have been paid by customer for which the contractual maintenance terms have not yet occurred. The majority of these amounts are related to maintenance contracts for which the revenue is recognized ratably over the applicable term, which generally is 12-60 months. Contracts greater than 12 months are segregated as long term deferred revenue. Maintenance contracts include provisions for unspecified when-and-if available product updates and customer telephone support services. At December 31, 2021 and 2020, amounts in deferred revenue were approximately $633,000 and $702,000, respectively.

 

4. Business Combinations

 

In accordance with ASC 805, Business Combinations (ASC 805), the Company recognizes the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. Determining these fair values requires management to make significant estimates and assumptions, especially with respect to intangible assets.

 

The Company recognizes identifiable assets acquired and liabilities assumed at their acquisition date fair value. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net acquisition date fair value of the assets acquired and the liabilities assumed and represents the expected future economic benefits arising from other assets acquired that are not individually identified and separately recognized. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, its estimates are inherently uncertain and subject to refinement. Assumptions may be incomplete or inaccurate, and unanticipated events or circumstances may occur, which may affect the accuracy or validity of such assumptions, estimates or actual results. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill to the extent that it identifies adjustments to the preliminary purchase price allocation. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statements of operations.

 

5. Goodwill and acquired intangible assets

 

Goodwill is not amortized, but is evaluated for impairment annually, or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. The Company has determined that there is a single reporting unit for the purpose of conducting this goodwill impairment assessment. For purposes of assessing potential impairment, the Company estimates the fair value of the reporting unit, based on the Company’s market capitalization, and compares this amount to the carrying value of the reporting unit. If the Company determines that the carrying value of the reporting unit exceeds its fair value, an impairment charge would be required. The annual goodwill impairment test will be performed as of  December 31st of each year. To date, the Company has not identified any impairment to goodwill.

 

Intangible assets acquired in a business combination are recorded at their estimated fair values at the date of acquisition. The Company amortizes acquired definite-lived intangible assets over their estimated useful lives based on the pattern of consumption of the economic benefits or, if that pattern cannot be readily determined, on a straight-line basis.

 

6. Cash Equivalents

 

Cash equivalents consist of liquid investments with original maturities of three months or less. At December 31, 2021 and 2020, cash equivalents consisted of a money market account.

 

7. Accounts Receivable

 

Accounts receivable are carried at original amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful receivables by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions. Accounts receivable are written off when deemed uncollectible.

 

Accounts receivable at December 31, 2021 and 2020 consisted of the following: 

 

  

December 31,

 
  

2021

  

2020

 
         

Accounts receivable

 $1,234,411  $561,834 
Loss on foreign currency  (50,000)  - 

Allowance for doubtful accounts

  (213,785

)

  (13,785

)

Accounts receivable, net of allowances for doubtful accounts

 $970,626  $548,049 

 

Bad debt expenses (if any) are recorded in selling, general, and administrative expense. 

 

48
 
 

8. Equipment and Leasehold Improvements, Intangible Assets and Depreciation and Amortization

 

Equipment and leasehold improvements are stated at cost.  Depreciation is provided for in amounts sufficient to relate the cost of depreciable assets to operations over the estimated service lives, principally using straight-line methods. Leasehold improvements are amortized over the shorter of the life of the improvement or the lease term, using the straight-line method.

 

The estimated useful lives used to compute depreciation and amortization for financial reporting purposes are as follows:

 

  

Years

 

Equipment and leasehold improvements

     

Equipment (years)

 

3

-

5

 

Furniture and fixtures (years)

 

3

-

5

 

Software (years)

  

3

  

Leasehold improvements

 

life or lease term

 

 

Intangible assets other than goodwill consist of patents, trade name, proprietary software, and customer relationships.  Patent costs are capitalized until patents are awarded. Upon award, such costs are amortized using the straight-line method over their respective economic lives. If a patent is denied, all costs are charged to operations in that year. Trade names, proprietary software, and customer relationships are amortized over the economic useful life.

 

9. Impairment or Disposal of Long Lived Assets, including Intangible Assets

 

The Company reviews long-lived assets, including intangible assets subject to amortization, whenever events or changes in circumstances indicate that the carrying amount of such an asset may not be recoverable. Recoverability of these assets is measured by comparison of their carrying amount to the future undiscounted cash flows the assets are expected to generate. If such assets are considered impaired, the impairment to be recognized is equal to the amount by which the carrying value of the assets exceeds their fair value determined by either a quoted market price, if any, or a value determined by utilizing a discounted cash flow technique. In assessing recoverability, the Company must make assumptions regarding estimated future cash flows and discount factors. If these estimates or related assumptions change in the future, the Company may be required to record impairment charges. Intangible assets with determinable lives are amortized over their estimated useful lives, based upon the pattern in which the expected benefits will be realized, or on a straight-line basis, whichever is greater. 

 

10. Advertising Expense

 

The Company expenses the costs of advertising as incurred. Advertising expenses for 2021 and 2020 were approximately $527,000 and $494,000, respectively.

 

11. Research and Development Expenditures

 

Research and development expenses include costs directly attributable to the conduct of research and development programs primarily related to the development of our software products and improving the efficiency and capabilities of our existing software. Such costs include salaries, payroll taxes, employee benefit costs, materials, supplies, depreciation on research equipment, services provided by outside contractors, and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation and general support services. All costs associated with research and development are expensed as incurred. 

 

12. Earnings Per Share of Common Stock (“EPS”)

 

The Company’s EPS is calculated by dividing net income (loss) applicable to common stockholders by the weighted-average number of common shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options and warrants, when the effect of their inclusion is dilutive.

 

49
 
 

13. Accounting for Stock-Based Compensation

 

The Company accounts for share based compensation in accordance with the provisions of ASC 718-10, “Compensation — Stock Compensation,” which requires measurement of compensation cost for all stock awards at fair value on date of grant and recognition of compensation over the service period for awards expected to vest. The majority of its share-based compensation arrangements vest over either a three or four year vesting schedule. The Company expenses its share-based compensation under the ratable method, which treats each vesting tranche as if it were an individual grant. The fair value of stock options is determined using the Black-Scholes valuation model and requires the input of highly subjective assumptions. These assumptions include estimating the length of time employees will retain their vested stock options before exercising them (the “expected option term”), the estimated volatility of its common stock price over the option’s expected term, the risk-free interest rate over the option’s expected term, and the Company’s expected annual dividend yield. Changes in these subjective assumptions can materially affect the estimate of fair value of stock-based compensation and consequently, the related amount recognized as an expense in the consolidated statements of operations. As required under the accounting rules, the Company reviews its valuation assumptions at each grant date and, as a result, the Company is likely to change its valuation assumptions used to value employee stock-based awards granted in future periods. The values derived from using the Black-Scholes model are recognized as expense over the service period, net of estimated forfeitures (the number of individuals that will ultimately not complete their vesting requirements). The estimation of stock awards that will ultimately vest requires significant judgment. The Company considers many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience. Actual results, and future changes in estimates, may differ substantially from current estimates. Options and warrants to outsiders are accounted for under ASC 718.

 

The following table presents share-based compensation expenses included in the Company’s consolidated statements of operations:

 

  

Year ended

December 31,

 
  

2021

  

2020

 
         

Selling, general and administrative

 $269,368  $705,971 

Research, development and engineering

  45,347   86,124 
  $314,715  $792,095 

 

Valuation Assumptions for Stock Options

 

In 2020, 28,440 stock options were granted. No options were granted in 2021. The fair value of each option was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:

 

  

Year ended

December 31,

 
  

2021

  

2020

 

Weighted average Risk free interest rate

  -   0.30

%

Expected life of options (in years)

  -   4.50 

Expected dividends

  -   0

%

Weighted average Volatility of stock price

  -   115

%

 

The stock volatility for each grant is determined based on the review of the experience of the weighted average of historical daily price changes of the Company’s common stock over the expected option term. The expected term was determined using the simplified method for estimating expected option life, which qualify as “plain-vanilla” options; and the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. 

 

14. Derivative Liabilities

 

In connection with the issuances of equity instruments or debt, the Company may issue options or warrants to purchase common stock. In certain circumstances, these options or warrants may be classified as liabilities, rather than as equity. In addition, the equity instrument or debt may contain embedded derivative instruments, such as conversion options or listing requirements, which in certain circumstances may be required to be bifurcated from the associated host instrument and accounted for separately as a derivative liability instrument. The Company early-adopted the new provisions issued July 2017, for derivative liability instruments under FASB ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception. Under ASU 2017-11, down round features do not meet the criteria for derivative accounting and no liability is to be recorded until an actual issuance of securities triggers the down-round feature. Prior to these provisions, the liabilities were recorded without the actual issuance of the securities triggering the down-round feature.

 

15. Income Taxes

 

The provision for, or benefit from, income taxes includes deferred taxes resulting from the temporary differences in income for financial and tax purposes using the liability method. Such temporary differences result primarily from the differences in the carrying value of assets and liabilities. Future realization of deferred income tax assets requires sufficient taxable income within the carryback, carryforward period available under tax law. The Company evaluates, on a quarterly basis whether, based on all available evidence, if it is probable that the deferred income tax assets are realizable. Valuation allowances are established when it is more likely than not that the tax benefit of the deferred tax asset will not be realized. The evaluation, as prescribed by ASC 740-10, “Income Taxes,” includes the consideration of all available evidence, both positive and negative, regarding historical operating results including recent years with reported losses, the estimated timing of future reversals of existing taxable temporary differences, estimated future taxable income exclusive of reversing temporary differences and carryforwards, and potential tax planning strategies which may be employed to prevent an operating loss or tax credit carryforward from expiring unused. Because of the Company’s historical performance and estimated future taxable income, a full valuation allowance has been established.

 

50
 
 

The Company accounts for uncertain tax provisions in accordance with ASC 740-10-05, “Accounting for Uncertainty in Income Taxes.” The ASC clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The ASC prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The ASC provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.

 

16. Leases

 

In accordance with ASC 842, Leases (ASC 842), the Company records a right-of-use (ROU) asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classifies them as either operating or finance leases. 

 

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, the Company has elected not to allocate the contract consideration, and to account for the lease and non-lease components as a single lease component.

 

Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate, adjusted for various factors including level of collateralization, term and currency to align with the terms of the lease. The operating lease ROU asset also includes any lease prepayments, offset by lease incentives.

 

An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain we will not exercise the option.

 

17. Recent Accounting Pronouncements

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), referred to herein as ASU 2016-13, which significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 replaces the existing incurred loss model with an expected credit loss model that requires entities to estimate an expected lifetime credit loss on most financial assets and certain other instruments. Under ASU 2016-13 credit impairment is recognized as an allowance for credit losses, rather than as a direct write-down of the amortized cost basis of a financial asset. The impairment allowance is a valuation account deducted from the amortized cost basis of financial assets to present the net amount expected to be collected on the financial asset. Once the new pronouncement is adopted by the Company, the allowance for credit losses must be adjusted for management’s current estimate at each reporting date. The new guidance provides no threshold for recognition of impairment allowance. Therefore, entities must also measure expected credit losses on assets that have a low risk of loss. For instance, trade receivables that are either current or not yet due may not require an allowance reserve under currently generally accepted accounting principles, but under the new standard, the Company will have to estimate an allowance for expected credit losses on trade receivables under ASU 2016-13. ASU 2016-13 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2022 for smaller reporting companies. Early adoption is permitted. The Company is currently assessing the impact ASU 2016-13 will have on its consolidated financial statements.

 

Effective January 1, 2021, the Company adopted ASU 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”) to reduce the cost and complexity in accounting for income taxes. ASU 2019-12 removes certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also amends other aspects of the guidance to help simplify and promote consistent application of U.S. GAAP. Most amendments within ASU 2019-12 are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The adoption of ASU 2019-12 did not have a significant impact on the Company’s consolidated financial statements.

 

Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.

 

51
 
 

 

 

NOTE B—REVENUE FROM CONTRACTS WITH CUSTOMERS

 

Disaggregation of Revenue

 

The following table summarizes revenue from contracts with customers for the years ended December 31, 2021 and 2020:

 

   

North

America

    

Africa

    

EMESA*

    

Asia

    

December

31,

2021

  
                                         

License fees

   $ 1,854,088     $ 521,751     $ 105,314     $ 74,656     $ 2,555,809  

Hardware

     278,655       698,264       265,996       42,411       1,285,326  

Services

     1,162,526       42,000       54,918       13,910       1,273,354  

Total Revenues

   $ 3,295,269     $ 1,262,015     $ 426,228     $ 130,977     $ 5,114,489  

 

   

North

America

    

Africa

    

EMESA*

    

Asia

    

December

31,

2020

  
                                         

License fees

   $ 842,307     $ -     $ 46,922     $ 72,809     $ 962,038  

Hardware

     267,996       -       144,647       29,873       442,516  

Services

     1,296,696       44,228       68,196       23,108       1,432,228  

Total Revenues

   $ 2,406,999     $ 44,228     $ 259,765     $ 125,790     $ 2,836,782  

 

* EMESA – Europe, Middle East, South America

 

Revenue recognized during the year ended December 31, 2021 from amounts included in deferred revenue at the beginning of the year was approximately $529,000. Revenue recognized during the year ended December 31, 2020 from amounts included in deferred revenue at the beginning of the year was approximately $290,000. The Company did not recognize any revenue from performance obligations satisfied in prior periods. Total deferred revenue (contract liability) was $632,655 and $702,336 at December 31, 2021 and 2020, respectively.

 

Transaction Price Allocated to the Remaining Performance Obligations

 

ASC 606 requires that the Company disclose the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as at December 31, 2021. The guidance provides certain practical expedients that limit this requirement, which the Company’s contracts meet as follows:

 

 

●

The performance obligation is part of a contract that has an original expected duration of one year or less, in accordance with ASC 606-10-50-14.

 

Deferred revenue represents the Company’s remaining performance obligations related to prepaid support and maintenance, all of which is expected to be recognized from one to five years.

 

 

NOTE C—PISTOLSTAR, INC. ACQUISITION

 

On  June 30, 2020, the Company acquired PistolStar, Inc., a private company based in the United States, which provides enterprise-ready identity access management solutions, including multi-factor authentication, identity-as-a-service, single sign-on and self-service password reset to commercial, government and education customers throughout the United States and internationally.

 

From April 10, 2020 until the Company acquired PistolStar, it licensed PortalGuard®, PistolStar’s authentication software, which the Company combines with its biometric authentication solutions offered to existing and prospective customers.

 

The total purchase price of $2.5 million included cash payment of $2.0 million and the issuance of a $500,000 promissory note.

 

The acquisition of PistolStar was accounted for as a business combination and, in accordance with ASC 805, the Company recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The following table summarizes the final purchase price allocation:

 

Purchase consideration:

    

Total cash paid, net of acquired cash

 $2,000,000 

Present value of 4% Promissory note

  464,000 

Total purchase price consideration

 $2,464,000 
     

Fair value of assets acquired and liabilities assumed:

    

Cash and cash equivalents

 $100,747 

Accounts receivable

  184,792 

Prepaid expenses and other current assets

  9,485 

Fixed assets

  36,467 

Intangible assets

  1,480,000 

Goodwill

  1,262,526 

Total assets acquired

  3,074,017 
     

Accrued expenses and other current liabilities

  738 

Accrued payroll

  19,279 

Deferred revenue

  590,000 

Total fair value of assets acquired and liabilities assumed

 $2,464,000 

 

The promissory note accrued interest at 4% per annum and was payable in four installments over the 12-month period following the closing. The balance of the note at December 31, 2020 was $232,000, net of the unamortized debt discount. On January 21, 2021, the Company paid the $250,000 balance due on the note.

 

The fair value of the assets acquired and liabilities assumed was less than the purchase price, resulting in the recognition of goodwill. The goodwill reflected the value of the synergies the Company expected to realize and the assembled workforce.

 

The significant intangible assets identified in the purchase price allocation discussed above include the trade name, proprietary software, and customer relationships. To value the trade name and proprietary software, the Company utilized the Relief from Royalty Method, which quantifies the cost savings associated with asset ownership via a discounted cash flow analysis. To value the customer relationships, the Company utilized the Excess Earnings Method, which isolates the value of the specific intangible asset by discounting its income stream to present value. 

 

The fair value of the assets acquired and liabilities assumed reflected in the tables above is less than the purchase price, resulting in the recognition of goodwill. The goodwill reflects the value of the synergies the Company expects to realize and the assembled workforce.

 

The following table presents the final fair values and useful lives of the identifiable intangible assets acquired:

 

   

Amount

    

Estimated useful

life

(in years)

  

Trade Name

  

$

130,000

      

15

    

Proprietary Software

    

420,000

      

5

    

Customer relationships

    

930,000

    

8

-

10

  

Total identifiable intangible assets

  

$

1,480,000

            

 

52
 
 

 

 

NOTE D—FACTORING

 

Due from factor consisted of the following as of December 31:

 

   

Original Invoice

Value

    

Factored

Amount

    

Factored

Balance due

  

Year Ended December 31, 2021

                        

Factored accounts receivable

   $ 99,000     $ 49,500     $ 49,500  

Year Ended December 31, 2020

                        

Factored accounts receivable

   $ 241,715     $ 181,262     $ 60,453  

 

The Company entered into an accounts receivable factoring arrangement with a financial institution (the “Factor”) which has been extended to  October 31, 2022. Pursuant to the terms of the arrangement, the Company, from time to time, sells to the Factor a minimum of $150,000 per quarter of certain of its accounts receivable balances on a non-recourse basis for credit approved accounts. The Factor remits 35% of the foreign and 75% of the domestic accounts receivable balance to the Company (the “Advance Amount”), with the remaining balance, less fees, forwarded to the Company once the Factor collects the full accounts receivable balance from the customer. In addition, the Company, from time to time, receives over advances from the Factor. Factoring fees range from 2.75% to 15% of the face value of the invoice factored and are determined by the number of days required for collection of the invoice. The cost of factoring is included in selling, general and administrative expenses. The cost of factoring was as follows:  

 

   

Years Ended December 31,

  
   

2021

    

2020

  
                 

Factoring fees

   $ 50,132     $ 98,748  

 

 

 

NOTE E—FAIR VALUES OF FINANCIAL INSTRUMENTS

 

Cash and cash equivalents, accounts receivable, due from factor, accounts payable and accrued liabilities are carried at, or approximate, fair value because of their short-term nature. The carrying value of the Company’s notes and loan payables approximated fair value as the interest rates related to the financial instruments approximated market.

 

 

 

NOTE F—CONCENTRATION OF RISK

 

Financial instruments which potentially subject the Company to risk primarily consist of cash, and cash equivalents, investment in debt security, and accounts receivables.

 

The Company maintains its cash and cash equivalents with various financial institutions, which, at times may exceed insured limits. The exposure to the Company is solely dependent upon daily bank balances and the respective strength of the financial institutions. The Company was in excess of coverage of approximately $7,057,000 and $16,020,000 at December 31, 2021 and 2020, respectively. The Company has not incurred any losses on these accounts.

 

The Company extends credit to customers on an unsecured basis in the normal course of business. The Company’s policy is to perform an analysis of the recoverability of its receivables at the end of each reporting period and to establish allowances where appropriate. The Company analyzes historical bad debts and contract losses, customer concentrations, and customer credit-worthiness when evaluating the adequacy of the allowances.

 

For the year ended December 31, 2021 and 2020, one customer accounted for 13% and 18% of total revenue, respectively.

 

Three customers accounted for 87% and one customer accounted for 31% of total accounts receivable, as of December 31, 2021 and 2020, respectively.

 

 

 

NOTE G—NOTE RECEIVABLE

 

During the third quarter 2020, the Company loaned $295,000 as an advance to Technology Transfer Institute (“TTI”) to aid in fulfilling the African contracts. The note does not bear any interest if paid within the nine (9) monthly installments beginning December 31, 2020. The note bears a default rate of 5%. Due to the ongoing delays in payment, the Company reserved $100,000 of the note as an allowance. On February 17, 2022, the Company amended the note to modify the payment terms to provide for lower monthly payments, with an updated maturity date on, or before December 6, 2023. A member of our board of directors served as Chief Executive Officer off TTI until August 12, 2020.

 

   

December 31,

    

December 31,

  
   

2021

    

2020

  
                 

Note receivable

   $ 295,000     $ 295,000  

Allowance for doubtful account

     (100,000 )     -  

Note receivable, net of allowance

     195,000       295,000  
Current portion, net of allowance   $ 82,000     $ 295,000  
Noncurrent portion, net of allowance   $ 113,000     $ -  

 

53
 
 

 

 

NOTE H—INVENTORY

 

Inventory is stated at the lower of cost, determined on a first in, first out basis, or realizable value, and consists primarily of fabricated assemblies and finished goods. Inventory is comprised of the following as of December 31: 

 

   

2021

    

2020

  
                 

Finished goods

   $ 4,798,203     $ 221,130  

Fabricated assemblies

     142,457       109,817  

Total inventory

   $ 4,940,660     $ 330,947  

 

 

 

NOTE I—RESALABLE SOFTWARE LICENSES RIGHTS

 

On December 31, 2015, the Company purchased third-party software licenses in the amount of $180,000 in anticipation of a large pending deployment that has yet to materialize. The Company is amortizing the total cost at the greater of the actual unit cost per license sold or straight line amortization over 10 years. A total of $10,130 and $14,920 was charged to cost of sales during the years ended December 31, 2021 and 2020, respectively. Since the license purchase, the actual per unit cost (actual usage) of such license rights in the cumulative amount of $131,248 has been charged to cost of sales, with a carrying balance of $48,752 and $58,882 as of December 31, 2021 and 2020, respectively.

 

The Company has classified the balance as non-current until a larger deployment occurs.

 

Estimated minimum amortization expense based on straight line amortization of the software license rights over the remaining useful life approximates the following:

 

Years ending December 31

        

2022

   $ 18,000  

2023

     18,000  

2024

     12,752  

Total

   $ 48,752  

 

 

NOTE J—INVESTMENT IN DEBT SECURITY

 

During 2019, the Company purchased a 4,000,000 Hong Kong dollar denominated Bond Certificate with a financial institution in Hong Kong. The Bond Certificate translated to $512,821 U.S. Dollars on the June 2019 purchase date. The bond had a one-year term which matured in June 2020, bearing interest at 5% per annum. The Company redeemed the bond and recorded interest income of approximately $25,800.

 

The Company then purchased a new 4,000,000 Hong Kong dollar denominated Bond Certificate with a financial institution in Hong Kong in June 2020. The new Bond Certificate translated to $512,821 U.S. Dollars, based on the exchange rate at the purchase date. The Company can invest up to 20,000,000 Hong Kong dollars under the terms of the certificate, bearing interest at 5% per annum. The investment is recorded at amortized cost which approximates fair value was held to maturity. The Company has yet to receive the proceeds and accrued interest from the investment. The Company has sent a legal letter of demand to confirm the status of the bond, and as such, the debt security was classified as noncurrent. In addition, due to the delay in the receipt of the proceeds, the Company recorded a $60,000 reserve.

 

 

 

NOTE K—EQUIPMENT AND LEASEHOLD IMPROVEMENTS

 

Equipment and leasehold improvements consisted of the following as of December 31:

 

   

2021

    

2020

  
                 

Equipment

   $ 831,784     $ 789,760  

Furniture and fixtures

     164,079       164,079  

Software

     32,045       32,045  

Leasehold improvements

     25,135       25,135  
      1,053,043       1,011,019  
                 
                 

Less accumulated depreciation and amortization

     (983,875

)

     (929,226

)
                 

Total

   $ 69,168     $ 81,793  

 

54
 
 

Depreciation was $54,649 and $85,751 for 2021 and 2020, respectively. Amounts are recorded in selling, general, and administrative expense as well as in cost of services.

 

 

 

NOTE L—INTANGIBLE ASSETS

 

Intangible assets consisted of the following as of December 31:

 

   

2021

             12/31/21    

2020

             12/31/20  
   

Gross

Carrying

Amount

    

Accumulated

Amortization

    

Net

Carrying

Amount

    

Gross

Carrying

Amount

    

Accumulated

Amortization

    

Net

Carrying

Amount

 
                                                 

Trade name

   $ 130,000     $ (12,960

)

   $ 117,040     $ 130,000     $ (4,333

)

   $ 125,667  

Proprietary software

     420,000       (126,000

)

     294,000       420,000       (42,000

)

     378,000  

Customer relationships

     930,000       (155,000

)

     775,000       930,000       (51,667

)

     878,333  

Patents and patents pending

     365,080       (253,043

)

     112,037       365,080       (232,934

)

     132,146  

Total

   $ 1,845,080     $ (547,003

)

   $ 1,298,077     $ 1,845,080     $ (330,934

)

   $ 1,514,146  

 

 

Aggregate amortization expense for 2021 and 2020 was approximately $216,000 and $120,000, respectively. Estimated minimum amortization expense based on straight line amortization of the software license rights for each of the next five years and thereafter approximates the following:

 

Years ending December 31

        

2022

   $ 215,000  

2023

     213,000  

2024

     209,000  

2025

     165,000  
2026     121,000  

Thereafter

     375,077  

Total

   $ 1,298,077  

 

 

NOTE M—ACCRUED LIABILITIES

 

Accrued liabilities consisted of the following as of December 31:

 

   

2021

    

2020

  
                 

Compensation

   $ 254,433     $ 87,015  

Compensated absences

     293,297       227,147  

Accrued legal and accounting fees

     95,738       83,738  
Franchise taxes     40,000       -  
Employee expenses reimbursement     76,000       67,000  

Sales tax payable

     18,548       17,544  

Factoring fees

     495       5,495  

Other

     50,486       20,548  
                 

Total

   $ 828,997     $ 508,487  

 

 

NOTE N—RELATED PARTY TRANSACTIONS

 

Non-Interest-Bearing Advances

 

During the 2019 fiscal year, the Company received a series of non-interest-bearing advances from Mr. Wong Kwok Fong, and Mr. Michael DePasquale, to pay current liabilities. The balance of the advances as at December 31, 2019 was $74,737 and $114,000, respectively, which were both repaid in full during 2020.

 

 

NOTE O—CONVERTIBLE NOTES PAYABLE

 

There was no balance outstanding for convertible notes payable as of December 31, 2021 and 2020. Details for Notes that were either converted or redeemed during the 2020 fiscal year were as follows: 

 

55
 
 

Securities Purchase Agreement dated July 10, 2019

 

On July 10, 2019, the Company issued a $3,060,000 principal amount senior secured convertible note (the “Original Note”). At closing, a total of $2,550,000 was funded. The original issue discount was $510,000. The principal amount due of the Original Note was due and payable as follows: $918,000 was due 180 days after funding, $1,071,000 was due 270 days after funding, and the remaining balance due 12 months after the date of funding.

 

The Original Note was secured by a lien on substantially all of the Company’s assets and properties and was convertible at the option of the Investor in shares of common stock at a fixed conversion price of $12.00 per share.

 

In connection with the closing of the Original Note, the Company issued a five-year warrant to the Investor to purchase 250,000 shares of common stock at a fixed exercise price of $12.00 per share, paid a $50,000 commitment fee, and issued 33,334 shares of common stock in payment of a $400,000 due diligence fee. The Company also paid banker fees of $193,500 and legal fees of $71,330. The valuation of the warrant of $595,662 was recorded to debt discount and was amortized over the life of the Original Note. The fees associated with the agreement were allocated to debt issuance costs and additional paid-in capital based on the respective ratio of the valuation of the note and warrant. Amortization of the debt issuance costs and debt discount are included in interest expense on the statement of operations.

 

On March 12, 2020, the Company issued a $3,789,000 principal amount senior secured convertible note (the “Amended Note”), which replaced the Original Note and included an additional $729,000 in interest due to the debt restructuring. The principal amount was due and payable in full on April 13, 2020. The Amended Note was secured by a lien on substantially all of the Company’s assets and properties and was convertible at the option of the Investor into shares of common stock at a fixed conversion price of $5.20 per share. The Company accounted for the transaction as a debt extinguishment and, therefore, the balance of the fees and unamortized discount associated with the Original Note were written off and included as loss on extinguishment of debt. On the day of the amendment, the closing stock price for the day was $6.08, which resulted in a beneficial conversion of $0.88 per share outstanding or $641,215 to be amortized to interest expense over the term of the Amended Note, as adjusted for any debt conversion.

 

On April 12, 2020 and May 6, 2020, the Company entered into amendments (the “Amendments”) to the Amended Note. The Amendments extended the maturity date to June 12, 2020 and extended the Investor’s right to convert the Amended Note into shares of the Company’s common stock at a price of $5.20 per share through June 12, 2020. All other provisions of the Amended Note remained the same.

 

On June 10, 2020, the investor converted the last of the remaining principal into shares of common stock for payment in full, and the remaining principal balance was $0. The Amended Note amount of $3,789,000 was converted into 728,654 shares of common stock in 2020.

 

January 2020 Note

 

On January 13, 2020, the Company issued a $157,000 principal amount secured 10% convertible redeemable note (the “January 2020 Note”) to an institutional investor with a maturity date of June 13, 2020 which was convertible into common stock at a conversion price of $12.00 per share. At the closing, the Company agreed to issue 81,250 shares of common stock in lieu of payment of a $75,000 commitment fee which was reduced to 6,250 shares as the January 2020 Note was repaid prior to the maturity date.

 

On June 12, 2020, the January 2020 Note was paid in full by payment of $211,984.

 

February 2020 Note

 

On February 13, 2020, the Company issued a $126,000 principal amount secured 10% convertible redeemable note (the “February 2020 Note”) to an institutional investor with a maturity date of July 13, 2020 which was convertible into common stock at a conversion price of $9.20 per share.  On March 12, 2020, the Original Note was amended to reduce the conversion price to $5.20 per share, which reduced the conversion price of the February Note to $5.20 and resulted in a deemed dividend of $70,998. The February 2020 Note was redeemable at any time by payment of a premium to the principal balance starting at 10% and increasing to 30%.   The Company issued 6,250 shares of common stock to the investor in lieu of payment of a $57,500 commitment fee. The Company paid $6,000 of legal fees in connection with the issuance of February 2020 Note.  The February 2020 Note was paid in full on July 10, 2020 by payment of $170,442.

 

56
 
 

May 2020 Note

 

On May 6, 2020, the Company issued a $2,415,000 principal amount senior secured convertible note (the “May 2020 Note”). At closing, $2,100,000 was funded. The principal amount was due and payable in five equal monthly installments of $268,333 beginning seven months after the funding date with the remaining balance due on the twelfth month after the date of funding. The May 2020 Note was convertible at a fixed convertible price of $9.28 per share. In connection with the issuance of the May 2020 Note, the Company paid a $133,333 due diligence fee by issuing 14,368 shares of common stock to the Investor priced at $9.28 per share. The Company also paid a placement fee of 7% of the gross proceeds to a placement agent. In connection with the closing of the May 2020 Note, the Company issued a five-year warrant to the investor to purchase 237,500 shares of common stock at a fixed exercise price of $9.28 and was immediately exercisable. The valuation of the warrant of $876,937 was recorded to debt discount and was amortized over the life of the May 2020 Note. The fees associated with the agreement were allocated to debt issuance costs and additional paid-in-capital based on the respective ratio of the valuation of the note and warrant. Amortization of the debt issuance costs and debt discount were included in the interest expense on the statement of operations.

 

Following the completion of the underwritten offering in July 2020, the principal balance of $2,415,000 was paid in full during the third quarter of 2020.  As a result of the repayment, the Company expensed the remaining debt discounts and issuance costs of $1,218,163 in July 2020.

 

June 2020 Note

 

On June 29, 2020, the Company issued a $1,811,250 principal amount senior secured convertible note (the “June 2020 Note”).  At closing, $1,575,000 was funded. The principal amount was due and payable in nine equal monthly installments of $201,250 beginning four months after the funding date with the remaining balance due on the twelfth month after the date of funding. The June 2020 Note was convertible at a fixed convertible price of $9.28 per share. In connection with the issuance of the June 2020 Note, the Company paid a $100,000 due diligence fee by issuing 17,071 shares to the Investor priced at $5.86 per share. The Company also paid a placement fee of 7% of the gross proceeds to a placement agent.

 

In connection with the closing of the June 2020 Note, the Company issued a five-year warrant to the Investor to purchase 178,125 shares of common stock at a fixed exercise price of $9.28 per share and was immediately exercisable. The valuation of the warrant of $511,402 was recorded to debt discount and is was amortized over the life of the June 2020 Note. The fees associated with the agreement were allocated to debt issuance costs and additional paid-in capital based on the respective ratio of the valuation of the note and warrant. Amortization of the debt issuance costs and debt discount are included in interest expense on the statement of operations.

 

Following the completion of the underwritten offering in July 2020, the principal balance of $1,811,250 was paid in full during the third quarter of 2020. As a result of the repayment, the Company expensed the remaining debt discounts and issuance costs of $957,919 in July 2020.

 

 

NOTE P—LEASES

 

The Company’s leases office space in New Jersey under a lease terminating in 2023 and Hong Kong, Minnesota, and New Hampshire with lease termination dates in 2022. The property leased in China is paid monthly as used, without a formal agreement. The leases include non-lease components with variable payments. The following tables present the components of lease expense and supplemental balance sheet information related to the operating leases were:

 

   

Year ended

December 31,

2021

    

Year ended

December 31,

2020

  

Lease cost

                

Operating lease cost

   $ 255,892     $ 239,192  

Short-term lease cost

     -       -  

Total lease cost

   $ 255,892     $ 239,192  
                 

Balance sheet information

          

Operating right-of-use assets

   $ 254,100     $ 487,325  
                 

Operating lease liabilities, current portion

   $ 177,188     $ 234,309  

Operating lease liabilities, non-current portion

     86,974       264,163  

Total operating lease liabilities

   $ 264,162     $ 498,472  
                 

Weighted average remaining lease term (in years) – operating leases

     1.45       2.26  

Weighted average discount rate – operating leases

     5.50

%

     5.50

%
                 
Supplemental cash flow information related to leases were as follows:                
                 

Cash paid for amounts included in the measurement of operating lease liabilities

   $ 256,977     $ 235,186  
                 
Maturities of operating lease liabilities were as follows as of December 31, 2021:                
                 

2022

   $ 187,594          

2023

     89,225          

Total future lease payments

   $ 276,819          

Less: imputed interest

     (12,657

)

        

Total

   $ 264,162          

 

57
 
 

 

 

NOTE Q—COMMITMENTS AND CONTINGENCIES

 

Sales Incentive Agreement with TTI

 

On March 25, 2020, the Company entered into a sales incentive agreement Technology Transfer Institute (“TTI”). Terms of the agreement include the following:

 

 

1.

The original term of the agreement was one year and has been automatically extended for an additional one-year term.

 

 

2.

For each $5,000,000 in revenue (up to a maximum of $20,000,000) the Company generates from contracts sourced by TTI which are executed during the original term and generate net income of at least 20% (as defined) within eighteen months after the date such contract is executed, the Company will pay TTI a sales incentive fee of $500,000 payable by the issuance of 62,500 shares of common stock.

 

 

3.

In the event that the Company generates revenue in excess of $20,000,000 from contracts sourced by TTI which are executed during the original term and generate net income of at least 20% (as defined) within eighteen months after the date such contract is executed, the Company will issue TTI a five-year warrant to purchase 12,500 shares of Common Stock at an exercise price of $12.00 per share for each $1,000,000 of revenue in excess of $20,000,000 (up to a maximum of $25,000,000).

 

In no event will the Company be obligated to issue more than 250,000 shares of common stock or warrants to purchase more than 62,500 shares of common stock pursuant to this agreement. 

 

There has been no revenue generated nor sales incentive fees paid during the periods ended December 31, 2021 and 2020.

 

Litigation

 

From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of December 31, 2021, the Company was not a party to any pending lawsuits.

 

 

 

NOTE R— EQUITY

 

1. Preferred Stock

 

Within the limits and restrictions provided in the Company’s Certificate of Incorporation, the Board of Directors has the authority, without further action by the shareholders, to issue up to 5,000,000 shares of preferred stock, $.0001 par value per share, in one or more series, and to fix, as to any such series, any dividend rate, redemption price, preference on liquidation or dissolution, sinking fund terms, conversion rights, voting rights, and any other preference or special rights and qualifications.

 

2. Common Stock

 

Effective November 20, 2020, the Company implemented a reverse stock split of its outstanding common stock at a ratio of 1-for-8. The number of authorized shares and the par value of the Company's common stock and preferred stock were not affected by the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares were rounded up to the nearest whole share. The reverse stock split became effective at the opening of trading on November 20, 2020.

 

Holders of common stock have equal rights to receive dividends when, as and if declared by the Board of Directors, out of funds legally available therefor. Holders of common stock have one vote for each share held of record and do not have cumulative voting rights.

 

Holders of common stock are entitled, upon liquidation of the Company, to share ratably in the net assets available for distribution, subject to the rights, if any, of holders of any preferred stock then outstanding. Shares of common stock are not redeemable and have no preemptive or similar rights. All outstanding shares of common stock are fully paid and nonassessable.

 

58
 
 

Issuances of Common Stock

 

On June 18, 2021, the stockholders approved the Employee Stock Purchase Plan. Under the terms of this plan, 789,000 shares of common stock are reserved for issuance to employees and officers of the Company at 85% of the lower of the closing price of the common stock as reported on the Nasdaq Capital Market at the first day or the last day of the offering period. Eligible employees are granted an option to purchase shares under the plan funded by payroll deductions. The Board may suspend or terminate the plan at any time, otherwise the plan expires June 17, 2031. On December 31, 2021, 19,484 shares were issued to employees which resulted in a $10,680 non-cash compensation expense for the Company.

 

On July 23, 2020, the Company completed an underwritten public offering of shares of common stock and warrants resulting in net proceeds of approximately $22.7 million, after deducting underwriting discounts and commissions and estimated offering expenses. 4,264,313 shares of common stock were issued as a result of this offering, and a further 797,038 shares of common stock were issued upon the exercise of 512,500 prefunded warrants and 284,538 warrants exercised in conjunction with the offering.

 

On March 30, 2020, the Company issued 121,500 shares of common stock upon exercise of warrants at $12.00 per share, resulting in proceeds of $1,458,000 to the Company.

 

See Note O Convertible Notes Payable for common stock issuances related to conversion of convertible notes payable and shares of common stock issued for fees in connection with the agreements during fiscal 2020. 

 

Issuances of Restricted Stock

 

Restricted stock consists of shares of common stock that are subject to restrictions on transfer and risk of forfeiture until the fulfillment of specified conditions. The fair value of nonvested shares is determined based on the market price of the Company's common stock on the grant date. Restricted stock is expensed ratably over the term of the restriction period.

 

The Company issued 13,125 shares of restricted common stock to certain employees of the Company and 1,250 of shares of restricted common stock were forfeited during fiscal year 2021. These shares vest in equal annual installments over a three-year period from the date of grant and had a fair value on the date of issuance of $44,025.

 

The Company issued 38,250 and 3,125 shares of restricted common stock in August and November of 2020, respectively to certain employees and directors of the Company. These shares vest in equal annual installments over a three-year period from the date of grant and had a fair value on the date of issuance of $198,900, and $11,250, respectively.

 

Restricted stock compensation for the years ended December 31, 2021 and 2020 was $71,819 and $23,764, respectively.

 

Issuances to Directors, Executive Officers & Consultants

 

During the year ended December 31, 2021, the Company issued 7,828 shares of common stock to its directors in lieu of payment of board fees, valued at $25,536.

 

During the year ended December 31, 2020, the Company issued 5,270 shares of common stock to its directors in lieu of payment of board fees, valued at $28,511.

 

Employees’ exercise options

 

During 2021 and 2020, no employee stock options were exercised.

 

3. Warrants

 

There were no warrants issued during fiscal 2021.

 

Warrants Issued for Services:

 

During the second quarter of 2020, the Company issued a warrant to purchase 15,625 shares of common stock to an investor in payment for a business referral valued at $94,655.

 

During the third quarter of 2020, the Company issued a warrant to purchase 3,125 shares of common stock to a former employee for a business referral valued at $12,921.

 

Warrants Issued with Convertible Notes:

 

See Note O Convertible Notes Payable for warrants issued with convertible notes in connection with the agreements during fiscal 2020.

 

59
 
 

Valuation Assumptions for Warrants:

 

The Company records the warrants at their fair value which is determined using the Black-Scholes valuation model on the date of the grant. The fair value of each warrant was estimated with the following assumptions:

 

  

Year ended

December 31,

 
  

2021

  

2020

 

Weighted average Risk free interest rate

  -

%

  0.33

%

Weighted average price

 $-  $9.25 

Weighted average exercise period

  -   5 

Weighted average Volatility of stock price

  -

%

  110

%

 

The warrant volatility for each issuance is determined based on the review of the experience of the weighted average of historical daily price changes of the Company’s common stock over the expected exercise period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the years to maturity.

 

A summary of warrant activity is as follows:

 

  

Total

Warrants

  

Weighted

average

exercise

price

  

Weighted

average

remaining

life

(in years)

  

Aggregate

intrinsic

value

 
                 

Outstanding, as of December 31, 2019

  423,559   12.80   3.94   — 

Granted – public offering

  4,264,313   5.20         

Granted – prefunded warrants from the public offering

  512,500   0.08         

Granted – other

  434,375   9.25         

Increase due to trigger of anti-dilution provision feature

  27,244   5.20         

Exercised – public offering

  (284,538

)

  5.20         

Exercised – prefunded warranted from the public offering

  (512,500

)

  0.08         

Exercised – other

  (121,500

)

  12.00         

Forfeited

  —   —         

Expired

  (54,066

)

  6.86         

Outstanding, as of December 31, 2020

  4,689,387   6.04   4.48   — 

Granted

  —   —         

Exercised

  —   —         

Forfeited

  —   —         

Expired

  —   —         

Outstanding, as of December 31, 2021

  4,689,387   6.04   3.48   — 

 

The aggregate intrinsic value in the table above represents the total intrinsic value, based on the Company’s closing stock price of $2.21, $3.52 and $4.00 as of December 31, 2021, 2020 and 2019, respectively, which would have been received by the warrant holders had all warrant holders exercised their options as of that date. There were no in-the-money warrants exercisable as of December 31, 2021, 2020 and 2019.

 

4.  Securities Purchase Agreement dated September 23, 2015

 

On September 23, 2015, the Company issued warrants (the “2015 Warrants”) to purchase 8,681 shares of common stock in connection with the issuance of a promissory note. The warrants were immediately exercisable at an initial exercise price of $28.80 per share and had a term of five years.  The 2015 Warrants expired in September 2020.

 

The 2015 Warrants had a “full ratchet” anti-dilution adjustment provision.  The anti-dilution adjustment provision was triggered in the first quarter of 2020 from the February 2020 Note and amendments to the Original Note. As a result of the forgoing transactions, the number of shares of common stock issuable upon the full exercise of the 2015 Warrants increased to 48,078, the exercise price was reduced to $5.20 per share, and the Company recorded a non-cash deemed dividend in amount of $41,688. 

 

60
 

 

 

NOTE S—STOCK OPTIONS

 

2004 Stock Option Plan

 

On October 12, 2004, the Board of Directors of the Company approved the 2004 Stock Option Plan (the “2004 Plan”). The 2004 Plan was not presented to stockholders for approval and thus incentive stock options were not available under this plan. Under the terms of this plan, 20,834 shares of common stock were reserved for issuance to employees, officers, directors, and consultants of the Company at exercise prices which may not be below 85% of fair market value. The term of stock options granted may not exceed ten years. Options issued under the 2004 Plan vest pursuant to the terms of stock option agreements with the recipients. In the event of a change in control, as defined, all options outstanding vest immediately. The 2004 Plan expired in October 2014.

 

2015 Stock Option Plan

 

On January 27, 2016, the stockholders approved the 2015 Equity Incentive Plan (the “2015 Plan”). The 2015 Plan initially reserved 187,500 shares of common stock for issuance of options, restricted stock, and other equity based awards to employees, officers, directors, and consultants of the Company. In 2019, the stockholders approved an amendment to the 2015 Plan which increases the number of shares of common stock authorized for issuance under the 2015 Plan from 83,334 shares to 187,500 shares and also effected certain changes in light of the Tax Cuts and Jobs Act of 2017 and its impact on Section 162(m) of the United States Internal Revenue Code of 1986, as amended. In 2021, the stockholders approved an amendment to the 2015 to increase the shares of common stock authorized for issuance under the 2015 Plan from 187,500 shares to 789,000 shares together with other technical changes. In 2021, the stockholders approved an amendment to the 2015 to increase the shares of common stock authorized for issuance under the 2015 Plan from 187,500 shares to 789,000 shares together with other technical changes.  The term of stock options granted under the 2015 Plan, may not exceed ten years, exercise prices may not be below 100-110% of fair market value, and vesting occurs over time periods set forth in written agreements with the recipients. In the event of a change in control, certain stock awards issued under the 2015 Plan may be subject to additional acceleration of vesting as may be provided in the participants’ written agreement. The 2015 Plan expires in December 2025.

 

Non-Plan Stock Options

 

Periodically, the Company has granted options outside of the 2004 and 2015 Plans to various employees and consultants. In the event of change in control, as defined, certain of the non-plan options outstanding vest immediately.

 

Stock Option Activity

 

Information summarizing option activity is as follows:

 

  

Number of Options

  

Weighted

average

  

Weighted

average

remaining

  

Aggregate

 
  

2004

Plan

  

2015

Plan

  

Non

Plan

  

Total

  

exercise

price

  

life

(in years)

  

intrinsic

value

 
                             

Outstanding, as of December 31, 2019

  3,906   70,991   144,070   218,967  $20.08   5.00  $0 

Granted

  —   28,440   —   28,440   5.04         

Exercised

  —   —   —   —   —         

Forfeited

  —   (4,545

)

  —   (4,545

)

  17.34         

Expired

  (3,906

)

  (703

)

  (10,979

)

  (15,588

)

  29.17         

Outstanding, as of December 31, 2020

  —   94,183   133,091   227,274  $17.61   3.87  $0 
                             

Granted

  —   —   —   —  

‐—

         

Exercised

  —   —   —   —   —         

Forfeited

  —   (3,291

)

  —   (3,291

)

  3.87         

Expired

  —   (84

)

  (11,438

)

  (11,522

)

  39.13         

Outstanding, as of December 31, 2021

  —   90,808   121,653   212,461  $16.65   3.03  $0 

Vested or expected to vest at December 31, 2021

           206,283  $16.98   2.95  $0 

Exercisable at December 31, 2021

           186,538  $18.04   2.73  $0 

 

61
 
 

The options outstanding and exercisable at December 31, 2021 were in the following exercise price ranges:

 

      

Options Outstanding

  

Options Exercisable

 

Range of exercise prices

  

Number of

shares

  

Weighted

average

exercise

price

  

Weighted

average

remaining

life (in years)

  

Number

exercisable

  

Weighted

average

exercise

price

 
$4.08-5.20   24,940  $5.19   5.64   8,402  $5.17 
$5.21-15.68   49,669   12.17   3.79   40,284   12.85 
$15.69-39.36   137,852   20.34   2.27   137,852   20.34 
$4.08-39.36   212,461           186,538     

 

The aggregate intrinsic value in the table above represents the total intrinsic value, based on the Company’s closing stock price of $2.21, $3.52 and $4.00 as of December 31, 2021, 2020 and 2019, respectively, which would have been received by the option holders had all option holders exercised their options as of that date. There were no in-the-money options exercisable as of December 31, 2021, 2020 and 2019.

 

The weighted average fair value of options granted during the year ended December 31, 2020 was $3.16 per share. The total intrinsic value of options exercised during the years ended December 31, 2021 and 2020 was $0 as no options were exercised in either year. The total fair value of shares vested during the years ended December 31, 2021 and 2020 was $252,874 and $899,750, respectively.

 

As of December 31, 2021, future forfeiture adjusted compensation cost related to nonvested stock options is $75,035 and will be recognized over an estimated weighted average period of 0.86 years.

 

 

 

NOTE T—INCOME TAXES

 

There was no provision for federal or state taxes as at December 31, 2021 and 2020.

 

The Company has deferred taxes due to income tax credits, net operating loss carryforwards, and the effect of temporary differences between the carrying values of certain assets and liabilities for financial reporting and income tax purposes. Significant components of deferred taxes are as follows at December 31:

 

  

2021

  

2020

 
         

Accrued compensation

 $135,000  $81,000 

Accounts receivable allowance

  75,000   474,000 

Stock-based compensation

  1,149,000   1,073,000 

Basis differences in fixed assets

  (10,000

)

  (14,000

)

Basis differences in intangible assets

  75,000   65,000 

Net operating loss and credit carryforwards

  14,467,000   13,337,000 

Valuation allowances

  (15,891,000

)

  (15,016,000

)

         
  $—  $— 

 

The Company has a valuation allowance against the full amount of its net deferred taxes due to the uncertainty of realization of the deferred tax assets due to operating loss history of the Company. The Company currently provides a valuation allowance against deferred taxes when it is more likely than not that some portion, or all of its deferred tax assets will not be realized. The valuation allowance could be reduced or eliminated based on future earnings and future estimates of taxable income. Similarly, income tax benefits related to stock options exercised have not been recognized in the financial statements.

 

As of December 31, 2021, the Company has federal net operating loss carryforwards of approximately $61 million. Approximately $46 million are subject to expiration between 2021 and 2037, and $15 million net operating loss carryforwards have no expiration date. These net operating loss carryforwards are subject to the limitations under Section 382 of the Internal Revenue Code due to changes in the equity ownership of the Company.

 

62
 
 

A reconciliation of the effective income tax rate on operations reflected in the Statements of Operations to the US Federal statutory income tax rate is presented below.

 

  

2021

  

2020

 
         

Federal statutory income tax rate

  21

%

  21

%

Permanent differences

  -

 

  (9

)

Effect of net operating loss

  (21

)

  (12

)

         

Effective tax rate

  —

%

  —

%

 

The Company has not been audited by the Internal Revenue Service (“IRS”) or any states in connection with income taxes. The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The periods from 2018 through 2021 remain open to examination by the IRS and state jurisdictions. The Company believes it is not subject to any tax audit risk beyond those periods. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company does not have any accrued interest or penalties associated with any unrecognized tax benefits, nor was any interest expense incurred during the years ended December 31, 2021 and 2020.

 

 

 

NOTE U—PROFIT SHARING PLAN

 

The Company has established a savings plan under section 401(k) of the Internal Revenue Code. All employees of the Company, after completing one day of service, are eligible to enroll in the 401(k) plan. Participating employees may elect to defer a portion of their salary on a pre-tax basis up to the limits as provided by the IRS Code. The Company is not required to match employee contributions but may do so at its discretion. The Company made no contributions during the years ended December 31, 2021 and 2020.

 

 

 

NOTE V—EARNINGS PER SHARE (EPS)

 

The Company’s basic EPS is calculated using net income (loss) available to common shareholders and the weighted-average number of shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuance of common stock, such as stock issuable pursuant to the exercise of stock options and warrants and the assumed conversion of preferred stock.

 

The reconciliation of the numerator of the basic and diluted EPS calculations for the following fiscal years ended December 31:

 

   

2021

    

2020

  
                 

Basic Numerator:

                

Net Loss

   $ (5,065,781

)

   $ (9,673,987

)

Deemed dividend from trigger of anti-dilution provision feature

     -       (112,686

)

Net loss available to common stockholders (basic and diluted EPS)

   $ (5,065,781

)

   $ (9,786,673

)

 

The following table summarizes the weighted average securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive due to net losses.

 

   

Years ended December 31,

  
   

2021

    

2020

  
                 

Stock options

     -       1,002  

Restricted stock

     -       3,098  

Potentially dilutive securities

     -       4,100  

 

63
 
 

Items excluded from the diluted per share calculation because the exercise price was greater than the average market price of the common shares:

 

   

Years ended December 31,

  
   

2021

    

2020

  
                 

Stock options

     212,461       223,899  

Warrants

     4,689,387       4,689,387  

Total

     4,901,848       4,913,286  

 

 

 

NOTE W—SUBSEQUENT EVENTS

 

On March 8, 2022, the Company completed the acquisition of 100% of the issued and outstanding capital stock of Swivel Secure Europe, SA pursuant to the terms of a stock purchase agreement. The aggregate purchase price consisted of a base purchase price of $1.75 million, subject to closing adjustments based on the closing date working capital, indebtedness and unpaid transaction expenses, and an earn-out of up to $500,000. At the closing, the Company made a cash payment of $1.27 million and issued 269,060 shares of common stock of which 89,687 shares were held back by the Company to secure certain indemnification obligations under the stock purchase agreement.

 

On March 10, 2022, the Company issued 6,360 shares of common stock to its directors in payment of board fees. Additionally, the Company issued an aggregate of 848 shares of common stock to its directors in payment of board committee fees. 

 

On March 11, 2022, the Company issued 932 shares of common stock to its directors in payment of board committee fees. The Company issued an aggregate of 274,250 shares of restricted common stock to employees and the board of directors which vest in equal annual installments over a three-year period from the date of grant.

 

The Company has reviewed subsequent events through the date of this filing. 

 

64
 

 

 

EXHIBIT INDEX

 

Exhibit

  

Exhibit 

No.

    
     

2.1

  

Stock Purchase Agreement by and among the Company, Thomas J. Hoey, and PistolStar, Inc. dated June 6, 2020 (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K, filed with the SEC on July 7, 2020)
     
2.2   Stock Purchase Agreement by and among the Company, Alex Rocha and Swivel Secure Europe, SA dated February 2, 2022 (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K, filed with the SEC on February 3, 2022)
     
2.3   Amendment No. 1 to Stock Purchase Agreement by and among the Company, Alex Rocha and Swivel Secure Europe, SA dated March 4, 2022 (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K, filed with the SEC on March 9, 2022)
     

3.1

  

Certificate of Incorporation of BIO-key International, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed with the SEC on January 5, 2005)
     

3.2

  

Bylaws (incorporated by reference to Exhibit 3.3 to the current report on Form 8-K, filed with the SEC on January 5, 2005)
     

3.3

  

Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Appendix A to the definitive proxy statement, filed with the SEC on January 18, 2006)
     

3.4

  

Certificate of Amendment of Certificate of Incorporation of Bio-key International, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed with the SEC on March 31, 2015)
     

3.5

  

Certificate of Elimination of BIO-key International, Inc. filed October 6, 2015 (incorporated by reference to Exhibit 3.5 to the registration statement on Form S-1 File No. 333-208747 filed with the SEC on December 23, 2015)
     

3.6

  

Certificate of Designation of Preferences, Rights and Limitations of Series A-1 Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed with the SEC on November 2, 2015)
     

3.7

  

Certificate of Designation of Preferences, Rights and Limitations of Series B-1 Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the quarterly report on Form 10-Q, filed with the SEC on November 16, 2015)
     

3.8

  

Certificate of Amendment of Certificate of Incorporation of Bio-key International, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed with the SEC on December 28, 2016)
     

3.9

  

Certificate of Amendment of Certificate of Incorporation of Bio-Key International, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed with the SEC on November 19, 2020)
     

4.1

  

Specimen Stock Certificate (incorporated by reference to Exhibit 4.1 to the registration statement on Form SB-2, File No. 333-16451)

     

4.2

  

Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.2 to Amendment No. 1 to the Registration Statement on Form S-1/A, filed with the SEC on July 17, 2020)
     

4.3

  

Form of Warrant (incorporated by reference to Exhibit 4.3 to Amendment No. 1 to the Registration Statement on Form S-1/A, filed with the SEC on July 17, 2020)
     

4.4

  

Form of Warrant Agency Agreement (incorporated by reference to Exhibit 4.4 to Amendment No. 2 to the Registration Statement on Form S-1/A, filed with the SEC on July 20, 2020)
     
4.5   BIO-key International, Inc. Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934*
     

10.1

  

Employment Agreement by and between BIO-key International, Inc. and Mira LaCous dated November 20, 2001 (incorporated by reference to Exhibit 10.39 to the current report on Form 8-K, filed with the SEC on January 22, 2002)***
     

10.2

  

BIO-key International, Inc. 2004 Stock Incentive Plan (incorporated by reference to Exhibit 10.48 to amendment no. 1 the registrant’s registration statement on Form SB-2, File No. 33-120104, filed with the SEC on December 14, 2004)***
     

10.3

  

Employment Agreement, effective March 25, 2010, by and between the Company and Michael W. DePasquale (incorporated by reference to Exhibit 10.93 to the annual report on Form 10-K, filed with the SEC on March 26, 2010)***
     

10.4

  

Employment Agreement by and between BIO-key International, Inc. and Cecilia Welch dated May 15, 2013 (incorporated by reference to Exhibit 10.42 to the annual report on Form 10-K, filed with the SEC on March 31, 2014)***
     

10.5

  

Employment Agreement by and between BIO-key International, Inc. and James Sullivan dated April 5, 2017 (incorporated by reference to Exhibit 10.42 to the annual report on Form 10-K, filed with the SEC on March 29, 2021)***

 

65
 

 

10.6

  

First Amendment to Lease Agreement by and between BIO-key International, Inc. and BRE/DP MN LLC dated September 12, 2013 (incorporated by reference to Exhibit 10.44 to the annual report on Form 10-K, filed with the SEC on March 31, 2014)
     

10.7

  

BIO-key International, Inc. 2015 Equity Incentive Plan (incorporated by reference to Appendix B to the definitive proxy statement filed with the SEC on December 15, 2015)***
     

10.9

  

Software License Purchase Agreement Dated November 11, 2015 by and among BIO-key Hong Kong Limited, Shining Union Limited, WWTT Technology China, Golden Vast Macao Commercial Offshore Limited, Giant Leap International Limited (incorporated by reference to Exhibit 10.36 to the registration statement on Form S-1 File No. 333-208747 filed with the SEC on December 23, 2015)**
     

10.11

  

Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.3 to the current report on Form 8-K, filed with the SEC on May 3, 2017)
     

10.12

  

Form Non-Plan Option Agreement between the Company and certain of its directors, officers, employees and contractors (incorporated by reference to Exhibit 10.4 to the quarterly report on Form 10-Q filed with the SEC on May 15, 2017)***
     

10.13

  

Securities Purchase Agreement dated April 3, 2018 by and between the Registrant and Wong Kwok Fong (Kelvin) (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the SEC on April 4, 2018)
     

10.14

  

Securities Purchase Agreement dated May 23, 2018 by and between the Registrant and Giant Leap International Limited (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the SEC on May 30, 2018)
     

10.15

  

Securities Purchase Agreement dated May 23, 2018 by and between the Registrant and Micron Technology Development Limited (incorporated by reference to Exhibit 10.2 to the current report on Form 8-K, filed with the SEC on May 30, 2018)
     

10.16

  

Securities Purchase Agreement dated May 31, 2018 by and between the Registrant and Wong Kwok Fong (Kelvin) (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the SEC on June 4, 2018)
     

10.17

  

Underwriting Agreement dated August 22, 2018 by and between the Registrant and Maxim Group LLP (incorporated by reference to Exhibit 1.1 to the current report on Form 8-K, filed with the SEC on August 27, 2018)
     

10.18

  

Form of Common Stock Purchase Warrant dated August 24, 2018 (incorporated by reference to Exhibit 4.1 to the current report on Form 8-K, filed with the SEC on August 27, 2018)
     

10.19

  

GLP 2nd Amendment to Lease dated July 27, 2018 (incorporated by reference to Exhibit 10.26 to the annual report on Form 10-K, filed with the SEC on April 1, 2019)
     

10.20

  

Marlen 4th Amendment to Lease dated June 2, 2018 (incorporated by reference to Exhibit 10.27 to the annual report on Form 10-K, filed with the SEC on April 1, 2019)
     

10.21

  

Securities Purchase Agreement dated July 10, 2019 by and between the Registrant and Lind Global Macro Fund, LP. (incorporated by reference to Exhibit 10.1 to the quarterly report on Form 10-Q, filed with the SEC on August 14, 2019)
     

10.22

  

Security Agreement dated July 10, 2019 by and between the Registrant and Lind Global Macro Fund, LP. (incorporated by reference to Exhibit 10.2 to the quarterly report on Form 10-Q, filed with the SEC on August 14, 2019)
     

10.23

  

Collateral Sharing Agreement dated July 10, 2019 by and among the Registrant, Lind Global Macro Fund, LP and Versant Funding LLC (incorporated by reference to Exhibit 10.3 to the quarterly report on Form 10-Q, filed with the SEC on August 14, 2019)
     

10.24

  

$3,060,00 Senior Secured Convertible Promissory Note dated July 10, 2019 (incorporated by reference to Exhibit 10.4 to the quarterly report on Form 10-Q, filed with the SEC on August 14, 2019)
     

10.25

  

Common Stock Purchase Warrant dated July 10, 2019 (incorporated by reference to Exhibit 10.5 to the quarterly report on Form 10-Q, filed with the SEC on August 14, 2019)
     

10.26

  

BIO-key International, Inc. Amended and Restated 2015 Equity Incentive Plan (incorporated by reference to Appendix A to the definitive proxy statement filed with the SEC on April 30, 2019)***

 

66
 

 

10.27

  

Sales Incentive Agreement with Technology Transfer Institute dated March 25, 2020. (incorporated by reference to Exhibit 10.1 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)
     

10.28

  

Form of Technology Transfer Institute Warrant. (incorporated by reference to Exhibit 10.2 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)
     

10.29

  

Amended and Restated Senior Secured Convertible Promissory Note, due April 13, 2020 issued by the Company to Lind Global Macro Fund, LP. (incorporated by reference to Exhibit 10.3 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)
     

10.30

  

Amendment to Amended and Restated Senior Secured Convertible Promissory Note, due April 13, 2020 by and between the Company and Lind Global Macro Fund, LP dated April 12, 2020. (incorporated by reference to Exhibit 10.4 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)
     

10.31

  

Securities Purchase Agreement dated May 6, 2020 by and between the Company and Lind Global Macro Fund, LP. (incorporated by reference to Exhibit 10.5 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)
     

10.32

  

$2,415,000 Senior Secured Convertible Promissory Note dated May 6, 2020. (incorporated by reference to Exhibit 10.6 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)
     

10.33

  

Common Stock Purchase Warrant dated May 6, 2020. (incorporated by reference to Exhibit 10.7 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)
     

10.34

  

Amended and Restated Security Agreement dated May 6, 2020 by and between the Company and Lind Global Macro Fund, LP. (incorporated by reference to Exhibit 10.8 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)
     

10.35

  

Amendment No. 2 to Amended and Restated Senior Secured Convertible Promissory Note, due April 13, 2020 by and between the Company and Lind Global Macro Fund, LP dated May 13, 2020. (incorporated by reference to Exhibit 10.9 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)
     

10.36

  

Securities Purchase Agreement dated June 29, 2020 by and between the Company and Lind Global Macro Fund, LP (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the SEC on July 1, 2020)
     

10.37

  

$1,811,250 Senior Secured Convertible Promissory Note dated June 29, 2020. (incorporated by reference to Exhibit 10.2 to the current report on Form 8-K, filed with the SEC on July 1, 2020)
     

10.38

  

Common Stock Purchase Warrant dated May 6, 2020. (incorporated by reference to Exhibit 10.3 to the current report on Form 8-K, filed with the SEC on July 1, 2020)
     

10.39

  

Second Amended and Restated Security Agreement dated June 29, 2020 by and between the Company and Lind Global Macro Fund, LP (incorporated by reference to Exhibit 10.4 to the current report on Form 8-K, filed with the SEC on July 1, 2020)
     

10.40

  

$500,000 Promissory note, dated June 30, 2020 (Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the SEC on July 7, 2020)
     

10.41

  

Form of Restricted Stock Award Agreement under the BIO-key International, Inc. Amended & Restated 2015 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the SEC on August 28, 2020)***
     
10.42   BIO-key International, Inc. 2021 Employee Stock Purchase Plan (incorporated by reference to Appendix A to the definitive proxy statement filed with the SEC on May 4, 2021)
     
10.43   BIO-key International, Inc. Amended and Restated 2015 Equity Incentive Plan (incorporated by reference to Appendix B to the definitive proxy statement filed with the SEC on May 4, 2021)
     

21.1*

  

List of subsidiaries of BIO-key International, Inc.
     

23.1*

  

Consent of RMSBG

 

31.1*

  

Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*

  

Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1*

  

Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2*

  

Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

67
 

 

101.INS*

Inline XBRL Instance
   

101.SCH*

Inline XBRL Taxonomy Extension Schema
   

101.CAL*

Inline XBRL Taxonomy Extension Calculation
   

101.DEF*

Inline XBRL Taxonomy Extension Definition
   

101.LAB*

Inline XBRL Taxonomy Extension Labels
   

101.PRE*

Inline XBRL Taxonomy Extension Presentation
   
104 Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101)

 

*  filed herewith

 

** Confidential treatment has been requested with respect to certain portions of this exhibit. Omitted sections have been filed separately with the Securities and Exchange Commission

 

*** Management compensatory plan.

 

68
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

BIO-KEY INTERNATIONAL, INC.
     

Date: March 31, 2022

By:

/s/  MICHAEL W. DEPASQUALE
   

Michael W. DePasquale
   

CHIEF EXECUTIVE OFFICER

(Principal Executive Officer)

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities on the dates indicated.

 

 

Signature

  

Title

  

Date
         

/s/  MICHAEL W.

DEPASQUALE

  

Chairman of the Board of Directors, Chief Executive Officer and Director

(Principal Executive Officer)

  

March 31, 2022

Michael W. DePasquale

        
         

/s/  CECILIA WELCH

  

Chief Financial Officer (Principal Financial and Accounting Officer)

  

March 31, 2022

Cecilia Welch

        
         

/s/ROBERT J. MICHEL

  

Director

  

March 31, 2022

Robert J. Michel

        
         

/s/  THOMAS E. BUSH III

  

Director

  

March 31, 2022

Thomas E. Bush

        
         

/s/  THOMAS GILLEY

  

Director

  

March 31, 2022

Thomas Gilley

        
         

/s/  WONG KWOK FONG

  

Director

  

March 31, 2022

Wong Kwok Fong

        
         

/s/  PIETER KNOOK

  

Director

  

March 31, 2022

Pieter Knook

        
         

/s/  MANNY ALIA

  

Director

  

March 31, 2022

Manny Alia

        

 

69
EX-4.5 2 ex_353505.htm EXHIBIT 4.5 HTML Editor

Exhibit 4.5

BIO-KEY INTERNATIONAL, INC.

DESCRIPTION OF SECURITIES REGISTERED

PURSUANT TO SECTION 12 OF

THE SECURITIES EXCHANGE ACT OF 1934

 

BIO-key International, Inc., a Delaware corporation (“we,” “us” and “our”), has only one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, $0.0001 par value per share (“common stock”).

 

Common Stock

 

The following summary description of our common stock is based on the provisions of our certificate of incorporation and bylaws, which are incorporated by reference into our most recently filed Annual Report on Form 10-K, and the applicable provisions of the Delaware General Corporation Law (“DGCL”). This information may not be complete in all respects and is qualified in its entirety by reference to the provisions of our certificate of incorporation, our bylaws and the DGCL. We encourage you to read our certificate of incorporation, our bylaws and the applicable provisions of the DGCL for additional information.

 

Authorized. We currently have authority to issue up to 170,000,000 shares of common stock. From time to time, we may amend our certificate of incorporation to increase the number of authorized shares of common stock. Any such amendment would require the approval of the holders of a majority of the voting power of the shares entitled to vote thereon.

 

Voting. For all matters submitted to a vote of stockholders, each holder of common stock is entitled to one vote for each share registered in the holder’s name on our books. Our common stock does not have cumulative voting rights. Holders of a plurality of our outstanding common stock can elect all of the directors who are up for election in a particular year. Holders of a majority of our outstanding common stock act by a majority for all other matters, except as limited by our certificate of incorporation, our bylaws and the DGCL.

 

Dividends. If our Board of Directors declares a dividend, holders of common stock will receive payments from our funds that are legally available to pay dividends. However, this dividend right is subject to any preferential dividend rights we may grant to the persons who hold preferred stock, $0.0001 par value per share (“preferred stock”), if any is outstanding.

 

Liquidation and Dissolution. If we are liquidated or dissolve, the holders of our common stock will be entitled to share ratably in all the assets that remain after we pay our liabilities and any amounts we may owe to the persons who hold preferred stock, if any is outstanding.

 

Fully Paid and Nonassessable. All shares of our outstanding common stock are fully paid and nonassessable and any additional shares of common stock that we issue will be fully paid and nonassessable.

 

Other Rights and Restrictions. Holders of our common stock do not have preemptive or subscription rights, and they have no right to convert their common stock into any other securities. Our common stock is not subject to redemption by us, and there are no sinking fund provisions applicable to our common stock. The rights, preferences and privileges of common stockholders are subject to the rights of the stockholders of any series of preferred stock which we may designate in the future. Our certificate of incorporation and bylaws do not restrict the ability of a holder of common stock to transfer his or her shares of common stock.

 

Listing. Our common stock is listed on The Nasdaq Capital Market under the symbol “BKYI.”

 

Transfer Agent and Registrar. The transfer agent and registrar for our common stock is Broadridge Corporate Issuer Solutions, Inc.

 

Certain Effects of Delaware Law and Certificate of Incorporation and Bylaw Provisions

 

Authorized But Unissued Stock. We are authorized to issue 175,000,000 shares of capital stock, consisting of 170,000,000 shares of common stock and 5,000,000 shares of preferred stock. We have shares of common stock and preferred stock available for future issuance without stockholder approval, subject to any limitations imposed by the listing standards of The Nasdaq Capital Market. We may use these additional shares for a variety of corporate purposes, including for future public or private offerings to raise additional capital or facilitate corporate acquisitions or for payment as a dividend on our capital stock. The existence of unissued and unreserved common stock and preferred stock may enable our Board of Directors to issue shares to persons friendly to current management that could render more difficult or discourage a third-party attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of our management.

 

 
 

 

Blank Check Preferred Stock. Our Board of Directors is authorized without further stockholder action, to designate any number of series of preferred stock with such rights, preferences and designations as determined by the Board of Directors. Shares of preferred stock issued by the Board of Directors could be utilized, under certain circumstances, to make an attempt to gain control of the Company more difficult or time-consuming. For example, shares of preferred stock could be issued with certain rights that might have the effect of diluting the percentage of common stock owned by a significant stockholder or issued to purchasers who might side with management in opposing a takeover bid that the Board of Directors determines is not in the best interests of the Company and its stockholders. The existence of the preferred stock may, therefore, be viewed as having possible anti-takeover effects.

 

Advance Notice Requirements for Stockholder Proposals and Director Nominations. Our bylaws provide that stockholders who desire to nominate a person for election to our Board of Directors must comply with specified notice and information provisions. Our bylaws contain similar advance notice provisions for stockholder proposals for action at stockholder meetings. These provisions prevent stockholders from making nominations for directors and stockholder proposals from the floor at any stockholder meeting and require any stockholder making a nomination or proposal to submit the name of the nominees for board seats or the stockholder proposal, together with specified information about the nominee or any stockholder proposal, prior to the meeting at which directors are to be elected or action is to be taken. These provisions ensure that stockholders have adequate time to consider nominations and proposals before action is required, and they may also have the effect of delaying stockholder action.

 

Supermajority Vote Requirements. Any director may be removed from office only with cause and only by the affirmative vote of the holders of 75% or more of our shares then entitled to vote at an election of directors. Additionally, our bylaws may be amended or repealed by the affirmative vote of at least 75% of the outstanding shares entitled to vote on such amendment or repeal, voting together as a single class. These provisions may prevent stockholders from removing existing directors and amending our bylaws, each of which could have the effect of delaying or preventing a change in control of our company.

 

Indemnification. Our certificate of incorporation and bylaws contain provisions to indemnify our directors and officers to the fullest extent permitted by the DGCL. These provisions do not limit or eliminate our right or the right of any stockholder of ours to seek non-monetary relief, such as an injunction or rescission in the event of a breach by a director or an officer of his duty of care to us.

 

Business Combinations. We are subject to the provisions of Section 203 of the DGCL. Subject to certain exceptions, Section 203 prohibits a publicly held Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A “business combination” includes mergers, asset sales and other transactions resulting in a financial benefit to the interested stockholder. Subject to exceptions, an “interested stockholder” is a person who, together with affiliates and associates, owns, or within the prior three years did own, 15% or more of the corporation’s voting stock. This provision could have the effect of delaying or preventing a change in control of our company.

 

 
 EX-21.1 3 ex_351264.htm EXHIBIT 21.1 ex_351264.htm

Exhibit 21.1

Subsidiaries

 

Name

State/Country of Incorporation

 

BIO-key Hong Kong Limited

Hong Kong
   

Public Safety Group, Inc. 

Delaware
   

PistolStar, Inc.

New Hampshire
   

BIOKEY AFRICA LIMITED

Nigeria
   
Swivel Secure Europe, SA Spain
   
Swivel Secure, Unipessoal LDA. Portugal

 

 

 
 EX-23.1 4 ex_351265.htm EXHIBIT 23.1 ex_351265.htm

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

 

We consent to the incorporation by reference into the registration statements of BIO-key International, Inc. on Form S-8 (file nos. 333- 233737, 333-212066, 333-257520 and 333-257754), Form S-1 (file no. 333-239782), and Form S-3 (file nos. 333-233713, 333-225934 and 333-257875) of our report dated March 31, 2022 relating to the financial statements which appear in this Form 10-K for the year ended December 31, 2021.

 

 

/s/ Rotenberg Meril Solomon Bertiger & Guttilla, P.C.

 

ROTENBERG MERIL SOLOMON BERTIGER & GUTTILLA, P.C.

Saddle Brook, New Jersey

March 31, 2022

 

 
 EX-31.1 5 ex_351266.htm EXHIBIT 31.1 ex_351266.htm

Exhibit 31.1

 

CERTIFICATION

 

I, Michael W. DePasquale, certify that: 

 

1. I have reviewed this annual report on Form 10-K of BIO-key International, Inc. (the “Company”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

 

4. The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 

 

(d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

 

5. The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions): 

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and 

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

 

 

Dated: March 31, 2022

  
   
 

/s/ Michael W. DePasquale
 

Michael W. DePasquale
 

Chief Executive Officer

 

 
 EX-31.2 6 ex_351267.htm EXHIBIT 31.2 ex_351267.htm

Exhibit 31.2

 

CERTIFICATION

 

I, Cecilia C. Welch, certify that: 

 

1. I have reviewed this annual report on Form 10-K of BIO-key International, Inc. (the “Company”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

 

4. The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

 

5. The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions): 

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and 

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

 

 

Dated: March 31, 2022

  
   
 

/s/ CECILIA C. WELCH
 

Cecilia C. Welch
 

Chief Financial Officer

 

 
 EX-32.1 7 ex_351268.htm EXHIBIT 32.1 ex_351268.htm

Exhibit 32.1

 

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of BIO-key International, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael W. DePasquale, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

 

 

BIO-KEY INTERNATIONAL, INC.
   
   
 

By:

/s/ Michael W. DePasquale
   

Michael W. DePasquale
   

Chief Executive Officer
   
 

Dated: March 31, 2022
 
 EX-32.2 8 ex_351269.htm EXHIBIT 32.2 ex_351269.htm

Exhibit 32.2

 

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of BIO-key International, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Cecilia Welch, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002, that to my knowledge:

 

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

 

 

BIO-KEY INTERNATIONAL, INC.
   
   
 

By:

/s/ CECILIA C. WELCH
   

Cecilia C. Welch
   

Chief Financial Officer
   
 

Dated: March 31, 2022

 

 

 
 EX-101.SCH 9 bkyi-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note B - Revenue From Contracts With Customers link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note C - PistolStar, Inc. Acquisition link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note D - Factoring link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note E - Fair Values of Financial Instruments link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note F - Concentration of Risk link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note G - Note Receivable link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note H - Inventory link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note I - Resalable Software Licenses Rights link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note J - Investment in Debt Security link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note K - Equipment and Leasehold Improvements link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note L - Intangible Assets link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note M - Accrued Liabilities link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note N - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note O - Convertible Notes Payable link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note P - Leases link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note Q - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note R - Equity link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note S - Stock Options link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note T - Income Taxes link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note U - Profit Sharing Plan link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note V - Earnings Per Share (EPS) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note W - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note B - Revenue From Contracts With Customers (Tables) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note C - PistolStar, Inc. Acquisition (Tables) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note D - Factoring (Tables) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note G - Note Receivable (Tables) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note H - Inventory (Tables) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note I - Resalable Software Licenses Rights (Tables) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note K - Equipment and Leasehold Improvements (Tables) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note L - Intangible Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note M - Accrued Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note P - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note R - Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note S - Stock Options (Tables) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note T - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note V - Earnings Per Share (EPS) (Tables) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Summary of Accounts Receivable (Details) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Estimated Useful Lives for Depreciation and Amortization (Details) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Share-based Compensation Expenses for Continuing Operations (Details) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Valuation Assumptions for Stock Options (Details) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note B - Revenue From Contracts With Customers (Details Textual) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note B - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note C - PistolStar, Inc. Acquisition (Details Textual) link:calculationLink link:definitionLink link:presentationLink 053 - Disclosure - Note C - PistolStar, Inc. Acquisition - Assets Acquired and Liabilities Assumed (Details) link:calculationLink link:definitionLink link:presentationLink 054 - Disclosure - Note C - PistolStar, Inc. Acquisition - Assets Acquired and Liabilities Assumed (Details) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 055 - Disclosure - Note C - PistolStar, Inc. Acquisition - Intangible Assets Acquired (Details) link:calculationLink link:definitionLink link:presentationLink 056 - Disclosure - Note D - Factoring (Details Textual) link:calculationLink link:definitionLink link:presentationLink 057 - Disclosure - Note D - Factoring - Due From Factor (Details) link:calculationLink link:definitionLink link:presentationLink 058 - Disclosure - Note D - Factoring - Fees (Details) link:calculationLink link:definitionLink link:presentationLink 059 - Disclosure - Note F - Concentration of Risk (Details Textual) link:calculationLink link:definitionLink link:presentationLink 060 - Disclosure - Note G - Note Receivable (Details Textual) link:calculationLink link:definitionLink link:presentationLink 061 - Disclosure - Note G - Note Receivable - Summary of Note Receivable (Details) link:calculationLink link:definitionLink link:presentationLink 062 - Disclosure - Note H - Inventory - Components of Inventory (Details) link:calculationLink link:definitionLink link:presentationLink 063 - Disclosure - Note I - Resalable Software Licenses Rights (Details Textual) link:calculationLink link:definitionLink link:presentationLink 064 - Disclosure - Note I - Resalable Software Licenses Rights - Amortization Expense (Details) link:calculationLink link:definitionLink link:presentationLink 065 - Disclosure - Note J - Investment in Debt Security (Details Textual) link:calculationLink link:definitionLink link:presentationLink 066 - Disclosure - Note K - Equipment and Leasehold Improvements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 067 - Disclosure - Note K - Equipment and Leasehold Improvements - Summary of Equipment and Leasehold Improvements (Details) link:calculationLink link:definitionLink link:presentationLink 068 - Disclosure - Note L - Intangible Assets (Details Textual) link:calculationLink link:definitionLink link:presentationLink 069 - Disclosure - Note L - Intangible Assets - Summary of Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 070 - Disclosure - Note L - Intangible Assets - Amortization Expense (Details) link:calculationLink link:definitionLink link:presentationLink 071 - Disclosure - Note M - Accrued Liabilities - Summary of Accrued Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 072 - Disclosure - Note N - Related Party Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 073 - Disclosure - Note O - Convertible Notes Payable (Details Textual) link:calculationLink link:definitionLink link:presentationLink 074 - Disclosure - Note P - Leases - Operating Lease Balance Sheet Information (Details) link:calculationLink link:definitionLink link:presentationLink 075 - Disclosure - Note Q - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 076 - Disclosure - Note R - Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 077 - Disclosure - Note R - Equity - Valuation Assumptions for Warrants (Details) link:calculationLink link:definitionLink link:presentationLink 078 - Disclosure - Note R - Equity - Summary of Warrant Activity (Details) link:calculationLink link:definitionLink link:presentationLink 079 - Disclosure - Note S - Stock Options (Details Textual) link:calculationLink link:definitionLink link:presentationLink 080 - Disclosure - Note S - Stock Options - Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 081 - Disclosure - Note S - Stock Options - Options Outstanding and Exercisable (Details) link:calculationLink link:definitionLink link:presentationLink 082 - Disclosure - Note T - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 083 - Disclosure - Note T - Income Taxes - Components of Deferred Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 084 - Disclosure - Note T - Income Taxes - Reconciliation of the Effective Income Tax Rate to US Federal Statutory Income Tax Rate (Details) link:calculationLink link:definitionLink link:presentationLink 085 - Disclosure - Note U - Profit Sharing Plan (Details Textual) link:calculationLink link:definitionLink link:presentationLink 086 - Disclosure - Note V - Earnings Per Share (EPS) - Reconciliation of Numerator of Basic and Diluted EPS Calculations (Details) link:calculationLink link:definitionLink link:presentationLink 087 - Disclosure - Note V - Earnings Per Share (EPS) - Securities Excluded from the Diluted Per Share Calculation (Details) link:calculationLink link:definitionLink link:presentationLink 088 - Disclosure - Note W - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 10 bkyi-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 11 bkyi-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 12 bkyi-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Intangible assets Expected dividends Note To Financial Statement Details Textual Significant Accounting Policies Note A - The Company and Summary of Significant Accounting Policies Note B - Revenue From Contracts With Customers Weighted average Risk free interest rate Note C - PistolStar, Inc. Acquisition Note D - Factoring Note G - Note Receivable Mr. Michael DePasquale [Member] Represents Mr. Michael DePasquale. Note H - Inventory Note I - Resalable Software Licenses Rights Prepaid expenses and other current assets Note K - Equipment and Leasehold Improvements Accounts receivable Income Tax Disclosure [Text Block] Note L - Intangible Assets Note M - Accrued Liabilities Note P - Leases us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents Cash and cash equivalents Accrued Liabilities (Other) [Member] Represents information pertaining to accrued liabilities (other). Note R - Equity Weighted average Volatility of stock price Mr. Wong Kwok Fong [Member] Represents Mr. Wong Kwok Fong. Note S - Stock Options us-gaap_LiabilitiesCurrent Total current liabilities us-gaap_DueToRelatedPartiesCurrent Due to Related Parties, Current, Total Conversion of Senior Secured Convertible Note to Common Stock [Member] Represents conversion of senior secured convertible note to common stock. Note T - Income Taxes bkyi_OperatingLossCarryforwardsSubjectToExpiration Operating Loss Carryforwards, Subject to Expiration Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws. Note V - Earnings Per Share (EPS) bkyi_OperatingLossCarryforwardsNotSubjectToExpiration Operating Loss Carryforwards, Not Subject to Expiration Amount of operating loss carryforward not subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws. Fair value of assets acquired and liabilities assumed: Note A - The Company and Summary of Significant Accounting Policies - Summary of Accounts Receivable (Details) Note A - The Company and Summary of Significant Accounting Policies - Estimated Useful Lives for Depreciation and Amortization (Details) Expected life of options (Year) Note A - The Company and Summary of Significant Accounting Policies - Share-based Compensation Expenses for Continuing Operations (Details) Amended Note [Member] Represents information pertaining to Amended Note. Note A - The Company and Summary of Significant Accounting Policies - Valuation Assumptions for Stock Options (Details) us-gaap_BusinessCombinationConsiderationTransferred1 Business Combination, Consideration Transferred, Total Total purchase price consideration Note B - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) Note C - PistolStar, Inc. Acquisition - Assets Acquired and Liabilities Assumed (Details) Note C - PistolStar, Inc. Acquisition - Assets Acquired and Liabilities Assumed (Details) (Parentheticals) Finite-lived Intangible Assets Acquired Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Note C - PistolStar, Inc. Acquisition - Intangible Assets Acquired (Details) Note D - Factoring - Due From Factor (Details) Present value of 4% Promissory note Business Combination, Consideration Transferred, Liabilities Incurred Note D - Factoring - Fees (Details) Note G - Note Receivable - Summary of Note Receivable (Details) Note H - Inventory - Components of Inventory (Details) bkyi_SoftwareLicenseRights Software License Rights Represents the amount of current and noncurrent software license rights as of the balance sheet date. Debt Security, Corporate, Non-US [Member] Share-based Payment Arrangement, Option, Activity [Table Text Block] Note I - Resalable Software Licenses Rights - Amortization Expense (Details) Note K - Equipment and Leasehold Improvements - Summary of Equipment and Leasehold Improvements (Details) Note L - Intangible Assets - Summary of Intangible Assets (Details) us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired Business Acquisition, Percentage of Voting Interests Acquired Note L - Intangible Assets - Amortization Expense (Details) Proceeds from maturity of debt security Note M - Accrued Liabilities - Summary of Accrued Liabilities (Details) Note P - Leases - Operating Lease Balance Sheet Information (Details) Note R - Equity - Valuation Assumptions for Warrants (Details) Note R - Equity - Summary of Warrant Activity (Details) Note S - Stock Options - Option Activity (Details) Note S - Stock Options - Options Outstanding and Exercisable (Details) Note T - Income Taxes - Components of Deferred Taxes (Details) Note T - Income Taxes - Reconciliation of the Effective Income Tax Rate to US Federal Statutory Income Tax Rate (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) Note V - Earnings Per Share (EPS) - Reconciliation of Numerator of Basic and Diluted EPS Calculations (Details) Note V - Earnings Per Share (EPS) - Securities Excluded from the Diluted Per Share Calculation (Details) Vested or expected to vest, weighted average remaining life (Year) Notes To Financial Statements Notes To Financial Statements [Abstract] us-gaap_ProceedsFromDebtNetOfIssuanceCosts Proceeds from Debt, Net of Issuance Costs Vested or expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block] Vested or expected, weighted average exercise price (in dollars per share) Vested or expected to vest, aggregate intrinsic value Options exercisable, weighted average exercise price (in dollars per share) bkyi_DebtInstrumentConvertiblePremiumPaymentPercentage Debt Instrument, Convertible, Premium Payment Percentage Percentage premium on principal of convertible debt instrument paid at time of redemption. Exercisable, weighted average remaining life (Year) Exercisable, aggregate intrinsic value us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares) Outstanding, weighted average remaining life (Year) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year) Outstanding, aggregate intrinsic value us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) us-gaap_PaymentsToAcquireHeldToMaturitySecurities Purchase of debt security Financial Instruments [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, weighted average exercise price (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) Forfeited, weighted average exercise price (in dollars per share) Deferred revenue - current Expired, weighted average exercise price (in dollars per share) Financial Instrument [Axis] bkyi_DebtInstrumentPeriodicPaymentPrincipalDueIn180Days Debt Instrument, Periodic Payment, Principal due in 180 Days Amount of the required periodic payments applied to principal due in 180 days. Sales tax payable Senior Secured Convertible Note [Member] Information pertaining to senior secured convertible note. The Note [Member] Information pertaining to The Note. Granted, weighted average exercise price (in dollars per share) Exercised, weighted average exercise price (in dollars per share) Accrued liabilities Total Investor Warrant [Member] Information pertaining to investor warrant. bkyi_DebtInstrumentPeriodicPaymentPrincipalDueIn270Days Debt Instrument, Periodic Payment, Principal due in 270 Days Amount of the required periodic payments applied to principal due in 270 days. Lessee, Operating Leases [Text Block] Accounts payable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Outstanding (in shares) Outstanding (in shares) bkyi_RelatedPartyTransactionRevenueToTriggerPaymentOfSalesIncentiveFeePeriod Related Party Transaction, Revenue to Trigger Payment of Sales Incentive Fee, Period (Month) The period of revenue to trigger payment of sales incentive fee under related party transaction. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Expired (in shares) Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Other Compensation us-gaap_PolicyTextBlockAbstract Accounting Policies bkyi_StockIssuedDuringPeriodValueIssuedForDueDiligenceFee Stock Issued During Period, Value, Issued for Due Diligence Fee Value of stock issued for due diligence fee. bkyi_ConcentrationRiskNumberOfMajorCustomers Concentration Risk, Number of Major Customers Represents the number of external customers that accounts for 10 percent or more of an entity's revenues or accounts receivable. bkyi_StockIssuedDuringPeriodSharesIssuedForDueDiligenceFee Stock Issued During Period, Shares, Issued for Due Diligence Fee (in shares) Number of shares issued for due diligence fee. Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Trade Names [Member] bkyi_PlacementFeePercentOfAggregateGrossProceeds Placement Fee, Percent of Aggregate Gross Proceeds Represents the placement fee as a percentage of gross proceeds. Reverse Stock Split [Member] The conversion of a reverse stock split where there is a reduction in the shares outstanding. Licensing Agreements [Member] Accrued legal and accounting fees Issuance of common stock for conversion of note payable Exercise Price Range 1 [Member] The first exercise price range. Exercise Price Range 2 [Member] The second exercise price range. us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Capital expenditures us-gaap_PaymentsToAcquireSoftware Payments to Acquire Software bkyi_StockIssuedDuringPeriodSharesCommitmentFees Stock Issued During Period, Shares, Commitment Fees (in shares) Number of shares issued during the period for commitment fees. Noncash investing and financing activities: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) Grantee Status [Domain] Weighted Average Shares Outstanding: Grantee Status [Axis] LIABILITIES Cash paid for: Operating lease liabilities us-gaap_Assets TOTAL ASSETS Patents [Member] Plan Name [Axis] Plan Name [Domain] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Net loss available to common stockholders (basic and diluted EPS) Net loss available to common stockholders Commitments Disclosure [Text Block] Customer Relationships [Member] Finite-Lived Intangible Assets by Major Class [Axis] Share-based Payment Arrangement [Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Stock Issued in Lieu of Board Fees [Member] Related to stock issued in lieu of board fees. Award Type [Domain] Business Description and Accounting Policies [Text Block] Award Type [Axis] Net loss Net Loss Net loss Net loss us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Accumulated amortization Net carrying amount Total Intangible assets, net Gross carrying amount Restricted Stock [Member] Share-based Payment Arrangement, Option [Member] Warrant [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Goodwill related to PistolStar acquisition bkyi_OperationalCostsPerMonth Operational Costs Per Month Amount of funds required to conduct operations on a monthly basis. Factoring [Text Block] Factoring text block. Business Combination Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less accumulated depreciation and amortization bkyi_PercentageOfAccountsReceivableRemittedByFactor Percentage Of Accounts Receivable Remitted By Factor Percentage of accounts receivable remitted by factor. Equipment and leasehold improvements, net Total bkyi_FactoringFeesPercent Factoring Fees Percent Factoring fees percent. Goodwill Factored Accounts Receivable [Member] Factored accounts receivable member. Original Invoice Value Factored accounts receivable original invoice value. Factored amount Factored accounts receivable factored amount. Property, plant, and equipment, gross Compensated absences bkyi_WarrantsOutstandingExercisePrice Outstanding, weighted average exercise price, warrants (in dollars per share) Outstanding, weighted average exercise price, warrants (in dollars per share) Warrants outstanding exercise price. Outstanding, weighted average remaining contractual life, warrants (Year) bkyi_WarrantsOutstandingWeightedAverageRemainingLife Warrants outstanding weighted average remaining life. Note receivable Nonstatutory Stock [Member] Nonstatutory stock member. The2004 Stock Option Plan [Member] The2004 stock option plan member. Non Plan [Member] Non plan member. Pre-Funded Warrants [Member] Represents the pre-funded warrants. Permanent differences Effective income tax reconciliation permanent differences. CASH FLOWS FROM INVESTING ACTIVITIES: bkyi_SharebasedCommitmentFees Issuance of common stock pursuant to securities purchase agreements Amount of share based commitment fees. Effect of net operating loss Effective income tax reconciliation effect of net operating loss. Stock based fees to directors The costs and payments related to stock-based fees to directors and consultants. us-gaap_RevenueFromRelatedParties Revenue from Related Parties Earnings Per Share [Text Block] Government grant – Paycheck Protection Program Represents income recognized from government grant under the CARES Act. June 2020 Note [Member] Represents the June 2020 note. bkyi_WarrantsIssuedWithConvertibleNotes Warrants issued with convertible notes Represents amount of warrants issued with convertible notes. May 2020 Note [Member] Represents the May 2020 note. bkyi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value Amount by which the current fair value of the underlying stock exceeds the exercise price of options granted during the period. Related Party Transactions Disclosure [Text Block] Useful Lives of Property Plan and Equipment [Table Text Block] Tabular disclosure of the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment). us-gaap_IncomeTaxExpenseBenefit Income Tax Expense (Benefit), Total us-gaap_IncreaseDecreaseInAccruedLiabilities Accrued liabilities Prepaid expenses acquired from PistolStar Represents prepaid expenses acquired. Equipment acquired from PistolStar Represents the amount of equipment acquired. Short-term Debt, Type [Axis] Intangible assets acquired from PistolStar Represents intangible assets acquired. Short-term Debt, Type [Domain] bkyi_AdjustmentsToAdditionalPaidInCapitalLegalFees Legal fees Represents the amount of decrease to additional paid in capital during the period resulting from legal fees. Accounts receivable acquired from PistolStar Represents the amount of accounts receivable acquired. us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable PistolStar [Member] Represents acquisition of PistolStar, Inc.("PistolStar"). Issuance of note payable for PistolStar acquisition, net of discount Represents issuance of notes payable in businesses combination. Accrued expenses acquired from PistolStar Represents amount of accrued expenses acquired. Deferred revenue acquired from PistolStar Represents amount of deferred revenue acquired. bkyi_DebtInstrumentNumberOfInstallments Debt Instrument, Number of Installments Represents number of installments in debt instrument. Fixed assets Amount of fixed assets recognized as of the acquisition date. us-gaap_OperatingExpenses Total operating expenses us-gaap_DebtInstrumentTerm Debt Instrument, Term (Month) bkyi_FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour Thereafter Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Ending Balance us-gaap_DebtInstrumentConvertibleConversionPrice1 Debt Instrument, Convertible, Conversion Price (in dollars per share) Share-based compensation expense Share-based Payment Arrangement, Expense us-gaap_LegalFees Legal Fees Amendment Flag Auditor Firm ID Auditor Name Auditor Location City Area Code Use of Estimates, Policy [Policy Text Block] Lessee, Operating Lease, Costs, Assets and Liabilities [Table Text Block] The tabular disclosure of costs, assets, and liabilities subject to operating lease by lessee. New Accounting Pronouncements, Policy [Policy Text Block] Forfeiture of restricted stock us-gaap_DebtInstrumentPeriodicPaymentPrincipal Debt Instrument, Periodic Payment, Principal us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Warrants Issued in Connection with Convertible Notes [Member] Represents warrants issued in connection with convertible notes. Common stock, shares outstanding (in shares) Current Fiscal Year End Date Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage us-gaap_NotesReceivableNet Note receivable, net of allowance Total lease cost Stock Issued in Lieu of Board Committee Fees [Member] refers to stock issued in lieu of board committee fees. us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other Weighted average discount rate – operating leases Document Fiscal Period Focus Operating lease cost Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Deemed dividends related to down-round features us-gaap_DividendsPaidinkind Dividends, Paid-in-kind, Total Deemed dividend from trigger of anti-dilution provision feature Swivel Secure Europe [Member] Information regarding the business acquisition of Swivel Secure Europe. Amortization of resalable software license rights The amount of amortization charged against earnings during the period for software license rights. Document Period End Date Weighted average remaining lease term (in years) – operating leases (Year) Entity File Number us-gaap_DebtInstrumentFeeAmount Debt Instrument, Fee Amount Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Document Type Loss on extinguishment of debt Loss on extinguishment of debt Research, Development, and Engineering Expense [Member] Primary financial statement caption in which the reported facts about research, development and engineering expense have been included. Entity Small Business Entity Shell Company Document Information [Line Items] Document Information [Table] Software License Rights [Member] The software license rights, generally of limited duration, for internal use. Service [Member] Entity Public Float Referral Fee Warrants [Member] Related to referral fee warrants. Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status Debt Instrument, Name [Domain] Exercised, warrants (in shares) Exercised, warrants (in shares) The number of warrants exercised during period. Entity Voluntary Filers Granted, warrants (in shares) Granted, warrants (in shares) The amount of warrants granted during the period. Entity Well-known Seasoned Issuer bkyi_TotalWarrantsExpired Expired, warrants (in shares) Number of warrants expired during period. bkyi_TotalWarrantsForfeited Forfeited, warrants (in shares) Number of warrants forfeited during period. Granted, weighted average exercise price, warrants (in dollars per share) Granted, weighted average exercise price, warrants (in dollars per share) Weighted average exercise price of warrants granted during period. Forfeited, weighted average exercise price, warrants (in dollars per share) bkyi_WeightedAverageExercisePriceWarrantsForfeited Weighted average exercise price of the warrants forfeited. Expired, weighted average exercise price, warrants (in dollars per share) bkyi_WeightedAverageExercisePriceWarrantsExpired Weighted average exercise price of the warrants expired during period. us-gaap_IncreaseDecreaseInOtherReceivables Due from factor Exercised, weighted average exercise price, warrants (in dollars per share) Exercised, weighted average exercise price, warrants (in dollars per share) Weighted average exercise price of the warrants exercised in the period. us-gaap_GoodwillImpairmentLoss Goodwill, Impairment Loss Warrants issued Amortization of capitalized contract costs us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage In The Money Options [Member] Represents in-the-money options exercisable. Share-based compensation us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Entity Tax Identification Number Beneficial conversion feature Entity Central Index Key us-gaap_DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction, Total Entity Registrant Name bkyi_AdjustmentsToAdditionalPaidInCapitalLegalAndCommitmentFees Legal and commitment fees Represents the amount of decrease to additional paid in capital during the period resulting from legal and commitment fees. Share based compensation for employee stock purchase plan Entity [Domain] us-gaap_CapitalizedContractCostAmortizationPeriod Capitalized Contract Cost, Amortization Period (Year) Customer Concentration Risk [Member] bkyi_PaymentsOfStockIssuanceCostsBankerFees Payments of Stock Issuance Costs, Banker Fees The cash outflow for banker fee cost incurred directly with the issuance of an equity security. Legal Entity [Axis] bkyi_PaymentsOfStockIssuanceCostsCommitmentFees Payments of Stock Issuance Costs, Commitment Fees The cash outflow for commitment fee cost incurred directly with the issuance of an equity security. Exercise Price Range 3 [Member] The third exercise price range. Entity Address, Address Line One bkyi_PaymentsForLegalFees Legal fees The amount of cash outflow for legal fees. Amortization of intangible assets and write-off Amortization of Intangible Assets, Total us-gaap_FinancingReceivableAllowanceForCreditLosses Allowance for doubtful account Entity Address, City or Town bkyi_ClassOfWarrantOrRightRecordedAsDebtDiscount Class of Warrant or Right, Recorded as Debt Discount Represents the amount of warrant or right recorded as a debt discount to be amortized over the life of the related debt. bkyi_PaymentsOfStockIssuanceCostsLegalFees Payments of Stock Issuance Costs, Legal Fees The cash outflow for legal fee cost incurred directly with the issuance of an equity security. Entity Address, Postal Zip Code Entity Address, State or Province Concentration Risk Type [Axis] Concentration Risk Type [Domain] us-gaap_AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss, Ending Balance Entity Common Stock, Shares Outstanding Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Operating lease liabilities under ASC 842 Amount of noncash operating lease liability incurred because of adoption of ASC 842. Right-of-use asset addition under ASC 842 The amount of noncash right of use asset added because of adoption of ASC 842. us-gaap_AdvertisingExpense Advertising Expense Revenue Benchmark [Member] Accounts Receivable [Member] us-gaap_IncreaseDecreaseInInventories Inventory Trading Symbol Concentration Risk Benchmark [Axis] Employee Stock Purchase Plan [Member] Information regarding employee stock purchase plan. Concentration Risk Benchmark [Domain] Investor [Member] Issuance of common stock for conversion of convertible note payable Issuance of common stock for conversion of convertible note payable (in shares) Issuance of common stock for Employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares) Local Phone Number us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares) Exercised (in shares) us-gaap_TableTextBlock Notes Tables Issuance of common stock for Employee stock purchase plan us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited Stock Issued During Period, Shares, Restricted Stock Award, Forfeited (in shares) Forfeiture of restricted stock (in shares) bkyi_IncreaseDecreaseInSoftwareLicenseRights Resalable software license rights The increase (decrease) during the period in the carrying value of software license rights associated with underlying transactions that are classified as operating activities. Issuance of restricted common stock to employees (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total (in shares) Resalable software license rights Carrying amounts as of the balance sheet date of software license rights classified as non-current. Issuance of restricted common stock to employees Related Party [Axis] Related Party [Domain] us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture (in shares) Issuance of common stock for directors’ fees (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Total (in shares) Selling, general and administrative us-gaap_SellingGeneralAndAdministrativeExpense Issuance of common stock for directors’ fees Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) Warrant measurement input us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Forfeited (in shares) us-gaap_WarrantsAndRightsOutstandingTerm Warrants and Rights Outstanding, Term (Year) Issuance of common stock pursuant to securities purchase agreements (in shares) Stock Issued During Period, Shares, New Issues (in shares) Fabricated assemblies us-gaap_LiabilitiesAndStockholdersEquity TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY us-gaap_CashUninsuredAmount Cash, Uninsured Amount Finished goods Issuance of common stock pursuant to securities purchase agreements Related Party Transaction [Axis] Related Party Transaction [Domain] Accumulated deficit Research, development and engineering us-gaap_AssetsNoncurrent Total non-current assets Measurement Input, Share Price [Member] Debt Disclosure [Text Block] us-gaap_InterestExpense Interest expense us-gaap_InterestExpenseDebt Interest Expense, Debt, Total Measurement Input, Price Volatility [Member] Change in assets and liabilities: Three Customers [Member] Information pertaining to three customers. One Customer [Member] Information pertaining to one customer. Measurement Input, Risk Free Interest Rate [Member] Amortization of debt issuance costs us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Employee [Member] Represents information about an employee. Inventory Disclosure [Text Block] Subsequent Event [Member] Operating lease liabilities, net of current portion Operating lease liabilities, non-current portion Schedule of Inventory, Current [Table Text Block] Measurement Input, Expected Term [Member] Total us-gaap_OperatingLeaseLiability Total operating lease liabilities Subsequent Event Type [Axis] Operating lease liabilities, current portion Operating lease liabilities, current portion Subsequent Event Type [Domain] bkyi_InvestmentInHeldtomaturityDebtSecuritiesInterestRate Investment in Held-to-maturity Debt Securities, Interest Rate Represents the interest rate of an investment in held-to-maturity debt securities. bkyi_LimitOfBond Limit of Bond Represents the limit of a bond held for investment. Retirement Benefits [Text Block] bkyi_InvestmentInHeldToMaturityDebtSecuritiesTerm Investment in Held-to-maturity Debt Securities, Term (Year) Represents the term of an investment in held-to-maturity debt securities. Subsequent Events [Text Block] Deposits and other assets Operating lease right-of-use assets us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total future lease payments us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less: imputed interest Measurement Input Type [Axis] Measurement Input Type [Domain] us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo 2023 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree 2024 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour 2025 2022 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive 2026 2023 Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths 2022 Share-based Payment Arrangement, Employee [Member] Capitalized contract costs, net Lessee, Leases [Policy Text Block] us-gaap_DebtConversionConvertedInstrumentSharesIssued1 Debt Conversion, Converted Instrument, Shares Issued (in shares) Business Combinations Policy [Policy Text Block] Finite-lived Intangible Assets Acquired (Year) Finite-Lived Intangible Asset, Useful Life (Year) Earnings Per Share, Policy [Policy Text Block] us-gaap_AmortizationOfFinancingCostsAndDiscounts Amortization of Debt Issuance Costs and Discounts, Total us-gaap_DebtConversionOriginalDebtAmount1 Debt Conversion, Original Debt, Amount Debt Conversion Description [Axis] Note receivable, net of allowance Debt Conversion, Name [Domain] Operating expenses Amortization of debt discount Income Tax, Policy [Policy Text Block] Schedule of Finite-Lived Intangible Assets [Table Text Block] Research and Development Expense, Policy [Policy Text Block] Investment - debt security, noncurrent us-gaap_Depreciation Depreciation us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio Intangible Assets Disclosure [Text Block] Proprietary Software [Member] Represents information pertaining to proprietary software. us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share (in dollars per share) us-gaap_AssetsCurrent Total current assets Share-based Payment Arrangement [Policy Text Block] Stockholders' Equity Note Disclosure [Text Block] bkyi_FactoringArrangementMinimumAmountOfAccountsReceivablePerQuarter Factoring Arrangement, Minimum Amount of Accounts Receivable Per Quarter Minimum amount of certain accounts receivable balances which must be sold to the Factor pursuant to the factoring arrangement. Factoring fees Amount of factoring fees incurred but not yet paid, due within one year or the normal operating cycle, if longer. Advertising Cost [Policy Text Block] Common stock — authorized, 170,000,000 shares; issued and outstanding; 7,853,759 and 7,814,572 of $.0001 par value at December 31, 2021 and December 31, 2020, respectively Adjustments to reconcile net loss to cash used for operating activities: Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Asia [Member] Revenue from Contract with Customer [Policy Text Block] us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance (in shares) us-gaap_DeferredTaxAssetsValuationAllowance Valuation allowances Statistical Measurement [Domain] Cash paid for amounts included in the measurement of operating lease liabilities Maximum [Member] Minimum [Member] us-gaap_OtherAssetsCurrent Due from factor Product and Service [Axis] Product and Service [Domain] Statistical Measurement [Axis] North America [Member] South America [Member] Interest Income taxes Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Property, Plant and Equipment Disclosure [Text Block] Geographical [Axis] Goodwill and Intangible Assets, Policy [Policy Text Block] Property, Plant and Equipment [Table Text Block] Geographical [Domain] us-gaap_PreferredStockSharesAuthorized Preferred Stock, Shares Authorized (in shares) Inventory Total inventory us-gaap_PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share (in dollars per share) EMEA [Member] us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Revenue from Contract with Customer, Including Assessed Tax Foreign currency loss Loss on foreign currency Customer [Axis] Customer [Domain] Basis differences in intangible assets Exercise Price Less Than Average Market Price Of Common Shares [Member] Exercise price less than average market price of common shares member. Property, Plant, and Equipment (Year) us-gaap_IncreaseDecreaseInDeferredRevenue Deferred revenue Exercise Price Greater Than Average Market Price Of Common Shares [Member] Exercise price greater than average market price of common shares member. CASH FLOW FROM OPERATING ACTIVITIES: Balance due from factor Accounts receivable allowance Current portion, net of allowance Financing Receivable, after Allowance for Credit Loss, Current, Total bkyi_InvestmentIncomeDebtSecurityReserveExpense Investment-debt security reserve Amount of expenses related to debt security reserve. us-gaap_WarrantsAndRightsOutstanding Warrants and Rights Outstanding Statement [Line Items] us-gaap_AccountsReceivableGrossCurrent Accounts receivable us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Allowance for doubtful accounts Accounts receivable, net of allowances for doubtful accounts Accounts receivable, net Furniture and Fixtures [Member] Accrued compensation Additional paid-in capital Issuance of common stock pursuant to warrant exercises Value of stock issued during the period upon the conversion of warrant. Stock-based compensation Deemed dividends related to down-round features Amount of (increase) decrease in equity for deemed dividend related to down-round features. Issuance of common stock pursuant to warrant exercises (in shares) Stock Issued During Period, Shares, Conversion of Warrant (in shares) The number of shares issued during the period upon the conversion of warrant. Amortization of beneficial conversion feature Amount of amortization expense attributable to beneficial conversion feature. Investment – debt security Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current Revenues Promissory Note [Member] Note issued to an investor pursuant to a Security Purchase Agreement. bkyi_ReserveForInvestmentSecurity Reserve for investment security Amount of reserve for investment security. bkyi_ReserveForNoteReceivable Allowance for note receivable Amount of reserve for note receivable. STOCKHOLDERS’ EQUITY Leasehold Improvements [Member] Property, Plant and Equipment, Policy [Policy Text Block] bkyi_BeneficialConversionFeature Beneficial conversion feature Fair value of beneficial conversion feature. bkyi_PercentageOfSupportAndMaintenanceRevenueToLicenseCost Percentage of Support and Maintenance Revenue to License Cost The percentage of support and maintenance revenue for SaaS license to total license cost. bkyi_ClassOfWarrantOrRightExercisedDuringPeriod Class of Warrant or Right, Exercised During Period (in shares) Represents the class of warrant or right, exercised during period. Long-Lived Tangible Asset [Axis] us-gaap_NonoperatingIncomeExpense Total other income (expense) Equity Warrants [Member] Represents the equity warrants. Long-Lived Tangible Asset [Domain] Net operating loss and credit carryforwards January 2020 Note [Member] Represents the January 2020 note. Secured Redeemable Convertible Note [Member] Represents secured redeemable convertible note. Fair Value Disclosures [Text Block] February 2020 Note [Member] Represents the February 2020 note. bkyi_DebtInstrumentDeemedDividendExpense Debt Instrument, Deemed Dividend Expense Amount of deemed dividend expense of debt instrument. us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR CASH AND CASH EQUIVALENTS, END OF YEAR ASSETS Interest income Investment Income, Interest License [Member] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS us-gaap_NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities, Total Net cash (used in) provided by financing activities us-gaap_Liabilities TOTAL LIABILITIES Increase due to trigger of anti-dilution provision feature, weighted average exercise price, warrants (in dollars per share) Represents weighted average exercise price of warrants increase due to trigger of anti-dilution provision feature. Commitments Increase due to trigger of anti-dilution provision feature, warrants (in shares) Represents increase in class of warrants or rights due to trigger of anti-dilution provision feature. Sale of Stock [Axis] Director [Member] Sale of Stock [Domain] us-gaap_OperatingIncomeLoss Operating loss us-gaap_ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized bkyi_DebtInstrumentConvertibleBeneficialConversionFeaturePerShare Debt Instrument, Convertible, Beneficial Conversion Feature, Per Share (in dollars per share) The amount per share of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date. Other income (expense) us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used for operating activities bkyi_DebtInstrumentCovenantSharesToBePaidCommitmentFeeRepaidPriorToMaturity Debt Instrument, Covenant, Shares to be Paid, Commitment Fee, Repaid Prior to Maturity (in shares) The number of shares to be paid in lieu of commitment fee on debt instrument if repaid prior to maturity date. Prepaid expenses and other us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used for investing activities bkyi_RelatedPartyAgreementTerm Related Party Agreement, Term (Year) The length of time of the agreement between two or more related parties. September 2015 Warrants [Member] The warrants issued in September 2015 warrants issuance. Technology Transfer Institute [Member] Information pertaining to the related party Technology Transfer Institute ("TTI"). Share based and warrant compensation for employees and consultants Amount of noncash expense for share-based payment arrangement, excluding directors fees. bkyi_CumulativeAmountOfAmortizationExpenseNetOfCredits Cumulative Amount of Amortization Expense, Net of Credits Represents cumulative amount of amortization expense net of credit expense. Sales Incentive Agreement With TTI [Member] Related to the Sales Incentive Agreement with Technology Transfer Institute ("TTI"). Factoring Fees [Table Text Block] Tabular disclosure of factoring fees related to trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. us-gaap_GrossProfit Gross Profit us-gaap_CostOfGoodsAndServicesSold Costs and other expenses bkyi_FactoringFees Factoring fees The cost of factoring related to accounts receivable. Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Derivatives, Policy [Policy Text Block] bkyi_StockIssuableForSalesIncentiveFeePerEach5MillionRevenue Stock Issuable for Sales Incentive Fee Per Each 5 Million Revenue (in shares) Number of common shares issuable for sales incentive fee per each 5 million revenue. Warrants Issuable for Each 1 Million Revenue in Excess of 20 Million [Member] Represents the warrants issuable for each 1 million revenue in excess of 20 million. bkyi_RelatedPartyTransactionMaximumRevenueWarrantsIssuable Related Party Transaction, Maximum Revenue, Warrants Issuable The maximum revenue for warrant issuable to a related party pursuant to the agreement. bkyi_StockIssuableForSalesIncentiveAgreement Stock Issuable for Sales Incentive Agreement (in shares) The number of shares issuable pursuant to the sales incentive agreement. us-gaap_ContractWithCustomerLiability Contract with Customer, Liability, Total bkyi_RelatedPartyTransactionRevenueNeededToTriggerPaymentOfSalesIncentiveFee Related Party Transaction, Revenue Needed to Trigger Payment of Sales Incentive Fee The amount of revenue which much be generated to trigger the payment of a sales incentive fee under the related party agreement. bkyi_RelatedPartyTransactionMaximumRevenueToTriggerPaymentOfSalesIncentiveFee Related Party Transaction, Maximum Revenue to Trigger Payment of Sales Incentive Fee The maximum agreed upon revenue generated under the related party agreement which may trigger the payment of a sales incentive fee. bkyi_RelatedPartyTransactionRevenueToTriggerPaymentOfSalesIncentiveFeePercentOfNetIncome Related Party Transaction, Revenue to Trigger Payment of Sales Incentive Fee, Percent of Net Income, Minimum The minimum percent of net income which the revenue generated under the related party agreement must amount to. bkyi_RelatedPartyTransactionSalesIncentiveFeeForEach5MillionRevenue Related Party Transaction, Sales Incentive Fee For Each 5 Million Revenue The amount of sales incentive fee for each 5 million revenue pursuant to the agreement. Accounting Standards Update 2016-02 [Member] us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total us-gaap_PaymentsOfStockIssuanceCosts Costs to issue notes and common stock Accounting Standards Update [Domain] bkyi_StockIssuedDuringPeriodSharesWarrantsExercises Stock Issued During Period, Shares, Warrants Exercises (in shares) The number of shares issued during the period for warrant exercises. us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment Basis differences in fixed assets Accounting Standards Update [Axis] Notes Receivable [Text Block] The entire disclosure for notes receivable. Costs and other expenses Geographic Distribution, Domestic [Member] Geographic Distribution, Foreign [Member] us-gaap_ProceedsFromIssuanceOrSaleOfEquity Proceeds from Issuance or Sale of Equity, Total Geographic Distribution [Axis] Proceeds from the exercise of warrants Proceeds from Warrant Exercises Geographic Distribution [Domain] Retained Earnings [Member] Proceeds from public offering The 2015 Software License [Member] Represents information about the 2015 Software License. Title of Individual [Domain] Title of Individual [Axis] Additional Paid-in Capital [Member] Common Stock [Member] Equity Components [Axis] Equity Component [Domain] us-gaap_LongTermDebt Long-term Debt, Total Public Offering Warrants [Member] Information related to the public offering warrants. us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Other Warrants [Member] Information related to other warrants. Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] us-gaap_NotesPayable Notes Payable, Total Schedule of Warrants Valuation Assumptions [Table Text Block] Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants. us-gaap_ClassOfWarrantOrRightOutstanding Outstanding, warrants (in shares) Outstanding, warrants (in shares) us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) bkyi_IncreaseDecreaseInCapitalizedContractCosts Capitalized contract costs The amount of increase (decrease) in capitalized contract costs. Hardware [Member] Represents information pertaining to hardware. Public Offering [Member] Related to a public offering. ICFR Auditor Attestation Flag us-gaap_PaymentsOfDebtIssuanceCosts Payments of Debt Issuance Costs bkyi_AllowanceForDoubtfulAccounts Allowance for doubtful account Amount of allowance for credit loss on accounts receivable. Income Tax Authority, Name [Axis] Proceeds from Employee Stock Purchase Plan Represents proceeds from employee stock purchase plan. Income Tax Authority, Name [Domain] Internal Revenue Service (IRS) [Member] Income Tax Authority [Axis] Income Tax Authority [Domain] Disaggregation of Revenue [Table Text Block] Domestic Tax Authority [Member] bkyi_AdditionalIncomeOfCashFlow Additional Income of Cash Flow Represents additional income of cash flow. Equipment [Member] Revenue from Contract with Customer [Text Block] Document Annual Report bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodWillTotal Total assets acquired Amount of assets including goodwill acquired at the acquisition date. us-gaap_RepaymentsOfConvertibleDebt Repayments of Convertible Debt Repayment of convertible notes Accrued expenses and other current liabilities Amount of accrued expenses and other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. Accrued payroll Amount of accrued payroll liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. us-gaap_RepaymentsOfRelatedPartyDebt Net repayments of loans payable to related parties Cash and Cash Equivalents, Policy [Policy Text Block] Balance Sheet Location [Axis] Balance Sheet Location [Domain] us-gaap_DebtInstrumentUnamortizedDiscount Debt Instrument, Unamortized Discount, Total Franchise taxes Represents current portion of accrued franchise taxes. Receivable [Policy Text Block] Software Development [Member] Employee expenses reimbursement Represents accrued employee expenses reimbursement, current. Entity Incorporation, State or Country Code Accounting Policies [Abstract] us-gaap_OpenTaxYear Open Tax Year Document Transition Report Basis of Accounting, Policy [Policy Text Block] Concentration Risk Disclosure [Text Block] Selling, General and Administrative Expenses [Member] Note payable – PistolStar acquisition, net of debt discount Entity Interactive Data Current Security Exchange Name Title of 12(b) Security Receivable Type [Axis] Receivable [Domain] Notes Receivable [Member] Proceeds from issuance of convertible notes Research and Development Expense [Member] Income Statement Location [Axis] Income Statement Location [Domain] Nonmonetary Transaction Type [Domain] Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Nonmonetary Transaction Type [Axis] Basic and Diluted (in shares) us-gaap_RepaymentsOfNotesPayable Repayments of Notes Payable Repayment of note payable - PistolStar us-gaap_SharePrice Share Price (in dollars per share) Antidilutive securities (in shares) Basic and Diluted Loss per Common Share (in dollars per share) us-gaap_OperatingLossCarryforwards Operating Loss Carryforwards, Total Statement [Table] Statement of Financial Position [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] us-gaap_EffectiveIncomeTaxRateContinuingOperations Effective tax rate Accounts Payable [Member] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Statement of Cash Flows [Abstract] Statement of Stockholders' Equity [Abstract] Income Statement [Abstract] us-gaap_BusinessCombinationContingentConsiderationLiability Business Combination, Contingent Consideration, Liability, Total Schedule of Accrued Liabilities [Table Text Block] us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossNoncurrent Debt Securities, Held-to-maturity, Allowance for Credit Loss, Noncurrent us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate Receivable with Imputed Interest, Effective Yield (Interest Rate) us-gaap_LiabilitiesNoncurrent Total non-current liabilities CASH FLOWS FROM FINANCING ACTIVITIES: Federal statutory income tax rate The 2015 Equity Incentive Plan [Member] Refers to information regarding the 2015 Equity Incentive plan. bkyi_ClassOfWarrantOrRightIssuedDuringPeriod Class of Warrant or Right, Issued During Period (in shares) The class of warrant or right issued during the period. us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate Business Combination, Indemnification Assets, Amount as of Acquisition Date Research, Development, and Computer Software Disclosure [Text Block] us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet Total fair value of assets acquired and liabilities assumed Deferred revenue, net of current portion us-gaap_StockholdersEquity TOTAL STOCKHOLDERS’ EQUITY Balance Balance Amortization of operating lease right-of-use assets Total cash paid, net of acquired cash Payments to Acquire Businesses, Net of Cash Acquired, Total Class of Stock [Axis] Cash acquired from purchase of PistolStar Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Deferred revenue us-gaap_PaymentsToAcquireBusinessesGross Payments to Acquire Businesses, Gross Purchase of PistolStar Options outstanding, weighted average exercise price (in dollars per share) Options outstanding, weighted average remaining remaining life (Year) Options exercisable (in shares) Range of exercise prices, upper range (in dollars per share) us-gaap_PaymentsToAcquireLoansReceivable Issuance of note receivable Options outstanding (in shares) Exercise Price Range [Axis] Exercise Price Range [Domain] Range of exercise prices, lower range (in dollars per share) EX-101.PRE 13 bkyi-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 14 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document And Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2021
Mar. 29, 2022
Jun. 30, 2021
Document Information [Line Items]      
Entity Central Index Key 0001019034    
Entity Registrant Name BIO KEY INTERNATIONAL INC    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2021    
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2021    
Document Transition Report false    
Entity File Number 1-13463    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 41-1741861    
Entity Address, Address Line One 3349 HIGHWAY 138, BUILDING A, SUITE E    
Entity Address, City or Town WALL    
Entity Address, State or Province NJ    
Entity Address, Postal Zip Code 07719    
City Area Code 732    
Local Phone Number 359-1100    
Title of 12(b) Security Common Stock, $0.0001 par value per share    
Trading Symbol BKYI    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Public Float     $ 27,600,000
Entity Common Stock, Shares Outstanding   8,405,209  
Auditor Name Rotenberg Meril Solomon Bertiger & Guttilla, P.C.    
Auditor Location Saddle Brook, NJ    
Auditor Firm ID 361    
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2021
Dec. 31, 2020
ASSETS    
Cash and cash equivalents $ 7,754,046 $ 16,993,096
Accounts receivable, net 970,626 548,049
Due from factor 49,500 60,453
Financing Receivable, after Allowance for Credit Loss, Current, Total 82,000 295,000
Inventory 4,940,660 330,947
Prepaid expenses and other 216,041 201,507
Investment – debt security 0 512,821
Total current assets 14,012,873 18,941,873
Resalable software license rights 48,752 58,882
Investment - debt security, noncurrent 452,821 0
Equipment and leasehold improvements, net 69,168 81,793
Capitalized contract costs, net 249,012 165,315
Deposits and other assets 8,712 8,712
Note receivable, net of allowance 113,000 0
Operating lease right-of-use assets 254,100 487,325
Intangible assets, net 1,298,077 1,514,146
Goodwill 1,262,526 1,262,526
Total non-current assets 3,756,168 3,578,699
TOTAL ASSETS 17,769,041 22,520,572
LIABILITIES    
Accounts payable 427,772 244,158
Accrued liabilities 828,997 508,487
Note payable – PistolStar acquisition, net of debt discount 0 232,000
Deferred revenue - current 565,355 657,349
Operating lease liabilities, current portion 177,188 234,309
Total current liabilities 1,999,312 1,876,303
Deferred revenue, net of current portion 67,300 44,987
Operating lease liabilities, net of current portion 86,974 264,163
Total non-current liabilities 154,274 309,150
TOTAL LIABILITIES 2,153,586 2,185,453
Commitments
STOCKHOLDERS’ EQUITY    
Common stock — authorized, 170,000,000 shares; issued and outstanding; 7,853,759 and 7,814,572 of $.0001 par value at December 31, 2021 and December 31, 2020, respectively 786 782
Additional paid-in capital 120,190,139 119,844,026
Accumulated deficit (104,575,470) (99,509,689)
TOTAL STOCKHOLDERS’ EQUITY 15,615,455 20,335,119
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 17,769,041 $ 22,520,572
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets (Parentheticals) - $ / shares
Dec. 31, 2021
Dec. 31, 2020
Common stock, shares authorized (in shares) 170,000,000 170,000,000
Common stock, shares issued (in shares) 7,853,759 7,814,572
Common stock, shares outstanding (in shares) 7,853,759 7,814,572
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Revenues    
Revenue from Contract with Customer, Including Assessed Tax $ 5,114,489 $ 2,836,782
Costs and other expenses    
Costs and other expenses 1,672,929 794,826
Gross Profit 3,441,560 2,041,956
Operating expenses    
Selling, general and administrative 6,028,360 5,848,687
Research, development and engineering 2,355,056 1,396,436
Total operating expenses 8,383,416 7,245,123
Operating loss (4,941,856) (5,203,167)
Other income (expense)    
Interest income 4,075 30,649
Foreign currency loss (50,000) (0)
Investment-debt security reserve (60,000)  
Government grant – Paycheck Protection Program 0 340,819
Interest expense (18,000) (4,343,212)
Loss on extinguishment of debt 0 (499,076)
Total other income (expense) (123,925) (4,470,820)
Net loss (5,065,781) (9,673,987)
Deemed dividend from trigger of anti-dilution provision feature 0 (112,686)
Net loss available to common stockholders $ (5,065,781) $ (9,786,673)
Basic and Diluted Loss per Common Share (in dollars per share) $ (0.65) $ (2.08)
Weighted Average Shares Outstanding:    
Basic and Diluted (in shares) 7,791,741 4,700,787
Service [Member]    
Revenues    
Revenue from Contract with Customer, Including Assessed Tax $ 1,273,354 $ 1,432,228
Costs and other expenses    
Costs and other expenses 686,175 502,214
License [Member]    
Revenues    
Revenue from Contract with Customer, Including Assessed Tax 2,555,809 962,038
Costs and other expenses    
Costs and other expenses 183,199 49,891
Hardware [Member]    
Revenues    
Revenue from Contract with Customer, Including Assessed Tax 1,285,326 442,516
Costs and other expenses    
Costs and other expenses $ 803,555 $ 242,721
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)
Public Offering [Member]
Common Stock [Member]
Public Offering [Member]
Additional Paid-in Capital [Member]
Public Offering [Member]
Retained Earnings [Member]
Public Offering [Member]
Warrants Issued in Connection with Convertible Notes [Member]
Common Stock [Member]
Warrants Issued in Connection with Convertible Notes [Member]
Additional Paid-in Capital [Member]
Warrants Issued in Connection with Convertible Notes [Member]
Retained Earnings [Member]
Warrants Issued in Connection with Convertible Notes [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance (in shares) at Dec. 31, 2019                 1,812,483      
Balance at Dec. 31, 2019                 $ 182 $ 87,437,661 $ (89,723,016) $ (2,285,173)
Issuance of common stock for directors’ fees (in shares)                 5,270      
Issuance of common stock for directors’ fees                 $ 0 28,511 0 28,511
Issuance of common stock pursuant to securities purchase agreements (in shares) 4,264,313               43,939      
Issuance of common stock pursuant to securities purchase agreements $ 426 $ 22,173,999 $ 0 $ 22,174,425         $ 5 277,828 0 277,833
Issuance of common stock pursuant to warrant exercises (in shares)                 918,538      
Issuance of common stock pursuant to warrant exercises                 $ 92 5,602,503 0 5,602,595
Issuance of common stock for conversion of convertible note payable (in shares)                 728,654      
Issuance of common stock for conversion of convertible note payable                 $ 73 3,788,927 0 3,789,000
Issuance of restricted common stock to employees (in shares)                 41,375      
Issuance of restricted common stock to employees                 $ 4 (4) 0 0
Warrants issued         $ 0 $ 1,388,339 $ 0 $ 1,388,339 0 107,576 0 107,576
Legal and commitment fees                 0 (2,371,223) 0 (2,371,223)
Beneficial conversion feature                 0 641,215 0 641,215
Deemed dividends related to down-round features                 0 112,686 (112,686) 0
Share-based compensation                 0 656,008 0 656,008
Net loss                 $ 0 0 (9,673,987) (9,673,987)
Balance (in shares) at Dec. 31, 2020                 7,814,572      
Balance at Dec. 31, 2020                 $ 782 119,844,026 (99,509,689) 20,335,119
Issuance of common stock for directors’ fees (in shares)                 7,828      
Issuance of common stock for directors’ fees                 $ 1 25,535 0 25,536
Issuance of restricted common stock to employees (in shares)                 13,125      
Issuance of restricted common stock to employees                 $ 1 (1) 0 0
Share-based compensation                 0 278,499 0 278,499
Net loss                 $ 0 0 (5,065,781) (5,065,781)
Forfeiture of restricted stock (in shares)                 (1,250)      
Forfeiture of restricted stock                 $ 0 0 0 0
Legal fees                 $ 0 (5,228) 0 (5,228)
Issuance of common stock for Employee stock purchase plan (in shares)                 19,484      
Issuance of common stock for Employee stock purchase plan                 $ 2 36,628 0 36,630
Share based compensation for employee stock purchase plan                 $ 0 10,680 0 10,680
Balance (in shares) at Dec. 31, 2021                 7,853,759      
Balance at Dec. 31, 2021                 $ 786 $ 120,190,139 $ (104,575,470) $ 15,615,455
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
CASH FLOW FROM OPERATING ACTIVITIES:    
Net loss $ (5,065,781) $ (9,673,987)
Adjustments to reconcile net loss to cash used for operating activities:    
Depreciation 54,649 85,751
Amortization of intangible assets and write-off 216,069 120,240
Amortization of resalable software license rights 10,130 0
Loss on foreign currency 50,000 0
Reserve for investment security 60,000  
Allowance for note receivable 100,000  
Allowance for doubtful account 200,000 0
Amortization of debt discount 18,000 1,425,040
Amortization of capitalized contract costs 110,681 152,714
Amortization of debt issuance costs 0 2,166,650
Loss on extinguishment of debt 0 499,076
Amortization of beneficial conversion feature 0 641,215
Share based and warrant compensation for employees and consultants 289,179 763,584
Stock based fees to directors 25,536 28,511
Amortization of operating lease right-of-use assets 233,225 220,915
Change in assets and liabilities:    
Accounts receivable (672,577) (237,257)
Due from factor 10,953 50,488
Capitalized contract costs (194,378) (86,510)
Inventory (4,609,713) 98,172
Resalable software license rights 0 14,920
Prepaid expenses and other (14,534) (83,625)
Accounts payable 183,614 (600,399)
Accrued liabilities 320,510 (84,415)
Deferred revenue (69,681) (246,876)
Operating lease liabilities (234,310) (204,315)
Net cash used for operating activities (8,978,428) (4,950,108)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Capital expenditures (42,024) (35,568)
Issuance of note receivable 0 (295,000)
Purchase of PistolStar 0 (2,000,000)
Cash acquired from purchase of PistolStar 0 100,747
Proceeds from maturity of debt security 0 512,821
Purchase of debt security 0 (512,821)
Net cash used for investing activities (42,024) (2,229,821)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from public offering 0 22,174,425
Proceeds from issuance of convertible notes 0 3,958,000
Proceeds from Employee Stock Purchase Plan 36,630 0
Repayment of convertible notes 0 (4,509,250)
Proceeds from the exercise of warrants 0 5,602,595
Costs to issue notes and common stock 0 (2,693,021)
Repayment of note payable - PistolStar (250,000) (250,000)
Legal fees (5,228) 0
Net repayments of loans payable to related parties 0 (188,737)
Net cash (used in) provided by financing activities (218,598) 24,094,012
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (9,239,050) 16,914,083
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR 16,993,096 79,013
CASH AND CASH EQUIVALENTS, END OF YEAR 7,754,046 16,993,096
Cash paid for:    
Interest 18,000 109,426
Income taxes 0 0
Noncash investing and financing activities:    
Accounts receivable acquired from PistolStar 0 184,792
Prepaid expenses acquired from PistolStar 0 9,485
Equipment acquired from PistolStar 0 36,467
Intangible assets acquired from PistolStar 0 1,480,000
Goodwill related to PistolStar acquisition 0 1,262,526
Issuance of note payable for PistolStar acquisition, net of discount 0 464,000
Accrued expenses acquired from PistolStar 0 20,017
Deferred revenue acquired from PistolStar 0 590,000
Operating lease liabilities under ASC 842 0 141,761
Issuance of common stock for conversion of note payable 0 3,789,000
Issuance of common stock pursuant to securities purchase agreements 0 277,833
Warrants issued with convertible notes 0 1,388,339
Beneficial conversion feature 0 641,215
Deemed dividends related to down-round features (0) 112,686
Accounting Standards Update 2016-02 [Member]    
Noncash investing and financing activities:    
Right-of-use asset addition under ASC 842 $ 0 $ 141,761
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Note A - The Company and Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Business Description and Accounting Policies [Text Block]

NOTE A —THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Nature of Business

 

The Company, founded in 1993, develops and markets proprietary fingerprint identification biometric technology and software solutions enterprise-ready identity access management solutions to commercial, government and education customers throughout the United States and internationally. The Company was a pioneer in developing automated, finger identification technology that supplements or compliments other methods of identification and verification, such as personal inspection identification, passwords, tokens, smart cards, ID cards, PKI, credit cards, passports, driver’s licenses, OTP or other form of possession or knowledge-based credentialing. Additionally, advanced BIO-key® technology has been, and is, used to improve both the accuracy and speed of competing finger-based biometrics.

 

Going Concern and Basis of Presentation

 

The Company has historically financed our operations through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. The Company currently requires approximately $735,000 per month to conduct operations, a monthly amount that it has been unable to consistently achieve through revenue generation. During 2021, the Company generated approximately $5,114,000 of revenue, which is below its average monthly requirements. During 2020, the Company raised approximately $24,000,000 from financing activities and at December 31, 2021 had approximately $7,800,000 in cash. With the addition of the Swivel Secure Europe, SA (see Note W), the Company expects $1,000,000 of additional cash flow, based on Swivel Secure’s current recurring revenue and expenses, to provide additional operating income. As of the date of this report, the Company has enough cash and receivables for twelve months of operations.

 

Effective November 20, 2020, the Company implemented a reverse stock split of its outstanding common stock at a ratio of 1-for-8. All share figures and results are reflected on a post-split basis.

 

Foreign Currency

 

The Company accounts for foreign currency transactions pursuant to ASC 830, Foreign Currency Matters ("ASC 830”). The functional currency of the Company is the U.S. dollar, which is the currency of the primary economic environment in which it operates. In accordance with ASC 830, monetary balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing at the applicable balance sheet date.  For foreign currency transactions included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates used in the translation of such transactions and from the remeasurement of the monetary balance sheet items are recorded as gain (loss) on foreign currency transactions.

 

 

Summary of Significant Accounting Policies

 

A summary of the significant accounting policies consistently applied in the preparation of the accompanying consolidated financial statements follows:

 

1.  Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of BIO-key International, Inc. and its wholly-owned subsidiaries (collectively, the “Company”). Intercompany accounts and transactions have been eliminated in consolidation. 

 

2. Use of Estimates

 

Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) as set forth in the Financial Accounting Standards Board’s (FASB) Accounting Standards Codification (ASC) and consider the various staff accounting bulletins and other applicable guidance issued by the U.S. Securities and Exchange Commission (SEC). These accounting principles require us to make certain estimates, judgments and assumptions. The Company believes that the estimates, judgments and assumptions upon which it relies are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Certain significant accounting policies that contain subjective management estimates and assumptions include those related to revenue recognition, accounts receivable, inventory, intangible assets and long-lived assets, and income taxes. To the extent there are material differences between these estimates, judgments or assumptions and actual results, its consolidated financial statements will be affected. In many cases, the accounting treatment of a particular transaction is specifically dictated by GAAP and does not require management’s judgment in its application. There are also areas in which management’s judgment in selecting among available alternatives would not produce a materially different result.

 

3. Revenue Recognition

 

In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. To achieve this core principle, the Company applies the following five steps: 

 

 

●

Identify the contract with a customer

 

●

Identify the performance obligations in the contract

 

●

Determine the transaction price

 

●

Allocate the transaction price to performance obligations in the contract

 

●

Recognize revenue when or as the Company satisfies a performance obligation

 

All of the Company's performance obligations, and associated revenues, are generally transferred to customers at a point in time, with the exception of support and maintenance, and professional services, which are generally transferred to the customer over time.

 

Software licenses

Software license revenue consist of fees for perpetual and subscription licenses for one or more of the Company’s biometric fingerprint solutions or identity access management solutions. Revenue is recognized at a point in time once the software is available to the customer for download. Software license contracts are generally invoiced in full on execution of the arrangement.

 

Hardware

Hardware revenue consists of fees for associated equipment sold with or without a software license arrangement, such as servers, locks and fingerprint readers. Customers are not obligated to buy third party hardware from the Company, and may procure these items from a number of suppliers. Revenue is recognized at a point in time once the hardware is shipped to the customer. Hardware items are generally invoiced in full on execution of the arrangement.

 

Support and Maintenance

Support and maintenance revenue consists of fees for unspecified upgrades, telephone assistance and bug fixes. The Company satisfies its support and maintenance performance obligation by providing “stand-ready” assistance as required over the contract period. The Company records deferred revenue (contract liability) at time of prepayment until the contracts term occurs. Revenue is recognized over time on a ratable basis over the contract term. Support and maintenance contracts are one to five years in length and are generally invoiced in advance at the beginning of the term. Support and Maintenance revenue for subscription licenses is carved out of the total license cost at 18% and recognized on a ratable basis over the license term.

 

Professional Services

Professional services revenues consist primarily of fees for deployment and optimization services, as well as training. The majority of the Company’s consulting contracts are billed on a time and materials basis, and revenue is recognized based on the amount billable to the customer in accordance with practical expedient ASC 606-10-55-18. For other professional services contracts, the Company utilizes an input method and recognizes revenue based on labor hours expended to date relative to the total labor hours expected to be required to satisfy its performance obligation.

 

Contracts with Multiple Performance Obligations

Some contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The standalone selling prices are determined based on overall pricing objectives, taking into consideration market conditions and other factors, including the value of the contracts, the cloud applications sold, customer demographics, geographic locations, and the number and types of users within the contracts.

 

The Company considered several factors in determining that control transfers to the customer upon shipment of hardware and availability of download of software.  These factors include that legal title transfers to the customer, the Company has a present right to payment, and the customer has assumed the risks and rewards of ownership.

 

Accounts receivable from customers are typically due within 30 days of invoicing.  The Company does not record a reserve for product returns or warranties as amounts are deemed immaterial based on historical experience.

 

Costs to Obtain and Fulfill a Contract

Costs to obtain and fulfill a contract are predominantly sales commissions earned by the sales force and are considered incremental and recoverable costs of obtaining a contract with a customer. These costs are deferred and then amortized over a period of benefit determined to be four years. These costs are included as capitalized contract costs on the balance sheet. The period of benefit was determined by taking into consideration customer contracts, technology, and other factors based on historical evidence. Amortization expense is included in selling, general and administrative expenses in the accompanying consolidated statements of operations.

 

Deferred Revenue 

Deferred revenue includes customer advances and amounts that have been paid by customer for which the contractual maintenance terms have not yet occurred. The majority of these amounts are related to maintenance contracts for which the revenue is recognized ratably over the applicable term, which generally is 12-60 months. Contracts greater than 12 months are segregated as long term deferred revenue. Maintenance contracts include provisions for unspecified when-and-if available product updates and customer telephone support services. At December 31, 2021 and 2020, amounts in deferred revenue were approximately $633,000 and $702,000, respectively.

 

4. Business Combinations

 

In accordance with ASC 805, Business Combinations (ASC 805), the Company recognizes the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. Determining these fair values requires management to make significant estimates and assumptions, especially with respect to intangible assets.

 

The Company recognizes identifiable assets acquired and liabilities assumed at their acquisition date fair value. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net acquisition date fair value of the assets acquired and the liabilities assumed and represents the expected future economic benefits arising from other assets acquired that are not individually identified and separately recognized. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, its estimates are inherently uncertain and subject to refinement. Assumptions may be incomplete or inaccurate, and unanticipated events or circumstances may occur, which may affect the accuracy or validity of such assumptions, estimates or actual results. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill to the extent that it identifies adjustments to the preliminary purchase price allocation. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statements of operations.

 

5. Goodwill and acquired intangible assets

 

Goodwill is not amortized, but is evaluated for impairment annually, or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. The Company has determined that there is a single reporting unit for the purpose of conducting this goodwill impairment assessment. For purposes of assessing potential impairment, the Company estimates the fair value of the reporting unit, based on the Company’s market capitalization, and compares this amount to the carrying value of the reporting unit. If the Company determines that the carrying value of the reporting unit exceeds its fair value, an impairment charge would be required. The annual goodwill impairment test will be performed as of  December 31st of each year. To date, the Company has not identified any impairment to goodwill.

 

Intangible assets acquired in a business combination are recorded at their estimated fair values at the date of acquisition. The Company amortizes acquired definite-lived intangible assets over their estimated useful lives based on the pattern of consumption of the economic benefits or, if that pattern cannot be readily determined, on a straight-line basis.

 

6. Cash Equivalents

 

Cash equivalents consist of liquid investments with original maturities of three months or less. At December 31, 2021 and 2020, cash equivalents consisted of a money market account.

 

7. Accounts Receivable

 

Accounts receivable are carried at original amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful receivables by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions. Accounts receivable are written off when deemed uncollectible.

 

Accounts receivable at December 31, 2021 and 2020 consisted of the following: 

 

  

December 31,

 
  

2021

  

2020

 
         

Accounts receivable

 $1,234,411  $561,834 
Loss on foreign currency  (50,000)  - 

Allowance for doubtful accounts

  (213,785

)

  (13,785

)

Accounts receivable, net of allowances for doubtful accounts

 $970,626  $548,049 

 

Bad debt expenses (if any) are recorded in selling, general, and administrative expense. 

 

8. Equipment and Leasehold Improvements, Intangible Assets and Depreciation and Amortization

 

Equipment and leasehold improvements are stated at cost.  Depreciation is provided for in amounts sufficient to relate the cost of depreciable assets to operations over the estimated service lives, principally using straight-line methods. Leasehold improvements are amortized over the shorter of the life of the improvement or the lease term, using the straight-line method.

 

The estimated useful lives used to compute depreciation and amortization for financial reporting purposes are as follows:

 

  

Years

 

Equipment and leasehold improvements

     

Equipment (years)

 

3

-

5

 

Furniture and fixtures (years)

 

3

-

5

 

Software (years)

  

3

  

Leasehold improvements

 

life or lease term

 

 

Intangible assets other than goodwill consist of patents, trade name, proprietary software, and customer relationships.  Patent costs are capitalized until patents are awarded. Upon award, such costs are amortized using the straight-line method over their respective economic lives. If a patent is denied, all costs are charged to operations in that year. Trade names, proprietary software, and customer relationships are amortized over the economic useful life.

 

9. Impairment or Disposal of Long Lived Assets, including Intangible Assets

 

The Company reviews long-lived assets, including intangible assets subject to amortization, whenever events or changes in circumstances indicate that the carrying amount of such an asset may not be recoverable. Recoverability of these assets is measured by comparison of their carrying amount to the future undiscounted cash flows the assets are expected to generate. If such assets are considered impaired, the impairment to be recognized is equal to the amount by which the carrying value of the assets exceeds their fair value determined by either a quoted market price, if any, or a value determined by utilizing a discounted cash flow technique. In assessing recoverability, the Company must make assumptions regarding estimated future cash flows and discount factors. If these estimates or related assumptions change in the future, the Company may be required to record impairment charges. Intangible assets with determinable lives are amortized over their estimated useful lives, based upon the pattern in which the expected benefits will be realized, or on a straight-line basis, whichever is greater. 

 

10. Advertising Expense

 

The Company expenses the costs of advertising as incurred. Advertising expenses for 2021 and 2020 were approximately $527,000 and $494,000, respectively.

 

11. Research and Development Expenditures

 

Research and development expenses include costs directly attributable to the conduct of research and development programs primarily related to the development of our software products and improving the efficiency and capabilities of our existing software. Such costs include salaries, payroll taxes, employee benefit costs, materials, supplies, depreciation on research equipment, services provided by outside contractors, and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation and general support services. All costs associated with research and development are expensed as incurred. 

 

12. Earnings Per Share of Common Stock (“EPS”)

 

The Company’s EPS is calculated by dividing net income (loss) applicable to common stockholders by the weighted-average number of common shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options and warrants, when the effect of their inclusion is dilutive.

 

13. Accounting for Stock-Based Compensation

 

The Company accounts for share based compensation in accordance with the provisions of ASC 718-10, “Compensation — Stock Compensation,” which requires measurement of compensation cost for all stock awards at fair value on date of grant and recognition of compensation over the service period for awards expected to vest. The majority of its share-based compensation arrangements vest over either a three or four year vesting schedule. The Company expenses its share-based compensation under the ratable method, which treats each vesting tranche as if it were an individual grant. The fair value of stock options is determined using the Black-Scholes valuation model and requires the input of highly subjective assumptions. These assumptions include estimating the length of time employees will retain their vested stock options before exercising them (the “expected option term”), the estimated volatility of its common stock price over the option’s expected term, the risk-free interest rate over the option’s expected term, and the Company’s expected annual dividend yield. Changes in these subjective assumptions can materially affect the estimate of fair value of stock-based compensation and consequently, the related amount recognized as an expense in the consolidated statements of operations. As required under the accounting rules, the Company reviews its valuation assumptions at each grant date and, as a result, the Company is likely to change its valuation assumptions used to value employee stock-based awards granted in future periods. The values derived from using the Black-Scholes model are recognized as expense over the service period, net of estimated forfeitures (the number of individuals that will ultimately not complete their vesting requirements). The estimation of stock awards that will ultimately vest requires significant judgment. The Company considers many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience. Actual results, and future changes in estimates, may differ substantially from current estimates. Options and warrants to outsiders are accounted for under ASC 718.

 

The following table presents share-based compensation expenses included in the Company’s consolidated statements of operations:

 

  

Year ended

December 31,

 
  

2021

  

2020

 
         

Selling, general and administrative

 $269,368  $705,971 

Research, development and engineering

  45,347   86,124 
  $314,715  $792,095 

 

Valuation Assumptions for Stock Options

 

In 2020, 28,440 stock options were granted. No options were granted in 2021. The fair value of each option was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:

 

  

Year ended

December 31,

 
  

2021

  

2020

 

Weighted average Risk free interest rate

  -   0.30

%

Expected life of options (in years)

  -   4.50 

Expected dividends

  -   0

%

Weighted average Volatility of stock price

  -   115

%

 

The stock volatility for each grant is determined based on the review of the experience of the weighted average of historical daily price changes of the Company’s common stock over the expected option term. The expected term was determined using the simplified method for estimating expected option life, which qualify as “plain-vanilla” options; and the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. 

 

14. Derivative Liabilities

 

In connection with the issuances of equity instruments or debt, the Company may issue options or warrants to purchase common stock. In certain circumstances, these options or warrants may be classified as liabilities, rather than as equity. In addition, the equity instrument or debt may contain embedded derivative instruments, such as conversion options or listing requirements, which in certain circumstances may be required to be bifurcated from the associated host instrument and accounted for separately as a derivative liability instrument. The Company early-adopted the new provisions issued July 2017, for derivative liability instruments under FASB ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception. Under ASU 2017-11, down round features do not meet the criteria for derivative accounting and no liability is to be recorded until an actual issuance of securities triggers the down-round feature. Prior to these provisions, the liabilities were recorded without the actual issuance of the securities triggering the down-round feature.

 

15. Income Taxes

 

The provision for, or benefit from, income taxes includes deferred taxes resulting from the temporary differences in income for financial and tax purposes using the liability method. Such temporary differences result primarily from the differences in the carrying value of assets and liabilities. Future realization of deferred income tax assets requires sufficient taxable income within the carryback, carryforward period available under tax law. The Company evaluates, on a quarterly basis whether, based on all available evidence, if it is probable that the deferred income tax assets are realizable. Valuation allowances are established when it is more likely than not that the tax benefit of the deferred tax asset will not be realized. The evaluation, as prescribed by ASC 740-10, “Income Taxes,” includes the consideration of all available evidence, both positive and negative, regarding historical operating results including recent years with reported losses, the estimated timing of future reversals of existing taxable temporary differences, estimated future taxable income exclusive of reversing temporary differences and carryforwards, and potential tax planning strategies which may be employed to prevent an operating loss or tax credit carryforward from expiring unused. Because of the Company’s historical performance and estimated future taxable income, a full valuation allowance has been established.

 

The Company accounts for uncertain tax provisions in accordance with ASC 740-10-05, “Accounting for Uncertainty in Income Taxes.” The ASC clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The ASC prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The ASC provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.

 

16. Leases

 

In accordance with ASC 842, Leases (ASC 842), the Company records a right-of-use (ROU) asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classifies them as either operating or finance leases. 

 

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, the Company has elected not to allocate the contract consideration, and to account for the lease and non-lease components as a single lease component.

 

Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate, adjusted for various factors including level of collateralization, term and currency to align with the terms of the lease. The operating lease ROU asset also includes any lease prepayments, offset by lease incentives.

 

An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain we will not exercise the option.

 

17. Recent Accounting Pronouncements

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), referred to herein as ASU 2016-13, which significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 replaces the existing incurred loss model with an expected credit loss model that requires entities to estimate an expected lifetime credit loss on most financial assets and certain other instruments. Under ASU 2016-13 credit impairment is recognized as an allowance for credit losses, rather than as a direct write-down of the amortized cost basis of a financial asset. The impairment allowance is a valuation account deducted from the amortized cost basis of financial assets to present the net amount expected to be collected on the financial asset. Once the new pronouncement is adopted by the Company, the allowance for credit losses must be adjusted for management’s current estimate at each reporting date. The new guidance provides no threshold for recognition of impairment allowance. Therefore, entities must also measure expected credit losses on assets that have a low risk of loss. For instance, trade receivables that are either current or not yet due may not require an allowance reserve under currently generally accepted accounting principles, but under the new standard, the Company will have to estimate an allowance for expected credit losses on trade receivables under ASU 2016-13. ASU 2016-13 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2022 for smaller reporting companies. Early adoption is permitted. The Company is currently assessing the impact ASU 2016-13 will have on its consolidated financial statements.

 

Effective January 1, 2021, the Company adopted ASU 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”) to reduce the cost and complexity in accounting for income taxes. ASU 2019-12 removes certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also amends other aspects of the guidance to help simplify and promote consistent application of U.S. GAAP. Most amendments within ASU 2019-12 are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The adoption of ASU 2019-12 did not have a significant impact on the Company’s consolidated financial statements.

 

Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.

 
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Note B - Revenue From Contracts With Customers
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

NOTE B—REVENUE FROM CONTRACTS WITH CUSTOMERS

 

Disaggregation of Revenue

 

The following table summarizes revenue from contracts with customers for the years ended December 31, 2021 and 2020:

 

   

North

America

    

Africa

    

EMESA*

    

Asia

    

December

31,

2021

  
                                         

License fees

   $ 1,854,088     $ 521,751     $ 105,314     $ 74,656     $ 2,555,809  

Hardware

     278,655       698,264       265,996       42,411       1,285,326  

Services

     1,162,526       42,000       54,918       13,910       1,273,354  

Total Revenues

   $ 3,295,269     $ 1,262,015     $ 426,228     $ 130,977     $ 5,114,489  

 

   

North

America

    

Africa

    

EMESA*

    

Asia

    

December

31,

2020

  
                                         

License fees

   $ 842,307     $ -     $ 46,922     $ 72,809     $ 962,038  

Hardware

     267,996       -       144,647       29,873       442,516  

Services

     1,296,696       44,228       68,196       23,108       1,432,228  

Total Revenues

   $ 2,406,999     $ 44,228     $ 259,765     $ 125,790     $ 2,836,782  

 

* EMESA – Europe, Middle East, South America

 

Revenue recognized during the year ended December 31, 2021 from amounts included in deferred revenue at the beginning of the year was approximately $529,000. Revenue recognized during the year ended December 31, 2020 from amounts included in deferred revenue at the beginning of the year was approximately $290,000. The Company did not recognize any revenue from performance obligations satisfied in prior periods. Total deferred revenue (contract liability) was $632,655 and $702,336 at December 31, 2021 and 2020, respectively.

 

Transaction Price Allocated to the Remaining Performance Obligations

 

ASC 606 requires that the Company disclose the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as at December 31, 2021. The guidance provides certain practical expedients that limit this requirement, which the Company’s contracts meet as follows:

 

 

●

The performance obligation is part of a contract that has an original expected duration of one year or less, in accordance with ASC 606-10-50-14.

 

Deferred revenue represents the Company’s remaining performance obligations related to prepaid support and maintenance, all of which is expected to be recognized from one to five years.
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Note C - PistolStar, Inc. Acquisition
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Business Combination Disclosure [Text Block]

NOTE C—PISTOLSTAR, INC. ACQUISITION

 

On  June 30, 2020, the Company acquired PistolStar, Inc., a private company based in the United States, which provides enterprise-ready identity access management solutions, including multi-factor authentication, identity-as-a-service, single sign-on and self-service password reset to commercial, government and education customers throughout the United States and internationally.

 

From April 10, 2020 until the Company acquired PistolStar, it licensed PortalGuard®, PistolStar’s authentication software, which the Company combines with its biometric authentication solutions offered to existing and prospective customers.

 

The total purchase price of $2.5 million included cash payment of $2.0 million and the issuance of a $500,000 promissory note.

 

The acquisition of PistolStar was accounted for as a business combination and, in accordance with ASC 805, the Company recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The following table summarizes the final purchase price allocation:

 

Purchase consideration:

    

Total cash paid, net of acquired cash

 $2,000,000 

Present value of 4% Promissory note

  464,000 

Total purchase price consideration

 $2,464,000 
     

Fair value of assets acquired and liabilities assumed:

    

Cash and cash equivalents

 $100,747 

Accounts receivable

  184,792 

Prepaid expenses and other current assets

  9,485 

Fixed assets

  36,467 

Intangible assets

  1,480,000 

Goodwill

  1,262,526 

Total assets acquired

  3,074,017 
     

Accrued expenses and other current liabilities

  738 

Accrued payroll

  19,279 

Deferred revenue

  590,000 

Total fair value of assets acquired and liabilities assumed

 $2,464,000 

 

The promissory note accrued interest at 4% per annum and was payable in four installments over the 12-month period following the closing. The balance of the note at December 31, 2020 was $232,000, net of the unamortized debt discount. On January 21, 2021, the Company paid the $250,000 balance due on the note.

 

The fair value of the assets acquired and liabilities assumed was less than the purchase price, resulting in the recognition of goodwill. The goodwill reflected the value of the synergies the Company expected to realize and the assembled workforce.

 

The significant intangible assets identified in the purchase price allocation discussed above include the trade name, proprietary software, and customer relationships. To value the trade name and proprietary software, the Company utilized the Relief from Royalty Method, which quantifies the cost savings associated with asset ownership via a discounted cash flow analysis. To value the customer relationships, the Company utilized the Excess Earnings Method, which isolates the value of the specific intangible asset by discounting its income stream to present value. 

 

The fair value of the assets acquired and liabilities assumed reflected in the tables above is less than the purchase price, resulting in the recognition of goodwill. The goodwill reflects the value of the synergies the Company expects to realize and the assembled workforce.

 

The following table presents the final fair values and useful lives of the identifiable intangible assets acquired:

 

   

Amount

    

Estimated useful

life

(in years)

  

Trade Name

  

$

130,000

      

15

    

Proprietary Software

    

420,000

      

5

    

Customer relationships

    

930,000

    

8

-

10

  

Total identifiable intangible assets

  

$

1,480,000

            

 
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Note D - Factoring
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Factoring [Text Block]

NOTE D—FACTORING

 

Due from factor consisted of the following as of December 31:

 

   

Original Invoice

Value

    

Factored

Amount

    

Factored

Balance due

  

Year Ended December 31, 2021

                        

Factored accounts receivable

   $ 99,000     $ 49,500     $ 49,500  

Year Ended December 31, 2020

                        

Factored accounts receivable

   $ 241,715     $ 181,262     $ 60,453  

 

The Company entered into an accounts receivable factoring arrangement with a financial institution (the “Factor”) which has been extended to  October 31, 2022. Pursuant to the terms of the arrangement, the Company, from time to time, sells to the Factor a minimum of $150,000 per quarter of certain of its accounts receivable balances on a non-recourse basis for credit approved accounts. The Factor remits 35% of the foreign and 75% of the domestic accounts receivable balance to the Company (the “Advance Amount”), with the remaining balance, less fees, forwarded to the Company once the Factor collects the full accounts receivable balance from the customer. In addition, the Company, from time to time, receives over advances from the Factor. Factoring fees range from 2.75% to 15% of the face value of the invoice factored and are determined by the number of days required for collection of the invoice. The cost of factoring is included in selling, general and administrative expenses. The cost of factoring was as follows:  

 

   

Years Ended December 31,

  
   

2021

    

2020

  
                 

Factoring fees

   $ 50,132     $ 98,748  
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Note E - Fair Values of Financial Instruments
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Fair Value Disclosures [Text Block]

NOTE E—FAIR VALUES OF FINANCIAL INSTRUMENTS

 

Cash and cash equivalents, accounts receivable, due from factor, accounts payable and accrued liabilities are carried at, or approximate, fair value because of their short-term nature. The carrying value of the Company’s notes and loan payables approximated fair value as the interest rates related to the financial instruments approximated market.
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Note F - Concentration of Risk
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Concentration Risk Disclosure [Text Block]

NOTE F—CONCENTRATION OF RISK

 

Financial instruments which potentially subject the Company to risk primarily consist of cash, and cash equivalents, investment in debt security, and accounts receivables.

 

The Company maintains its cash and cash equivalents with various financial institutions, which, at times may exceed insured limits. The exposure to the Company is solely dependent upon daily bank balances and the respective strength of the financial institutions. The Company was in excess of coverage of approximately $7,057,000 and $16,020,000 at December 31, 2021 and 2020, respectively. The Company has not incurred any losses on these accounts.

 

The Company extends credit to customers on an unsecured basis in the normal course of business. The Company’s policy is to perform an analysis of the recoverability of its receivables at the end of each reporting period and to establish allowances where appropriate. The Company analyzes historical bad debts and contract losses, customer concentrations, and customer credit-worthiness when evaluating the adequacy of the allowances.

 

For the year ended December 31, 2021 and 2020, one customer accounted for 13% and 18% of total revenue, respectively.

 

Three customers accounted for 87% and one customer accounted for 31% of total accounts receivable, as of December 31, 2021 and 2020, respectively.
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Note G - Note Receivable
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Notes Receivable [Text Block]

NOTE G—NOTE RECEIVABLE

 

During the third quarter 2020, the Company loaned $295,000 as an advance to Technology Transfer Institute (“TTI”) to aid in fulfilling the African contracts. The note does not bear any interest if paid within the nine (9) monthly installments beginning December 31, 2020. The note bears a default rate of 5%. Due to the ongoing delays in payment, the Company reserved $100,000 of the note as an allowance. On February 17, 2022, the Company amended the note to modify the payment terms to provide for lower monthly payments, with an updated maturity date on, or before December 6, 2023. A member of our board of directors served as Chief Executive Officer off TTI until August 12, 2020.

 

   

December 31,

    

December 31,

  
   

2021

    

2020

  
                 

Note receivable

   $ 295,000     $ 295,000  

Allowance for doubtful account

     (100,000 )     -  

Note receivable, net of allowance

     195,000       295,000  
Current portion, net of allowance   $ 82,000     $ 295,000  
Noncurrent portion, net of allowance   $ 113,000     $ -  

 
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Note H - Inventory
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Inventory Disclosure [Text Block]

NOTE H—INVENTORY

 

Inventory is stated at the lower of cost, determined on a first in, first out basis, or realizable value, and consists primarily of fabricated assemblies and finished goods. Inventory is comprised of the following as of December 31: 

 

   

2021

    

2020

  
                 

Finished goods

   $ 4,798,203     $ 221,130  

Fabricated assemblies

     142,457       109,817  

Total inventory

   $ 4,940,660     $ 330,947  
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Note I - Resalable Software Licenses Rights
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Research, Development, and Computer Software Disclosure [Text Block]

NOTE I—RESALABLE SOFTWARE LICENSES RIGHTS

 

On December 31, 2015, the Company purchased third-party software licenses in the amount of $180,000 in anticipation of a large pending deployment that has yet to materialize. The Company is amortizing the total cost at the greater of the actual unit cost per license sold or straight line amortization over 10 years. A total of $10,130 and $14,920 was charged to cost of sales during the years ended December 31, 2021 and 2020, respectively. Since the license purchase, the actual per unit cost (actual usage) of such license rights in the cumulative amount of $131,248 has been charged to cost of sales, with a carrying balance of $48,752 and $58,882 as of December 31, 2021 and 2020, respectively.

 

The Company has classified the balance as non-current until a larger deployment occurs.

 

Estimated minimum amortization expense based on straight line amortization of the software license rights over the remaining useful life approximates the following:

 

Years ending December 31

        

2022

   $ 18,000  

2023

     18,000  

2024

     12,752  

Total

   $ 48,752  
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Note J - Investment in Debt Security
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

NOTE J—INVESTMENT IN DEBT SECURITY

 

During 2019, the Company purchased a 4,000,000 Hong Kong dollar denominated Bond Certificate with a financial institution in Hong Kong. The Bond Certificate translated to $512,821 U.S. Dollars on the June 2019 purchase date. The bond had a one-year term which matured in June 2020, bearing interest at 5% per annum. The Company redeemed the bond and recorded interest income of approximately $25,800.

 

The Company then purchased a new 4,000,000 Hong Kong dollar denominated Bond Certificate with a financial institution in Hong Kong in June 2020. The new Bond Certificate translated to $512,821 U.S. Dollars, based on the exchange rate at the purchase date. The Company can invest up to 20,000,000 Hong Kong dollars under the terms of the certificate, bearing interest at 5% per annum. The investment is recorded at amortized cost which approximates fair value was held to maturity. The Company has yet to receive the proceeds and accrued interest from the investment. The Company has sent a legal letter of demand to confirm the status of the bond, and as such, the debt security was classified as noncurrent. In addition, due to the delay in the receipt of the proceeds, the Company recorded a $60,000 reserve.
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Note K - Equipment and Leasehold Improvements
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Property, Plant and Equipment Disclosure [Text Block]

NOTE K—EQUIPMENT AND LEASEHOLD IMPROVEMENTS

 

Equipment and leasehold improvements consisted of the following as of December 31:

 

   

2021

    

2020

  
                 

Equipment

   $ 831,784     $ 789,760  

Furniture and fixtures

     164,079       164,079  

Software

     32,045       32,045  

Leasehold improvements

     25,135       25,135  
      1,053,043       1,011,019  
                 
                 

Less accumulated depreciation and amortization

     (983,875

)

     (929,226

)
                 

Total

   $ 69,168     $ 81,793  

 

Depreciation was $54,649 and $85,751 for 2021 and 2020, respectively. Amounts are recorded in selling, general, and administrative expense as well as in cost of services.
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Note L - Intangible Assets
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Intangible Assets Disclosure [Text Block]

NOTE L—INTANGIBLE ASSETS

 

Intangible assets consisted of the following as of December 31:

 

   

2021

             12/31/21    

2020

             12/31/20  
   

Gross

Carrying

Amount

    

Accumulated

Amortization

    

Net

Carrying

Amount

    

Gross

Carrying

Amount

    

Accumulated

Amortization

    

Net

Carrying

Amount

 
                                                 

Trade name

   $ 130,000     $ (12,960

)

   $ 117,040     $ 130,000     $ (4,333

)

   $ 125,667  

Proprietary software

     420,000       (126,000

)

     294,000       420,000       (42,000

)

     378,000  

Customer relationships

     930,000       (155,000

)

     775,000       930,000       (51,667

)

     878,333  

Patents and patents pending

     365,080       (253,043

)

     112,037       365,080       (232,934

)

     132,146  

Total

   $ 1,845,080     $ (547,003

)

   $ 1,298,077     $ 1,845,080     $ (330,934

)

   $ 1,514,146  

 

 

Aggregate amortization expense for 2021 and 2020 was approximately $216,000 and $120,000, respectively. Estimated minimum amortization expense based on straight line amortization of the software license rights for each of the next five years and thereafter approximates the following:

 

Years ending December 31

        

2022

   $ 215,000  

2023

     213,000  

2024

     209,000  

2025

     165,000  
2026     121,000  

Thereafter

     375,077  

Total

   $ 1,298,077  
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Note M - Accrued Liabilities
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]

NOTE M—ACCRUED LIABILITIES

 

Accrued liabilities consisted of the following as of December 31:

 

   

2021

    

2020

  
                 

Compensation

   $ 254,433     $ 87,015  

Compensated absences

     293,297       227,147  

Accrued legal and accounting fees

     95,738       83,738  
Franchise taxes     40,000       -  
Employee expenses reimbursement     76,000       67,000  

Sales tax payable

     18,548       17,544  

Factoring fees

     495       5,495  

Other

     50,486       20,548  
                 

Total

   $ 828,997     $ 508,487  
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Note N - Related Party Transactions
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Related Party Transactions Disclosure [Text Block]

NOTE N—RELATED PARTY TRANSACTIONS

 

Non-Interest-Bearing Advances

 

During the 2019 fiscal year, the Company received a series of non-interest-bearing advances from Mr. Wong Kwok Fong, and Mr. Michael DePasquale, to pay current liabilities. The balance of the advances as at December 31, 2019 was $74,737 and $114,000, respectively, which were both repaid in full during 2020.
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Note O - Convertible Notes Payable
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Debt Disclosure [Text Block]

NOTE O—CONVERTIBLE NOTES PAYABLE

 

There was no balance outstanding for convertible notes payable as of December 31, 2021 and 2020. Details for Notes that were either converted or redeemed during the 2020 fiscal year were as follows: 

 

Securities Purchase Agreement dated July 10, 2019

 

On July 10, 2019, the Company issued a $3,060,000 principal amount senior secured convertible note (the “Original Note”). At closing, a total of $2,550,000 was funded. The original issue discount was $510,000. The principal amount due of the Original Note was due and payable as follows: $918,000 was due 180 days after funding, $1,071,000 was due 270 days after funding, and the remaining balance due 12 months after the date of funding.

 

The Original Note was secured by a lien on substantially all of the Company’s assets and properties and was convertible at the option of the Investor in shares of common stock at a fixed conversion price of $12.00 per share.

 

In connection with the closing of the Original Note, the Company issued a five-year warrant to the Investor to purchase 250,000 shares of common stock at a fixed exercise price of $12.00 per share, paid a $50,000 commitment fee, and issued 33,334 shares of common stock in payment of a $400,000 due diligence fee. The Company also paid banker fees of $193,500 and legal fees of $71,330. The valuation of the warrant of $595,662 was recorded to debt discount and was amortized over the life of the Original Note. The fees associated with the agreement were allocated to debt issuance costs and additional paid-in capital based on the respective ratio of the valuation of the note and warrant. Amortization of the debt issuance costs and debt discount are included in interest expense on the statement of operations.

 

On March 12, 2020, the Company issued a $3,789,000 principal amount senior secured convertible note (the “Amended Note”), which replaced the Original Note and included an additional $729,000 in interest due to the debt restructuring. The principal amount was due and payable in full on April 13, 2020. The Amended Note was secured by a lien on substantially all of the Company’s assets and properties and was convertible at the option of the Investor into shares of common stock at a fixed conversion price of $5.20 per share. The Company accounted for the transaction as a debt extinguishment and, therefore, the balance of the fees and unamortized discount associated with the Original Note were written off and included as loss on extinguishment of debt. On the day of the amendment, the closing stock price for the day was $6.08, which resulted in a beneficial conversion of $0.88 per share outstanding or $641,215 to be amortized to interest expense over the term of the Amended Note, as adjusted for any debt conversion.

 

On April 12, 2020 and May 6, 2020, the Company entered into amendments (the “Amendments”) to the Amended Note. The Amendments extended the maturity date to June 12, 2020 and extended the Investor’s right to convert the Amended Note into shares of the Company’s common stock at a price of $5.20 per share through June 12, 2020. All other provisions of the Amended Note remained the same.

 

On June 10, 2020, the investor converted the last of the remaining principal into shares of common stock for payment in full, and the remaining principal balance was $0. The Amended Note amount of $3,789,000 was converted into 728,654 shares of common stock in 2020.

 

January 2020 Note

 

On January 13, 2020, the Company issued a $157,000 principal amount secured 10% convertible redeemable note (the “January 2020 Note”) to an institutional investor with a maturity date of June 13, 2020 which was convertible into common stock at a conversion price of $12.00 per share. At the closing, the Company agreed to issue 81,250 shares of common stock in lieu of payment of a $75,000 commitment fee which was reduced to 6,250 shares as the January 2020 Note was repaid prior to the maturity date.

 

On June 12, 2020, the January 2020 Note was paid in full by payment of $211,984.

 

February 2020 Note

 

On February 13, 2020, the Company issued a $126,000 principal amount secured 10% convertible redeemable note (the “February 2020 Note”) to an institutional investor with a maturity date of July 13, 2020 which was convertible into common stock at a conversion price of $9.20 per share.  On March 12, 2020, the Original Note was amended to reduce the conversion price to $5.20 per share, which reduced the conversion price of the February Note to $5.20 and resulted in a deemed dividend of $70,998. The February 2020 Note was redeemable at any time by payment of a premium to the principal balance starting at 10% and increasing to 30%.   The Company issued 6,250 shares of common stock to the investor in lieu of payment of a $57,500 commitment fee. The Company paid $6,000 of legal fees in connection with the issuance of February 2020 Note.  The February 2020 Note was paid in full on July 10, 2020 by payment of $170,442.

 

May 2020 Note

 

On May 6, 2020, the Company issued a $2,415,000 principal amount senior secured convertible note (the “May 2020 Note”). At closing, $2,100,000 was funded. The principal amount was due and payable in five equal monthly installments of $268,333 beginning seven months after the funding date with the remaining balance due on the twelfth month after the date of funding. The May 2020 Note was convertible at a fixed convertible price of $9.28 per share. In connection with the issuance of the May 2020 Note, the Company paid a $133,333 due diligence fee by issuing 14,368 shares of common stock to the Investor priced at $9.28 per share. The Company also paid a placement fee of 7% of the gross proceeds to a placement agent. In connection with the closing of the May 2020 Note, the Company issued a five-year warrant to the investor to purchase 237,500 shares of common stock at a fixed exercise price of $9.28 and was immediately exercisable. The valuation of the warrant of $876,937 was recorded to debt discount and was amortized over the life of the May 2020 Note. The fees associated with the agreement were allocated to debt issuance costs and additional paid-in-capital based on the respective ratio of the valuation of the note and warrant. Amortization of the debt issuance costs and debt discount were included in the interest expense on the statement of operations.

 

Following the completion of the underwritten offering in July 2020, the principal balance of $2,415,000 was paid in full during the third quarter of 2020.  As a result of the repayment, the Company expensed the remaining debt discounts and issuance costs of $1,218,163 in July 2020.

 

June 2020 Note

 

On June 29, 2020, the Company issued a $1,811,250 principal amount senior secured convertible note (the “June 2020 Note”).  At closing, $1,575,000 was funded. The principal amount was due and payable in nine equal monthly installments of $201,250 beginning four months after the funding date with the remaining balance due on the twelfth month after the date of funding. The June 2020 Note was convertible at a fixed convertible price of $9.28 per share. In connection with the issuance of the June 2020 Note, the Company paid a $100,000 due diligence fee by issuing 17,071 shares to the Investor priced at $5.86 per share. The Company also paid a placement fee of 7% of the gross proceeds to a placement agent.

 

In connection with the closing of the June 2020 Note, the Company issued a five-year warrant to the Investor to purchase 178,125 shares of common stock at a fixed exercise price of $9.28 per share and was immediately exercisable. The valuation of the warrant of $511,402 was recorded to debt discount and is was amortized over the life of the June 2020 Note. The fees associated with the agreement were allocated to debt issuance costs and additional paid-in capital based on the respective ratio of the valuation of the note and warrant. Amortization of the debt issuance costs and debt discount are included in interest expense on the statement of operations.

 

Following the completion of the underwritten offering in July 2020, the principal balance of $1,811,250 was paid in full during the third quarter of 2020. As a result of the repayment, the Company expensed the remaining debt discounts and issuance costs of $957,919 in July 2020.
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Note P - Leases
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Lessee, Operating Leases [Text Block]

NOTE P—LEASES

 

The Company’s leases office space in New Jersey under a lease terminating in 2023 and Hong Kong, Minnesota, and New Hampshire with lease termination dates in 2022. The property leased in China is paid monthly as used, without a formal agreement. The leases include non-lease components with variable payments. The following tables present the components of lease expense and supplemental balance sheet information related to the operating leases were:

 

   

Year ended

December 31,

2021

    

Year ended

December 31,

2020

  

Lease cost

                

Operating lease cost

   $ 255,892     $ 239,192  

Short-term lease cost

     -       -  

Total lease cost

   $ 255,892     $ 239,192  
                 

Balance sheet information

          

Operating right-of-use assets

   $ 254,100     $ 487,325  
                 

Operating lease liabilities, current portion

   $ 177,188     $ 234,309  

Operating lease liabilities, non-current portion

     86,974       264,163  

Total operating lease liabilities

   $ 264,162     $ 498,472  
                 

Weighted average remaining lease term (in years) – operating leases

     1.45       2.26  

Weighted average discount rate – operating leases

     5.50

%

     5.50

%
                 
Supplemental cash flow information related to leases were as follows:                
                 

Cash paid for amounts included in the measurement of operating lease liabilities

   $ 256,977     $ 235,186  
                 
Maturities of operating lease liabilities were as follows as of December 31, 2021:                
                 

2022

   $ 187,594          

2023

     89,225          

Total future lease payments

   $ 276,819          

Less: imputed interest

     (12,657

)

        

Total

   $ 264,162          

 
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Note Q - Commitments and Contingencies
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Commitments Disclosure [Text Block]

NOTE Q—COMMITMENTS AND CONTINGENCIES

 

Sales Incentive Agreement with TTI

 

On March 25, 2020, the Company entered into a sales incentive agreement Technology Transfer Institute (“TTI”). Terms of the agreement include the following:

 

 

1.

The original term of the agreement was one year and has been automatically extended for an additional one-year term.

 

 

2.

For each $5,000,000 in revenue (up to a maximum of $20,000,000) the Company generates from contracts sourced by TTI which are executed during the original term and generate net income of at least 20% (as defined) within eighteen months after the date such contract is executed, the Company will pay TTI a sales incentive fee of $500,000 payable by the issuance of 62,500 shares of common stock.

 

 

3.

In the event that the Company generates revenue in excess of $20,000,000 from contracts sourced by TTI which are executed during the original term and generate net income of at least 20% (as defined) within eighteen months after the date such contract is executed, the Company will issue TTI a five-year warrant to purchase 12,500 shares of Common Stock at an exercise price of $12.00 per share for each $1,000,000 of revenue in excess of $20,000,000 (up to a maximum of $25,000,000).

 

In no event will the Company be obligated to issue more than 250,000 shares of common stock or warrants to purchase more than 62,500 shares of common stock pursuant to this agreement. 

 

There has been no revenue generated nor sales incentive fees paid during the periods ended December 31, 2021 and 2020.

 

Litigation

 

From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of December 31, 2021, the Company was not a party to any pending lawsuits.
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Note R - Equity
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]

NOTE R— EQUITY

 

1. Preferred Stock

 

Within the limits and restrictions provided in the Company’s Certificate of Incorporation, the Board of Directors has the authority, without further action by the shareholders, to issue up to 5,000,000 shares of preferred stock, $.0001 par value per share, in one or more series, and to fix, as to any such series, any dividend rate, redemption price, preference on liquidation or dissolution, sinking fund terms, conversion rights, voting rights, and any other preference or special rights and qualifications.

 

2. Common Stock

 

Effective November 20, 2020, the Company implemented a reverse stock split of its outstanding common stock at a ratio of 1-for-8. The number of authorized shares and the par value of the Company's common stock and preferred stock were not affected by the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares were rounded up to the nearest whole share. The reverse stock split became effective at the opening of trading on November 20, 2020.

 

Holders of common stock have equal rights to receive dividends when, as and if declared by the Board of Directors, out of funds legally available therefor. Holders of common stock have one vote for each share held of record and do not have cumulative voting rights.

 

Holders of common stock are entitled, upon liquidation of the Company, to share ratably in the net assets available for distribution, subject to the rights, if any, of holders of any preferred stock then outstanding. Shares of common stock are not redeemable and have no preemptive or similar rights. All outstanding shares of common stock are fully paid and nonassessable.

 

Issuances of Common Stock

 

On June 18, 2021, the stockholders approved the Employee Stock Purchase Plan. Under the terms of this plan, 789,000 shares of common stock are reserved for issuance to employees and officers of the Company at 85% of the lower of the closing price of the common stock as reported on the Nasdaq Capital Market at the first day or the last day of the offering period. Eligible employees are granted an option to purchase shares under the plan funded by payroll deductions. The Board may suspend or terminate the plan at any time, otherwise the plan expires June 17, 2031. On December 31, 2021, 19,484 shares were issued to employees which resulted in a $10,680 non-cash compensation expense for the Company.

 

On July 23, 2020, the Company completed an underwritten public offering of shares of common stock and warrants resulting in net proceeds of approximately $22.7 million, after deducting underwriting discounts and commissions and estimated offering expenses. 4,264,313 shares of common stock were issued as a result of this offering, and a further 797,038 shares of common stock were issued upon the exercise of 512,500 prefunded warrants and 284,538 warrants exercised in conjunction with the offering.

 

On March 30, 2020, the Company issued 121,500 shares of common stock upon exercise of warrants at $12.00 per share, resulting in proceeds of $1,458,000 to the Company.

 

See Note O Convertible Notes Payable for common stock issuances related to conversion of convertible notes payable and shares of common stock issued for fees in connection with the agreements during fiscal 2020. 

 

Issuances of Restricted Stock

 

Restricted stock consists of shares of common stock that are subject to restrictions on transfer and risk of forfeiture until the fulfillment of specified conditions. The fair value of nonvested shares is determined based on the market price of the Company's common stock on the grant date. Restricted stock is expensed ratably over the term of the restriction period.

 

The Company issued 13,125 shares of restricted common stock to certain employees of the Company and 1,250 of shares of restricted common stock were forfeited during fiscal year 2021. These shares vest in equal annual installments over a three-year period from the date of grant and had a fair value on the date of issuance of $44,025.

 

The Company issued 38,250 and 3,125 shares of restricted common stock in August and November of 2020, respectively to certain employees and directors of the Company. These shares vest in equal annual installments over a three-year period from the date of grant and had a fair value on the date of issuance of $198,900, and $11,250, respectively.

 

Restricted stock compensation for the years ended December 31, 2021 and 2020 was $71,819 and $23,764, respectively.

 

Issuances to Directors, Executive Officers & Consultants

 

During the year ended December 31, 2021, the Company issued 7,828 shares of common stock to its directors in lieu of payment of board fees, valued at $25,536.

 

During the year ended December 31, 2020, the Company issued 5,270 shares of common stock to its directors in lieu of payment of board fees, valued at $28,511.

 

Employees’ exercise options

 

During 2021 and 2020, no employee stock options were exercised.

 

3. Warrants

 

There were no warrants issued during fiscal 2021.

 

Warrants Issued for Services:

 

During the second quarter of 2020, the Company issued a warrant to purchase 15,625 shares of common stock to an investor in payment for a business referral valued at $94,655.

 

During the third quarter of 2020, the Company issued a warrant to purchase 3,125 shares of common stock to a former employee for a business referral valued at $12,921.

 

Warrants Issued with Convertible Notes:

 

See Note O Convertible Notes Payable for warrants issued with convertible notes in connection with the agreements during fiscal 2020.

 

Valuation Assumptions for Warrants:

 

The Company records the warrants at their fair value which is determined using the Black-Scholes valuation model on the date of the grant. The fair value of each warrant was estimated with the following assumptions:

 

  

Year ended

December 31,

 
  

2021

  

2020

 

Weighted average Risk free interest rate

  -

%

  0.33

%

Weighted average price

 $-  $9.25 

Weighted average exercise period

  -   5 

Weighted average Volatility of stock price

  -

%

  110

%

 

The warrant volatility for each issuance is determined based on the review of the experience of the weighted average of historical daily price changes of the Company’s common stock over the expected exercise period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the years to maturity.

 

A summary of warrant activity is as follows:

 

  

Total

Warrants

  

Weighted

average

exercise

price

  

Weighted

average

remaining

life

(in years)

  

Aggregate

intrinsic

value

 
                 

Outstanding, as of December 31, 2019

  423,559   12.80   3.94   — 

Granted – public offering

  4,264,313   5.20         

Granted – prefunded warrants from the public offering

  512,500   0.08         

Granted – other

  434,375   9.25         

Increase due to trigger of anti-dilution provision feature

  27,244   5.20         

Exercised – public offering

  (284,538

)

  5.20         

Exercised – prefunded warranted from the public offering

  (512,500

)

  0.08         

Exercised – other

  (121,500

)

  12.00         

Forfeited

  —   —         

Expired

  (54,066

)

  6.86         

Outstanding, as of December 31, 2020

  4,689,387   6.04   4.48   — 

Granted

  —   —         

Exercised

  —   —         

Forfeited

  —   —         

Expired

  —   —         

Outstanding, as of December 31, 2021

  4,689,387   6.04   3.48   — 

 

The aggregate intrinsic value in the table above represents the total intrinsic value, based on the Company’s closing stock price of $2.21, $3.52 and $4.00 as of December 31, 2021, 2020 and 2019, respectively, which would have been received by the warrant holders had all warrant holders exercised their options as of that date. There were no in-the-money warrants exercisable as of December 31, 2021, 2020 and 2019.

 

4.  Securities Purchase Agreement dated September 23, 2015

 

On September 23, 2015, the Company issued warrants (the “2015 Warrants”) to purchase 8,681 shares of common stock in connection with the issuance of a promissory note. The warrants were immediately exercisable at an initial exercise price of $28.80 per share and had a term of five years.  The 2015 Warrants expired in September 2020.

 

The 2015 Warrants had a “full ratchet” anti-dilution adjustment provision.  The anti-dilution adjustment provision was triggered in the first quarter of 2020 from the February 2020 Note and amendments to the Original Note. As a result of the forgoing transactions, the number of shares of common stock issuable upon the full exercise of the 2015 Warrants increased to 48,078, the exercise price was reduced to $5.20 per share, and the Company recorded a non-cash deemed dividend in amount of $41,688. 

 
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Note S - Stock Options
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Share-based Payment Arrangement [Text Block]

NOTE S—STOCK OPTIONS

 

2004 Stock Option Plan

 

On October 12, 2004, the Board of Directors of the Company approved the 2004 Stock Option Plan (the “2004 Plan”). The 2004 Plan was not presented to stockholders for approval and thus incentive stock options were not available under this plan. Under the terms of this plan, 20,834 shares of common stock were reserved for issuance to employees, officers, directors, and consultants of the Company at exercise prices which may not be below 85% of fair market value. The term of stock options granted may not exceed ten years. Options issued under the 2004 Plan vest pursuant to the terms of stock option agreements with the recipients. In the event of a change in control, as defined, all options outstanding vest immediately. The 2004 Plan expired in October 2014.

 

2015 Stock Option Plan

 

On January 27, 2016, the stockholders approved the 2015 Equity Incentive Plan (the “2015 Plan”). The 2015 Plan initially reserved 187,500 shares of common stock for issuance of options, restricted stock, and other equity based awards to employees, officers, directors, and consultants of the Company. In 2019, the stockholders approved an amendment to the 2015 Plan which increases the number of shares of common stock authorized for issuance under the 2015 Plan from 83,334 shares to 187,500 shares and also effected certain changes in light of the Tax Cuts and Jobs Act of 2017 and its impact on Section 162(m) of the United States Internal Revenue Code of 1986, as amended. In 2021, the stockholders approved an amendment to the 2015 to increase the shares of common stock authorized for issuance under the 2015 Plan from 187,500 shares to 789,000 shares together with other technical changes. In 2021, the stockholders approved an amendment to the 2015 to increase the shares of common stock authorized for issuance under the 2015 Plan from 187,500 shares to 789,000 shares together with other technical changes.  The term of stock options granted under the 2015 Plan, may not exceed ten years, exercise prices may not be below 100-110% of fair market value, and vesting occurs over time periods set forth in written agreements with the recipients. In the event of a change in control, certain stock awards issued under the 2015 Plan may be subject to additional acceleration of vesting as may be provided in the participants’ written agreement. The 2015 Plan expires in December 2025.

 

Non-Plan Stock Options

 

Periodically, the Company has granted options outside of the 2004 and 2015 Plans to various employees and consultants. In the event of change in control, as defined, certain of the non-plan options outstanding vest immediately.

 

Stock Option Activity

 

Information summarizing option activity is as follows:

 

  

Number of Options

  

Weighted

average

  

Weighted

average

remaining

  

Aggregate

 
  

2004

Plan

  

2015

Plan

  

Non

Plan

  

Total

  

exercise

price

  

life

(in years)

  

intrinsic

value

 
                             

Outstanding, as of December 31, 2019

  3,906   70,991   144,070   218,967  $20.08   5.00  $0 

Granted

  —   28,440   —   28,440   5.04         

Exercised

  —   —   —   —   —         

Forfeited

  —   (4,545

)

  —   (4,545

)

  17.34         

Expired

  (3,906

)

  (703

)

  (10,979

)

  (15,588

)

  29.17         

Outstanding, as of December 31, 2020

  —   94,183   133,091   227,274  $17.61   3.87  $0 
                             

Granted

  —   —   —   —  

‐—

         

Exercised

  —   —   —   —   —         

Forfeited

  —   (3,291

)

  —   (3,291

)

  3.87         

Expired

  —   (84

)

  (11,438

)

  (11,522

)

  39.13         

Outstanding, as of December 31, 2021

  —   90,808   121,653   212,461  $16.65   3.03  $0 

Vested or expected to vest at December 31, 2021

           206,283  $16.98   2.95  $0 

Exercisable at December 31, 2021

           186,538  $18.04   2.73  $0 

 

The options outstanding and exercisable at December 31, 2021 were in the following exercise price ranges:

 

      

Options Outstanding

  

Options Exercisable

 

Range of exercise prices

  

Number of

shares

  

Weighted

average

exercise

price

  

Weighted

average

remaining

life (in years)

  

Number

exercisable

  

Weighted

average

exercise

price

 
$4.08-5.20   24,940  $5.19   5.64   8,402  $5.17 
$5.21-15.68   49,669   12.17   3.79   40,284   12.85 
$15.69-39.36   137,852   20.34   2.27   137,852   20.34 
$4.08-39.36   212,461           186,538     

 

The aggregate intrinsic value in the table above represents the total intrinsic value, based on the Company’s closing stock price of $2.21, $3.52 and $4.00 as of December 31, 2021, 2020 and 2019, respectively, which would have been received by the option holders had all option holders exercised their options as of that date. There were no in-the-money options exercisable as of December 31, 2021, 2020 and 2019.

 

The weighted average fair value of options granted during the year ended December 31, 2020 was $3.16 per share. The total intrinsic value of options exercised during the years ended December 31, 2021 and 2020 was $0 as no options were exercised in either year. The total fair value of shares vested during the years ended December 31, 2021 and 2020 was $252,874 and $899,750, respectively.

 

As of December 31, 2021, future forfeiture adjusted compensation cost related to nonvested stock options is $75,035 and will be recognized over an estimated weighted average period of 0.86 years.
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Note T - Income Taxes
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

NOTE T—INCOME TAXES

 

There was no provision for federal or state taxes as at December 31, 2021 and 2020.

 

The Company has deferred taxes due to income tax credits, net operating loss carryforwards, and the effect of temporary differences between the carrying values of certain assets and liabilities for financial reporting and income tax purposes. Significant components of deferred taxes are as follows at December 31:

 

  

2021

  

2020

 
         

Accrued compensation

 $135,000  $81,000 

Accounts receivable allowance

  75,000   474,000 

Stock-based compensation

  1,149,000   1,073,000 

Basis differences in fixed assets

  (10,000

)

  (14,000

)

Basis differences in intangible assets

  75,000   65,000 

Net operating loss and credit carryforwards

  14,467,000   13,337,000 

Valuation allowances

  (15,891,000

)

  (15,016,000

)

         
  $—  $— 

 

The Company has a valuation allowance against the full amount of its net deferred taxes due to the uncertainty of realization of the deferred tax assets due to operating loss history of the Company. The Company currently provides a valuation allowance against deferred taxes when it is more likely than not that some portion, or all of its deferred tax assets will not be realized. The valuation allowance could be reduced or eliminated based on future earnings and future estimates of taxable income. Similarly, income tax benefits related to stock options exercised have not been recognized in the financial statements.

 

As of December 31, 2021, the Company has federal net operating loss carryforwards of approximately $61 million. Approximately $46 million are subject to expiration between 2021 and 2037, and $15 million net operating loss carryforwards have no expiration date. These net operating loss carryforwards are subject to the limitations under Section 382 of the Internal Revenue Code due to changes in the equity ownership of the Company.

 

A reconciliation of the effective income tax rate on operations reflected in the Statements of Operations to the US Federal statutory income tax rate is presented below.

 

  

2021

  

2020

 
         

Federal statutory income tax rate

  21

%

  21

%

Permanent differences

  -

 

  (9

)

Effect of net operating loss

  (21

)

  (12

)

         

Effective tax rate

  —

%

  —

%

 

The Company has not been audited by the Internal Revenue Service (“IRS”) or any states in connection with income taxes. The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The periods from 2018 through 2021 remain open to examination by the IRS and state jurisdictions. The Company believes it is not subject to any tax audit risk beyond those periods. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company does not have any accrued interest or penalties associated with any unrecognized tax benefits, nor was any interest expense incurred during the years ended December 31, 2021 and 2020.
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Note U - Profit Sharing Plan
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Retirement Benefits [Text Block]

NOTE U—PROFIT SHARING PLAN

 

The Company has established a savings plan under section 401(k) of the Internal Revenue Code. All employees of the Company, after completing one day of service, are eligible to enroll in the 401(k) plan. Participating employees may elect to defer a portion of their salary on a pre-tax basis up to the limits as provided by the IRS Code. The Company is not required to match employee contributions but may do so at its discretion. The Company made no contributions during the years ended December 31, 2021 and 2020.
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Note V - Earnings Per Share (EPS)
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Earnings Per Share [Text Block]

NOTE V—EARNINGS PER SHARE (EPS)

 

The Company’s basic EPS is calculated using net income (loss) available to common shareholders and the weighted-average number of shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuance of common stock, such as stock issuable pursuant to the exercise of stock options and warrants and the assumed conversion of preferred stock.

 

The reconciliation of the numerator of the basic and diluted EPS calculations for the following fiscal years ended December 31:

 

   

2021

    

2020

  
                 

Basic Numerator:

                

Net Loss

   $ (5,065,781

)

   $ (9,673,987

)

Deemed dividend from trigger of anti-dilution provision feature

     -       (112,686

)

Net loss available to common stockholders (basic and diluted EPS)

   $ (5,065,781

)

   $ (9,786,673

)

 

The following table summarizes the weighted average securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive due to net losses.

 

   

Years ended December 31,

  
   

2021

    

2020

  
                 

Stock options

     -       1,002  

Restricted stock

     -       3,098  

Potentially dilutive securities

     -       4,100  

 

Items excluded from the diluted per share calculation because the exercise price was greater than the average market price of the common shares:

 

   

Years ended December 31,

  
   

2021

    

2020

  
                 

Stock options

     212,461       223,899  

Warrants

     4,689,387       4,689,387  

Total

     4,901,848       4,913,286  
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Note W - Subsequent Events
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Subsequent Events [Text Block]

NOTE W—SUBSEQUENT EVENTS

 

On March 8, 2022, the Company completed the acquisition of 100% of the issued and outstanding capital stock of Swivel Secure Europe, SA pursuant to the terms of a stock purchase agreement. The aggregate purchase price consisted of a base purchase price of $1.75 million, subject to closing adjustments based on the closing date working capital, indebtedness and unpaid transaction expenses, and an earn-out of up to $500,000. At the closing, the Company made a cash payment of $1.27 million and issued 269,060 shares of common stock of which 89,687 shares were held back by the Company to secure certain indemnification obligations under the stock purchase agreement.

 

On March 10, 2022, the Company issued 6,360 shares of common stock to its directors in payment of board fees. Additionally, the Company issued an aggregate of 848 shares of common stock to its directors in payment of board committee fees. 

 

On March 11, 2022, the Company issued 932 shares of common stock to its directors in payment of board committee fees. The Company issued an aggregate of 274,250 shares of restricted common stock to employees and the board of directors which vest in equal annual installments over a three-year period from the date of grant.

 

The Company has reviewed subsequent events through the date of this filing. 

 
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Basis of Accounting, Policy [Policy Text Block]

Going Concern and Basis of Presentation

 

The Company has historically financed our operations through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. The Company currently requires approximately $735,000 per month to conduct operations, a monthly amount that it has been unable to consistently achieve through revenue generation. During 2021, the Company generated approximately $5,114,000 of revenue, which is below its average monthly requirements. During 2020, the Company raised approximately $24,000,000 from financing activities and at December 31, 2021 had approximately $7,800,000 in cash. With the addition of the Swivel Secure Europe, SA (see Note W), the Company expects $1,000,000 of additional cash flow, based on Swivel Secure’s current recurring revenue and expenses, to provide additional operating income. As of the date of this report, the Company has enough cash and receivables for twelve months of operations.

 

Effective November 20, 2020, the Company implemented a reverse stock split of its outstanding common stock at a ratio of 1-for-8. All share figures and results are reflected on a post-split basis.

 
Consolidation, Policy [Policy Text Block]

1.  Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of BIO-key International, Inc. and its wholly-owned subsidiaries (collectively, the “Company”). Intercompany accounts and transactions have been eliminated in consolidation. 

 
Use of Estimates, Policy [Policy Text Block]

2. Use of Estimates

 

Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) as set forth in the Financial Accounting Standards Board’s (FASB) Accounting Standards Codification (ASC) and consider the various staff accounting bulletins and other applicable guidance issued by the U.S. Securities and Exchange Commission (SEC). These accounting principles require us to make certain estimates, judgments and assumptions. The Company believes that the estimates, judgments and assumptions upon which it relies are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Certain significant accounting policies that contain subjective management estimates and assumptions include those related to revenue recognition, accounts receivable, inventory, intangible assets and long-lived assets, and income taxes. To the extent there are material differences between these estimates, judgments or assumptions and actual results, its consolidated financial statements will be affected. In many cases, the accounting treatment of a particular transaction is specifically dictated by GAAP and does not require management’s judgment in its application. There are also areas in which management’s judgment in selecting among available alternatives would not produce a materially different result.

 
Revenue from Contract with Customer [Policy Text Block]

3. Revenue Recognition

 

In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. To achieve this core principle, the Company applies the following five steps: 

 

 

●

Identify the contract with a customer

 

●

Identify the performance obligations in the contract

 

●

Determine the transaction price

 

●

Allocate the transaction price to performance obligations in the contract

 

●

Recognize revenue when or as the Company satisfies a performance obligation

 

All of the Company's performance obligations, and associated revenues, are generally transferred to customers at a point in time, with the exception of support and maintenance, and professional services, which are generally transferred to the customer over time.

 

Software licenses

Software license revenue consist of fees for perpetual and subscription licenses for one or more of the Company’s biometric fingerprint solutions or identity access management solutions. Revenue is recognized at a point in time once the software is available to the customer for download. Software license contracts are generally invoiced in full on execution of the arrangement.

 

Hardware

Hardware revenue consists of fees for associated equipment sold with or without a software license arrangement, such as servers, locks and fingerprint readers. Customers are not obligated to buy third party hardware from the Company, and may procure these items from a number of suppliers. Revenue is recognized at a point in time once the hardware is shipped to the customer. Hardware items are generally invoiced in full on execution of the arrangement.

 

Support and Maintenance

Support and maintenance revenue consists of fees for unspecified upgrades, telephone assistance and bug fixes. The Company satisfies its support and maintenance performance obligation by providing “stand-ready” assistance as required over the contract period. The Company records deferred revenue (contract liability) at time of prepayment until the contracts term occurs. Revenue is recognized over time on a ratable basis over the contract term. Support and maintenance contracts are one to five years in length and are generally invoiced in advance at the beginning of the term. Support and Maintenance revenue for subscription licenses is carved out of the total license cost at 18% and recognized on a ratable basis over the license term.

 

Professional Services

Professional services revenues consist primarily of fees for deployment and optimization services, as well as training. The majority of the Company’s consulting contracts are billed on a time and materials basis, and revenue is recognized based on the amount billable to the customer in accordance with practical expedient ASC 606-10-55-18. For other professional services contracts, the Company utilizes an input method and recognizes revenue based on labor hours expended to date relative to the total labor hours expected to be required to satisfy its performance obligation.

 

Contracts with Multiple Performance Obligations

Some contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The standalone selling prices are determined based on overall pricing objectives, taking into consideration market conditions and other factors, including the value of the contracts, the cloud applications sold, customer demographics, geographic locations, and the number and types of users within the contracts.

 

The Company considered several factors in determining that control transfers to the customer upon shipment of hardware and availability of download of software.  These factors include that legal title transfers to the customer, the Company has a present right to payment, and the customer has assumed the risks and rewards of ownership.

 

Accounts receivable from customers are typically due within 30 days of invoicing.  The Company does not record a reserve for product returns or warranties as amounts are deemed immaterial based on historical experience.

 

Costs to Obtain and Fulfill a Contract

Costs to obtain and fulfill a contract are predominantly sales commissions earned by the sales force and are considered incremental and recoverable costs of obtaining a contract with a customer. These costs are deferred and then amortized over a period of benefit determined to be four years. These costs are included as capitalized contract costs on the balance sheet. The period of benefit was determined by taking into consideration customer contracts, technology, and other factors based on historical evidence. Amortization expense is included in selling, general and administrative expenses in the accompanying consolidated statements of operations.

 

Deferred Revenue 

Deferred revenue includes customer advances and amounts that have been paid by customer for which the contractual maintenance terms have not yet occurred. The majority of these amounts are related to maintenance contracts for which the revenue is recognized ratably over the applicable term, which generally is 12-60 months. Contracts greater than 12 months are segregated as long term deferred revenue. Maintenance contracts include provisions for unspecified when-and-if available product updates and customer telephone support services. At December 31, 2021 and 2020, amounts in deferred revenue were approximately $633,000 and $702,000, respectively.

 
Business Combinations Policy [Policy Text Block]

4. Business Combinations

 

In accordance with ASC 805, Business Combinations (ASC 805), the Company recognizes the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. Determining these fair values requires management to make significant estimates and assumptions, especially with respect to intangible assets.

 

The Company recognizes identifiable assets acquired and liabilities assumed at their acquisition date fair value. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net acquisition date fair value of the assets acquired and the liabilities assumed and represents the expected future economic benefits arising from other assets acquired that are not individually identified and separately recognized. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, its estimates are inherently uncertain and subject to refinement. Assumptions may be incomplete or inaccurate, and unanticipated events or circumstances may occur, which may affect the accuracy or validity of such assumptions, estimates or actual results. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill to the extent that it identifies adjustments to the preliminary purchase price allocation. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statements of operations.

 
Goodwill and Intangible Assets, Policy [Policy Text Block]

5. Goodwill and acquired intangible assets

 

Goodwill is not amortized, but is evaluated for impairment annually, or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. The Company has determined that there is a single reporting unit for the purpose of conducting this goodwill impairment assessment. For purposes of assessing potential impairment, the Company estimates the fair value of the reporting unit, based on the Company’s market capitalization, and compares this amount to the carrying value of the reporting unit. If the Company determines that the carrying value of the reporting unit exceeds its fair value, an impairment charge would be required. The annual goodwill impairment test will be performed as of  December 31st of each year. To date, the Company has not identified any impairment to goodwill.

 

Intangible assets acquired in a business combination are recorded at their estimated fair values at the date of acquisition. The Company amortizes acquired definite-lived intangible assets over their estimated useful lives based on the pattern of consumption of the economic benefits or, if that pattern cannot be readily determined, on a straight-line basis.

 
Cash and Cash Equivalents, Policy [Policy Text Block]

6. Cash Equivalents

 

Cash equivalents consist of liquid investments with original maturities of three months or less. At December 31, 2021 and 2020, cash equivalents consisted of a money market account.

 
Receivable [Policy Text Block]

7. Accounts Receivable

 

Accounts receivable are carried at original amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful receivables by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions. Accounts receivable are written off when deemed uncollectible.

 

Accounts receivable at December 31, 2021 and 2020 consisted of the following: 

 

  

December 31,

 
  

2021

  

2020

 
         

Accounts receivable

 $1,234,411  $561,834 
Loss on foreign currency  (50,000)  - 

Allowance for doubtful accounts

  (213,785

)

  (13,785

)

Accounts receivable, net of allowances for doubtful accounts

 $970,626  $548,049 

 

Bad debt expenses (if any) are recorded in selling, general, and administrative expense. 

 
Property, Plant and Equipment, Policy [Policy Text Block]

8. Equipment and Leasehold Improvements, Intangible Assets and Depreciation and Amortization

 

Equipment and leasehold improvements are stated at cost.  Depreciation is provided for in amounts sufficient to relate the cost of depreciable assets to operations over the estimated service lives, principally using straight-line methods. Leasehold improvements are amortized over the shorter of the life of the improvement or the lease term, using the straight-line method.

 

The estimated useful lives used to compute depreciation and amortization for financial reporting purposes are as follows:

 

  

Years

 

Equipment and leasehold improvements

     

Equipment (years)

 

3

-

5

 

Furniture and fixtures (years)

 

3

-

5

 

Software (years)

  

3

  

Leasehold improvements

 

life or lease term

 

 

Intangible assets other than goodwill consist of patents, trade name, proprietary software, and customer relationships.  Patent costs are capitalized until patents are awarded. Upon award, such costs are amortized using the straight-line method over their respective economic lives. If a patent is denied, all costs are charged to operations in that year. Trade names, proprietary software, and customer relationships are amortized over the economic useful life.

 
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]

9. Impairment or Disposal of Long Lived Assets, including Intangible Assets

 

The Company reviews long-lived assets, including intangible assets subject to amortization, whenever events or changes in circumstances indicate that the carrying amount of such an asset may not be recoverable. Recoverability of these assets is measured by comparison of their carrying amount to the future undiscounted cash flows the assets are expected to generate. If such assets are considered impaired, the impairment to be recognized is equal to the amount by which the carrying value of the assets exceeds their fair value determined by either a quoted market price, if any, or a value determined by utilizing a discounted cash flow technique. In assessing recoverability, the Company must make assumptions regarding estimated future cash flows and discount factors. If these estimates or related assumptions change in the future, the Company may be required to record impairment charges. Intangible assets with determinable lives are amortized over their estimated useful lives, based upon the pattern in which the expected benefits will be realized, or on a straight-line basis, whichever is greater. 

 
Advertising Cost [Policy Text Block]

10. Advertising Expense

 

The Company expenses the costs of advertising as incurred. Advertising expenses for 2021 and 2020 were approximately $527,000 and $494,000, respectively.

 
Research and Development Expense, Policy [Policy Text Block]

11. Research and Development Expenditures

 

Research and development expenses include costs directly attributable to the conduct of research and development programs primarily related to the development of our software products and improving the efficiency and capabilities of our existing software. Such costs include salaries, payroll taxes, employee benefit costs, materials, supplies, depreciation on research equipment, services provided by outside contractors, and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation and general support services. All costs associated with research and development are expensed as incurred. 

 
Earnings Per Share, Policy [Policy Text Block]

12. Earnings Per Share of Common Stock (“EPS”)

 

The Company’s EPS is calculated by dividing net income (loss) applicable to common stockholders by the weighted-average number of common shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options and warrants, when the effect of their inclusion is dilutive.

 
Share-based Payment Arrangement [Policy Text Block]

13. Accounting for Stock-Based Compensation

 

The Company accounts for share based compensation in accordance with the provisions of ASC 718-10, “Compensation — Stock Compensation,” which requires measurement of compensation cost for all stock awards at fair value on date of grant and recognition of compensation over the service period for awards expected to vest. The majority of its share-based compensation arrangements vest over either a three or four year vesting schedule. The Company expenses its share-based compensation under the ratable method, which treats each vesting tranche as if it were an individual grant. The fair value of stock options is determined using the Black-Scholes valuation model and requires the input of highly subjective assumptions. These assumptions include estimating the length of time employees will retain their vested stock options before exercising them (the “expected option term”), the estimated volatility of its common stock price over the option’s expected term, the risk-free interest rate over the option’s expected term, and the Company’s expected annual dividend yield. Changes in these subjective assumptions can materially affect the estimate of fair value of stock-based compensation and consequently, the related amount recognized as an expense in the consolidated statements of operations. As required under the accounting rules, the Company reviews its valuation assumptions at each grant date and, as a result, the Company is likely to change its valuation assumptions used to value employee stock-based awards granted in future periods. The values derived from using the Black-Scholes model are recognized as expense over the service period, net of estimated forfeitures (the number of individuals that will ultimately not complete their vesting requirements). The estimation of stock awards that will ultimately vest requires significant judgment. The Company considers many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience. Actual results, and future changes in estimates, may differ substantially from current estimates. Options and warrants to outsiders are accounted for under ASC 718.

 

The following table presents share-based compensation expenses included in the Company’s consolidated statements of operations:

 

  

Year ended

December 31,

 
  

2021

  

2020

 
         

Selling, general and administrative

 $269,368  $705,971 

Research, development and engineering

  45,347   86,124 
  $314,715  $792,095 

 

Valuation Assumptions for Stock Options

 

In 2020, 28,440 stock options were granted. No options were granted in 2021. The fair value of each option was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:

 

  

Year ended

December 31,

 
  

2021

  

2020

 

Weighted average Risk free interest rate

  -   0.30

%

Expected life of options (in years)

  -   4.50 

Expected dividends

  -   0

%

Weighted average Volatility of stock price

  -   115

%

 

The stock volatility for each grant is determined based on the review of the experience of the weighted average of historical daily price changes of the Company’s common stock over the expected option term. The expected term was determined using the simplified method for estimating expected option life, which qualify as “plain-vanilla” options; and the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. 

 
Derivatives, Policy [Policy Text Block]

14. Derivative Liabilities

 

In connection with the issuances of equity instruments or debt, the Company may issue options or warrants to purchase common stock. In certain circumstances, these options or warrants may be classified as liabilities, rather than as equity. In addition, the equity instrument or debt may contain embedded derivative instruments, such as conversion options or listing requirements, which in certain circumstances may be required to be bifurcated from the associated host instrument and accounted for separately as a derivative liability instrument. The Company early-adopted the new provisions issued July 2017, for derivative liability instruments under FASB ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception. Under ASU 2017-11, down round features do not meet the criteria for derivative accounting and no liability is to be recorded until an actual issuance of securities triggers the down-round feature. Prior to these provisions, the liabilities were recorded without the actual issuance of the securities triggering the down-round feature.

 
Income Tax, Policy [Policy Text Block]

15. Income Taxes

 

The provision for, or benefit from, income taxes includes deferred taxes resulting from the temporary differences in income for financial and tax purposes using the liability method. Such temporary differences result primarily from the differences in the carrying value of assets and liabilities. Future realization of deferred income tax assets requires sufficient taxable income within the carryback, carryforward period available under tax law. The Company evaluates, on a quarterly basis whether, based on all available evidence, if it is probable that the deferred income tax assets are realizable. Valuation allowances are established when it is more likely than not that the tax benefit of the deferred tax asset will not be realized. The evaluation, as prescribed by ASC 740-10, “Income Taxes,” includes the consideration of all available evidence, both positive and negative, regarding historical operating results including recent years with reported losses, the estimated timing of future reversals of existing taxable temporary differences, estimated future taxable income exclusive of reversing temporary differences and carryforwards, and potential tax planning strategies which may be employed to prevent an operating loss or tax credit carryforward from expiring unused. Because of the Company’s historical performance and estimated future taxable income, a full valuation allowance has been established.

 

The Company accounts for uncertain tax provisions in accordance with ASC 740-10-05, “Accounting for Uncertainty in Income Taxes.” The ASC clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The ASC prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The ASC provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.

 
Lessee, Leases [Policy Text Block]

16. Leases

 

In accordance with ASC 842, Leases (ASC 842), the Company records a right-of-use (ROU) asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classifies them as either operating or finance leases. 

 

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, the Company has elected not to allocate the contract consideration, and to account for the lease and non-lease components as a single lease component.

 

Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate, adjusted for various factors including level of collateralization, term and currency to align with the terms of the lease. The operating lease ROU asset also includes any lease prepayments, offset by lease incentives.

 

An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain we will not exercise the option.

 
New Accounting Pronouncements, Policy [Policy Text Block]

17. Recent Accounting Pronouncements

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), referred to herein as ASU 2016-13, which significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 replaces the existing incurred loss model with an expected credit loss model that requires entities to estimate an expected lifetime credit loss on most financial assets and certain other instruments. Under ASU 2016-13 credit impairment is recognized as an allowance for credit losses, rather than as a direct write-down of the amortized cost basis of a financial asset. The impairment allowance is a valuation account deducted from the amortized cost basis of financial assets to present the net amount expected to be collected on the financial asset. Once the new pronouncement is adopted by the Company, the allowance for credit losses must be adjusted for management’s current estimate at each reporting date. The new guidance provides no threshold for recognition of impairment allowance. Therefore, entities must also measure expected credit losses on assets that have a low risk of loss. For instance, trade receivables that are either current or not yet due may not require an allowance reserve under currently generally accepted accounting principles, but under the new standard, the Company will have to estimate an allowance for expected credit losses on trade receivables under ASU 2016-13. ASU 2016-13 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2022 for smaller reporting companies. Early adoption is permitted. The Company is currently assessing the impact ASU 2016-13 will have on its consolidated financial statements.

 

Effective January 1, 2021, the Company adopted ASU 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”) to reduce the cost and complexity in accounting for income taxes. ASU 2019-12 removes certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also amends other aspects of the guidance to help simplify and promote consistent application of U.S. GAAP. Most amendments within ASU 2019-12 are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The adoption of ASU 2019-12 did not have a significant impact on the Company’s consolidated financial statements.

 

Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.

 
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Note A - The Company and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]
  

December 31,

 
  

2021

  

2020

 
         

Accounts receivable

 $1,234,411  $561,834 
Loss on foreign currency  (50,000)  - 

Allowance for doubtful accounts

  (213,785

)

  (13,785

)

Accounts receivable, net of allowances for doubtful accounts

 $970,626  $548,049 
Useful Lives of Property Plan and Equipment [Table Text Block]
  

Years

 

Equipment and leasehold improvements

     

Equipment (years)

 

3

-

5

 

Furniture and fixtures (years)

 

3

-

5

 

Software (years)

  

3

  

Leasehold improvements

 

life or lease term

 
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
  

Year ended

December 31,

 
  

2021

  

2020

 
         

Selling, general and administrative

 $269,368  $705,971 

Research, development and engineering

  45,347   86,124 
  $314,715  $792,095 
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
  

Year ended

December 31,

 
  

2021

  

2020

 

Weighted average Risk free interest rate

  -   0.30

%

Expected life of options (in years)

  -   4.50 

Expected dividends

  -   0

%

Weighted average Volatility of stock price

  -   115

%
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Note B - Revenue From Contracts With Customers (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Disaggregation of Revenue [Table Text Block]
   

North

America

    

Africa

    

EMESA*

    

Asia

    

December

31,

2021

  
                                         

License fees

   $ 1,854,088     $ 521,751     $ 105,314     $ 74,656     $ 2,555,809  

Hardware

     278,655       698,264       265,996       42,411       1,285,326  

Services

     1,162,526       42,000       54,918       13,910       1,273,354  

Total Revenues

   $ 3,295,269     $ 1,262,015     $ 426,228     $ 130,977     $ 5,114,489  
   

North

America

    

Africa

    

EMESA*

    

Asia

    

December

31,

2020

  
                                         

License fees

   $ 842,307     $ -     $ 46,922     $ 72,809     $ 962,038  

Hardware

     267,996       -       144,647       29,873       442,516  

Services

     1,296,696       44,228       68,196       23,108       1,432,228  

Total Revenues

   $ 2,406,999     $ 44,228     $ 259,765     $ 125,790     $ 2,836,782  
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Note C - PistolStar, Inc. Acquisition (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

Purchase consideration:

    

Total cash paid, net of acquired cash

 $2,000,000 

Present value of 4% Promissory note

  464,000 

Total purchase price consideration

 $2,464,000 
     

Fair value of assets acquired and liabilities assumed:

    

Cash and cash equivalents

 $100,747 

Accounts receivable

  184,792 

Prepaid expenses and other current assets

  9,485 

Fixed assets

  36,467 

Intangible assets

  1,480,000 

Goodwill

  1,262,526 

Total assets acquired

  3,074,017 
     

Accrued expenses and other current liabilities

  738 

Accrued payroll

  19,279 

Deferred revenue

  590,000 

Total fair value of assets acquired and liabilities assumed

 $2,464,000 
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]
   

Amount

    

Estimated useful

life

(in years)

  

Trade Name

  

$

130,000

      

15

    

Proprietary Software

    

420,000

      

5

    

Customer relationships

    

930,000

    

8

-

10

  

Total identifiable intangible assets

  

$

1,480,000

            
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Note D - Factoring (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]
  

December 31,

 
  

2021

  

2020

 
         

Accounts receivable

 $1,234,411  $561,834 
Loss on foreign currency  (50,000)  - 

Allowance for doubtful accounts

  (213,785

)

  (13,785

)

Accounts receivable, net of allowances for doubtful accounts

 $970,626  $548,049 
Factoring Fees [Table Text Block]
   

Years Ended December 31,

  
   

2021

    

2020

  
                 

Factoring fees

   $ 50,132     $ 98,748  
Factored Accounts Receivable [Member]  
Notes Tables  
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]
   

Original Invoice

Value

    

Factored

Amount

    

Factored

Balance due

  

Year Ended December 31, 2021

                        

Factored accounts receivable

   $ 99,000     $ 49,500     $ 49,500  

Year Ended December 31, 2020

                        

Factored accounts receivable

   $ 241,715     $ 181,262     $ 60,453  
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Note G - Note Receivable (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]
  

December 31,

 
  

2021

  

2020

 
         

Accounts receivable

 $1,234,411  $561,834 
Loss on foreign currency  (50,000)  - 

Allowance for doubtful accounts

  (213,785

)

  (13,785

)

Accounts receivable, net of allowances for doubtful accounts

 $970,626  $548,049 
Notes Receivable [Member]  
Notes Tables  
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]
   

December 31,

    

December 31,

  
   

2021

    

2020

  
                 

Note receivable

   $ 295,000     $ 295,000  

Allowance for doubtful account

     (100,000 )     -  

Note receivable, net of allowance

     195,000       295,000  
Current portion, net of allowance   $ 82,000     $ 295,000  
Noncurrent portion, net of allowance   $ 113,000     $ -  
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Note H - Inventory (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Inventory, Current [Table Text Block]
   

2021

    

2020

  
                 

Finished goods

   $ 4,798,203     $ 221,130  

Fabricated assemblies

     142,457       109,817  

Total inventory

   $ 4,940,660     $ 330,947  
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Note I - Resalable Software Licenses Rights (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Years ending December 31

        

2022

   $ 215,000  

2023

     213,000  

2024

     209,000  

2025

     165,000  
2026     121,000  

Thereafter

     375,077  

Total

   $ 1,298,077  
Software License Rights [Member]  
Notes Tables  
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Years ending December 31

        

2022

   $ 18,000  

2023

     18,000  

2024

     12,752  

Total

   $ 48,752  
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Note K - Equipment and Leasehold Improvements (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Property, Plant and Equipment [Table Text Block]
   

2021

    

2020

  
                 

Equipment

   $ 831,784     $ 789,760  

Furniture and fixtures

     164,079       164,079  

Software

     32,045       32,045  

Leasehold improvements

     25,135       25,135  
      1,053,043       1,011,019  
                 
                 

Less accumulated depreciation and amortization

     (983,875

)

     (929,226

)
                 

Total

   $ 69,168     $ 81,793  
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Note L - Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Finite-Lived Intangible Assets [Table Text Block]
   

2021

             12/31/21    

2020

             12/31/20  
   

Gross

Carrying

Amount

    

Accumulated

Amortization

    

Net

Carrying

Amount

    

Gross

Carrying

Amount

    

Accumulated

Amortization

    

Net

Carrying

Amount

 
                                                 

Trade name

   $ 130,000     $ (12,960

)

   $ 117,040     $ 130,000     $ (4,333

)

   $ 125,667  

Proprietary software

     420,000       (126,000

)

     294,000       420,000       (42,000

)

     378,000  

Customer relationships

     930,000       (155,000

)

     775,000       930,000       (51,667

)

     878,333  

Patents and patents pending

     365,080       (253,043

)

     112,037       365,080       (232,934

)

     132,146  

Total

   $ 1,845,080     $ (547,003

)

   $ 1,298,077     $ 1,845,080     $ (330,934

)

   $ 1,514,146  
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Years ending December 31

        

2022

   $ 215,000  

2023

     213,000  

2024

     209,000  

2025

     165,000  
2026     121,000  

Thereafter

     375,077  

Total

   $ 1,298,077  
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Note M - Accrued Liabilities (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Accrued Liabilities [Table Text Block]
   

2021

    

2020

  
                 

Compensation

   $ 254,433     $ 87,015  

Compensated absences

     293,297       227,147  

Accrued legal and accounting fees

     95,738       83,738  
Franchise taxes     40,000       -  
Employee expenses reimbursement     76,000       67,000  

Sales tax payable

     18,548       17,544  

Factoring fees

     495       5,495  

Other

     50,486       20,548  
                 

Total

   $ 828,997     $ 508,487  
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Note P - Leases (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Lessee, Operating Lease, Costs, Assets and Liabilities [Table Text Block]
   

Year ended

December 31,

2021

    

Year ended

December 31,

2020

  

Lease cost

                

Operating lease cost

   $ 255,892     $ 239,192  

Short-term lease cost

     -       -  

Total lease cost

   $ 255,892     $ 239,192  
                 

Balance sheet information

          

Operating right-of-use assets

   $ 254,100     $ 487,325  
                 

Operating lease liabilities, current portion

   $ 177,188     $ 234,309  

Operating lease liabilities, non-current portion

     86,974       264,163  

Total operating lease liabilities

   $ 264,162     $ 498,472  
                 

Weighted average remaining lease term (in years) – operating leases

     1.45       2.26  

Weighted average discount rate – operating leases

     5.50

%

     5.50

%
                 
Supplemental cash flow information related to leases were as follows:                
                 

Cash paid for amounts included in the measurement of operating lease liabilities

   $ 256,977     $ 235,186  
                 
Maturities of operating lease liabilities were as follows as of December 31, 2021:                
                 

2022

   $ 187,594          

2023

     89,225          

Total future lease payments

   $ 276,819          

Less: imputed interest

     (12,657

)

        

Total

   $ 264,162          
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.22.1
Note R - Equity (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Warrants Valuation Assumptions [Table Text Block]
  

Year ended

December 31,

 
  

2021

  

2020

 

Weighted average Risk free interest rate

  -

%

  0.33

%

Weighted average price

 $-  $9.25 

Weighted average exercise period

  -   5 

Weighted average Volatility of stock price

  -

%

  110

%
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
  

Total

Warrants

  

Weighted

average

exercise

price

  

Weighted

average

remaining

life

(in years)

  

Aggregate

intrinsic

value

 
                 

Outstanding, as of December 31, 2019

  423,559   12.80   3.94   — 

Granted – public offering

  4,264,313   5.20         

Granted – prefunded warrants from the public offering

  512,500   0.08         

Granted – other

  434,375   9.25         

Increase due to trigger of anti-dilution provision feature

  27,244   5.20         

Exercised – public offering

  (284,538

)

  5.20         

Exercised – prefunded warranted from the public offering

  (512,500

)

  0.08         

Exercised – other

  (121,500

)

  12.00         

Forfeited

  —   —         

Expired

  (54,066

)

  6.86         

Outstanding, as of December 31, 2020

  4,689,387   6.04   4.48   — 

Granted

  —   —         

Exercised

  —   —         

Forfeited

  —   —         

Expired

  —   —         

Outstanding, as of December 31, 2021

  4,689,387   6.04   3.48   — 
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.22.1
Note S - Stock Options (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Share-based Payment Arrangement, Option, Activity [Table Text Block]
  

Number of Options

  

Weighted

average

  

Weighted

average

remaining

  

Aggregate

 
  

2004

Plan

  

2015

Plan

  

Non

Plan

  

Total

  

exercise

price

  

life

(in years)

  

intrinsic

value

 
                             

Outstanding, as of December 31, 2019

  3,906   70,991   144,070   218,967  $20.08   5.00  $0 

Granted

  —   28,440   —   28,440   5.04         

Exercised

  —   —   —   —   —         

Forfeited

  —   (4,545

)

  —   (4,545

)

  17.34         

Expired

  (3,906

)

  (703

)

  (10,979

)

  (15,588

)

  29.17         

Outstanding, as of December 31, 2020

  —   94,183   133,091   227,274  $17.61   3.87  $0 
                             

Granted

  —   —   —   —  

‐—

         

Exercised

  —   —   —   —   —         

Forfeited

  —   (3,291

)

  —   (3,291

)

  3.87         

Expired

  —   (84

)

  (11,438

)

  (11,522

)

  39.13         

Outstanding, as of December 31, 2021

  —   90,808   121,653   212,461  $16.65   3.03  $0 

Vested or expected to vest at December 31, 2021

           206,283  $16.98   2.95  $0 

Exercisable at December 31, 2021

           186,538  $18.04   2.73  $0 
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]
      

Options Outstanding

  

Options Exercisable

 

Range of exercise prices

  

Number of

shares

  

Weighted

average

exercise

price

  

Weighted

average

remaining

life (in years)

  

Number

exercisable

  

Weighted

average

exercise

price

 
$4.08-5.20   24,940  $5.19   5.64   8,402  $5.17 
$5.21-15.68   49,669   12.17   3.79   40,284   12.85 
$15.69-39.36   137,852   20.34   2.27   137,852   20.34 
$4.08-39.36   212,461           186,538     
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.22.1
Note T - Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
  

2021

  

2020

 
         

Accrued compensation

 $135,000  $81,000 

Accounts receivable allowance

  75,000   474,000 

Stock-based compensation

  1,149,000   1,073,000 

Basis differences in fixed assets

  (10,000

)

  (14,000

)

Basis differences in intangible assets

  75,000   65,000 

Net operating loss and credit carryforwards

  14,467,000   13,337,000 

Valuation allowances

  (15,891,000

)

  (15,016,000

)

         
  $—  $— 
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
  

2021

  

2020

 
         

Federal statutory income tax rate

  21

%

  21

%

Permanent differences

  -

 

  (9

)

Effect of net operating loss

  (21

)

  (12

)

         

Effective tax rate

  —

%

  —

%
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.22.1
Note V - Earnings Per Share (EPS) (Tables)
 12 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
   

2021

    

2020

  
                 

Basic Numerator:

                

Net Loss

   $ (5,065,781

)

   $ (9,673,987

)

Deemed dividend from trigger of anti-dilution provision feature

     -       (112,686

)

Net loss available to common stockholders (basic and diluted EPS)

   $ (5,065,781

)

   $ (9,786,673

)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
   

Years ended December 31,

  
   

2021

    

2020

  
                 

Stock options

     -       1,002  

Restricted stock

     -       3,098  

Potentially dilutive securities

     -       4,100  
   

Years ended December 31,

  
   

2021

    

2020

  
                 

Stock options

     212,461       223,899  

Warrants

     4,689,387       4,689,387  

Total

     4,901,848       4,913,286  
XML 59 R46.htm IDEA: XBRL DOCUMENT v3.22.1
Note A - The Company and Summary of Significant Accounting Policies (Details Textual)
 12 Months Ended
Nov. 20, 2020
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2020
USD ($)
shares
Operational Costs Per Month   $ 735,000  
Revenue from Contract with Customer, Including Assessed Tax   5,114,489 $ 2,836,782
Net Cash Provided by (Used in) Financing Activities, Total   (218,598) 24,094,012
Cash and Cash Equivalents, at Carrying Value, Ending Balance   7,754,046 16,993,096
Additional Income of Cash Flow   $ 1,000,000  
Percentage of Support and Maintenance Revenue to License Cost   18.00%  
Capitalized Contract Cost, Amortization Period (Year)   4 years  
Contract with Customer, Liability, Total   $ 632,655 702,336
Goodwill, Impairment Loss   0  
Advertising Expense   $ 527,000 $ 494,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | shares   0 28,440
Minimum [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)   3 years  
Maximum [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)   4 years  
Reverse Stock Split [Member]      
Stockholders' Equity Note, Stock Split, Conversion Ratio 8    
XML 60 R47.htm IDEA: XBRL DOCUMENT v3.22.1
Note A - The Company and Summary of Significant Accounting Policies - Summary of Accounts Receivable (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Accounts receivable $ 1,234,411 $ 561,834
Foreign currency loss (50,000) (0)
Allowance for doubtful accounts (213,785) (13,785)
Accounts receivable, net of allowances for doubtful accounts $ 970,626 $ 548,049
XML 61 R48.htm IDEA: XBRL DOCUMENT v3.22.1
Note A - The Company and Summary of Significant Accounting Policies - Estimated Useful Lives for Depreciation and Amortization (Details)
 12 Months Ended
Dec. 31, 2021
Equipment [Member] | Minimum [Member]  
Property, Plant, and Equipment (Year) 3 years
Equipment [Member] | Maximum [Member]  
Property, Plant, and Equipment (Year) 5 years
Furniture and Fixtures [Member] | Minimum [Member]  
Property, Plant, and Equipment (Year) 3 years
Furniture and Fixtures [Member] | Maximum [Member]  
Property, Plant, and Equipment (Year) 5 years
Software Development [Member]  
Property, Plant, and Equipment (Year) 3 years
XML 62 R49.htm IDEA: XBRL DOCUMENT v3.22.1
Note A - The Company and Summary of Significant Accounting Policies - Share-based Compensation Expenses for Continuing Operations (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based compensation expense $ 314,715 $ 792,095
Selling, General and Administrative Expenses [Member]    
Share-based compensation expense 269,368 705,971
Research and Development Expense [Member]    
Share-based compensation expense $ 45,347 $ 86,124
XML 63 R50.htm IDEA: XBRL DOCUMENT v3.22.1
Note A - The Company and Summary of Significant Accounting Policies - Valuation Assumptions for Stock Options (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Weighted average Risk free interest rate 0.00% 0.30%
Expected life of options (Year)   4 years 6 months
Expected dividends 0.00% 0.00%
Weighted average Volatility of stock price 0.00% 115.00%
XML 64 R51.htm IDEA: XBRL DOCUMENT v3.22.1
Note B - Revenue From Contracts With Customers (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Contract with Customer, Liability, Revenue Recognized $ 529,000 $ 290,000
Contract with Customer, Liability, Total $ 632,655 $ 702,336
XML 65 R52.htm IDEA: XBRL DOCUMENT v3.22.1
Note B - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Revenue from Contract with Customer, Including Assessed Tax $ 5,114,489 $ 2,836,782
North America [Member]    
Revenue from Contract with Customer, Including Assessed Tax 3,295,269 2,406,999
South America [Member]    
Revenue from Contract with Customer, Including Assessed Tax 1,262,015 44,228
EMEA [Member]    
Revenue from Contract with Customer, Including Assessed Tax [1] 426,228 259,765
Asia [Member]    
Revenue from Contract with Customer, Including Assessed Tax 130,977 125,790
License [Member]    
Revenue from Contract with Customer, Including Assessed Tax 2,555,809 962,038
License [Member] | North America [Member]    
Revenue from Contract with Customer, Including Assessed Tax 1,854,088 842,307
License [Member] | South America [Member]    
Revenue from Contract with Customer, Including Assessed Tax 521,751 0
License [Member] | EMEA [Member]    
Revenue from Contract with Customer, Including Assessed Tax [1] 105,314 46,922
License [Member] | Asia [Member]    
Revenue from Contract with Customer, Including Assessed Tax 74,656 72,809
Hardware [Member]    
Revenue from Contract with Customer, Including Assessed Tax 1,285,326 442,516
Hardware [Member] | North America [Member]    
Revenue from Contract with Customer, Including Assessed Tax 278,655 267,996
Hardware [Member] | South America [Member]    
Revenue from Contract with Customer, Including Assessed Tax 698,264 0
Hardware [Member] | EMEA [Member]    
Revenue from Contract with Customer, Including Assessed Tax [1] 265,996 144,647
Hardware [Member] | Asia [Member]    
Revenue from Contract with Customer, Including Assessed Tax 42,411 29,873
Service [Member]    
Revenue from Contract with Customer, Including Assessed Tax 1,273,354 1,432,228
Service [Member] | North America [Member]    
Revenue from Contract with Customer, Including Assessed Tax 1,162,526 1,296,696
Service [Member] | South America [Member]    
Revenue from Contract with Customer, Including Assessed Tax 42,000 44,228
Service [Member] | EMEA [Member]    
Revenue from Contract with Customer, Including Assessed Tax 54,918 68,196
Service [Member] | Asia [Member]    
Revenue from Contract with Customer, Including Assessed Tax $ 13,910 $ 23,108
[1] EMEA - Europe, Middle East, Africa
XML 66 R53.htm IDEA: XBRL DOCUMENT v3.22.1
Note C - PistolStar, Inc. Acquisition (Details Textual) - USD ($)
 12 Months Ended
Jan. 21, 2021
Jun. 30, 2020
Dec. 31, 2021
Dec. 31, 2020
Repayments of Notes Payable     $ 250,000 $ 250,000
PistolStar [Member]        
Business Combination, Consideration Transferred, Total   $ 2,464,000    
Payments to Acquire Businesses, Net of Cash Acquired, Total   2,000,000    
Business Combination, Consideration Transferred, Liabilities Incurred   $ 464,000    
PistolStar [Member] | Promissory Note [Member]        
Debt Instrument, Interest Rate, Stated Percentage   4.00%    
Debt Instrument, Number of Installments   4    
Debt Instrument, Term (Month)   12 months    
Notes Payable, Total       $ 232,000
Repayments of Notes Payable $ 250,000      
XML 67 R54.htm IDEA: XBRL DOCUMENT v3.22.1
Note C - PistolStar, Inc. Acquisition - Assets Acquired and Liabilities Assumed (Details) - USD ($)
Jun. 30, 2020
Dec. 31, 2021
Dec. 31, 2020
Fair value of assets acquired and liabilities assumed:      
Goodwill   $ 1,262,526 $ 1,262,526
PistolStar [Member]      
Total cash paid, net of acquired cash $ 2,000,000    
Present value of 4% Promissory note 464,000    
Total purchase price consideration 2,464,000    
Fair value of assets acquired and liabilities assumed:      
Cash and cash equivalents 100,747    
Accounts receivable 184,792    
Prepaid expenses and other current assets 9,485    
Fixed assets 36,467    
Intangible assets 1,480,000    
Goodwill 1,262,526    
Total assets acquired 3,074,017    
Accrued expenses and other current liabilities 738    
Accrued payroll 19,279    
Deferred revenue 590,000    
Total fair value of assets acquired and liabilities assumed $ 2,464,000    
XML 68 R55.htm IDEA: XBRL DOCUMENT v3.22.1
Note C - PistolStar, Inc. Acquisition - Assets Acquired and Liabilities Assumed (Details) (Parentheticals)
Jun. 30, 2020
PistolStar [Member] | Promissory Note [Member]  
Debt Instrument, Interest Rate, Stated Percentage 4.00%
XML 69 R56.htm IDEA: XBRL DOCUMENT v3.22.1
Note C - PistolStar, Inc. Acquisition - Intangible Assets Acquired (Details) - PistolStar [Member]
Jun. 30, 2020
USD ($)
Finite-lived Intangible Assets Acquired $ 1,480,000
Trade Names [Member]  
Finite-lived Intangible Assets Acquired $ 130,000
Finite-lived Intangible Assets Acquired (Year) 15 years
Proprietary Software [Member]  
Finite-lived Intangible Assets Acquired $ 420,000
Finite-lived Intangible Assets Acquired (Year) 5 years
Customer Relationships [Member]  
Finite-lived Intangible Assets Acquired $ 930,000
Customer Relationships [Member] | Minimum [Member]  
Finite-lived Intangible Assets Acquired (Year) 8 years
Customer Relationships [Member] | Maximum [Member]  
Finite-lived Intangible Assets Acquired (Year) 10 years
XML 70 R57.htm IDEA: XBRL DOCUMENT v3.22.1
Note D - Factoring (Details Textual)
 12 Months Ended
Dec. 31, 2021
USD ($)
Factoring Arrangement, Minimum Amount of Accounts Receivable Per Quarter $ 150,000
Minimum [Member]  
Factoring Fees Percent 2.75%
Maximum [Member]  
Factoring Fees Percent 15.00%
Geographic Distribution, Foreign [Member]  
Percentage Of Accounts Receivable Remitted By Factor 35.00%
Geographic Distribution, Domestic [Member]  
Percentage Of Accounts Receivable Remitted By Factor 75.00%
XML 71 R58.htm IDEA: XBRL DOCUMENT v3.22.1
Note D - Factoring - Due From Factor (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Original Invoice Value $ 99,000 $ 241,715
Factored amount 49,500 181,262
Balance due from factor $ 49,500 $ 60,453
XML 72 R59.htm IDEA: XBRL DOCUMENT v3.22.1
Note D - Factoring - Fees (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Factoring fees $ 50,132 $ 98,748
XML 73 R60.htm IDEA: XBRL DOCUMENT v3.22.1
Note F - Concentration of Risk (Details Textual)
 12 Months Ended
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Cash, Uninsured Amount $ 7,057,000 $ 16,020,000
Customer Concentration Risk [Member] | Revenue Benchmark [Member]    
Concentration Risk, Number of Major Customers 1  
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member]    
Concentration Risk, Percentage 13.00% 18.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member]    
Concentration Risk, Number of Major Customers   1
Concentration Risk, Percentage   31.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Customers [Member]    
Concentration Risk, Percentage 87.00%  
XML 74 R61.htm IDEA: XBRL DOCUMENT v3.22.1
Note G - Note Receivable (Details Textual) - USD ($)
 9 Months Ended
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Financing Receivable, after Allowance for Credit Loss, Current, Total   $ 82,000 $ 295,000 $ 295,000
Receivable with Imputed Interest, Effective Yield (Interest Rate) 5.00%      
Accounts Receivable, Allowance for Credit Loss, Ending Balance   $ 100,000    
XML 75 R62.htm IDEA: XBRL DOCUMENT v3.22.1
Note G - Note Receivable - Summary of Note Receivable (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Note receivable $ 295,000 $ 295,000  
Allowance for doubtful account (100,000) 0  
Note receivable, net of allowance 195,000 295,000  
Current portion, net of allowance 82,000 295,000 $ 295,000
Note receivable, net of allowance $ 113,000 $ 0  
XML 76 R63.htm IDEA: XBRL DOCUMENT v3.22.1
Note H - Inventory - Components of Inventory (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Finished goods $ 4,798,203 $ 221,130
Fabricated assemblies 142,457 109,817
Total inventory $ 4,940,660 $ 330,947
XML 77 R64.htm IDEA: XBRL DOCUMENT v3.22.1
Note I - Resalable Software Licenses Rights (Details Textual) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2015
Mar. 31, 2017
Dec. 31, 2021
Dec. 31, 2020
Amortization of Intangible Assets, Total     $ 216,069 $ 120,240
Software License Rights [Member]        
Payments to Acquire Software $ 180,000      
Finite-Lived Intangible Asset, Useful Life (Year)   10 years    
Amortization of Intangible Assets, Total     10,130 14,920
The 2015 Software License [Member]        
Cumulative Amount of Amortization Expense, Net of Credits     131,248  
Software License Rights     $ 48,752 $ 58,882
XML 78 R65.htm IDEA: XBRL DOCUMENT v3.22.1
Note I - Resalable Software Licenses Rights - Amortization Expense (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Total $ 1,298,077 $ 1,514,146
Software License Rights [Member]    
2022 18,000  
2023 18,000  
2024 12,752  
Total $ 48,752  
XML 79 R66.htm IDEA: XBRL DOCUMENT v3.22.1
Note J - Investment in Debt Security (Details Textual)
 12 Months Ended
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Sep. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2020
HKD ($)
Dec. 31, 2019
HKD ($)
Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current $ 0 $ 512,821          
Investment Income, Interest $ 4,075 $ 30,649          
Debt Security, Corporate, Non-US [Member]              
Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current     $ 512,821   $ 512,821 $ 4,000,000 $ 4,000,000
Investment in Held-to-maturity Debt Securities, Term (Year)     1 year        
Investment in Held-to-maturity Debt Securities, Interest Rate     5.00%   5.00% 5.00% 5.00%
Investment Income, Interest     $ 25,800        
Limit of Bond           $ 20,000,000  
Debt Securities, Held-to-maturity, Allowance for Credit Loss, Noncurrent       $ 60,000      
XML 80 R67.htm IDEA: XBRL DOCUMENT v3.22.1
Note K - Equipment and Leasehold Improvements (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Selling, General and Administrative Expenses [Member]    
Depreciation, Depletion and Amortization, Nonproduction, Total $ 54,649 $ 85,751
XML 81 R68.htm IDEA: XBRL DOCUMENT v3.22.1
Note K - Equipment and Leasehold Improvements - Summary of Equipment and Leasehold Improvements (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Property, plant, and equipment, gross $ 1,053,043 $ 1,011,019
Less accumulated depreciation and amortization (983,875) (929,226)
Total 69,168 81,793
Equipment [Member]    
Property, plant, and equipment, gross 831,784 789,760
Furniture and Fixtures [Member]    
Property, plant, and equipment, gross 164,079 164,079
Software Development [Member]    
Property, plant, and equipment, gross 32,045 32,045
Leasehold Improvements [Member]    
Property, plant, and equipment, gross $ 25,135 $ 25,135
XML 82 R69.htm IDEA: XBRL DOCUMENT v3.22.1
Note L - Intangible Assets (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Amortization of Intangible Assets, Total $ 216,069 $ 120,240
Research, Development, and Engineering Expense [Member]    
Amortization of Intangible Assets, Total $ 216,000 $ 120,000
XML 83 R70.htm IDEA: XBRL DOCUMENT v3.22.1
Note L - Intangible Assets - Summary of Intangible Assets (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Gross carrying amount $ 1,845,080 $ 1,845,080
Accumulated amortization (547,003) (330,934)
Net carrying amount 1,298,077 1,514,146
Trade Names [Member]    
Gross carrying amount 130,000 130,000
Accumulated amortization (12,960) (4,333)
Net carrying amount 117,040 125,667
Proprietary Software [Member]    
Gross carrying amount 420,000 420,000
Accumulated amortization (126,000) (42,000)
Net carrying amount 294,000 378,000
Customer Relationships [Member]    
Gross carrying amount 930,000 930,000
Accumulated amortization (155,000) (51,667)
Net carrying amount 775,000 878,333
Patents [Member]    
Gross carrying amount 365,080 365,080
Accumulated amortization (253,043) (232,934)
Net carrying amount $ 112,037 $ 132,146
XML 84 R71.htm IDEA: XBRL DOCUMENT v3.22.1
Note L - Intangible Assets - Amortization Expense (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Total $ 1,298,077 $ 1,514,146
Licensing Agreements [Member]    
2022 215,000  
2023 213,000  
2024 209,000  
2025 165,000  
2026 121,000  
Thereafter 375,077  
Total $ 1,298,077  
XML 85 R72.htm IDEA: XBRL DOCUMENT v3.22.1
Note M - Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Compensation $ 254,433 $ 87,015
Compensated absences 293,297 227,147
Accrued legal and accounting fees 95,738 83,738
Franchise taxes 40,000 0
Employee expenses reimbursement 76,000 67,000
Sales tax payable 18,548 17,544
Factoring fees 495 5,495
Other 50,486 20,548
Total $ 828,997 $ 508,487
XML 86 R73.htm IDEA: XBRL DOCUMENT v3.22.1
Note N - Related Party Transactions (Details Textual)
Dec. 31, 2019
USD ($)
Accounts Payable [Member] | Mr. Wong Kwok Fong [Member]  
Due to Related Parties, Current, Total $ 74,737
Accrued Liabilities (Other) [Member] | Mr. Michael DePasquale [Member]  
Due to Related Parties, Current, Total $ 114,000
XML 87 R74.htm IDEA: XBRL DOCUMENT v3.22.1
Note O - Convertible Notes Payable (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Jul. 10, 2020
Jun. 29, 2020
Jun. 12, 2020
Jun. 10, 2020
May 06, 2020
Mar. 12, 2020
Feb. 13, 2020
Jan. 13, 2020
Jul. 10, 2019
Jul. 31, 2020
Sep. 30, 2020
Dec. 31, 2021
Dec. 31, 2020
Mar. 30, 2020
Dec. 31, 2019
Sep. 23, 2015
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)                               8,681
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)                           $ 12.00   $ 28.80
Payments of Stock Issuance Costs, Commitment Fees                 $ 50,000              
Stock Issued During Period, Shares, Issued for Due Diligence Fee (in shares)   17,071     14,368       33,334              
Stock Issued During Period, Value, Issued for Due Diligence Fee   $ 100,000     $ 133,333       $ 400,000              
Payments of Stock Issuance Costs, Banker Fees                 193,500              
Payments of Stock Issuance Costs, Legal Fees                 71,330              
Class of Warrant or Right, Recorded as Debt Discount                 $ 595,662              
Share Price (in dollars per share)     $ 5.20     $ 6.08           $ 2.21 $ 3.52   $ 4.00  
Repayments of Convertible Debt                       $ (0) $ 4,509,250      
Shares Issued, Price Per Share (in dollars per share)   $ 5.86     $ 9.28                      
Conversion of Senior Secured Convertible Note to Common Stock [Member]                                
Debt Conversion, Original Debt, Amount       $ 3,789,000                        
Debt Conversion, Converted Instrument, Shares Issued (in shares)       728,654                        
Investor Warrant [Member]                                
Warrants and Rights Outstanding, Term (Year)   5 years     5 years       5 years              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)   178,125     237,500       250,000              
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)   $ 9.28     $ 9.28       $ 12.00              
Repayments of Convertible Debt                   $ 2,415,000            
Warrants and Rights Outstanding   $ 511,402     $ 876,937                      
Payments of Debt Issuance Costs                   1,218,163            
Secured Redeemable Convertible Note [Member] | February 2020 Note [Member]                                
Debt Instrument, Convertible, Conversion Price (in dollars per share)           $ 5.20 $ 9.20                  
The Note [Member] | Senior Secured Convertible Note [Member]                                
Debt Instrument, Face Amount                 $ 3,060,000              
Proceeds from Debt, Net of Issuance Costs                 2,550,000              
Debt Instrument, Unamortized Discount, Total                 510,000              
Debt Instrument, Periodic Payment, Principal due in 180 Days                 918,000              
Debt Instrument, Periodic Payment, Principal due in 270 Days                 $ 1,071,000              
Debt Instrument, Convertible, Conversion Price (in dollars per share)                 $ 12.00              
Amended Note [Member] | Senior Secured Convertible Note [Member]                                
Debt Instrument, Face Amount           $ 3,789,000                    
Debt Instrument, Unamortized Discount, Total           $ 641,215                    
Debt Instrument, Convertible, Conversion Price (in dollars per share)           $ 5.20                    
Interest Expense, Debt, Total           $ 729,000                    
Debt Instrument, Convertible, Beneficial Conversion Feature, Per Share (in dollars per share)           $ 0.88                    
Long-term Debt, Total       $ 0                        
January 2020 Note [Member] | Secured Redeemable Convertible Note [Member]                                
Debt Instrument, Face Amount               $ 157,000                
Debt Instrument, Convertible, Conversion Price (in dollars per share)               $ 12.00                
Debt Instrument, Interest Rate, Stated Percentage               10.00%                
Stock Issued During Period, Shares, Commitment Fees (in shares)               81,250                
Debt Instrument, Fee Amount               $ 75,000                
Debt Instrument, Covenant, Shares to be Paid, Commitment Fee, Repaid Prior to Maturity (in shares)               6,250                
Repayments of Convertible Debt     $ 211,984                          
February 2020 Note [Member] | Secured Redeemable Convertible Note [Member]                                
Debt Instrument, Face Amount             $ 126,000                  
Debt Instrument, Interest Rate, Stated Percentage             10.00%                  
Stock Issued During Period, Shares, Commitment Fees (in shares)             6,250                  
Debt Instrument, Fee Amount             $ 57,500                  
Repayments of Convertible Debt $ 170,442                              
Debt Instrument, Deemed Dividend Expense           $ 70,998                    
Legal Fees             $ 6,000                  
February 2020 Note [Member] | Secured Redeemable Convertible Note [Member] | Minimum [Member]                                
Debt Instrument, Convertible, Premium Payment Percentage             10.00%                  
February 2020 Note [Member] | Secured Redeemable Convertible Note [Member] | Maximum [Member]                                
Debt Instrument, Convertible, Premium Payment Percentage             30.00%                  
May 2020 Note [Member] | Secured Redeemable Convertible Note [Member]                                
Debt Instrument, Face Amount         2,415,000                      
Proceeds from Debt, Net of Issuance Costs         $ 2,100,000                      
Debt Instrument, Convertible, Conversion Price (in dollars per share)         $ 9.28                      
Debt Instrument, Periodic Payment, Principal         $ 268,333                      
Placement Fee, Percent of Aggregate Gross Proceeds         7.00%                      
June 2020 Note [Member] | Secured Redeemable Convertible Note [Member]                                
Debt Instrument, Face Amount   1,811,250                            
Proceeds from Debt, Net of Issuance Costs   $ 1,575,000                            
Debt Instrument, Convertible, Conversion Price (in dollars per share)   $ 9.28                            
Repayments of Convertible Debt                     $ 1,811,250          
Debt Instrument, Periodic Payment, Principal   $ 201,250                            
Placement Fee, Percent of Aggregate Gross Proceeds   7.00%                            
Amortization of Debt Issuance Costs and Discounts, Total                   $ 957,919            
XML 88 R75.htm IDEA: XBRL DOCUMENT v3.22.1
Note P - Leases - Operating Lease Balance Sheet Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Operating lease cost $ 255,892 $ 239,192
Total lease cost 255,892 239,192
Operating lease right-of-use assets 254,100 487,325
Operating lease liabilities, current portion 177,188 234,309
Operating lease liabilities, non-current portion 86,974 264,163
Total operating lease liabilities $ 264,162 $ 498,472
Weighted average remaining lease term (in years) – operating leases (Year) 1 year 5 months 12 days 2 years 3 months 3 days
Weighted average discount rate – operating leases 5.50% 5.50%
Cash paid for amounts included in the measurement of operating lease liabilities $ 256,977 $ 235,186
2022 187,594  
2023 89,225  
Total future lease payments 276,819  
Less: imputed interest (12,657)  
Total $ 264,162 $ 498,472
XML 89 R76.htm IDEA: XBRL DOCUMENT v3.22.1
Note Q - Commitments and Contingencies (Details Textual) - USD ($)
 12 Months Ended
Mar. 25, 2020
Dec. 31, 2021
Dec. 31, 2020
Mar. 30, 2020
Sep. 23, 2015
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)         8,681
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)       $ 12.00 $ 28.80
Technology Transfer Institute [Member] | Sales Incentive Agreement With TTI [Member]          
Related Party Agreement, Term (Year) 1 year        
Related Party Transaction, Revenue Needed to Trigger Payment of Sales Incentive Fee $ 5,000,000        
Related Party Transaction, Revenue to Trigger Payment of Sales Incentive Fee, Percent of Net Income, Minimum 20.00%        
Related Party Transaction, Revenue to Trigger Payment of Sales Incentive Fee, Period (Month) 18 months        
Related Party Transaction, Sales Incentive Fee For Each 5 Million Revenue $ 500,000        
Stock Issuable for Sales Incentive Fee Per Each 5 Million Revenue (in shares) 62,500        
Related Party Transaction, Maximum Revenue, Warrants Issuable $ 25,000,000        
Revenue from Related Parties   $ 0 $ 0    
Technology Transfer Institute [Member] | Sales Incentive Agreement With TTI [Member] | Warrants Issuable for Each 1 Million Revenue in Excess of 20 Million [Member]          
Warrants and Rights Outstanding, Term (Year) 5 years        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 12,500        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 12.00        
Technology Transfer Institute [Member] | Sales Incentive Agreement With TTI [Member] | Maximum [Member]          
Related Party Transaction, Maximum Revenue to Trigger Payment of Sales Incentive Fee $ 20,000,000        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 62,500        
Stock Issuable for Sales Incentive Agreement (in shares) 250,000        
XML 90 R77.htm IDEA: XBRL DOCUMENT v3.22.1
Note R - Equity (Details Textual)
 6 Months Ended 9 Months Ended 12 Months Ended
Jun. 18, 2021
USD ($)
shares
Nov. 30, 2020
USD ($)
shares
Nov. 20, 2020
Aug. 31, 2020
USD ($)
shares
Jul. 23, 2020
USD ($)
shares
Mar. 30, 2020
USD ($)
$ / shares
shares
Sep. 23, 2015
USD ($)
$ / shares
shares
Jun. 30, 2020
shares
Sep. 30, 2020
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Jun. 12, 2020
$ / shares
Mar. 12, 2020
$ / shares
Dec. 31, 2019
$ / shares
Preferred Stock, Shares Authorized (in shares)                   5,000,000        
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares                   $ 1        
Share-based Payment Arrangement, Expense | $                   $ 314,715 $ 792,095      
Stock Issued During Period, Shares, Warrants Exercises (in shares)           121,500                
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares           $ 12.00 $ 28.80              
Proceeds from Warrant Exercises | $           $ 1,458,000       0 5,602,595      
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total | $                   $ 25,536 $ 28,511      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)                   (0) (0)      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)             8,681              
Share Price (in dollars per share) | $ / shares                   $ 2.21 $ 3.52 $ 5.20 $ 6.08 $ 4.00
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares)                   186,538        
Dividends, Paid-in-kind, Total | $             $ 41,688     $ (0) $ 112,686      
Common Stock [Member]                            
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)                   19,484        
Stock Issued During Period, Shares, New Issues (in shares)                     43,939      
Stock Issued During Period, Shares, Conversion of Warrant (in shares)                     918,538      
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total (in shares)                   13,125 41,375      
Stock Issued During Period, Shares, Restricted Stock Award, Forfeited (in shares)                   1,250        
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Total (in shares)                   7,828 5,270      
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total | $                   $ 1 $ 0      
Director [Member] | Common Stock [Member]                            
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Total (in shares)                   7,828 5,270      
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total | $                   $ 25,536 $ 28,511      
Restricted Stock [Member]                            
Share-based Payment Arrangement, Expense | $                   $ 71,819 $ 23,764      
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total (in shares)   3,125   38,250           13,125        
Stock Issued During Period, Shares, Restricted Stock Award, Forfeited (in shares)                   1,250        
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)                   3 years        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value | $   $ 11,250   $ 198,900           $ 44,025        
In The Money Options [Member]                            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares)                   0 0      
Pre-Funded Warrants [Member]                            
Class of Warrant or Right, Exercised During Period (in shares)         512,500                  
Equity Warrants [Member]                            
Class of Warrant or Right, Exercised During Period (in shares)         284,538                  
Referral Fee Warrants [Member] | Investor [Member]                            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)               15,625            
Class of Warrant or Right, Issued During Period (in shares)               94,655            
Referral Fee Warrants [Member] | Employee [Member]                            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)                 3,125          
Class of Warrant or Right, Issued During Period (in shares)                 12,921          
September 2015 Warrants [Member]                            
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares             $ 5.20              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)             48,078              
Warrants and Rights Outstanding, Term (Year)             5 years              
Public Offering [Member]                            
Proceeds from Issuance or Sale of Equity, Total | $         $ 22.7                  
Stock Issued During Period, Shares, New Issues (in shares)         4,264,313                  
Stock Issued During Period, Shares, Conversion of Warrant (in shares)         797,038                  
Public Offering [Member] | Common Stock [Member]                            
Stock Issued During Period, Shares, New Issues (in shares)                     4,264,313      
Employee Stock Purchase Plan [Member]                            
Common Stock, Capital Shares Reserved for Future Issuance (in shares) 789,000                          
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent 85.00%                          
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares) 19,484                          
Share-based Payment Arrangement, Expense | $ $ 10,680                          
Reverse Stock Split [Member]                            
Stockholders' Equity Note, Stock Split, Conversion Ratio     8                      
XML 91 R78.htm IDEA: XBRL DOCUMENT v3.22.1
Note R - Equity - Valuation Assumptions for Warrants (Details) - Referral Fee Warrants [Member]
Dec. 31, 2021
Dec. 31, 2020
Measurement Input, Risk Free Interest Rate [Member]    
Warrant measurement input 0 0.0033
Measurement Input, Share Price [Member]    
Warrant measurement input 0 9.25
Measurement Input, Expected Term [Member]    
Warrant measurement input 0 5
Measurement Input, Price Volatility [Member]    
Warrant measurement input 0 1.10
XML 92 R79.htm IDEA: XBRL DOCUMENT v3.22.1
Note R - Equity - Summary of Warrant Activity (Details) - $ / shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Outstanding, warrants (in shares) 4,689,387 423,559  
Outstanding, weighted average exercise price, warrants (in dollars per share) $ 6.04 $ 12.80  
Outstanding, weighted average remaining contractual life, warrants (Year) 3 years 5 months 23 days 4 years 5 months 23 days 3 years 11 months 8 days
Granted, warrants (in shares) 0    
Granted, weighted average exercise price, warrants (in dollars per share) $ 0    
Increase due to trigger of anti-dilution provision feature, warrants (in shares)   27,244  
Increase due to trigger of anti-dilution provision feature, weighted average exercise price, warrants (in dollars per share)   $ 5.20  
Exercised, warrants (in shares) (0)    
Exercised, weighted average exercise price, warrants (in dollars per share) $ 0    
Forfeited, warrants (in shares) 0 0  
Forfeited, weighted average exercise price, warrants (in dollars per share) $ 0 $ 0  
Expired, warrants (in shares) 0 (54,066)  
Expired, weighted average exercise price, warrants (in dollars per share) $ 0 $ 6.86  
Granted, warrants (in shares) 0    
Granted, weighted average exercise price, warrants (in dollars per share) $ 0    
Exercised, warrants (in shares) 0    
Exercised, weighted average exercise price, warrants (in dollars per share) $ 0    
Outstanding, warrants (in shares) 4,689,387 4,689,387 423,559
Outstanding, weighted average exercise price, warrants (in dollars per share) $ 6.04 $ 6.04 $ 12.80
Public Offering Warrants [Member]      
Granted, warrants (in shares)   4,264,313  
Granted, weighted average exercise price, warrants (in dollars per share)   $ 5.20  
Exercised, warrants (in shares)   (284,538)  
Exercised, weighted average exercise price, warrants (in dollars per share)   $ 5.20  
Granted, warrants (in shares)   4,264,313  
Granted, weighted average exercise price, warrants (in dollars per share)   $ 5.20  
Exercised, warrants (in shares)   284,538  
Exercised, weighted average exercise price, warrants (in dollars per share)   $ 5.20  
Pre-Funded Warrants [Member]      
Granted, warrants (in shares)   512,500  
Granted, weighted average exercise price, warrants (in dollars per share)   $ 0.08  
Exercised, warrants (in shares)   (512,500)  
Exercised, weighted average exercise price, warrants (in dollars per share)   $ 0.08  
Granted, warrants (in shares)   512,500  
Granted, weighted average exercise price, warrants (in dollars per share)   $ 0.08  
Exercised, warrants (in shares)   512,500  
Exercised, weighted average exercise price, warrants (in dollars per share)   $ 0.08  
Other Warrants [Member]      
Granted, warrants (in shares)   434,375  
Granted, weighted average exercise price, warrants (in dollars per share)   $ 9.25  
Exercised, warrants (in shares)   (121,500)  
Exercised, weighted average exercise price, warrants (in dollars per share)   $ 12.00  
Granted, warrants (in shares)   434,375  
Granted, weighted average exercise price, warrants (in dollars per share)   $ 9.25  
Exercised, warrants (in shares)   121,500  
Exercised, weighted average exercise price, warrants (in dollars per share)   $ 12.00  
XML 93 R80.htm IDEA: XBRL DOCUMENT v3.22.1
Note S - Stock Options (Details Textual) - USD ($)
 12 Months Ended
Jan. 27, 2016
Oct. 12, 2004
Dec. 31, 2021
Dec. 31, 2020
Jun. 12, 2020
Mar. 12, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)     3 years 10 days 3 years 10 months 13 days      
Share Price (in dollars per share)     $ 2.21 $ 3.52 $ 5.20 $ 6.08 $ 4.00
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares)     186,538        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)       $ 3.16      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value     $ 0 $ 0      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)     (0) (0)      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value     $ 252,874 $ 899,750      
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount     $ 75,035        
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)     10 months 9 days        
In The Money Options [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares)     0 0      
The2004 Stock Option Plan [Member]              
Common Stock, Capital Shares Reserved for Future Issuance (in shares)   20,834          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares)            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)     (0) (0)      
The2004 Stock Option Plan [Member] | Nonstatutory Stock [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)   10 years          
The2004 Stock Option Plan [Member] | Minimum [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent   85.00%          
The 2015 Equity Incentive Plan [Member]              
Common Stock, Capital Shares Reserved for Future Issuance (in shares) 83,334   789,000 187,500     187,500
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) 10 years            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares)            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)     (0) (0)      
The 2015 Equity Incentive Plan [Member] | Minimum [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent     100.00%        
The 2015 Equity Incentive Plan [Member] | Maximum [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent     110.00%        
XML 94 R81.htm IDEA: XBRL DOCUMENT v3.22.1
Note S - Stock Options - Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Outstanding (in shares) 227,274 218,967
Outstanding, weighted average exercise price (in dollars per share) $ 17.61 $ 20.08
Granted (in shares) 0 28,440
Granted, weighted average exercise price (in dollars per share) $ 5.04
Exercised (in shares) 0 0
Exercised, weighted average exercise price (in dollars per share) $ 0 $ 0
Forfeited (in shares) (3,291) (4,545)
Forfeited, weighted average exercise price (in dollars per share) $ 3.87 $ 17.34
Expired (in shares) (11,522) (15,588)
Expired, weighted average exercise price (in dollars per share) $ 39.13 $ 29.17
Outstanding, weighted average remaining life (Year) 3 years 10 days 3 years 10 months 13 days
Outstanding, aggregate intrinsic value $ 0 $ 0
Outstanding (in shares) 212,461 227,274
Outstanding, weighted average exercise price (in dollars per share) $ 16.65 $ 17.61
Vested or expected to vest (in shares) 206,283  
Vested or expected, weighted average exercise price (in dollars per share) $ 16.98  
Vested or expected to vest, weighted average remaining life (Year) 2 years 11 months 12 days  
Vested or expected to vest, aggregate intrinsic value $ 0  
Exercisable (in shares) 186,538  
Options exercisable, weighted average exercise price (in dollars per share) $ 18.04  
Exercisable, weighted average remaining life (Year) 2 years 8 months 23 days  
Exercisable, aggregate intrinsic value $ 0  
The2004 Stock Option Plan [Member]    
Outstanding (in shares) 0 3,906
Granted (in shares) 0 0
Exercised (in shares) 0 0
Forfeited (in shares) 0 0
Expired (in shares) 0 (3,906)
Outstanding (in shares) 0 0
Vested or expected to vest (in shares)  
Exercisable (in shares)  
The 2015 Equity Incentive Plan [Member]    
Outstanding (in shares) 94,183 70,991
Granted (in shares) 0 28,440
Exercised (in shares) 0 0
Forfeited (in shares) (3,291) (4,545)
Expired (in shares) (84) (703)
Outstanding (in shares) 90,808 94,183
Vested or expected to vest (in shares)  
Exercisable (in shares)  
Non Plan [Member]    
Outstanding (in shares) 133,091 144,070
Granted (in shares) 0 0
Exercised (in shares) 0 0
Forfeited (in shares) 0 0
Expired (in shares) (11,438) (10,979)
Outstanding (in shares) 121,653 133,091
Vested or expected to vest (in shares)  
Exercisable (in shares)  
XML 95 R82.htm IDEA: XBRL DOCUMENT v3.22.1
Note S - Stock Options - Options Outstanding and Exercisable (Details)
 12 Months Ended
Dec. 31, 2021
$ / shares
shares
Range of exercise prices, upper range (in dollars per share) $ 39.36
Options outstanding (in shares) | shares 212,461
Options exercisable (in shares) | shares 186,538
Options exercisable, weighted average exercise price (in dollars per share) $ 18.04
Exercise Price Range 1 [Member]  
Range of exercise prices, upper range (in dollars per share) $ 5.20
Options outstanding (in shares) | shares 24,940
Options outstanding, weighted average exercise price (in dollars per share) $ 5.19
Options outstanding, weighted average remaining remaining life (Year) 5 years 7 months 20 days
Options exercisable (in shares) | shares 8,402
Options exercisable, weighted average exercise price (in dollars per share) $ 5.17
Exercise Price Range 2 [Member]  
Range of exercise prices, upper range (in dollars per share) $ 15.68
Options outstanding (in shares) | shares 49,669
Options outstanding, weighted average exercise price (in dollars per share) $ 12.17
Options outstanding, weighted average remaining remaining life (Year) 3 years 9 months 14 days
Options exercisable (in shares) | shares 40,284
Options exercisable, weighted average exercise price (in dollars per share) $ 12.85
Exercise Price Range 3 [Member]  
Range of exercise prices, upper range (in dollars per share) $ 39.36
Options outstanding (in shares) | shares 137,852
Options outstanding, weighted average exercise price (in dollars per share) $ 20.34
Options outstanding, weighted average remaining remaining life (Year) 2 years 3 months 7 days
Options exercisable (in shares) | shares 137,852
Options exercisable, weighted average exercise price (in dollars per share) $ 20.34
XML 96 R83.htm IDEA: XBRL DOCUMENT v3.22.1
Note T - Income Taxes (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Expense (Benefit), Total $ 0 $ 0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total 0 $ 0
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]    
Operating Loss Carryforwards, Total 61,000  
Operating Loss Carryforwards, Subject to Expiration 46,000  
Operating Loss Carryforwards, Not Subject to Expiration $ 15,000  
Open Tax Year 2018  
XML 97 R84.htm IDEA: XBRL DOCUMENT v3.22.1
Note T - Income Taxes - Components of Deferred Taxes (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Accrued compensation $ 135,000 $ 81,000
Accounts receivable allowance 75,000 474,000
Stock-based compensation 1,149,000 1,073,000
Basis differences in fixed assets (10,000) (14,000)
Basis differences in intangible assets 75,000 65,000
Net operating loss and credit carryforwards 14,467,000 13,337,000
Valuation allowances $ (15,891,000) $ (15,016,000)
XML 98 R85.htm IDEA: XBRL DOCUMENT v3.22.1
Note T - Income Taxes - Reconciliation of the Effective Income Tax Rate to US Federal Statutory Income Tax Rate (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Federal statutory income tax rate 21.00% 21.00%
Permanent differences 0.00% (9.00%)
Effect of net operating loss (21.00%) (12.00%)
Effective tax rate 0.00% 0.00%
XML 99 R86.htm IDEA: XBRL DOCUMENT v3.22.1
Note U - Profit Sharing Plan (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Defined Contribution Plan, Employer Discretionary Contribution Amount $ 0 $ 0
XML 100 R87.htm IDEA: XBRL DOCUMENT v3.22.1
Note V - Earnings Per Share (EPS) - Reconciliation of Numerator of Basic and Diluted EPS Calculations (Details) - USD ($)
 12 Months Ended
Sep. 23, 2015
Dec. 31, 2021
Dec. 31, 2020
Net Loss   $ (5,065,781) $ (9,673,987)
Deemed dividend from trigger of anti-dilution provision feature $ (41,688) 0 (112,686)
Net loss available to common stockholders (basic and diluted EPS)   $ (5,065,781) $ (9,786,673)
XML 101 R88.htm IDEA: XBRL DOCUMENT v3.22.1
Note V - Earnings Per Share (EPS) - Securities Excluded from the Diluted Per Share Calculation (Details) - shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Exercise Price Less Than Average Market Price Of Common Shares [Member]    
Antidilutive securities (in shares) 0 4,100
Exercise Price Greater Than Average Market Price Of Common Shares [Member]    
Antidilutive securities (in shares) 4,901,848 4,913,286
Share-based Payment Arrangement, Option [Member] | Exercise Price Less Than Average Market Price Of Common Shares [Member]    
Antidilutive securities (in shares) 0 1,002
Share-based Payment Arrangement, Option [Member] | Exercise Price Greater Than Average Market Price Of Common Shares [Member]    
Antidilutive securities (in shares) 212,461 223,899
Restricted Stock [Member] | Exercise Price Less Than Average Market Price Of Common Shares [Member]    
Antidilutive securities (in shares) 0 3,098
Warrant [Member] | Exercise Price Greater Than Average Market Price Of Common Shares [Member]    
Antidilutive securities (in shares) 4,689,387 4,689,387
XML 102 R89.htm IDEA: XBRL DOCUMENT v3.22.1
Note W - Subsequent Events (Details Textual) - USD ($)
 12 Months Ended
Mar. 11, 2022
Mar. 10, 2022
Mar. 08, 2022
Dec. 31, 2021
Dec. 31, 2020
Payments to Acquire Businesses, Gross       $ (0) $ 2,000,000
Restricted Stock [Member]          
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)       3 years  
Subsequent Event [Member] | Restricted Stock [Member] | Share-based Payment Arrangement, Employee [Member]          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 274,250        
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) 3 years        
Subsequent Event [Member] | Director [Member] | Common Stock [Member] | Stock Issued in Lieu of Board Fees [Member]          
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture (in shares)   6,360      
Subsequent Event [Member] | Director [Member] | Common Stock [Member] | Stock Issued in Lieu of Board Committee Fees [Member]          
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture (in shares) 932 848      
Subsequent Event [Member] | Swivel Secure Europe [Member]          
Business Acquisition, Percentage of Voting Interests Acquired     100.00%    
Business Combination, Consideration Transferred, Total     $ 1,750,000    
Business Combination, Contingent Consideration, Liability, Total     500,000    
Payments to Acquire Businesses, Gross     $ 1,270,000    
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)     269,060    
Business Combination, Indemnification Assets, Amount as of Acquisition Date     $ 89,687    
XML 103 bkyi20211231_10k_htm.xml IDEA: XBRL DOCUMENT 0001019034 2021-01-01 2021-12-31 0001019034 2021-06-30 0001019034 2022-03-29 0001019034 2021-12-31 0001019034 2020-12-31 0001019034 us-gaap:ServiceMember 2021-01-01 2021-12-31 0001019034 us-gaap:ServiceMember 2020-01-01 2020-12-31 0001019034 us-gaap:LicenseMember 2021-01-01 2021-12-31 0001019034 us-gaap:LicenseMember 2020-01-01 2020-12-31 0001019034 bkyi:HardwareMember 2021-01-01 2021-12-31 0001019034 bkyi:HardwareMember 2020-01-01 2020-12-31 0001019034 2020-01-01 2020-12-31 0001019034 us-gaap:CommonStockMember 2019-12-31 0001019034 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001019034 us-gaap:RetainedEarningsMember 2019-12-31 0001019034 2019-12-31 0001019034 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001019034 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001019034 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001019034 us-gaap:CommonStockMember bkyi:PublicOfferingMember 2020-01-01 2020-12-31 0001019034 us-gaap:AdditionalPaidInCapitalMember bkyi:PublicOfferingMember 2020-01-01 2020-12-31 0001019034 us-gaap:RetainedEarningsMember bkyi:PublicOfferingMember 2020-01-01 2020-12-31 0001019034 bkyi:PublicOfferingMember 2020-01-01 2020-12-31 0001019034 bkyi:WarrantsIssuedInConnectionWithConvertibleNotesMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001019034 bkyi:WarrantsIssuedInConnectionWithConvertibleNotesMember us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001019034 bkyi:WarrantsIssuedInConnectionWithConvertibleNotesMember us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001019034 bkyi:WarrantsIssuedInConnectionWithConvertibleNotesMember 2020-01-01 2020-12-31 0001019034 us-gaap:CommonStockMember 2020-12-31 0001019034 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001019034 us-gaap:RetainedEarningsMember 2020-12-31 0001019034 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001019034 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001019034 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001019034 us-gaap:CommonStockMember 2021-12-31 0001019034 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001019034 us-gaap:RetainedEarningsMember 2021-12-31 0001019034 us-gaap:AccountingStandardsUpdate201602Member 2021-01-01 2021-12-31 0001019034 us-gaap:AccountingStandardsUpdate201602Member 2020-01-01 2020-12-31 0001019034 bkyi:ReverseStockSplitMember 2020-11-20 2020-11-20 0001019034 srt:MinimumMember us-gaap:EquipmentMember 2021-01-01 2021-12-31 0001019034 srt:MaximumMember us-gaap:EquipmentMember 2021-01-01 2021-12-31 0001019034 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-12-31 0001019034 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-12-31 0001019034 us-gaap:SoftwareDevelopmentMember 2021-01-01 2021-12-31 0001019034 srt:MinimumMember 2021-01-01 2021-12-31 0001019034 srt:MaximumMember 2021-01-01 2021-12-31 0001019034 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0001019034 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0001019034 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001019034 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001019034 us-gaap:LicenseMember srt:NorthAmericaMember 2021-01-01 2021-12-31 0001019034 us-gaap:LicenseMember srt:SouthAmericaMember 2021-01-01 2021-12-31 0001019034 us-gaap:LicenseMember us-gaap:EMEAMember 2021-01-01 2021-12-31 0001019034 us-gaap:LicenseMember srt:AsiaMember 2021-01-01 2021-12-31 0001019034 bkyi:HardwareMember srt:NorthAmericaMember 2021-01-01 2021-12-31 0001019034 bkyi:HardwareMember srt:SouthAmericaMember 2021-01-01 2021-12-31 0001019034 bkyi:HardwareMember us-gaap:EMEAMember 2021-01-01 2021-12-31 0001019034 bkyi:HardwareMember srt:AsiaMember 2021-01-01 2021-12-31 0001019034 us-gaap:ServiceMember srt:NorthAmericaMember 2021-01-01 2021-12-31 0001019034 us-gaap:ServiceMember srt:SouthAmericaMember 2021-01-01 2021-12-31 0001019034 us-gaap:ServiceMember us-gaap:EMEAMember 2021-01-01 2021-12-31 0001019034 us-gaap:ServiceMember srt:AsiaMember 2021-01-01 2021-12-31 0001019034 srt:NorthAmericaMember 2021-01-01 2021-12-31 0001019034 srt:SouthAmericaMember 2021-01-01 2021-12-31 0001019034 us-gaap:EMEAMember 2021-01-01 2021-12-31 0001019034 srt:AsiaMember 2021-01-01 2021-12-31 0001019034 us-gaap:LicenseMember srt:NorthAmericaMember 2020-01-01 2020-12-31 0001019034 us-gaap:LicenseMember srt:SouthAmericaMember 2020-01-01 2020-12-31 0001019034 us-gaap:LicenseMember us-gaap:EMEAMember 2020-01-01 2020-12-31 0001019034 us-gaap:LicenseMember srt:AsiaMember 2020-01-01 2020-12-31 0001019034 bkyi:HardwareMember srt:NorthAmericaMember 2020-01-01 2020-12-31 0001019034 bkyi:HardwareMember srt:SouthAmericaMember 2020-01-01 2020-12-31 0001019034 bkyi:HardwareMember us-gaap:EMEAMember 2020-01-01 2020-12-31 0001019034 bkyi:HardwareMember srt:AsiaMember 2020-01-01 2020-12-31 0001019034 us-gaap:ServiceMember srt:NorthAmericaMember 2020-01-01 2020-12-31 0001019034 us-gaap:ServiceMember srt:SouthAmericaMember 2020-01-01 2020-12-31 0001019034 us-gaap:ServiceMember us-gaap:EMEAMember 2020-01-01 2020-12-31 0001019034 us-gaap:ServiceMember srt:AsiaMember 2020-01-01 2020-12-31 0001019034 srt:NorthAmericaMember 2020-01-01 2020-12-31 0001019034 srt:SouthAmericaMember 2020-01-01 2020-12-31 0001019034 us-gaap:EMEAMember 2020-01-01 2020-12-31 0001019034 srt:AsiaMember 2020-01-01 2020-12-31 0001019034 bkyi:PistolstarMember 2020-06-30 2020-06-30 0001019034 bkyi:PistolstarMember bkyi:PromissoryNoteMember 2020-06-30 0001019034 bkyi:PistolstarMember 2020-06-30 0001019034 bkyi:PistolstarMember bkyi:PromissoryNoteMember 2020-06-30 2020-06-30 0001019034 bkyi:PistolstarMember bkyi:PromissoryNoteMember 2020-12-31 0001019034 bkyi:PistolstarMember bkyi:PromissoryNoteMember 2021-01-21 2021-01-21 0001019034 bkyi:PistolstarMember us-gaap:TradeNamesMember 2020-06-30 2020-06-30 0001019034 bkyi:PistolstarMember bkyi:ProprietarySoftwareMember 2020-06-30 2020-06-30 0001019034 bkyi:PistolstarMember us-gaap:CustomerRelationshipsMember 2020-06-30 2020-06-30 0001019034 srt:MinimumMember bkyi:PistolstarMember us-gaap:CustomerRelationshipsMember 2020-06-30 2020-06-30 0001019034 srt:MaximumMember bkyi:PistolstarMember us-gaap:CustomerRelationshipsMember 2020-06-30 2020-06-30 0001019034 us-gaap:GeographicDistributionForeignMember 2021-12-31 0001019034 us-gaap:GeographicDistributionDomesticMember 2021-12-31 0001019034 srt:MinimumMember 2021-12-31 0001019034 srt:MaximumMember 2021-12-31 0001019034 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001019034 bkyi:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001019034 bkyi:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001019034 bkyi:ThreeCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001019034 bkyi:OneCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001019034 2020-09-30 0001019034 2021-01-01 2021-09-30 0001019034 bkyi:SoftwareLicenseRightsMember 2015-12-31 2015-12-31 0001019034 bkyi:SoftwareLicenseRightsMember 2017-01-01 2017-03-31 0001019034 bkyi:SoftwareLicenseRightsMember 2021-01-01 2021-12-31 0001019034 bkyi:SoftwareLicenseRightsMember 2020-01-01 2020-12-31 0001019034 bkyi:The2015SoftwareLicenseMember 2021-01-01 2021-12-31 0001019034 bkyi:The2015SoftwareLicenseMember 2021-12-31 0001019034 bkyi:The2015SoftwareLicenseMember 2020-12-31 0001019034 bkyi:SoftwareLicenseRightsMember 2021-12-31 0001019034 us-gaap:ForeignCorporateDebtSecuritiesMember 2019-12-31 0001019034 us-gaap:ForeignCorporateDebtSecuritiesMember 2019-01-01 2019-12-31 0001019034 us-gaap:ForeignCorporateDebtSecuritiesMember 2020-06-30 0001019034 us-gaap:ForeignCorporateDebtSecuritiesMember 2021-09-30 0001019034 us-gaap:EquipmentMember 2021-12-31 0001019034 us-gaap:EquipmentMember 2020-12-31 0001019034 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001019034 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001019034 us-gaap:SoftwareDevelopmentMember 2021-12-31 0001019034 us-gaap:SoftwareDevelopmentMember 2020-12-31 0001019034 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001019034 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001019034 us-gaap:TradeNamesMember 2021-12-31 0001019034 us-gaap:TradeNamesMember 2020-12-31 0001019034 bkyi:ProprietarySoftwareMember 2021-12-31 0001019034 bkyi:ProprietarySoftwareMember 2020-12-31 0001019034 us-gaap:CustomerRelationshipsMember 2021-12-31 0001019034 us-gaap:CustomerRelationshipsMember 2020-12-31 0001019034 us-gaap:PatentsMember 2021-12-31 0001019034 us-gaap:PatentsMember 2020-12-31 0001019034 bkyi:ResearchDevelopmentAndEngineeringExpenseMember 2021-01-01 2021-12-31 0001019034 bkyi:ResearchDevelopmentAndEngineeringExpenseMember 2020-01-01 2020-12-31 0001019034 us-gaap:LicensingAgreementsMember 2021-12-31 0001019034 us-gaap:AccountsPayableMember bkyi:MrWongKwokFongMember 2019-12-31 0001019034 bkyi:AccruedLiabilitiesOtherMember bkyi:MrMichaelDepasqualeMember 2019-12-31 0001019034 bkyi:TheNoteMember bkyi:SeniorSecuredConvertibleNoteMember 2019-07-10 0001019034 bkyi:TheNoteMember bkyi:SeniorSecuredConvertibleNoteMember 2019-07-10 2019-07-10 0001019034 bkyi:InvestorWarrantMember 2019-07-10 0001019034 2019-07-10 2019-07-10 0001019034 2019-07-10 0001019034 bkyi:AmendedNoteMember bkyi:SeniorSecuredConvertibleNoteMember 2020-03-12 0001019034 bkyi:AmendedNoteMember bkyi:SeniorSecuredConvertibleNoteMember 2020-03-12 2020-03-12 0001019034 2020-03-12 0001019034 2020-06-12 0001019034 bkyi:AmendedNoteMember bkyi:SeniorSecuredConvertibleNoteMember 2020-06-10 0001019034 bkyi:ConversionOfSeniorSecuredConvertibleNoteToCommonStockMember 2020-06-10 2020-06-10 0001019034 bkyi:January2020NoteMember bkyi:SecuredRedeemableConvertibleNoteMember 2020-01-13 0001019034 bkyi:January2020NoteMember bkyi:SecuredRedeemableConvertibleNoteMember 2020-01-13 2020-01-13 0001019034 bkyi:January2020NoteMember bkyi:SecuredRedeemableConvertibleNoteMember 2020-06-12 2020-06-12 0001019034 bkyi:February2020NoteMember bkyi:SecuredRedeemableConvertibleNoteMember 2020-02-13 0001019034 bkyi:February2020NoteMember bkyi:SecuredRedeemableConvertibleNoteMember 2020-02-13 0001019034 bkyi:February2020NoteMember bkyi:SecuredRedeemableConvertibleNoteMember 2020-03-12 0001019034 bkyi:February2020NoteMember bkyi:SecuredRedeemableConvertibleNoteMember 2020-03-12 2020-03-12 0001019034 srt:MinimumMember bkyi:February2020NoteMember bkyi:SecuredRedeemableConvertibleNoteMember 2020-02-13 0001019034 srt:MaximumMember bkyi:February2020NoteMember bkyi:SecuredRedeemableConvertibleNoteMember 2020-02-13 0001019034 bkyi:February2020NoteMember bkyi:SecuredRedeemableConvertibleNoteMember 2020-02-13 2020-02-13 0001019034 bkyi:February2020NoteMember bkyi:SecuredRedeemableConvertibleNoteMember 2020-07-10 2020-07-10 0001019034 bkyi:May2020NoteMember bkyi:SecuredRedeemableConvertibleNoteMember 2020-05-06 0001019034 bkyi:May2020NoteMember bkyi:SecuredRedeemableConvertibleNoteMember 2020-05-06 2020-05-06 0001019034 2020-05-06 2020-05-06 0001019034 2020-05-06 0001019034 bkyi:InvestorWarrantMember 2020-05-06 0001019034 bkyi:InvestorWarrantMember 2020-07-01 2020-07-31 0001019034 bkyi:June2020NoteMember bkyi:SecuredRedeemableConvertibleNoteMember 2020-06-29 0001019034 bkyi:June2020NoteMember bkyi:SecuredRedeemableConvertibleNoteMember 2020-06-29 2020-06-29 0001019034 2020-06-29 2020-06-29 0001019034 2020-06-29 0001019034 bkyi:InvestorWarrantMember 2020-06-29 0001019034 bkyi:June2020NoteMember bkyi:SecuredRedeemableConvertibleNoteMember 2020-07-01 2020-09-30 0001019034 bkyi:June2020NoteMember bkyi:SecuredRedeemableConvertibleNoteMember 2020-07-01 2020-07-31 0001019034 bkyi:SalesIncentiveAgreementWithTTIMember bkyi:TechnologyTransferInstituteMember 2020-03-25 2020-03-25 0001019034 bkyi:SalesIncentiveAgreementWithTTIMember bkyi:TechnologyTransferInstituteMember 2020-03-25 0001019034 srt:MaximumMember bkyi:SalesIncentiveAgreementWithTTIMember bkyi:TechnologyTransferInstituteMember 2020-03-25 0001019034 bkyi:WarrantsIssuableForEach1MillionRevenueInExcessOf20MilllionMember bkyi:SalesIncentiveAgreementWithTTIMember bkyi:TechnologyTransferInstituteMember 2020-03-25 0001019034 srt:MaximumMember bkyi:SalesIncentiveAgreementWithTTIMember bkyi:TechnologyTransferInstituteMember 2020-03-25 2020-03-25 0001019034 bkyi:SalesIncentiveAgreementWithTTIMember bkyi:TechnologyTransferInstituteMember 2021-01-01 2021-12-31 0001019034 bkyi:SalesIncentiveAgreementWithTTIMember bkyi:TechnologyTransferInstituteMember 2020-01-01 2020-12-31 0001019034 bkyi:EmployeeStockPurchasePlanMember 2021-06-18 0001019034 bkyi:EmployeeStockPurchasePlanMember 2021-06-18 2021-06-18 0001019034 bkyi:PublicOfferingMember 2020-07-23 2020-07-23 0001019034 bkyi:PrefundedWarrantsMember 2020-07-23 2020-07-23 0001019034 bkyi:EquityWarrantsMember 2020-07-23 2020-07-23 0001019034 2020-03-30 2020-03-30 0001019034 2020-03-30 0001019034 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001019034 us-gaap:RestrictedStockMember 2020-08-31 2020-08-31 0001019034 us-gaap:RestrictedStockMember 2020-11-30 2020-11-30 0001019034 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001019034 srt:DirectorMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001019034 srt:DirectorMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001019034 us-gaap:InvestorMember bkyi:ReferralFeeWarrantsMember 2020-06-30 0001019034 us-gaap:InvestorMember bkyi:ReferralFeeWarrantsMember 2020-01-01 2020-06-30 0001019034 bkyi:EmployeeMember bkyi:ReferralFeeWarrantsMember 2020-09-30 0001019034 bkyi:EmployeeMember bkyi:ReferralFeeWarrantsMember 2020-01-01 2020-09-30 0001019034 bkyi:ReferralFeeWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001019034 bkyi:ReferralFeeWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001019034 bkyi:ReferralFeeWarrantsMember us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001019034 bkyi:ReferralFeeWarrantsMember us-gaap:MeasurementInputSharePriceMember 2020-12-31 0001019034 bkyi:ReferralFeeWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001019034 bkyi:ReferralFeeWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2020-12-31 0001019034 bkyi:ReferralFeeWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001019034 bkyi:ReferralFeeWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001019034 2019-01-01 2019-12-31 0001019034 bkyi:PublicOfferingWarrantsMember 2020-01-01 2020-12-31 0001019034 bkyi:PrefundedWarrantsMember 2020-01-01 2020-12-31 0001019034 bkyi:OtherWarrantsMember 2020-01-01 2020-12-31 0001019034 bkyi:InTheMoneyOptionsMember 2021-12-31 0001019034 bkyi:InTheMoneyOptionsMember 2020-12-31 0001019034 2015-09-23 0001019034 bkyi:September2015WarrantsMember 2015-09-23 0001019034 2015-09-23 2015-09-23 0001019034 bkyi:The2004StockOptionPlanMember 2004-10-12 0001019034 srt:MinimumMember bkyi:The2004StockOptionPlanMember 2004-10-12 2004-10-12 0001019034 bkyi:NonstatutoryStockMember bkyi:The2004StockOptionPlanMember 2004-10-12 2004-10-12 0001019034 bkyi:The2015EquityIncentivePlanMember 2020-12-31 0001019034 bkyi:The2015EquityIncentivePlanMember 2016-01-27 0001019034 bkyi:The2015EquityIncentivePlanMember 2019-12-31 0001019034 bkyi:The2015EquityIncentivePlanMember 2021-12-31 0001019034 bkyi:The2015EquityIncentivePlanMember 2016-01-27 2016-01-27 0001019034 srt:MinimumMember bkyi:The2015EquityIncentivePlanMember 2021-01-01 2021-12-31 0001019034 srt:MaximumMember bkyi:The2015EquityIncentivePlanMember 2021-01-01 2021-12-31 0001019034 bkyi:The2004StockOptionPlanMember 2019-12-31 0001019034 bkyi:NonPlanMember 2019-12-31 0001019034 bkyi:The2004StockOptionPlanMember 2020-01-01 2020-12-31 0001019034 bkyi:The2015EquityIncentivePlanMember 2020-01-01 2020-12-31 0001019034 bkyi:NonPlanMember 2020-01-01 2020-12-31 0001019034 bkyi:The2004StockOptionPlanMember 2020-12-31 0001019034 bkyi:NonPlanMember 2020-12-31 0001019034 bkyi:The2004StockOptionPlanMember 2021-01-01 2021-12-31 0001019034 bkyi:The2015EquityIncentivePlanMember 2021-01-01 2021-12-31 0001019034 bkyi:NonPlanMember 2021-01-01 2021-12-31 0001019034 bkyi:The2004StockOptionPlanMember 2021-12-31 0001019034 bkyi:NonPlanMember 2021-12-31 0001019034 bkyi:ExercisePriceRange1Member 2021-01-01 2021-12-31 0001019034 bkyi:ExercisePriceRange1Member 2021-12-31 0001019034 bkyi:ExercisePriceRange2Member 2021-01-01 2021-12-31 0001019034 bkyi:ExercisePriceRange2Member 2021-12-31 0001019034 bkyi:ExercisePriceRange3Member 2021-01-01 2021-12-31 0001019034 bkyi:ExercisePriceRange3Member 2021-12-31 0001019034 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2021-12-31 0001019034 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2021-01-01 2021-12-31 0001019034 us-gaap:EmployeeStockOptionMember bkyi:ExercisePriceLessThanAverageMarketPriceOfCommonSharesMember 2021-01-01 2021-12-31 0001019034 us-gaap:EmployeeStockOptionMember bkyi:ExercisePriceLessThanAverageMarketPriceOfCommonSharesMember 2020-01-01 2020-12-31 0001019034 us-gaap:RestrictedStockMember bkyi:ExercisePriceLessThanAverageMarketPriceOfCommonSharesMember 2021-01-01 2021-12-31 0001019034 us-gaap:RestrictedStockMember bkyi:ExercisePriceLessThanAverageMarketPriceOfCommonSharesMember 2020-01-01 2020-12-31 0001019034 bkyi:ExercisePriceLessThanAverageMarketPriceOfCommonSharesMember 2021-01-01 2021-12-31 0001019034 bkyi:ExercisePriceLessThanAverageMarketPriceOfCommonSharesMember 2020-01-01 2020-12-31 0001019034 us-gaap:EmployeeStockOptionMember bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember 2021-01-01 2021-12-31 0001019034 us-gaap:EmployeeStockOptionMember bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember 2020-01-01 2020-12-31 0001019034 us-gaap:WarrantMember bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember 2021-01-01 2021-12-31 0001019034 us-gaap:WarrantMember bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember 2020-01-01 2020-12-31 0001019034 bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember 2021-01-01 2021-12-31 0001019034 bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember 2020-01-01 2020-12-31 0001019034 bkyi:SwivelSecureEuropeMember us-gaap:SubsequentEventMember 2022-03-08 0001019034 bkyi:SwivelSecureEuropeMember us-gaap:SubsequentEventMember 2022-03-08 2022-03-08 0001019034 srt:DirectorMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember bkyi:StockIssuedInLieuOfBoardFeesMember 2022-03-10 2022-03-10 0001019034 srt:DirectorMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember bkyi:StockIssuedInLieuOfBoardCommitteeFeesMember 2022-03-10 2022-03-10 0001019034 srt:DirectorMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember bkyi:StockIssuedInLieuOfBoardCommitteeFeesMember 2022-03-11 2022-03-11 0001019034 us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:SubsequentEventMember 2022-03-11 2022-03-11 0001019034 bkyi:FactoredAccountsReceivableMember 2021-01-01 2021-12-31 0001019034 us-gaap:NotesReceivableMember 2021-01-01 2021-12-31 iso4217:USD shares thunderdome:item iso4217:USD shares pure utr:Y utr:M iso4217:HKD 0001019034 BIO KEY INTERNATIONAL INC false --12-31 FY 2021 170000000 170000000 7853759 7853759 7814572 7814572 0.0001 0.0001 1250 5114000 24000000 7800000 1000000 P4Y 633000 702000 0 P3Y P4Y 500000 0.04 4 1 1 P1Y P5Y P5Y P5Y P1Y P18M P5Y 0 0 P3Y 0 0 0 P5Y P10Y P10Y 0 0 0 0 0 0 0 0 P3Y 10-K true 2021-12-31 false 1-13463 DE 41-1741861 3349 HIGHWAY 138, BUILDING A, SUITE E WALL NJ 07719 732 359-1100 Common Stock, $0.0001 par value per share BKYI NASDAQ No No Yes Yes Non-accelerated Filer true false false false 27600000 8405209 Rotenberg Meril Solomon Bertiger & Guttilla, P.C. Saddle Brook, NJ 361 7754046 16993096 970626 548049 49500 60453 82000 295000 4940660 330947 216041 201507 0 512821 14012873 18941873 48752 58882 452821 0 69168 81793 249012 165315 8712 8712 113000 0 254100 487325 1298077 1514146 1262526 1262526 3756168 3578699 17769041 22520572 427772 244158 828997 508487 0 232000 565355 657349 177188 234309 1999312 1876303 67300 44987 86974 264163 154274 309150 2153586 2185453 786 782 120190139 119844026 -104575470 -99509689 15615455 20335119 17769041 22520572 1273354 1432228 2555809 962038 1285326 442516 5114489 2836782 686175 502214 183199 49891 803555 242721 1672929 794826 3441560 2041956 6028360 5848687 2355056 1396436 8383416 7245123 -4941856 -5203167 4075 30649 -50000 60000 0 340819 18000 4343212 0 -499076 -123925 -4470820 -5065781 -9673987 -0 112686 -5065781 -9786673 -0.65 -2.08 7791741 4700787 1812483 182 87437661 -89723016 -2285173 5270 0 28511 0 28511 43939 5 277828 0 277833 4264313 426 22173999 0 22174425 918538 92 5602503 0 5602595 728654 73 3788927 0 3789000 41375 4 -4 0 0 0 1388339 0 1388339 0 107576 0 107576 -0 2371223 -0 2371223 0 641215 0 641215 0 112686 -112686 0 0 656008 0 656008 0 0 -9673987 -9673987 7814572 782 119844026 -99509689 20335119 7828 1 25535 0 25536 13125 1 -1 0 0 0 0 0 0 -0 5228 -0 5228 19484 2 36628 0 36630 0 10680 0 10680 0 278499 0 278499 0 0 -5065781 -5065781 7853759 786 120190139 -104575470 15615455 -5065781 -9673987 54649 85751 216069 120240 10130 0 -50000 -0 -60000 -100000 -200000 -0 18000 1425040 110681 152714 0 2166650 -0 -499076 0 641215 289179 763584 25536 28511 233225 220915 672577 237257 -10953 -50488 194378 86510 4609713 -98172 -0 -14920 14534 83625 183614 -600399 320510 -84415 -69681 -246876 -234310 -204315 -8978428 -4950108 42024 35568 -0 295000 -0 2000000 0 100747 0 512821 -0 512821 -42024 -2229821 0 22174425 0 3958000 36630 0 -0 4509250 0 5602595 -0 2693021 250000 250000 5228 -0 -0 188737 -218598 24094012 -9239050 16914083 16993096 79013 7754046 16993096 18000 109426 0 0 0 184792 0 9485 0 36467 0 1480000 0 1262526 0 464000 0 20017 0 590000 0 141761 0 141761 0 3789000 0 277833 0 1388339 0 641215 0 112686 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><b>NOTE A </b>—<b>THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><i>Nature of Business</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company, founded in <em style="font: inherit;">1993,</em> develops and markets proprietary fingerprint identification biometric technology and software solutions enterprise-ready identity access management solutions to commercial, government and education customers throughout the United States and internationally. The Company was a pioneer in developing automated, finger identification technology that supplements or compliments other methods of identification and verification, such as personal inspection identification, passwords, tokens, smart cards, ID cards, PKI, credit cards, passports, driver’s licenses, OTP or other form of possession or knowledge-based credentialing. Additionally, advanced BIO-key® technology has been, and is, used to improve both the accuracy and speed of competing finger-based biometrics.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><i/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><i>Going Concern and Basis of Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 5pt; text-indent: 18pt;">The Company has historically financed our operations through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. The Company currently requires approximately $735,000 per month to conduct operations, a monthly amount that it has been unable to consistently achieve through revenue generation. During <em style="font: inherit;">2021,</em> the Company generated approximately <span style="-sec-ix-hidden:c82797158">$5,114,000</span> of revenue, which is below its average monthly requirements. During <em style="font: inherit;">2020,</em> the Company raised approximately <span style="-sec-ix-hidden:c82797162">$24,000,000</span> from financing activities and at <em style="font: inherit;"> December 31, 2021 </em>had approximately <span style="-sec-ix-hidden:c82797164">$7,800,000</span> in cash. With the addition of the Swivel Secure Europe, SA (see Note W), the Company expects <span style="-sec-ix-hidden:c82797166">$1,000,000</span> of additional cash flow, based on Swivel Secure’s current recurring revenue and expenses, to provide additional operating income. As of the date of this report, the Company has enough cash and receivables for <em style="font: inherit;">twelve</em> months of operations.</p> <p style="margin: 0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Effective <em style="font: inherit;"> November 20, 2020, </em>the Company implemented a reverse stock split of its outstanding common stock at a ratio of <em style="font: inherit;">1</em>-for-8. All share figures and results are reflected on a post-split basis.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt;"><i>Foreign Currency</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 5pt; text-indent: 18pt;">The Company accounts for foreign currency transactions pursuant to ASC <em style="font: inherit;">830,</em> <i>Foreign Currency Matters</i> ("ASC <em style="font: inherit;">830”</em>). The functional currency of the Company is the U.S. dollar, which is the currency of the primary economic environment in which it operates. In accordance with ASC <em style="font: inherit;">830,</em> monetary balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing at the applicable balance sheet date.  For foreign currency transactions included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates used in the translation of such transactions and from the remeasurement of the monetary balance sheet items are recorded as gain (loss) on foreign currency transactions.</p> <p style="margin: 0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><i>Summary of Significant Accounting Policies</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">A summary of the significant accounting policies consistently applied in the preparation of the accompanying consolidated financial statements follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;"/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">1.</em>  <i>Principles</i> <i>of Consolidation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The accompanying consolidated financial statements include the accounts of BIO-key International, Inc. and its wholly-owned subsidiaries (collectively, the “Company”). Intercompany accounts and transactions have been eliminated in consolidation. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;"/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">2.</em> <i>Use of Estimates</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 5pt; text-indent: 18pt;">Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) as set forth in the Financial Accounting Standards Board’s (FASB) Accounting Standards Codification (ASC) and consider the various staff accounting bulletins and other applicable guidance issued by the U.S. Securities and Exchange Commission (SEC). These accounting principles require us to make certain estimates, judgments and assumptions. The Company believes that the estimates, judgments and assumptions upon which it relies are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Certain significant accounting policies that contain subjective management estimates and assumptions include those related to revenue recognition, accounts receivable, inventory, intangible assets and long-lived assets, and income taxes. To the extent there are material differences between these estimates, judgments or assumptions and actual results, its consolidated financial statements will be affected. In many cases, the accounting treatment of a particular transaction is specifically dictated by GAAP and does <em style="font: inherit;">not</em> require management’s judgment in its application. There are also areas in which management’s judgment in selecting among available alternatives would <em style="font: inherit;">not</em> produce a materially different result.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;"/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">3.</em> <i>Revenue Recognition</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;text-indent:16pt;">In accordance with ASC <em style="font: inherit;">606,</em> revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. To achieve this core principle, the Company applies the following <em style="font: inherit;">five</em> steps: </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Identify the contract with a customer</p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Identify the performance obligations in the contract</p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Determine the transaction price</p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Allocate the transaction price to performance obligations in the contract</p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Recognize revenue when or as the Company satisfies a performance obligation</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">All of the Company's performance obligations, and associated revenues, are generally transferred to customers at a point in time, with the exception of support and maintenance, and professional services, which are generally transferred to the customer over time.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"><i>Software licenses</i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Software license revenue consist of fees for perpetual and subscription licenses for <em style="font: inherit;">one</em> or more of the Company’s biometric fingerprint solutions or identity access management solutions. Revenue is recognized at a point in time once the software is available to the customer for download. Software license contracts are generally invoiced in full on execution of the arrangement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"><i>Hardware</i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Hardware revenue consists of fees for associated equipment sold with or without a software license arrangement, such as servers, locks and fingerprint readers. Customers are <em style="font: inherit;">not</em> obligated to buy <em style="font: inherit;">third</em> party hardware from the Company, and <em style="font: inherit;"> may </em>procure these items from a number of suppliers. Revenue is recognized at a point in time once the hardware is shipped to the customer. Hardware items are generally invoiced in full on execution of the arrangement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"><i>Support and Maintenance</i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Support and maintenance revenue consists of fees for unspecified upgrades, telephone assistance and bug fixes. The Company satisfies its support and maintenance performance obligation by providing “stand-ready” assistance as required over the contract period. The Company records deferred revenue (contract liability) at time of prepayment until the contracts term occurs. Revenue is recognized over time on a ratable basis over the contract term. Support and maintenance contracts are <em style="font: inherit;">one</em> to <em style="font: inherit;">five</em> years in length and are generally invoiced in advance at the beginning of the term. Support and Maintenance revenue for subscription licenses is carved out of the total license cost at 18% and recognized on a ratable basis over the license term.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"><i>Professional Services</i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Professional services revenues consist primarily of fees for deployment and optimization services, as well as training. The majority of the Company’s consulting contracts are billed on a time and materials basis, and revenue is recognized based on the amount billable to the customer in accordance with practical expedient ASC <em style="font: inherit;">606</em>-<em style="font: inherit;">10</em>-<em style="font: inherit;">55</em>-<em style="font: inherit;">18.</em> For other professional services contracts, the Company utilizes an input method and recognizes revenue based on labor hours expended to date relative to the total labor hours expected to be required to satisfy its performance obligation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"><i>Contracts with Multiple Performance Obligations</i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Some contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The standalone selling prices are determined based on overall pricing objectives, taking into consideration market conditions and other factors, including the value of the contracts, the cloud applications sold, customer demographics, geographic locations, and the number and types of users within the contracts.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company considered several factors in determining that control transfers to the customer upon shipment of hardware and availability of download of software.  These factors include that legal title transfers to the customer, the Company has a present right to payment, and the customer has assumed the risks and rewards of ownership.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Accounts receivable from customers are typically due within <em style="font: inherit;">30</em> days of invoicing.  The Company does <em style="font: inherit;">not</em> record a reserve for product returns or warranties as amounts are deemed immaterial based on historical experience.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"><i>Costs to Obtain and Fulfill a Contract</i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Costs to obtain and fulfill a contract are predominantly sales commissions earned by the sales force and are considered incremental and recoverable costs of obtaining a contract with a customer. These costs are deferred and then amortized over a period of benefit determined to be <span style="-sec-ix-hidden:c82797204">four</span> years. These costs are included as capitalized contract costs on the balance sheet. The period of benefit was determined by taking into consideration customer contracts, technology, and other factors based on historical evidence. Amortization expense is included in selling, general and administrative expenses in the accompanying consolidated statements of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"><i>Deferred Revenue</i> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Deferred revenue includes customer advances and amounts that have been paid by customer for which the contractual maintenance terms have <em style="font: inherit;">not</em> yet occurred. The majority of these amounts are related to maintenance contracts for which the revenue is recognized ratably over the applicable term, which generally is <em style="font: inherit;">12</em>-<em style="font: inherit;">60</em> months. Contracts greater than <em style="font: inherit;">12</em> months are segregated as long term deferred revenue. Maintenance contracts include provisions for unspecified when-and-if available product updates and customer telephone support services. At <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> amounts in deferred revenue were approximately <span style="-sec-ix-hidden:c82797211">$633,000</span> and <span style="-sec-ix-hidden:c82797212">$702,000,</span> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;"/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">4.</em> <i>Business Combinations</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">In accordance with ASC <em style="font: inherit;">805,</em> <i>Business Combinations</i> (ASC <em style="font: inherit;">805</em>), the Company recognizes the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. Determining these fair values requires management to make significant estimates and assumptions, especially with respect to intangible assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">The Company recognizes identifiable assets acquired and liabilities assumed at their acquisition date fair value. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net acquisition date fair value of the assets acquired and the liabilities assumed and represents the expected future economic benefits arising from other assets acquired that are <em style="font: inherit;">not</em> individually identified and separately recognized. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, its estimates are inherently uncertain and subject to refinement. Assumptions <em style="font: inherit;"> may </em>be incomplete or inaccurate, and unanticipated events or circumstances <em style="font: inherit;"> may </em>occur, which <em style="font: inherit;"> may </em>affect the accuracy or validity of such assumptions, estimates or actual results. As a result, during the measurement period, which <em style="font: inherit;"> may </em>be up to <em style="font: inherit;">one</em> year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill to the extent that it identifies adjustments to the preliminary purchase price allocation. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statements of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;"/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">5.</em><i> Goodwill and acquired intangible assets</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">Goodwill is <em style="font: inherit;">not</em> amortized, but is evaluated for impairment annually, or whenever events or changes in circumstances indicate that the carrying value <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. The Company has determined that there is a single reporting unit for the purpose of conducting this goodwill impairment assessment. For purposes of assessing potential impairment, the Company estimates the fair value of the reporting unit, based on the Company’s market capitalization, and compares this amount to the carrying value of the reporting unit. If the Company determines that the carrying value of the reporting unit exceeds its fair value, an impairment charge would be required. The annual goodwill impairment test will be performed as of <em style="font: inherit;"> December </em><em style="font: inherit;">31st</em> of each year. To date, the Company has <span style="-sec-ix-hidden:c82797222">not</span> identified any impairment to goodwill.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">Intangible assets acquired in a business combination are recorded at their estimated fair values at the date of acquisition. The Company amortizes acquired definite-lived intangible assets over their estimated useful lives based on the pattern of consumption of the economic benefits or, if that pattern cannot be readily determined, on a straight-line basis.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;"/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">6.</em> <i>Cash Equivalents</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Cash equivalents consist of liquid investments with original maturities of <em style="font: inherit;">three</em> months or less. At <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> cash equivalents consisted of a money market account.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;"/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">7.</em> <i>Accounts Receivable</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Accounts receivable are carried at original amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful receivables by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions. Accounts receivable are written off when deemed uncollectible.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Accounts receivable at <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> consisted of the following: </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,234,411</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">561,834</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;">Loss on foreign currency</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(50,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Allowance for doubtful accounts</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(213,785</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(13,785</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accounts receivable, net of allowances for doubtful accounts</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">970,626</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">548,049</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;">Bad debt expenses (if any) are recorded in selling, general, and administrative expense. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><em style="font: inherit;"/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><em style="font: inherit;">8.</em> <i>Equipment and Leasehold Improvements,</i> <i>Intangible Assets and</i> <i>Depreciation and Amortization</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Equipment and leasehold improvements are stated at cost.  Depreciation is provided for in amounts sufficient to relate the cost of depreciable assets to operations over the estimated service lives, principally using straight-line methods. Leasehold improvements are amortized over the shorter of the life of the improvement or the lease term, using the straight-line method.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The estimated useful lives used to compute depreciation and amortization for financial reporting purposes are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:bottom;width:38.8%;"> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td colspan="3" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Years</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:38.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Equipment and leasehold improvements</i></p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:2.3%;"> </td><td style="vertical-align:bottom;width:1.4%;"> </td><td style="vertical-align:bottom;width:2.3%;"> </td><td style="vertical-align:bottom;width:0.5%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:38.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Equipment (years)</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3</p> </td><td style="vertical-align:bottom;width:1.4%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p> </td><td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:38.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Furniture and fixtures (years)</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3</p> </td><td style="vertical-align:bottom;width:1.4%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p> </td><td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:38.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Software (years)</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:2.3%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:1.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3</p> </td><td style="vertical-align:bottom;width:2.3%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:0.5%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:38.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Leasehold improvements</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td colspan="3" style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">life or lease term</em></em></em></p> </td><td style="vertical-align:bottom;width:0.5%;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Intangible assets other than goodwill consist of patents, trade name, proprietary software, and customer relationships.  Patent costs are capitalized until patents are awarded. Upon award, such costs are amortized using the straight-line method over their respective economic lives. If a patent is denied, all costs are charged to operations in that year. Trade names, proprietary software, and customer relationships are amortized over the economic useful life.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;"/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">9.</em> <i>Impairment or Disposal of Long Lived Assets, including Intangible Assets</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company reviews long-lived assets, including intangible assets subject to amortization, whenever events or changes in circumstances indicate that the carrying amount of such an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Recoverability of these assets is measured by comparison of their carrying amount to the future undiscounted cash flows the assets are expected to generate. If such assets are considered impaired, the impairment to be recognized is equal to the amount by which the carrying value of the assets exceeds their fair value determined by either a quoted market price, if any, or a value determined by utilizing a discounted cash flow technique. In assessing recoverability, the Company must make assumptions regarding estimated future cash flows and discount factors. If these estimates or related assumptions change in the future, the Company <em style="font: inherit;"> may </em>be required to record impairment charges. Intangible assets with determinable lives are amortized over their estimated useful lives, based upon the pattern in which the expected benefits will be realized, or on a straight-line basis, whichever is greater. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;"/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">10.</em> <i>Advertising Expense</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company expenses the costs of advertising as incurred. Advertising expenses for <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> were approximately $527,000 and $494,000, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;"/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">11.</em> <i>Research and Development Expenditures</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Research and development expenses include costs directly attributable to the conduct of research and development programs primarily related to the development of our software products and improving the efficiency and capabilities of our existing software. Such costs include salaries, payroll taxes, employee benefit costs, materials, supplies, depreciation on research equipment, services provided by outside contractors, and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation and general support services. All costs associated with research and development are expensed as incurred. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;"/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">12.</em> <i>Earnings Per Share of Common Stock (</i>“<i>EPS</i>”<i>)</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company’s EPS is calculated by dividing net income (loss) applicable to common stockholders by the weighted-average number of common shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options and warrants, when the effect of their inclusion is dilutive.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;"/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">13.</em> <i>Accounting for Stock-Based Compensation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company accounts for share based compensation in accordance with the provisions of ASC <em style="font: inherit;">718</em>-<em style="font: inherit;">10,</em> “Compensation — Stock Compensation,” which requires measurement of compensation cost for all stock awards at fair value on date of grant and recognition of compensation over the service period for awards expected to vest. The majority of its share-based compensation arrangements vest over either a <span style="-sec-ix-hidden:c82797248">three</span> or <span style="-sec-ix-hidden:c82797249">four</span> year vesting schedule. The Company expenses its share-based compensation under the ratable method, which treats each vesting tranche as if it were an individual grant. The fair value of stock options is determined using the Black-Scholes valuation model and requires the input of highly subjective assumptions. These assumptions include estimating the length of time employees will retain their vested stock options before exercising them (the “expected option term”), the estimated volatility of its common stock price over the option’s expected term, the risk-free interest rate over the option’s expected term, and the Company’s expected annual dividend yield. Changes in these subjective assumptions can materially affect the estimate of fair value of stock-based compensation and consequently, the related amount recognized as an expense in the consolidated statements of operations. As required under the accounting rules, the Company reviews its valuation assumptions at each grant date and, as a result, the Company is likely to change its valuation assumptions used to value employee stock-based awards granted in future periods. The values derived from using the Black-Scholes model are recognized as expense over the service period, net of estimated forfeitures (the number of individuals that will ultimately <em style="font: inherit;">not</em> complete their vesting requirements). The estimation of stock awards that will ultimately vest requires significant judgment. The Company considers many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience. Actual results, and future changes in estimates, <em style="font: inherit;"> may </em>differ substantially from current estimates. Options and warrants to outsiders are accounted for under ASC <em style="font: inherit;">718.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The following table presents share-based compensation expenses included in the Company’s consolidated statements of operations:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Selling, general and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">269,368</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">705,971</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research, development and engineering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">45,347</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">86,124</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">314,715</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">792,095</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"><i>Valuation Assumptions for Stock Options</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">In <em style="font: inherit;">2020,</em> 28,440 stock options were granted. No options were granted in <em style="font: inherit;">2021.</em> The fair value of each option was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average Risk free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life of options (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividends</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average Volatility of stock price</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">115</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The stock volatility for each grant is determined based on the review of the experience of the weighted average of historical daily price changes of the Company’s common stock over the expected option term. The expected term was determined using the simplified method for estimating expected option life, which qualify as “plain-vanilla” options; and the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;"/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">14.</em> <i>Derivative Liabilities</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">In connection with the issuances of equity instruments or debt, the Company <em style="font: inherit;"> may </em>issue options or warrants to purchase common stock. In certain circumstances, these options or warrants <em style="font: inherit;"> may </em>be classified as liabilities, rather than as equity. In addition, the equity instrument or debt <em style="font: inherit;"> may </em>contain embedded derivative instruments, such as conversion options or listing requirements, which in certain circumstances <em style="font: inherit;"> may </em>be required to be bifurcated from the associated host instrument and accounted for separately as a derivative liability instrument. The Company early-adopted the new provisions issued <em style="font: inherit;"> July 2017, </em>for derivative liability instruments under FASB ASU <em style="font: inherit;">2017</em>-<em style="font: inherit;">11,</em> Earnings Per Share (Topic <em style="font: inherit;">260</em>), Distinguishing Liabilities from Equity (Topic <em style="font: inherit;">480</em>) and Derivatives and Hedging (Topic <em style="font: inherit;">815</em>): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception. Under ASU <em style="font: inherit;">2017</em>-<em style="font: inherit;">11,</em> down round features do <em style="font: inherit;">not</em> meet the criteria for derivative accounting and <em style="font: inherit;">no</em> liability is to be recorded until an actual issuance of securities triggers the down-round feature. Prior to these provisions, the liabilities were recorded without the actual issuance of the securities triggering the down-round feature.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;"/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;"/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">15.</em> <i>Income Taxes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The provision for, or benefit from, income taxes includes deferred taxes resulting from the temporary differences in income for financial and tax purposes using the liability method. Such temporary differences result primarily from the differences in the carrying value of assets and liabilities. Future realization of deferred income tax assets requires sufficient taxable income within the carryback, carryforward period available under tax law. The Company evaluates, on a quarterly basis whether, based on all available evidence, if it is probable that the deferred income tax assets are realizable. Valuation allowances are established when it is more likely than <em style="font: inherit;">not</em> that the tax benefit of the deferred tax asset will <em style="font: inherit;">not</em> be realized. The evaluation, as prescribed by ASC <em style="font: inherit;">740</em>-<em style="font: inherit;">10,</em> “Income Taxes,” includes the consideration of all available evidence, both positive and negative, regarding historical operating results including recent years with reported losses, the estimated timing of future reversals of existing taxable temporary differences, estimated future taxable income exclusive of reversing temporary differences and carryforwards, and potential tax planning strategies which <em style="font: inherit;"> may </em>be employed to prevent an operating loss or tax credit carryforward from expiring unused. Because of the Company’s historical performance and estimated future taxable income, a full valuation allowance has been established.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company accounts for uncertain tax provisions in accordance with ASC <em style="font: inherit;">740</em>-<em style="font: inherit;">10</em>-<em style="font: inherit;">05,</em> “Accounting for Uncertainty in Income Taxes.” The ASC clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The ASC prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The ASC provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;"/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">16</em><i>. Leases</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">In accordance with ASC <em style="font: inherit;">842,</em> <i>Lease</i>s (ASC <em style="font: inherit;">842</em>), the Company records a right-of-use (ROU) asset and a lease liability on the balance sheet for all leases with terms longer than <em style="font: inherit;">12</em> months and classifies them as either operating or finance leases. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than <em style="font: inherit;">one</em> year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected <em style="font: inherit;">not</em> to recognize on the balance sheet leases with terms of <em style="font: inherit;">one</em> year or less under practical expedient in paragraph ASC <em style="font: inherit;">842</em>-<em style="font: inherit;">20</em>-<em style="font: inherit;">25</em>-<em style="font: inherit;">2.</em> For contracts with lease and non-lease components, the Company has elected <em style="font: inherit;">not</em> to allocate the contract consideration, and to account for the lease and non-lease components as a single lease component.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally <em style="font: inherit;">not</em> determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate, adjusted for various factors including level of collateralization, term and currency to align with the terms of the lease. The operating lease ROU asset also includes any lease prepayments, offset by lease incentives.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain we will <em style="font: inherit;">not</em> exercise the option.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;"/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">17.</em> <i>Recent Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:20pt;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments-Credit Losses</i> (Topic <em style="font: inherit;">326</em>), referred to herein as ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> which significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are <em style="font: inherit;">not</em> measured at fair value through net income. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> replaces the existing incurred loss model with an expected credit loss model that requires entities to estimate an expected lifetime credit loss on most financial assets and certain other instruments. Under ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> credit impairment is recognized as an allowance for credit losses, rather than as a direct write-down of the amortized cost basis of a financial asset. The impairment allowance is a valuation account deducted from the amortized cost basis of financial assets to present the net amount expected to be collected on the financial asset. Once the new pronouncement is adopted by the Company, the allowance for credit losses must be adjusted for management’s current estimate at each reporting date. The new guidance provides <em style="font: inherit;">no</em> threshold for recognition of impairment allowance. Therefore, entities must also measure expected credit losses on assets that have a low risk of loss. For instance, trade receivables that are either current or <em style="font: inherit;">not</em> yet due <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> require an allowance reserve under currently generally accepted accounting principles, but under the new standard, the Company will have to estimate an allowance for expected credit losses on trade receivables under ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13.</em> ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> is effective for annual periods, including interim periods within those annual periods, beginning after <em style="font: inherit;"> December 15, 2022 </em>for smaller reporting companies. Early adoption is permitted. The Company is currently assessing the impact ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> will have on its consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 5pt; text-indent: 20pt;">Effective <em style="font: inherit;"> January 1, 2021, </em>the Company adopted ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em> Simplifying the Accounting for Income Taxes (“ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12”</em>) to reduce the cost and complexity in accounting for income taxes. ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> removes certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> also amends other aspects of the guidance to help simplify and promote consistent application of U.S. GAAP. Most amendments within ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The adoption of ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> did <em style="font: inherit;">not</em> have a significant impact on the Company’s consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Management does <em style="font: inherit;">not</em> believe that any other recently issued, but <em style="font: inherit;">not</em> yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><i>Going Concern and Basis of Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 5pt; text-indent: 18pt;">The Company has historically financed our operations through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. The Company currently requires approximately $735,000 per month to conduct operations, a monthly amount that it has been unable to consistently achieve through revenue generation. During <em style="font: inherit;">2021,</em> the Company generated approximately <span style="-sec-ix-hidden:c82797158">$5,114,000</span> of revenue, which is below its average monthly requirements. During <em style="font: inherit;">2020,</em> the Company raised approximately <span style="-sec-ix-hidden:c82797162">$24,000,000</span> from financing activities and at <em style="font: inherit;"> December 31, 2021 </em>had approximately <span style="-sec-ix-hidden:c82797164">$7,800,000</span> in cash. With the addition of the Swivel Secure Europe, SA (see Note W), the Company expects <span style="-sec-ix-hidden:c82797166">$1,000,000</span> of additional cash flow, based on Swivel Secure’s current recurring revenue and expenses, to provide additional operating income. As of the date of this report, the Company has enough cash and receivables for <em style="font: inherit;">twelve</em> months of operations.</p> <p style="margin: 0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Effective <em style="font: inherit;"> November 20, 2020, </em>the Company implemented a reverse stock split of its outstanding common stock at a ratio of <em style="font: inherit;">1</em>-for-8. All share figures and results are reflected on a post-split basis.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 735000 8 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">1.</em>  <i>Principles</i> <i>of Consolidation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The accompanying consolidated financial statements include the accounts of BIO-key International, Inc. and its wholly-owned subsidiaries (collectively, the “Company”). Intercompany accounts and transactions have been eliminated in consolidation. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">2.</em> <i>Use of Estimates</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 5pt; text-indent: 18pt;">Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) as set forth in the Financial Accounting Standards Board’s (FASB) Accounting Standards Codification (ASC) and consider the various staff accounting bulletins and other applicable guidance issued by the U.S. Securities and Exchange Commission (SEC). These accounting principles require us to make certain estimates, judgments and assumptions. The Company believes that the estimates, judgments and assumptions upon which it relies are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Certain significant accounting policies that contain subjective management estimates and assumptions include those related to revenue recognition, accounts receivable, inventory, intangible assets and long-lived assets, and income taxes. To the extent there are material differences between these estimates, judgments or assumptions and actual results, its consolidated financial statements will be affected. In many cases, the accounting treatment of a particular transaction is specifically dictated by GAAP and does <em style="font: inherit;">not</em> require management’s judgment in its application. There are also areas in which management’s judgment in selecting among available alternatives would <em style="font: inherit;">not</em> produce a materially different result.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">3.</em> <i>Revenue Recognition</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;text-indent:16pt;">In accordance with ASC <em style="font: inherit;">606,</em> revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. To achieve this core principle, the Company applies the following <em style="font: inherit;">five</em> steps: </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Identify the contract with a customer</p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Identify the performance obligations in the contract</p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Determine the transaction price</p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Allocate the transaction price to performance obligations in the contract</p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Recognize revenue when or as the Company satisfies a performance obligation</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">All of the Company's performance obligations, and associated revenues, are generally transferred to customers at a point in time, with the exception of support and maintenance, and professional services, which are generally transferred to the customer over time.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"><i>Software licenses</i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Software license revenue consist of fees for perpetual and subscription licenses for <em style="font: inherit;">one</em> or more of the Company’s biometric fingerprint solutions or identity access management solutions. Revenue is recognized at a point in time once the software is available to the customer for download. Software license contracts are generally invoiced in full on execution of the arrangement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"><i>Hardware</i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Hardware revenue consists of fees for associated equipment sold with or without a software license arrangement, such as servers, locks and fingerprint readers. Customers are <em style="font: inherit;">not</em> obligated to buy <em style="font: inherit;">third</em> party hardware from the Company, and <em style="font: inherit;"> may </em>procure these items from a number of suppliers. Revenue is recognized at a point in time once the hardware is shipped to the customer. Hardware items are generally invoiced in full on execution of the arrangement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"><i>Support and Maintenance</i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Support and maintenance revenue consists of fees for unspecified upgrades, telephone assistance and bug fixes. The Company satisfies its support and maintenance performance obligation by providing “stand-ready” assistance as required over the contract period. The Company records deferred revenue (contract liability) at time of prepayment until the contracts term occurs. Revenue is recognized over time on a ratable basis over the contract term. Support and maintenance contracts are <em style="font: inherit;">one</em> to <em style="font: inherit;">five</em> years in length and are generally invoiced in advance at the beginning of the term. Support and Maintenance revenue for subscription licenses is carved out of the total license cost at 18% and recognized on a ratable basis over the license term.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"><i>Professional Services</i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Professional services revenues consist primarily of fees for deployment and optimization services, as well as training. The majority of the Company’s consulting contracts are billed on a time and materials basis, and revenue is recognized based on the amount billable to the customer in accordance with practical expedient ASC <em style="font: inherit;">606</em>-<em style="font: inherit;">10</em>-<em style="font: inherit;">55</em>-<em style="font: inherit;">18.</em> For other professional services contracts, the Company utilizes an input method and recognizes revenue based on labor hours expended to date relative to the total labor hours expected to be required to satisfy its performance obligation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"><i>Contracts with Multiple Performance Obligations</i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Some contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The standalone selling prices are determined based on overall pricing objectives, taking into consideration market conditions and other factors, including the value of the contracts, the cloud applications sold, customer demographics, geographic locations, and the number and types of users within the contracts.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company considered several factors in determining that control transfers to the customer upon shipment of hardware and availability of download of software.  These factors include that legal title transfers to the customer, the Company has a present right to payment, and the customer has assumed the risks and rewards of ownership.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Accounts receivable from customers are typically due within <em style="font: inherit;">30</em> days of invoicing.  The Company does <em style="font: inherit;">not</em> record a reserve for product returns or warranties as amounts are deemed immaterial based on historical experience.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"><i>Costs to Obtain and Fulfill a Contract</i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Costs to obtain and fulfill a contract are predominantly sales commissions earned by the sales force and are considered incremental and recoverable costs of obtaining a contract with a customer. These costs are deferred and then amortized over a period of benefit determined to be <span style="-sec-ix-hidden:c82797204">four</span> years. These costs are included as capitalized contract costs on the balance sheet. The period of benefit was determined by taking into consideration customer contracts, technology, and other factors based on historical evidence. Amortization expense is included in selling, general and administrative expenses in the accompanying consolidated statements of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"><i>Deferred Revenue</i> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Deferred revenue includes customer advances and amounts that have been paid by customer for which the contractual maintenance terms have <em style="font: inherit;">not</em> yet occurred. The majority of these amounts are related to maintenance contracts for which the revenue is recognized ratably over the applicable term, which generally is <em style="font: inherit;">12</em>-<em style="font: inherit;">60</em> months. Contracts greater than <em style="font: inherit;">12</em> months are segregated as long term deferred revenue. Maintenance contracts include provisions for unspecified when-and-if available product updates and customer telephone support services. At <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> amounts in deferred revenue were approximately <span style="-sec-ix-hidden:c82797211">$633,000</span> and <span style="-sec-ix-hidden:c82797212">$702,000,</span> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 0.18 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">4.</em> <i>Business Combinations</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">In accordance with ASC <em style="font: inherit;">805,</em> <i>Business Combinations</i> (ASC <em style="font: inherit;">805</em>), the Company recognizes the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. Determining these fair values requires management to make significant estimates and assumptions, especially with respect to intangible assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">The Company recognizes identifiable assets acquired and liabilities assumed at their acquisition date fair value. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net acquisition date fair value of the assets acquired and the liabilities assumed and represents the expected future economic benefits arising from other assets acquired that are <em style="font: inherit;">not</em> individually identified and separately recognized. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, its estimates are inherently uncertain and subject to refinement. Assumptions <em style="font: inherit;"> may </em>be incomplete or inaccurate, and unanticipated events or circumstances <em style="font: inherit;"> may </em>occur, which <em style="font: inherit;"> may </em>affect the accuracy or validity of such assumptions, estimates or actual results. As a result, during the measurement period, which <em style="font: inherit;"> may </em>be up to <em style="font: inherit;">one</em> year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill to the extent that it identifies adjustments to the preliminary purchase price allocation. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statements of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">5.</em><i> Goodwill and acquired intangible assets</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">Goodwill is <em style="font: inherit;">not</em> amortized, but is evaluated for impairment annually, or whenever events or changes in circumstances indicate that the carrying value <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. The Company has determined that there is a single reporting unit for the purpose of conducting this goodwill impairment assessment. For purposes of assessing potential impairment, the Company estimates the fair value of the reporting unit, based on the Company’s market capitalization, and compares this amount to the carrying value of the reporting unit. If the Company determines that the carrying value of the reporting unit exceeds its fair value, an impairment charge would be required. The annual goodwill impairment test will be performed as of <em style="font: inherit;"> December </em><em style="font: inherit;">31st</em> of each year. To date, the Company has <span style="-sec-ix-hidden:c82797222">not</span> identified any impairment to goodwill.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">Intangible assets acquired in a business combination are recorded at their estimated fair values at the date of acquisition. The Company amortizes acquired definite-lived intangible assets over their estimated useful lives based on the pattern of consumption of the economic benefits or, if that pattern cannot be readily determined, on a straight-line basis.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">6.</em> <i>Cash Equivalents</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Cash equivalents consist of liquid investments with original maturities of <em style="font: inherit;">three</em> months or less. At <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> cash equivalents consisted of a money market account.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">7.</em> <i>Accounts Receivable</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Accounts receivable are carried at original amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful receivables by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions. Accounts receivable are written off when deemed uncollectible.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Accounts receivable at <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> consisted of the following: </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,234,411</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">561,834</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;">Loss on foreign currency</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(50,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Allowance for doubtful accounts</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(213,785</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(13,785</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accounts receivable, net of allowances for doubtful accounts</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">970,626</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">548,049</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;">Bad debt expenses (if any) are recorded in selling, general, and administrative expense. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,234,411</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">561,834</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;">Loss on foreign currency</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(50,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Allowance for doubtful accounts</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(213,785</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(13,785</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accounts receivable, net of allowances for doubtful accounts</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">970,626</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">548,049</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 1234411 561834 -50000 0 213785 13785 970626 548049 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><em style="font: inherit;">8.</em> <i>Equipment and Leasehold Improvements,</i> <i>Intangible Assets and</i> <i>Depreciation and Amortization</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Equipment and leasehold improvements are stated at cost.  Depreciation is provided for in amounts sufficient to relate the cost of depreciable assets to operations over the estimated service lives, principally using straight-line methods. Leasehold improvements are amortized over the shorter of the life of the improvement or the lease term, using the straight-line method.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The estimated useful lives used to compute depreciation and amortization for financial reporting purposes are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:bottom;width:38.8%;"> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td colspan="3" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Years</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:38.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Equipment and leasehold improvements</i></p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:2.3%;"> </td><td style="vertical-align:bottom;width:1.4%;"> </td><td style="vertical-align:bottom;width:2.3%;"> </td><td style="vertical-align:bottom;width:0.5%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:38.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Equipment (years)</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3</p> </td><td style="vertical-align:bottom;width:1.4%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p> </td><td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:38.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Furniture and fixtures (years)</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3</p> </td><td style="vertical-align:bottom;width:1.4%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p> </td><td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:38.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Software (years)</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:2.3%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:1.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3</p> </td><td style="vertical-align:bottom;width:2.3%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:0.5%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:38.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Leasehold improvements</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td colspan="3" style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">life or lease term</em></em></em></p> </td><td style="vertical-align:bottom;width:0.5%;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Intangible assets other than goodwill consist of patents, trade name, proprietary software, and customer relationships.  Patent costs are capitalized until patents are awarded. Upon award, such costs are amortized using the straight-line method over their respective economic lives. If a patent is denied, all costs are charged to operations in that year. Trade names, proprietary software, and customer relationships are amortized over the economic useful life.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:bottom;width:38.8%;"> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td colspan="3" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Years</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:38.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Equipment and leasehold improvements</i></p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:2.3%;"> </td><td style="vertical-align:bottom;width:1.4%;"> </td><td style="vertical-align:bottom;width:2.3%;"> </td><td style="vertical-align:bottom;width:0.5%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:38.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Equipment (years)</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3</p> </td><td style="vertical-align:bottom;width:1.4%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p> </td><td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:38.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Furniture and fixtures (years)</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3</p> </td><td style="vertical-align:bottom;width:1.4%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p> </td><td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:38.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Software (years)</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:2.3%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:1.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3</p> </td><td style="vertical-align:bottom;width:2.3%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:0.5%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:38.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Leasehold improvements</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td colspan="3" style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">life or lease term</em></em></em></p> </td><td style="vertical-align:bottom;width:0.5%;"> </td></tr> </tbody></table> P3Y P5Y P3Y P5Y P3Y <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">9.</em> <i>Impairment or Disposal of Long Lived Assets, including Intangible Assets</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company reviews long-lived assets, including intangible assets subject to amortization, whenever events or changes in circumstances indicate that the carrying amount of such an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Recoverability of these assets is measured by comparison of their carrying amount to the future undiscounted cash flows the assets are expected to generate. If such assets are considered impaired, the impairment to be recognized is equal to the amount by which the carrying value of the assets exceeds their fair value determined by either a quoted market price, if any, or a value determined by utilizing a discounted cash flow technique. In assessing recoverability, the Company must make assumptions regarding estimated future cash flows and discount factors. If these estimates or related assumptions change in the future, the Company <em style="font: inherit;"> may </em>be required to record impairment charges. Intangible assets with determinable lives are amortized over their estimated useful lives, based upon the pattern in which the expected benefits will be realized, or on a straight-line basis, whichever is greater. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">10.</em> <i>Advertising Expense</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company expenses the costs of advertising as incurred. Advertising expenses for <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> were approximately $527,000 and $494,000, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 527000 494000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">11.</em> <i>Research and Development Expenditures</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Research and development expenses include costs directly attributable to the conduct of research and development programs primarily related to the development of our software products and improving the efficiency and capabilities of our existing software. Such costs include salaries, payroll taxes, employee benefit costs, materials, supplies, depreciation on research equipment, services provided by outside contractors, and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation and general support services. All costs associated with research and development are expensed as incurred. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">12.</em> <i>Earnings Per Share of Common Stock (</i>“<i>EPS</i>”<i>)</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company’s EPS is calculated by dividing net income (loss) applicable to common stockholders by the weighted-average number of common shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options and warrants, when the effect of their inclusion is dilutive.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">13.</em> <i>Accounting for Stock-Based Compensation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company accounts for share based compensation in accordance with the provisions of ASC <em style="font: inherit;">718</em>-<em style="font: inherit;">10,</em> “Compensation — Stock Compensation,” which requires measurement of compensation cost for all stock awards at fair value on date of grant and recognition of compensation over the service period for awards expected to vest. The majority of its share-based compensation arrangements vest over either a <span style="-sec-ix-hidden:c82797248">three</span> or <span style="-sec-ix-hidden:c82797249">four</span> year vesting schedule. The Company expenses its share-based compensation under the ratable method, which treats each vesting tranche as if it were an individual grant. The fair value of stock options is determined using the Black-Scholes valuation model and requires the input of highly subjective assumptions. These assumptions include estimating the length of time employees will retain their vested stock options before exercising them (the “expected option term”), the estimated volatility of its common stock price over the option’s expected term, the risk-free interest rate over the option’s expected term, and the Company’s expected annual dividend yield. Changes in these subjective assumptions can materially affect the estimate of fair value of stock-based compensation and consequently, the related amount recognized as an expense in the consolidated statements of operations. As required under the accounting rules, the Company reviews its valuation assumptions at each grant date and, as a result, the Company is likely to change its valuation assumptions used to value employee stock-based awards granted in future periods. The values derived from using the Black-Scholes model are recognized as expense over the service period, net of estimated forfeitures (the number of individuals that will ultimately <em style="font: inherit;">not</em> complete their vesting requirements). The estimation of stock awards that will ultimately vest requires significant judgment. The Company considers many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience. Actual results, and future changes in estimates, <em style="font: inherit;"> may </em>differ substantially from current estimates. Options and warrants to outsiders are accounted for under ASC <em style="font: inherit;">718.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The following table presents share-based compensation expenses included in the Company’s consolidated statements of operations:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Selling, general and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">269,368</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">705,971</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research, development and engineering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">45,347</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">86,124</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">314,715</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">792,095</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"><i>Valuation Assumptions for Stock Options</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">In <em style="font: inherit;">2020,</em> 28,440 stock options were granted. No options were granted in <em style="font: inherit;">2021.</em> The fair value of each option was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average Risk free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life of options (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividends</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average Volatility of stock price</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">115</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The stock volatility for each grant is determined based on the review of the experience of the weighted average of historical daily price changes of the Company’s common stock over the expected option term. The expected term was determined using the simplified method for estimating expected option life, which qualify as “plain-vanilla” options; and the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Selling, general and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">269,368</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">705,971</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research, development and engineering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">45,347</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">86,124</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">314,715</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">792,095</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 269368 705971 45347 86124 314715 792095 28440 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average Risk free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life of options (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividends</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average Volatility of stock price</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">115</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> </tbody></table> 0 0.0030 P4Y6M 0 0 0 1.15 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">14.</em> <i>Derivative Liabilities</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">In connection with the issuances of equity instruments or debt, the Company <em style="font: inherit;"> may </em>issue options or warrants to purchase common stock. In certain circumstances, these options or warrants <em style="font: inherit;"> may </em>be classified as liabilities, rather than as equity. In addition, the equity instrument or debt <em style="font: inherit;"> may </em>contain embedded derivative instruments, such as conversion options or listing requirements, which in certain circumstances <em style="font: inherit;"> may </em>be required to be bifurcated from the associated host instrument and accounted for separately as a derivative liability instrument. The Company early-adopted the new provisions issued <em style="font: inherit;"> July 2017, </em>for derivative liability instruments under FASB ASU <em style="font: inherit;">2017</em>-<em style="font: inherit;">11,</em> Earnings Per Share (Topic <em style="font: inherit;">260</em>), Distinguishing Liabilities from Equity (Topic <em style="font: inherit;">480</em>) and Derivatives and Hedging (Topic <em style="font: inherit;">815</em>): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception. Under ASU <em style="font: inherit;">2017</em>-<em style="font: inherit;">11,</em> down round features do <em style="font: inherit;">not</em> meet the criteria for derivative accounting and <em style="font: inherit;">no</em> liability is to be recorded until an actual issuance of securities triggers the down-round feature. Prior to these provisions, the liabilities were recorded without the actual issuance of the securities triggering the down-round feature.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">15.</em> <i>Income Taxes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The provision for, or benefit from, income taxes includes deferred taxes resulting from the temporary differences in income for financial and tax purposes using the liability method. Such temporary differences result primarily from the differences in the carrying value of assets and liabilities. Future realization of deferred income tax assets requires sufficient taxable income within the carryback, carryforward period available under tax law. The Company evaluates, on a quarterly basis whether, based on all available evidence, if it is probable that the deferred income tax assets are realizable. Valuation allowances are established when it is more likely than <em style="font: inherit;">not</em> that the tax benefit of the deferred tax asset will <em style="font: inherit;">not</em> be realized. The evaluation, as prescribed by ASC <em style="font: inherit;">740</em>-<em style="font: inherit;">10,</em> “Income Taxes,” includes the consideration of all available evidence, both positive and negative, regarding historical operating results including recent years with reported losses, the estimated timing of future reversals of existing taxable temporary differences, estimated future taxable income exclusive of reversing temporary differences and carryforwards, and potential tax planning strategies which <em style="font: inherit;"> may </em>be employed to prevent an operating loss or tax credit carryforward from expiring unused. Because of the Company’s historical performance and estimated future taxable income, a full valuation allowance has been established.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company accounts for uncertain tax provisions in accordance with ASC <em style="font: inherit;">740</em>-<em style="font: inherit;">10</em>-<em style="font: inherit;">05,</em> “Accounting for Uncertainty in Income Taxes.” The ASC clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The ASC prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The ASC provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">16</em><i>. Leases</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">In accordance with ASC <em style="font: inherit;">842,</em> <i>Lease</i>s (ASC <em style="font: inherit;">842</em>), the Company records a right-of-use (ROU) asset and a lease liability on the balance sheet for all leases with terms longer than <em style="font: inherit;">12</em> months and classifies them as either operating or finance leases. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than <em style="font: inherit;">one</em> year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected <em style="font: inherit;">not</em> to recognize on the balance sheet leases with terms of <em style="font: inherit;">one</em> year or less under practical expedient in paragraph ASC <em style="font: inherit;">842</em>-<em style="font: inherit;">20</em>-<em style="font: inherit;">25</em>-<em style="font: inherit;">2.</em> For contracts with lease and non-lease components, the Company has elected <em style="font: inherit;">not</em> to allocate the contract consideration, and to account for the lease and non-lease components as a single lease component.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally <em style="font: inherit;">not</em> determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate, adjusted for various factors including level of collateralization, term and currency to align with the terms of the lease. The operating lease ROU asset also includes any lease prepayments, offset by lease incentives.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain we will <em style="font: inherit;">not</em> exercise the option.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><em style="font: inherit;">17.</em> <i>Recent Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:20pt;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments-Credit Losses</i> (Topic <em style="font: inherit;">326</em>), referred to herein as ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> which significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are <em style="font: inherit;">not</em> measured at fair value through net income. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> replaces the existing incurred loss model with an expected credit loss model that requires entities to estimate an expected lifetime credit loss on most financial assets and certain other instruments. Under ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> credit impairment is recognized as an allowance for credit losses, rather than as a direct write-down of the amortized cost basis of a financial asset. The impairment allowance is a valuation account deducted from the amortized cost basis of financial assets to present the net amount expected to be collected on the financial asset. Once the new pronouncement is adopted by the Company, the allowance for credit losses must be adjusted for management’s current estimate at each reporting date. The new guidance provides <em style="font: inherit;">no</em> threshold for recognition of impairment allowance. Therefore, entities must also measure expected credit losses on assets that have a low risk of loss. For instance, trade receivables that are either current or <em style="font: inherit;">not</em> yet due <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> require an allowance reserve under currently generally accepted accounting principles, but under the new standard, the Company will have to estimate an allowance for expected credit losses on trade receivables under ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13.</em> ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> is effective for annual periods, including interim periods within those annual periods, beginning after <em style="font: inherit;"> December 15, 2022 </em>for smaller reporting companies. Early adoption is permitted. The Company is currently assessing the impact ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> will have on its consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 5pt; text-indent: 20pt;">Effective <em style="font: inherit;"> January 1, 2021, </em>the Company adopted ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em> Simplifying the Accounting for Income Taxes (“ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12”</em>) to reduce the cost and complexity in accounting for income taxes. ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> removes certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> also amends other aspects of the guidance to help simplify and promote consistent application of U.S. GAAP. Most amendments within ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The adoption of ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> did <em style="font: inherit;">not</em> have a significant impact on the Company’s consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Management does <em style="font: inherit;">not</em> believe that any other recently issued, but <em style="font: inherit;">not</em> yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><b>NOTE B</b>—<b>REVENUE FROM CONTRACTS WITH CUSTOMERS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><b><i>Disaggregation of Revenue</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;">The following table summarizes revenue from contracts with customers for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>North </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>America</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Africa</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>EMESA*</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Asia</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">License fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,854,088</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">521,751</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">105,314</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">74,656</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,555,809</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Hardware</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">278,655</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">698,264</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">265,996</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">42,411</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,285,326</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Services</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,162,526</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">54,918</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,910</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,273,354</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Revenues</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,295,269</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,262,015</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">426,228</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">130,977</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,114,489</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>North </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>America</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Africa</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>EMESA*</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Asia</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">License fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">842,307</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">46,922</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">72,809</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">962,038</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Hardware</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">267,996</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">144,647</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">29,873</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">442,516</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Services</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,296,696</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">44,228</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">68,196</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23,108</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,432,228</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Revenues</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,406,999</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">44,228</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">259,765</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">125,790</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,836,782</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">* EMESA – Europe, Middle East, South America</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">Revenue recognized during the year ended <em style="font: inherit;"> December 31, 2021 </em>from amounts included in deferred revenue at the beginning of the year was approximately $529,000. Revenue recognized during the year ended <em style="font: inherit;"> December 31, 2020 </em>from amounts included in deferred revenue at the beginning of the year was approximately $290,000. The Company did <em style="font: inherit;">not</em> recognize any revenue from performance obligations satisfied in prior periods. Total deferred revenue (contract liability) was $632,655 and $702,336 at <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><b><i>Transaction Price Allocated to the Remaining Performance Obligations</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">ASC <em style="font: inherit;">606</em> requires that the Company disclose the aggregate amount of transaction price that is allocated to performance obligations that have <em style="font: inherit;">not</em> yet been satisfied as at <em style="font: inherit;"> December 31, 2021. </em>The guidance provides certain practical expedients that limit this requirement, which the Company’s contracts meet as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The performance obligation is part of a contract that has an original expected duration of <em style="font: inherit;">one</em> year or less, in accordance with ASC <em style="font: inherit;">606</em>-<em style="font: inherit;">10</em>-<em style="font: inherit;">50</em>-<em style="font: inherit;">14.</em></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">Deferred revenue represents the Company’s remaining performance obligations related to prepaid support and maintenance, all of which is expected to be recognized from <em style="font: inherit;">one</em> to <em style="font: inherit;">five</em> years.</p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>North </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>America</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Africa</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>EMESA*</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Asia</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">License fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,854,088</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">521,751</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">105,314</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">74,656</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,555,809</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Hardware</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">278,655</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">698,264</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">265,996</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">42,411</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,285,326</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Services</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,162,526</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">54,918</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,910</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,273,354</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Revenues</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,295,269</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,262,015</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">426,228</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">130,977</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,114,489</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>North </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>America</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Africa</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>EMESA*</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Asia</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">License fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">842,307</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">46,922</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">72,809</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">962,038</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Hardware</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">267,996</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">144,647</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">29,873</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">442,516</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Services</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,296,696</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">44,228</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">68,196</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23,108</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,432,228</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Revenues</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,406,999</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">44,228</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">259,765</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">125,790</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,836,782</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody> </table> 1854088 521751 105314 74656 2555809 278655 698264 265996 42411 1285326 1162526 42000 54918 13910 1273354 3295269 1262015 426228 130977 5114489 842307 0 46922 72809 962038 267996 0 144647 29873 442516 1296696 44228 68196 23108 1432228 2406999 44228 259765 125790 2836782 529000 290000 632655 702336 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><b>NOTE C</b>—<b>PISTOLSTAR, INC. ACQUISITION</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">On <em style="font: inherit;"> June 30, 2020, </em>the Company acquired PistolStar, Inc., a private company based in the United States, which provides enterprise-ready identity access management solutions, including multi-factor authentication, identity-as-a-service, single sign-on and self-service password reset to commercial, government and education customers throughout the United States and internationally.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">From <em style="font: inherit;"> April 10, 2020 </em>until the Company acquired PistolStar, it licensed PortalGuard®, PistolStar’s authentication software, which the Company combines with its biometric authentication solutions offered to existing and prospective customers.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">The total purchase price of $2.5 million included cash payment of $2.0 million and the issuance of a <span style="-sec-ix-hidden:c82797418">$500,000</span> promissory note.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 5pt; text-indent: 32pt;">The acquisition of PistolStar was accounted for as a business combination and, in accordance with ASC <em style="font: inherit;">805,</em> the Company recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The following table summarizes the final purchase price allocation:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 36pt;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Purchase consideration:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total cash paid, net of acquired cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,000,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Present value of <span style="-sec-ix-hidden:c82797429">4</span>% Promissory note</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">464,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total purchase price consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,464,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fair value of assets acquired and liabilities assumed:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">100,747</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">184,792</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9,485</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fixed assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">36,467</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,480,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,262,526</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total assets acquired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,074,017</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued expenses and other current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">738</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued payroll</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,279</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">590,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total fair value of assets acquired and liabilities assumed</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,464,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">The promissory note accrued interest at 4% per annum and was payable in <span style="-sec-ix-hidden:c82797421">four</span> installments over the 12-month period following the closing. The balance of the note at <em style="font: inherit;"> December 31, 2020 </em>was $232,000, net of the unamortized debt discount. On <em style="font: inherit;"> January 21, 2021, </em>the Company paid the $250,000 balance due on the note.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">The fair value of the assets acquired and liabilities assumed was less than the purchase price, resulting in the recognition of goodwill. The goodwill reflected the value of the synergies the Company expected to realize and the assembled workforce.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 5pt; text-indent: 32pt;">The significant intangible assets identified in the purchase price allocation discussed above include the trade name, proprietary software, and customer relationships. To value the trade name and proprietary software, the Company utilized the Relief from Royalty Method, which quantifies the cost savings associated with asset ownership via a discounted cash flow analysis. To value the customer relationships, the Company utilized the Excess Earnings Method, which isolates the value of the specific intangible asset by discounting its income stream to present value. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 5pt; text-indent: 32pt;">The fair value of the assets acquired and liabilities assumed reflected in the tables above is less than the purchase price, resulting in the recognition of goodwill. The goodwill reflects the value of the synergies the Company expects to realize and the assembled workforce.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 5pt; text-align: justify; text-indent: 32pt;">The following table presents the final fair values and useful lives of the identifiable intangible assets acquired:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%; margin-left: 18pt; margin-right: auto;"> <tbody> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 71%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="vertical-align: bottom; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Estimated useful</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>life</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in years)</b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom; width: 71%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Trade Name</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">$</p> </td> <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">130,000</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td> <td style="vertical-align: bottom; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">15</p> </td> <td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="vertical-align: bottom; width: 71%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Proprietary Software</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">420,000</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td> <td style="vertical-align: bottom; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5</p> </td> <td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom; width: 71%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer relationships</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">930,000</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">8</p> </td> <td style="vertical-align: bottom; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">-</p> </td> <td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="vertical-align: bottom; width: 71%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total identifiable intangible assets</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">$</p> </td> <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">1,480,000</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td> <td style="vertical-align: bottom; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td> <td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 2500000 2000000.0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 36pt;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Purchase consideration:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total cash paid, net of acquired cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,000,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Present value of <span style="-sec-ix-hidden:c82797429">4</span>% Promissory note</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">464,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total purchase price consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,464,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fair value of assets acquired and liabilities assumed:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">100,747</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">184,792</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9,485</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fixed assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">36,467</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,480,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,262,526</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total assets acquired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,074,017</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued expenses and other current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">738</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued payroll</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,279</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">590,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total fair value of assets acquired and liabilities assumed</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,464,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 2000000 464000 2464000 100747 184792 9485 36467 1480000 1262526 3074017 738 19279 590000 2464000 0.04 P12M 232000 250000 <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%; margin-left: 18pt; margin-right: auto;"> <tbody> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 71%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="3" style="vertical-align: bottom; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Estimated useful</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>life</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in years)</b></p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom; width: 71%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Trade Name</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">$</p> </td> <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">130,000</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td> <td style="vertical-align: bottom; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">15</p> </td> <td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="vertical-align: bottom; width: 71%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Proprietary Software</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">420,000</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td> <td style="vertical-align: bottom; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5</p> </td> <td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom; width: 71%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer relationships</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">930,000</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">8</p> </td> <td style="vertical-align: bottom; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">-</p> </td> <td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="vertical-align: bottom; width: 71%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total identifiable intangible assets</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">$</p> </td> <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">1,480,000</p> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td> <td style="vertical-align: bottom; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td> <td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td> <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> </tbody> </table> 130000 P15Y 420000 P5Y 930000 P8Y P10Y 1480000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><b>NOTE D</b>—<b>FACTORING</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;">Due from factor consisted of the following as of <em style="font: inherit;"> December 31:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Original Invoice</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Value</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Factored</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Amount</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Factored</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance due</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><i>Year Ended December 31, 2021</i></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Factored accounts receivable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">99,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">49,500</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">49,500</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><i>Year Ended December 31, 2020</i></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Factored accounts receivable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">241,715</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">181,262</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">60,453</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company entered into an accounts receivable factoring arrangement with a financial institution (the “Factor”) which has been extended to <em style="font: inherit;"> October 31, </em><em style="font: inherit;">2022.</em> Pursuant to the terms of the arrangement, the Company, from time to time, sells to the Factor a minimum of $150,000 per quarter of certain of its accounts receivable balances on a non-recourse basis for credit approved accounts. The Factor remits 35% of the foreign and 75% of the domestic accounts receivable balance to the Company (the “Advance Amount”), with the remaining balance, less fees, forwarded to the Company once the Factor collects the full accounts receivable balance from the customer. In addition, the Company, from time to time, receives over advances from the Factor. Factoring fees range from 2.75% to 15% of the face value of the invoice factored and are determined by the number of days required for collection of the invoice. The cost of factoring is included in selling, general and administrative expenses. The cost of factoring was as follows:  </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Years Ended December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Factoring fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">50,132</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">98,748</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Original Invoice</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Value</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Factored</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Amount</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Factored</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance due</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><i>Year Ended December 31, 2021</i></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Factored accounts receivable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">99,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">49,500</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">49,500</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><i>Year Ended December 31, 2020</i></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Factored accounts receivable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">241,715</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">181,262</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">60,453</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> 99000 49500 49500 241715 181262 60453 150000 0.35 0.75 0.0275 0.15 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Years Ended December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Factoring fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">50,132</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">98,748</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> 50132 98748 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><b>NOTE E</b>—<b>FAIR VALUES OF FINANCIAL INSTRUMENTS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Cash and cash equivalents, accounts receivable, due from factor, accounts payable and accrued liabilities are carried at, or approximate, fair value because of their short-term nature. The carrying value of the Company’s notes and loan payables approximated fair value as the interest rates related to the financial instruments approximated market.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><b>NOTE F</b>—<b>CONCENTRATION OF RISK</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Financial instruments which potentially subject the Company to risk primarily consist of cash, and cash equivalents, investment in debt security, and accounts receivables.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company maintains its cash and cash equivalents with various financial institutions, which, at times <em style="font: inherit;"> may </em>exceed insured limits. The exposure to the Company is solely dependent upon daily bank balances and the respective strength of the financial institutions. The Company was in excess of coverage of approximately $7,057,000 and $16,020,000 at <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively. The Company has <em style="font: inherit;">not</em> incurred any losses on these accounts.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company extends credit to customers on an unsecured basis in the normal course of business. The Company’s policy is to perform an analysis of the recoverability of its receivables at the end of each reporting period and to establish allowances where appropriate. The Company analyzes historical bad debts and contract losses, customer concentrations, and customer credit-worthiness when evaluating the adequacy of the allowances.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 5pt; text-indent: 18pt;">For the year ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> <span style="-sec-ix-hidden:c82797480">one</span> customer accounted for 13% and 18% of total revenue, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 5pt; text-align: justify; text-indent: 18pt;">Three customers accounted for 87% and <span style="-sec-ix-hidden:c82797485">one</span> customer accounted for 31% of total accounts receivable, as of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively.</p> 7057000 16020000 0.13 0.18 0.87 0.31 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><b>NOTE G</b>—<b>NOTE RECEIVABLE</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 5pt; text-align: justify; text-indent: 18pt;">During the <em style="font: inherit;">third</em> quarter <em style="font: inherit;">2020,</em> the Company loaned $295,000 as an advance to Technology Transfer Institute (“TTI”) to aid in fulfilling the African contracts. The note does <em style="font: inherit;">not</em> bear any interest if paid within the <em style="font: inherit;">nine</em> (<em style="font: inherit;">9</em>) monthly installments beginning <em style="font: inherit;"> December 31, 2020. </em>The note bears a default rate of 5%. Due to the ongoing delays in payment, the Company reserved $100,000 of the note as an allowance. On <em style="font: inherit;"> February 17, 2022, </em>the Company amended the note to modify the payment terms to provide for lower monthly payments, with an updated maturity date on, or before <em style="font: inherit;"> December 6, 2023. </em>A member of our board of directors served as Chief Executive Officer off TTI until <em style="font: inherit;"> August 12, 2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 9pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>December 31,</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>December 31,</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>2021</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>2020</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Note receivable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">295,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">295,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Allowance for doubtful account</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(100,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Note receivable, net of allowance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">195,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">295,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Current portion, net of allowance</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">82,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">295,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Noncurrent portion, net of allowance</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">113,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 295000 0.05 100000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 9pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>December 31,</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>December 31,</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>2021</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>2020</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Note receivable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">295,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">295,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Allowance for doubtful account</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(100,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Note receivable, net of allowance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">195,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">295,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Current portion, net of allowance</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">82,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">295,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Noncurrent portion, net of allowance</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">113,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 295000 295000 100000 -0 195000 295000 82000 295000 113000 0 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><b>NOTE H</b>—<b>INVENTORY</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Inventory is stated at the lower of cost, determined on a <em style="font: inherit;">first</em> in, <em style="font: inherit;">first</em> out basis, or realizable value, and consists primarily of fabricated assemblies and finished goods. Inventory is comprised of the following as of <em style="font: inherit;"> December 31: </em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2020</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finished goods</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,798,203</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">221,130</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fabricated assemblies</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">142,457</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">109,817</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total inventory</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,940,660</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">330,947</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2020</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finished goods</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,798,203</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">221,130</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fabricated assemblies</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">142,457</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">109,817</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total inventory</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,940,660</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">330,947</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody> </table> 4798203 221130 142457 109817 4940660 330947 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><b>NOTE I</b>—<b>RESALABLE SOFTWARE LICENSES</b> <b>RIGHTS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 5pt; text-indent: 18pt;">On <em style="font: inherit;"> December 31, 2015, </em>the Company purchased <em style="font: inherit;">third</em>-party software licenses in the amount of $180,000 in anticipation of a large pending deployment that has yet to materialize. The Company is amortizing the total cost at the greater of the actual unit cost per license sold or straight line amortization over 10 years. A total of $10,130 and $14,920 was charged to cost of sales during the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively. Since the license purchase, the actual per unit cost (actual usage) of such license rights in the cumulative amount of $131,248 has been charged to cost of sales, with a carrying balance of $48,752 and $58,882 as of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company has classified the balance as non-current until a larger deployment occurs.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Estimated minimum amortization expense based on straight line amortization of the software license rights over the remaining useful life approximates the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Years ending December 31</span></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">18,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">18,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,752</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">48,752</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 180000 P10Y 10130 14920 131248 48752 58882 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Years ending December 31</span></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">18,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">18,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,752</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">48,752</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 18000 18000 12752 48752 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><b>NOTE J</b>—<b>INVESTMENT IN DEBT SECURITY</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:16pt;">During <em style="font: inherit;">2019,</em> the Company purchased a 4,000,000 Hong Kong dollar denominated Bond Certificate with a financial institution in Hong Kong. The Bond Certificate translated to $512,821 U.S. Dollars on the <em style="font: inherit;"> June 2019 </em>purchase date. The bond had a <span style="-sec-ix-hidden:c82797539">one</span>-year term which matured in <em style="font: inherit;"> June 2020, </em>bearing interest at 5% per annum. The Company redeemed the bond and recorded interest income of approximately $25,800.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:13pt;">The Company then purchased a new 4,000,000 Hong Kong dollar denominated Bond Certificate with a financial institution in Hong Kong in <em style="font: inherit;"> June 2020. </em>The new Bond Certificate translated to $512,821 U.S. Dollars, based on the exchange rate at the purchase date. The Company can invest up to 20,000,000 Hong Kong dollars under the terms of the certificate, bearing interest at 5% per annum. The investment is recorded at amortized cost which approximates fair value was held to maturity. The Company has yet to receive the proceeds and accrued interest from the investment. The Company has sent a legal letter of demand to confirm the status of the bond, and as such, the debt security was classified as noncurrent. In addition, due to the delay in the receipt of the proceeds, the Company recorded a $60,000 reserve.</p> 4000000 512821 0.05 25800 4000000 512821 20000000 0.05 60000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><b>NOTE K</b>—<b>EQUIPMENT AND LEASEHOLD IMPROVEMENTS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Equipment and leasehold improvements consisted of the following as of <em style="font: inherit;"> December </em><em style="font: inherit;">31:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">831,784</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">789,760</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and fixtures</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">164,079</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">164,079</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Software</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">32,045</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">32,045</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,135</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,135</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,053,043</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,011,019</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less accumulated depreciation and amortization</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(983,875</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(929,226</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">69,168</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">81,793</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Depreciation was $54,649 and $85,751 for <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively. Amounts are recorded in selling, general, and administrative expense as well as in cost of services.</p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">831,784</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">789,760</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and fixtures</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">164,079</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">164,079</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Software</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">32,045</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">32,045</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,135</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,135</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,053,043</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,011,019</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less accumulated depreciation and amortization</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(983,875</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(929,226</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">69,168</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">81,793</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 831784 789760 164079 164079 32045 32045 25135 25135 1053043 1011019 983875 929226 69168 81793 54649 85751 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><b>NOTE L</b>—<b>INTANGIBLE ASSETS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;">Intangible assets consisted of the following as of <em style="font: inherit;"> December </em><em style="font: inherit;">31:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b><b>2021</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b><b>12/31/21</b></b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2020</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>12/31/20 </b><b> </b></b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Gross</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Carrying</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Amount</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Accumulated</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Amortization</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Net</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Carrying</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Amount</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Gross</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Carrying</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Amount</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Accumulated</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Amortization</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Net</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Carrying</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b><b style="font-size: 10pt;"> </b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Trade name</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">130,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(12,960</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">117,040</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">130,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(4,333</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">125,667</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Proprietary software</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">420,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(126,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">294,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">420,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(42,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">378,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Customer relationships</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">930,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(155,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">775,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">930,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(51,667</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">878,333</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Patents and patents pending</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">365,080</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(253,043</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">112,037</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">365,080</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(232,934</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">132,146</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,845,080</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(547,003</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,298,077</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,845,080</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(330,934</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,514,146</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Aggregate amortization expense for <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> was approximately $216,000 and $120,000, respectively. Estimated minimum amortization expense based on straight line amortization of the software license rights for each of the next <em style="font: inherit;">five</em> years and thereafter approximates the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Years ending December 31</span></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">215,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">213,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">209,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">2025</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">165,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 27pt; text-indent: -9pt;">2026</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">121,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Thereafter</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">375,077</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,298,077</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b><b>2021</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b><b>12/31/21</b></b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2020</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>12/31/20 </b><b> </b></b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Gross</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Carrying</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Amount</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Accumulated</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Amortization</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Net</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Carrying</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Amount</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Gross</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Carrying</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Amount</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Accumulated</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Amortization</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Net</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Carrying</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b><b style="font-size: 10pt;"> </b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Trade name</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">130,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(12,960</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">117,040</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">130,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(4,333</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">125,667</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Proprietary software</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">420,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(126,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">294,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">420,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(42,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">378,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Customer relationships</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">930,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(155,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">775,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">930,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(51,667</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">878,333</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Patents and patents pending</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">365,080</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(253,043</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">112,037</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">365,080</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(232,934</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">132,146</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,845,080</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(547,003</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,298,077</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,845,080</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(330,934</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,514,146</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 130000 12960 117040 130000 4333 125667 420000 126000 294000 420000 42000 378000 930000 155000 775000 930000 51667 878333 365080 253043 112037 365080 232934 132146 1845080 547003 1298077 1845080 330934 1514146 216000 120000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Years ending December 31</span></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">215,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">213,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">209,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">2025</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">165,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 27pt; text-indent: -9pt;">2026</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">121,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Thereafter</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">375,077</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,298,077</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 215000 213000 209000 165000 121000 375077 1298077 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><b>NOTE M</b>—<b>ACCRUED LIABILITIES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;">Accrued liabilities consisted of the following as of <em style="font: inherit;"> December </em><em style="font: inherit;">31:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Compensation</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">254,433</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">87,015</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Compensated absences</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">293,297</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">227,147</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued legal and accounting fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">95,738</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">83,738</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Franchise taxes</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">40,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Employee expenses reimbursement</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">76,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">67,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Sales tax payable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">18,548</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17,544</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Factoring fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">495</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,495</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">50,486</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,548</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">828,997</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">508,487</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Compensation</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">254,433</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">87,015</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Compensated absences</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">293,297</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">227,147</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued legal and accounting fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">95,738</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">83,738</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Franchise taxes</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">40,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Employee expenses reimbursement</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">76,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">67,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Sales tax payable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">18,548</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17,544</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Factoring fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">495</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,495</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">50,486</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,548</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">828,997</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">508,487</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 254433 87015 293297 227147 95738 83738 40000 0 76000 67000 18548 17544 495 5495 50486 20548 828997 508487 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><b>NOTE N</b>—<b>RELATED PARTY TRANSACTIONS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><b>Non-Interest-Bearing Advances</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">During the <em style="font: inherit;">2019</em> fiscal year, the Company received a series of non-interest-bearing advances from Mr. Wong Kwok Fong, and Mr. Michael DePasquale, to pay current liabilities. The balance of the advances as at <em style="font: inherit;"> December 31, 2019 </em>was $74,737 and $114,000, respectively, which were both repaid in full during <em style="font: inherit;">2020.</em></p> 74737 114000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>NOTE O</b>—<b>CONVERTIBLE NOTES PAYABLE</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:29pt;">There was <em style="font: inherit;">no</em> balance outstanding for convertible notes payable as of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020.</em> Details for Notes that were either converted or redeemed during the <em style="font: inherit;">2020</em> fiscal year were as follows: </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><span style="text-decoration: underline; ">Securities Purchase Agreement dated <em style="font: inherit;"> July 10, 2019</em></span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:29pt;">On <em style="font: inherit;"> July 10, 2019, </em>the Company issued a $3,060,000 principal amount senior secured convertible note (the “Original Note”). At closing, a total of $2,550,000 was funded. The original issue discount was $510,000. The principal amount due of the Original Note was due and payable as follows: $918,000 was due <em style="font: inherit;">180</em> days after funding, $1,071,000 was due <em style="font: inherit;">270</em> days after funding, and the remaining balance due <em style="font: inherit;">12</em> months after the date of funding.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:29pt;">The Original Note was secured by a lien on substantially all of the Company’s assets and properties and was convertible at the option of the Investor in shares of common stock at a fixed conversion price of $12.00 per share.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:29pt;">In connection with the closing of the Original Note, the Company issued a <span style="-sec-ix-hidden:c82797647">five</span>-year warrant to the Investor to purchase 250,000 shares of common stock at a fixed exercise price of $12.00 per share, paid a $50,000 commitment fee, and issued 33,334 shares of common stock in payment of a $400,000 due diligence fee. The Company also paid banker fees of $193,500 and legal fees of $71,330. The valuation of the warrant of $595,662 was recorded to debt discount and was amortized over the life of the Original Note. The fees associated with the agreement were allocated to debt issuance costs and additional paid-in capital based on the respective ratio of the valuation of the note and warrant. Amortization of the debt issuance costs and debt discount are included in interest expense on the statement of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:29pt;">On <em style="font: inherit;"> March 12, 2020, </em>the Company issued a $3,789,000 principal amount senior secured convertible note (the “Amended Note”), which replaced the Original Note and included an additional $729,000 in interest due to the debt restructuring. The principal amount was due and payable in full on <em style="font: inherit;"> April 13, 2020. </em>The Amended Note was secured by a lien on substantially all of the Company’s assets and properties and was convertible at the option of the Investor into shares of common stock at a fixed conversion price of $5.20 per share. The Company accounted for the transaction as a debt extinguishment and, therefore, the balance of the fees and unamortized discount associated with the Original Note were written off and included as loss on extinguishment of debt. On the day of the amendment, the closing stock price for the day was $6.08, which resulted in a beneficial conversion of $0.88 per share outstanding or $641,215 to be amortized to interest expense over the term of the Amended Note, as adjusted for any debt conversion.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:29pt;">On <em style="font: inherit;"> April 12, 2020 </em>and <em style="font: inherit;"> May 6, 2020, </em>the Company entered into amendments (the “Amendments”) to the Amended Note. The Amendments extended the maturity date to <em style="font: inherit;"> June 12, 2020 </em>and extended the Investor’s right to convert the Amended Note into shares of the Company’s common stock at a price of $5.20 per share through <em style="font: inherit;"> June 12, 2020. </em>All other provisions of the Amended Note remained the same.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:29pt;">On <em style="font: inherit;"> June 10, 2020, </em>the investor converted the last of the remaining principal into shares of common stock for payment in full, and the remaining principal balance was $0. The Amended Note amount of $3,789,000 was converted into 728,654 shares of common stock in <em style="font: inherit;">2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><span style="text-decoration: underline; "><em style="font: inherit;"> January 2020 </em>Note</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:29pt;">On <em style="font: inherit;"> January 13, 2020, </em>the Company issued a $157,000 principal amount secured 10% convertible redeemable note (the <em style="font: inherit;"> “January 2020 </em>Note”) to an institutional investor with a maturity date of <em style="font: inherit;"> June 13, 2020 </em>which was convertible into common stock at a conversion price of $12.00 per share. At the closing, the Company agreed to issue 81,250 shares of common stock in lieu of payment of a $75,000 commitment fee which was reduced to 6,250 shares as the <em style="font: inherit;"> January 2020 </em>Note was repaid prior to the maturity date.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:29pt;">On <em style="font: inherit;"> June 12, 2020, </em>the <em style="font: inherit;"> January 2020 </em>Note was paid in full by payment of $211,984.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><span style="text-decoration: underline; "><em style="font: inherit;"> February 2020 </em>Note</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:29pt;">On <em style="font: inherit;"> February 13, 2020, </em>the Company issued a $126,000 principal amount secured 10% convertible redeemable note (the <em style="font: inherit;"> “February 2020 </em>Note”) to an institutional investor with a maturity date of <em style="font: inherit;"> July 13, 2020 </em>which was convertible into common stock at a conversion price of $9.20 per share.  On <em style="font: inherit;"> March 12, 2020, </em>the Original Note was amended to reduce the conversion price to $5.20 per share, which reduced the conversion price of the <em style="font: inherit;"> February </em>Note to <em style="font: inherit;">$5.20</em> and resulted in a deemed dividend of $70,998. The <em style="font: inherit;"> February 2020 </em>Note was redeemable at any time by payment of a premium to the principal balance starting at 10% and increasing to 30%.   The Company issued 6,250 shares of common stock to the investor in lieu of payment of a $57,500 commitment fee. The Company paid $6,000 of legal fees in connection with the issuance of <em style="font: inherit;"> February 2020 </em>Note.  The <em style="font: inherit;"> February 2020 </em>Note was paid in full on <em style="font: inherit;"> July 10, 2020 </em>by payment of $170,442.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><span style="text-decoration: underline; "><em style="font: inherit;"> May 2020 </em>Note</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:29pt;">On <em style="font: inherit;"> May 6, 2020, </em>the Company issued a $2,415,000 principal amount senior secured convertible note (the <em style="font: inherit;"> “May 2020 </em>Note”). At closing, $2,100,000 was funded. The principal amount was due and payable in <em style="font: inherit;">five</em> equal monthly installments of $268,333 beginning <em style="font: inherit;">seven</em> months after the funding date with the remaining balance due on the <em style="font: inherit;">twelfth</em> month after the date of funding. The <em style="font: inherit;"> May 2020 </em>Note was convertible at a fixed convertible price of $9.28 per share. In connection with the issuance of the <em style="font: inherit;"> May 2020 </em>Note, the Company paid a $133,333 due diligence fee by issuing 14,368 shares of common stock to the Investor priced at $9.28 per share. The Company also paid a placement fee of 7% of the gross proceeds to a placement agent. In connection with the closing of the <em style="font: inherit;"> May 2020 </em>Note, the Company issued a <span style="-sec-ix-hidden:c82797698">five</span>-year warrant to the investor to purchase 237,500 shares of common stock at a fixed exercise price of $9.28 and was immediately exercisable. The valuation of the warrant of $876,937 was recorded to debt discount and was amortized over the life of the <em style="font: inherit;"> May 2020 </em>Note. The fees associated with the agreement were allocated to debt issuance costs and additional paid-in-capital based on the respective ratio of the valuation of the note and warrant. Amortization of the debt issuance costs and debt discount were included in the interest expense on the statement of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:29pt;">Following the completion of the underwritten offering in <em style="font: inherit;"> July 2020, </em>the principal balance of $2,415,000 was paid in full during the <em style="font: inherit;">third</em> quarter of <em style="font: inherit;">2020.</em>  As a result of the repayment, the Company expensed the remaining debt discounts and issuance costs of $1,218,163 in <em style="font: inherit;"> July 2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><span style="text-decoration: underline; "><em style="font: inherit;"> June 2020 </em>Note</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:29pt;">On <em style="font: inherit;"> June 29, 2020, </em>the Company issued a $1,811,250 principal amount senior secured convertible note (the <em style="font: inherit;"> “June 2020 </em>Note”).  At closing, $1,575,000 was funded. The principal amount was due and payable in <em style="font: inherit;">nine</em> equal monthly installments of $201,250 beginning <em style="font: inherit;">four</em> months after the funding date with the remaining balance due on the <em style="font: inherit;">twelfth</em> month after the date of funding. The <em style="font: inherit;"> June 2020 </em>Note was convertible at a fixed convertible price of $9.28 per share. In connection with the issuance of the <em style="font: inherit;"> June 2020 </em>Note, the Company paid a $100,000 due diligence fee by issuing 17,071 shares to the Investor priced at $5.86 per share. The Company also paid a placement fee of 7% of the gross proceeds to a placement agent.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:29pt;">In connection with the closing of the <em style="font: inherit;"> June 2020 </em>Note, the Company issued a <span style="-sec-ix-hidden:c82797717">five</span>-year warrant to the Investor to purchase 178,125 shares of common stock at a fixed exercise price of $9.28 per share and was immediately exercisable. The valuation of the warrant of $511,402 was recorded to debt discount and is was amortized over the life of the <em style="font: inherit;"> June 2020 </em>Note. The fees associated with the agreement were allocated to debt issuance costs and additional paid-in capital based on the respective ratio of the valuation of the note and warrant. Amortization of the debt issuance costs and debt discount are included in interest expense on the statement of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:29pt;">Following the completion of the underwritten offering in <em style="font: inherit;"> July 2020, </em>the principal balance of $1,811,250 was paid in full during the <em style="font: inherit;">third</em> quarter of <em style="font: inherit;">2020.</em> As a result of the repayment, the Company expensed the remaining debt discounts and issuance costs of $957,919 in <em style="font: inherit;"> July 2020.</em></p> 3060000 2550000 510000 918000 1071000 12.00 250000 12.00 50000 33334 400000 193500 71330 595662 3789000 729000 5.20 6.08 0.88 641215 5.20 0 3789000 728654 157000 0.10 12.00 81250 75000 6250 211984 126000 0.10 9.20 5.20 70998 0.10 0.30 6250 57500 6000 170442 2415000 2100000 268333 9.28 133333 14368 9.28 0.07 237500 9.28 876937 2415000 1218163 1811250 1575000 201250 9.28 100000 17071 5.86 0.07 178125 9.28 511402 1811250 957919 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><b>NOTE P</b>—<b>LEASES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 5pt; text-align: justify; text-indent: 18pt;">The Company’s leases office space in New Jersey under a lease terminating in <em style="font: inherit;">2023</em> and Hong Kong, Minnesota, and New Hampshire with lease termination dates in <em style="font: inherit;">2022.</em> The property leased in China is paid monthly as used, without a formal agreement. The leases include non-lease components with variable payments. The following tables present the components of lease expense and supplemental balance sheet information related to the operating leases were:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b> </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Lease cost</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease cost</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">255,892</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">239,192</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Short-term lease cost</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total lease cost</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">255,892</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">239,192</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="4" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b><em style="font: inherit;">Balance sheet information</em></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><em style="font: inherit;"> </em></b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating right-of-use assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">254,100</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">487,325</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease liabilities, current portion</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">177,188</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">234,309</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease liabilities, non-current portion</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">86,974</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">264,163</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total operating lease liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">264,162</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">498,472</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average remaining lease term (in years) – operating leases</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.45</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.26</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average discount rate – operating leases</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.50</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.50</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</p> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Supplemental cash flow information related to leases were as follows:</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash paid for amounts included in the measurement of operating lease liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">256,977</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">235,186</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;">Maturities of operating lease liabilities were as follows as of December 31, 2021:</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">187,594</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;"> </em></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">89,225</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;"> </em></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total future lease payments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">276,819</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;"> </em></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: imputed interest</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(12,657</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;"> </em></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">264,162</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;"> </em></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b> </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Lease cost</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease cost</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">255,892</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">239,192</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Short-term lease cost</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total lease cost</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">255,892</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">239,192</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="4" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b><em style="font: inherit;">Balance sheet information</em></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><em style="font: inherit;"> </em></b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating right-of-use assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">254,100</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">487,325</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease liabilities, current portion</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">177,188</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">234,309</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease liabilities, non-current portion</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">86,974</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">264,163</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total operating lease liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">264,162</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">498,472</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average remaining lease term (in years) – operating leases</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.45</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.26</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average discount rate – operating leases</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.50</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.50</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</p> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Supplemental cash flow information related to leases were as follows:</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash paid for amounts included in the measurement of operating lease liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">256,977</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">235,186</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;">Maturities of operating lease liabilities were as follows as of December 31, 2021:</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">187,594</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;"> </em></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">89,225</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;"> </em></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total future lease payments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">276,819</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;"> </em></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: imputed interest</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(12,657</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;"> </em></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">264,162</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;"> </em></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 255892 239192 255892 239192 254100 487325 177188 234309 86974 264163 264162 498472 P1Y5M12D P2Y3M3D 0.0550 0.0550 256977 235186 187594 89225 276819 12657 264162 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>NOTE Q</b>—<b>COMMITMENTS AND CONTINGENCIES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"><span style="text-decoration: underline; ">Sales Incentive Agreement with TTI</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">On <em style="font: inherit;"> March 25, 2020, </em>the Company entered into a sales incentive agreement Technology Transfer Institute (“TTI”). Terms of the agreement include the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 27pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">1.</em></p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; margin: 0pt; font-size: 10pt; text-align: justify;">The original term of the agreement was <em style="font: inherit;">one</em> year and has been automatically extended for an additional <span style="-sec-ix-hidden:c82797765">one</span>-year term.</p> </td></tr> </tbody></table> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 27pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">2.</em></p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; margin: 0pt; font-size: 10pt; text-align: justify;">For each $5,000,000 in revenue (up to a maximum of $20,000,000) the Company generates from contracts sourced by TTI which are executed during the original term and generate net income of at least 20% (as defined) within <span style="-sec-ix-hidden:c82797770">eighteen</span> months after the date such contract is executed, the Company will pay TTI a sales incentive fee of $500,000 payable by the issuance of 62,500 shares of common stock.</p> </td></tr> </tbody></table> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 27pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">3.</em></p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; margin: 0pt; font-size: 10pt; text-align: justify;">In the event that the Company generates revenue in excess of <em style="font: inherit;">$20,000,000</em> from contracts sourced by TTI which are executed during the original term and generate net income of at least <em style="font: inherit;">20%</em> (as defined) within <em style="font: inherit;">eighteen</em> months after the date such contract is executed, the Company will issue TTI a <span style="-sec-ix-hidden:c82797777">five</span>-year warrant to purchase 12,500 shares of Common Stock at an exercise price of $12.00 per share for each <em style="font: inherit;">$1,000,000</em> of revenue in excess of <em style="font: inherit;">$20,000,000</em> (up to a maximum of $25,000,000).</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">In <em style="font: inherit;">no</em> event will the Company be obligated to issue more than 250,000 shares of common stock or warrants to purchase more than 62,500 shares of common stock pursuant to this agreement. </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">There has been <span style="-sec-ix-hidden:c82797786"><span style="-sec-ix-hidden:c82797787">no</span></span> revenue generated nor sales incentive fees paid during the periods ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"><span style="text-decoration: underline; ">Litigation</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">From time to time, we <em style="font: inherit;"> may </em>be involved in litigation relating to claims arising out of our operations in the normal course of business. As of <em style="font: inherit;"> December 31, 2021, </em>the Company was <em style="font: inherit;">not</em> a party to any pending lawsuits.</p> 5000000 20000000 0.20 500000 62500 12500 12.00 25000000 250000 62500 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>NOTE R</b>—<b> EQUITY</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><span style="text-decoration: underline; "><em style="font: inherit;">1.</em> Preferred Stock</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">Within the limits and restrictions provided in the Company’s Certificate of Incorporation, the Board of Directors has the authority, without further action by the shareholders, to issue up to 5,000,000 shares of preferred stock, $.0001 par value per share, in <em style="font: inherit;">one</em> or more series, and to fix, as to any such series, any dividend rate, redemption price, preference on liquidation or dissolution, sinking fund terms, conversion rights, voting rights, and any other preference or special rights and qualifications.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><span style="text-decoration: underline; "><em style="font: inherit;">2.</em> Common Stock</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">Effective <em style="font: inherit;"> November 20, 2020, </em>the Company implemented a reverse stock split of its outstanding common stock at a ratio of <em style="font: inherit;">1</em>-for-8. The number of authorized shares and the par value of the Company's common stock and preferred stock were <em style="font: inherit;">not</em> affected by the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares were rounded up to the nearest whole share. The reverse stock split became effective at the opening of trading on <em style="font: inherit;"> November 20, 2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">Holders of common stock have equal rights to receive dividends when, as and if declared by the Board of Directors, out of funds legally available therefor. Holders of common stock have <em style="font: inherit;">one</em> vote for each share held of record and do <em style="font: inherit;">not</em> have cumulative voting rights.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">Holders of common stock are entitled, upon liquidation of the Company, to share ratably in the net assets available for distribution, subject to the rights, if any, of holders of any preferred stock then outstanding. Shares of common stock are <em style="font: inherit;">not</em> redeemable and have <em style="font: inherit;">no</em> preemptive or similar rights. All outstanding shares of common stock are fully paid and nonassessable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><i><span style="text-decoration: underline; ">Issuances of Common Stock</span></i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 5pt; text-indent: 29pt;">On <em style="font: inherit;"> June 18, 2021, </em>the stockholders approved the Employee Stock Purchase Plan. Under the terms of this plan, 789,000 shares of common stock are reserved for issuance to employees and officers of the Company at 85% of the lower of the closing price of the common stock as reported on the Nasdaq Capital Market at the <em style="font: inherit;">first</em> day or the last day of the offering period. Eligible employees are granted an option to purchase shares under the plan funded by payroll deductions. The Board <em style="font: inherit;"> may </em>suspend or terminate the plan at any time, otherwise the plan expires <em style="font: inherit;"> June 17, 2031. </em>On <em style="font: inherit;"> December 31, 2021, </em>19,484 shares were issued to employees which resulted in a $10,680 non-cash compensation expense for the Company.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">On <em style="font: inherit;"> July 23, 2020, </em>the Company completed an underwritten public offering of shares of common stock and warrants resulting in net proceeds of approximately $22.7 million, after deducting underwriting discounts and commissions and estimated offering expenses. 4,264,313 shares of common stock were issued as a result of this offering, and a further 797,038 shares of common stock were issued upon the exercise of 512,500 prefunded warrants and 284,538 warrants exercised in conjunction with the offering.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">On <em style="font: inherit;"> March 30, 2020, </em>the Company issued 121,500 shares of common stock upon exercise of warrants at $12.00 per share, resulting in proceeds of $1,458,000 to the Company.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">See Note O Convertible Notes Payable for common stock issuances related to conversion of convertible notes payable and shares of common stock issued for fees in connection with the agreements during fiscal <em style="font: inherit;">2020.</em> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><i><span style="text-decoration: underline; ">Issuances of Restricted Stock</span></i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:29pt;">Restricted stock consists of shares of common stock that are subject to restrictions on transfer and risk of forfeiture until the fulfillment of specified conditions. The fair value of nonvested shares is determined based on the market price of the Company's common stock on the grant date. Restricted stock is expensed ratably over the term of the restriction period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:29pt;">The Company issued 13,125 shares of restricted common stock to certain employees of the Company and 1,250 of shares of restricted common stock were forfeited during fiscal year <em style="font: inherit;">2021.</em> These shares vest in equal annual installments over a <span style="-sec-ix-hidden:c82797821">three</span>-year period from the date of grant and had a fair value on the date of issuance of $44,025.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">The Company issued 38,250 and 3,125 shares of restricted common stock in <em style="font: inherit;"> August </em>and <em style="font: inherit;"> November </em>of <em style="font: inherit;">2020,</em> respectively to certain employees and directors of the Company. These shares vest in equal annual installments over a <em style="font: inherit;">three</em>-year period from the date of grant and had a fair value on the date of issuance of $198,900, and $11,250, respectively.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">Restricted stock compensation for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> was $71,819 and $23,764, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><i><span style="text-decoration: underline; ">Issuances to Directors, Executive Officers &amp; Consultants</span></i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">During the year ended <em style="font: inherit;"> December 31, 2021, </em>the Company issued 7,828 shares of common stock to its directors in lieu of payment of board fees, valued at $25,536.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">During the year ended <em style="font: inherit;"> December 31, 2020, </em>the Company issued 5,270 shares of common stock to its directors in lieu of payment of board fees, valued at $28,511.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><i><span style="text-decoration: underline; ">Employees</span></i><span style="text-decoration: underline; ">’</span><i><span style="text-decoration: underline; "> exercise options</span></i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 5pt; text-indent: 32pt;">During <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> <span style="-sec-ix-hidden:c82797838">no</span> employee stock options were exercised.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><span style="text-decoration: underline; "><em style="font: inherit;">3.</em> Warrants</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:29pt;">There were <span style="-sec-ix-hidden:c82797840">no</span> warrants issued during fiscal <em style="font: inherit;">2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><i>Warrants Issued for Services:</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">During the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2020,</em> the Company issued a warrant to purchase 15,625 shares of common stock to an investor in payment for a business referral valued at $94,655.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">During the <em style="font: inherit;">third</em> quarter of <em style="font: inherit;">2020,</em> the Company issued a warrant to purchase 3,125 shares of common stock to a former employee for a business referral valued at $12,921.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><i>Warrants Issued with Convertible Notes:</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:29pt;">See Note O Convertible Notes Payable for warrants issued with convertible notes in connection with the agreements during fiscal <em style="font: inherit;">2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><i>Valuation Assumptions for Warrants:</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company records the warrants at their fair value which is determined using the Black-Scholes valuation model on the date of the grant. The fair value of each warrant was estimated with the following assumptions:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average Risk free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.33</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average price</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9.25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average exercise period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average Volatility of stock price</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">110</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The warrant volatility for each issuance is determined based on the review of the experience of the weighted average of historical daily price changes of the Company’s common stock over the expected exercise period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the years to maturity.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">A summary of warrant activity is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Warrants</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>exercise</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>price</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>remaining</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>life</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in years)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Aggregate</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>intrinsic</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding, as of December 31, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">423,559</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12.80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.94</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted – public offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,264,313</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted – prefunded warrants from the public offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">512,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.08</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted – other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">434,375</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9.25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Increase due to trigger of anti-dilution provision feature</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">27,244</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised – public offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(284,538</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised – prefunded warranted from the public offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(512,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.08</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised – other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(121,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(54,066</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6.86</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding, as of December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,689,387</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding, as of December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,689,387</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 8pt; text-indent: 29pt;">The aggregate intrinsic value in the table above represents the total intrinsic value, based on the Company’s closing stock price of $2.21, $3.52 and $4.00 as of <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> respectively, which would have been received by the warrant holders had all warrant holders exercised their options as of that date. There were no in-the-money warrants exercisable as of <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020</em> and <em style="font: inherit;">2019.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><span style="text-decoration: underline; "><em style="font: inherit;">4.</em></span><span style="text-decoration: underline; "> </span><span style="text-decoration: underline; "> Securities Purchase Agreement dated <em style="font: inherit;"> September 23, 2015</em></span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:29pt;">On <em style="font: inherit;"> September 23, 2015, </em>the Company issued warrants (the <em style="font: inherit;">“2015</em> Warrants”) to purchase 8,681 shares of common stock in connection with the issuance of a promissory note. The warrants were immediately exercisable at an initial exercise price of $28.80 per share and had a term of <span style="-sec-ix-hidden:c82797865">five</span> years.  The <em style="font: inherit;">2015</em> Warrants expired in <em style="font: inherit;"> September 2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:29pt;">The <em style="font: inherit;">2015</em> Warrants had a “full ratchet” anti-dilution adjustment provision.  The anti-dilution adjustment provision was triggered in the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2020</em> from the <em style="font: inherit;"> February 2020 </em>Note and amendments to the Original Note. As a result of the forgoing transactions, the number of shares of common stock issuable upon the full exercise of the <em style="font: inherit;">2015</em> Warrants increased to 48,078, the exercise price was reduced to $5.20 per share, and the Company recorded a non-cash deemed dividend in amount of $41,688. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 5000000 1 8 789000 0.85 19484 10680 22.7 4264313 797038 512500 284538 121500 12.00 1458000 13125 1250 44025 38250 3125 198900 11250 71819 23764 7828 25536 5270 28511 15625 94655 3125 12921 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average Risk free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.33</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average price</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9.25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average exercise period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average Volatility of stock price</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">110</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> </tbody></table> 0 0.0033 0 9.25 0 5 0 1.10 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Warrants</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>exercise</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>price</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>remaining</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>life</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in years)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Aggregate</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>intrinsic</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding, as of December 31, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">423,559</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12.80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.94</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted – public offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,264,313</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted – prefunded warrants from the public offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">512,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.08</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted – other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">434,375</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9.25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Increase due to trigger of anti-dilution provision feature</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">27,244</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised – public offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(284,538</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised – prefunded warranted from the public offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(512,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.08</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised – other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(121,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(54,066</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6.86</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding, as of December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,689,387</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding, as of December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,689,387</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 423559 12.80 P3Y11M8D 4264313 5.20 512500 0.08 434375 9.25 27244 5.20 -284538 5.20 -512500 0.08 -121500 12.00 -0 0 54066 6.86 4689387 6.04 P4Y5M23D 0 0 -0 0 -0 0 -0 0 4689387 6.04 P3Y5M23D 2.21 3.52 4.00 0 8681 28.80 48078 5.20 41688 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>NOTE S</b>—<b>STOCK OPTIONS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"><em style="font: inherit;">2004</em><i> Stock Option Plan</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">On <em style="font: inherit;"> October </em><em style="font: inherit;">12,</em> <em style="font: inherit;">2004,</em> the Board of Directors of the Company approved the <em style="font: inherit;">2004</em> Stock Option Plan (the <em style="font: inherit;">“2004</em> Plan”). The <em style="font: inherit;">2004</em> Plan was <em style="font: inherit;">not</em> presented to stockholders for approval and thus incentive stock options were <em style="font: inherit;">not</em> available under this plan. Under the terms of this plan, 20,834 shares of common stock were reserved for issuance to employees, officers, directors, and consultants of the Company at exercise prices which <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be below 85% of fair market value. The term of stock options granted <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> exceed <span style="-sec-ix-hidden:c82797971">ten</span> years. Options issued under the <em style="font: inherit;">2004</em> Plan vest pursuant to the terms of stock option agreements with the recipients. In the event of a change in control, as defined, all options outstanding vest immediately. The <em style="font: inherit;">2004</em> Plan expired in <em style="font: inherit;"> October </em><em style="font: inherit;">2014.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"><em style="font: inherit;">2015</em><i> Stock Option Plan</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 5pt; text-indent: 18pt;">On <em style="font: inherit;"> January 27, 2016, </em>the stockholders approved the <em style="font: inherit;">2015</em> Equity Incentive Plan (the <em style="font: inherit;">“2015</em> Plan”). The <em style="font: inherit;">2015</em> Plan initially reserved 187,500 shares of common stock for issuance of options, restricted stock, and other equity based awards to employees, officers, directors, and consultants of the Company. In <em style="font: inherit;">2019,</em> the stockholders approved an amendment to the <em style="font: inherit;">2015</em> Plan which increases the number of shares of common stock authorized for issuance under the <em style="font: inherit;">2015</em> Plan from 83,334 shares to 187,500 shares and also effected certain changes in light of the Tax Cuts and Jobs Act of <em style="font: inherit;">2017</em> and its impact on Section <em style="font: inherit;">162</em>(m) of the United States Internal Revenue Code of <em style="font: inherit;">1986,</em> as amended. In <em style="font: inherit;">2021,</em> the stockholders approved an amendment to the <em style="font: inherit;">2015</em> to increase the shares of common stock authorized for issuance under the <em style="font: inherit;">2015</em> Plan from <em style="font: inherit;">187,500</em> shares to 789,000 shares together with other technical changes. In <em style="font: inherit;">2021,</em> the stockholders approved an amendment to the <em style="font: inherit;">2015</em> to increase the shares of common stock authorized for issuance under the <em style="font: inherit;">2015</em> Plan from <em style="font: inherit;">187,500</em> shares to <em style="font: inherit;">789,000</em> shares together with other technical changes.  The term of stock options granted under the <em style="font: inherit;">2015</em> Plan, <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> exceed <span style="-sec-ix-hidden:c82797991">ten</span> years, exercise prices <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be below 100-110% of fair market value, and vesting occurs over time periods set forth in written agreements with the recipients. In the event of a change in control, certain stock awards issued under the <em style="font: inherit;">2015</em> Plan <em style="font: inherit;"> may </em>be subject to additional acceleration of vesting as <em style="font: inherit;"> may </em>be provided in the participants’ written agreement. The <em style="font: inherit;">2015</em> Plan expires in <em style="font: inherit;"> December 2025.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"><i>Non-Plan Stock Options</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Periodically, the Company has granted options outside of the <em style="font: inherit;">2004</em> and <em style="font: inherit;">2015</em> Plans to various employees and consultants. In the event of change in control, as defined, certain of the non-plan options outstanding vest immediately.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"><i>Stock Option Activity</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Information summarizing option activity is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Number of Options</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Weighted</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>average</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Weighted </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>average</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>remaining</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Aggregate</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2004 </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Plan</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2015 </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Plan</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Non </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Plan</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Total</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>exercise</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>price</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>life</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>(in years)</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>intrinsic</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>value</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 30%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Outstanding, as of December 31, 2019</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>3,906</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>70,991</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>144,070</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>218,967</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>20.08</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b><em style="font: inherit;">5.00</em></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b><em style="font: inherit;">0</em></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">28,440</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">28,440</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(4,545</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(4,545</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17.34</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,906</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(703</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(10,979</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15,588</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">29.17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Outstanding, as of December 31, 2020</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>94,183</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>133,091</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>227,274</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>17.61</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>3.87</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>0</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">‐—</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(3,291</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(3,291</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.87</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(84</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11,438</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11,522</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39.13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Outstanding, as of December 31, 2021</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>90,808</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>121,653</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>212,461</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>16.65</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>3.03</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>0</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Vested or expected to vest at December 31, 2021</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"><b> </b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>206,283</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>16.98</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>2.95</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>0</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Exercisable at December 31, 2021</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"><b> </b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>186,538</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>18.04</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>2.73</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>0</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The options outstanding and exercisable at <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> were in the following exercise price ranges:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Options Outstanding</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Options Exercisable</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td colspan="4" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Range of exercise prices</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>shares</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>exercise</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>price</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>remaining </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>life (in years)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>exercisable</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>exercise</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>price</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.08</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">24,940</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.64</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">8,402</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.21</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">15.68</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">49,669</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12.17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.79</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">40,284</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12.85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">15.69</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">39.36</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">137,852</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">20.34</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.27</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">137,852</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">20.34</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.08</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">39.36</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">212,461</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">186,538</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The aggregate intrinsic value in the table above represents the total intrinsic value, based on the Company’s closing stock price of $2.21, $3.52 and $4.00 as of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> respectively, which would have been received by the option holders had all option holders exercised their options as of that date. There were no in-the-money options exercisable as of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 5pt; text-align: justify; text-indent: 18pt;">The weighted average fair value of options granted during the year ended <em style="font: inherit;"> December 31, 2020 </em>was $3.16 per share. The total intrinsic value of options exercised during the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> was $0 as no options were exercised in either year. The total fair value of shares vested during the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> was $252,874 and $899,750, respectively.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">As of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> future forfeiture adjusted compensation cost related to nonvested stock options is $75,035 and will be recognized over an estimated weighted average period of 0.86 years.</p> 20834 0.85 187500 83334 187500 789000 1 1.10 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Number of Options</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Weighted</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>average</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Weighted </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>average</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>remaining</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Aggregate</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2004 </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Plan</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2015 </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Plan</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Non </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Plan</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Total</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>exercise</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>price</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>life</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>(in years)</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>intrinsic</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>value</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 30%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Outstanding, as of December 31, 2019</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>3,906</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>70,991</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>144,070</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>218,967</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>20.08</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b><em style="font: inherit;">5.00</em></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b><em style="font: inherit;">0</em></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">28,440</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">28,440</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(4,545</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(4,545</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17.34</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,906</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(703</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(10,979</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15,588</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">29.17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Outstanding, as of December 31, 2020</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>94,183</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>133,091</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>227,274</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>17.61</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>3.87</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>0</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">‐—</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(3,291</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(3,291</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.87</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(84</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11,438</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11,522</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39.13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Outstanding, as of December 31, 2021</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>90,808</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>121,653</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>212,461</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>16.65</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>3.03</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>0</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Vested or expected to vest at December 31, 2021</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"><b> </b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>206,283</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>16.98</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>2.95</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>0</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Exercisable at December 31, 2021</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"><b> </b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>186,538</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>18.04</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>2.73</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>0</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 3906 70991 144070 218967 20.08 0 28440 0 28440 5.04 -0 -0 -0 -0 0 -0 4545 -0 4545 17.34 3906 703 10979 15588 29.17 0 94183 133091 227274 17.61 P3Y10M13D 0 0 0 0 0 -0 -0 -0 -0 0 -0 3291 -0 3291 3.87 -0 84 11438 11522 39.13 0 90808 121653 212461 16.65 P3Y10D 0 206283 16.98 P2Y11M12D 0 186538 18.04 P2Y8M23D 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Options Outstanding</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Options Exercisable</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td colspan="4" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Range of exercise prices</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>shares</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>exercise</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>price</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>remaining </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>life (in years)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>exercisable</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>exercise</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>price</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.08</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">24,940</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.64</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">8,402</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.21</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">15.68</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">49,669</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12.17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.79</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">40,284</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12.85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">15.69</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">39.36</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">137,852</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">20.34</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.27</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">137,852</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">20.34</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.08</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">39.36</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">212,461</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">186,538</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td></tr> </tbody></table> 5.20 24940 5.19 P5Y7M20D 8402 5.17 15.68 49669 12.17 P3Y9M14D 40284 12.85 39.36 137852 20.34 P2Y3M7D 137852 20.34 39.36 212461 186538 2.21 3.52 4.00 0 3.16 0 0 252874 899750 75035 P0Y10M9D <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>NOTE T</b>—<b>INCOME TAXES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">There was <span style="-sec-ix-hidden:c82798147"><span style="-sec-ix-hidden:c82798171">no</span></span> provision for federal or state taxes as at <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company has deferred taxes due to income tax credits, net operating loss carryforwards, and the effect of temporary differences between the carrying values of certain assets and liabilities for financial reporting and income tax purposes. Significant components of deferred taxes are as follows at <em style="font: inherit;"> December </em><em style="font: inherit;">31:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">135,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">81,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accounts receivable allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">75,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">474,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,149,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,073,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Basis differences in fixed assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(10,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(14,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Basis differences in intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">75,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">65,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net operating loss and credit carryforwards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">14,467,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">13,337,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowances</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15,891,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15,016,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company has a valuation allowance against the full amount of its net deferred taxes due to the uncertainty of realization of the deferred tax assets due to operating loss history of the Company. The Company currently provides a valuation allowance against deferred taxes when it is more likely than <em style="font: inherit;">not</em> that some portion, or all of its deferred tax assets will <em style="font: inherit;">not</em> be realized. The valuation allowance could be reduced or eliminated based on future earnings and future estimates of taxable income. Similarly, income tax benefits related to stock options exercised have <em style="font: inherit;">not</em> been recognized in the financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">As of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> the Company has federal net operating loss carryforwards of approximately $61 million. Approximately $46 million are subject to expiration between <em style="font: inherit;">2021</em> and <em style="font: inherit;">2037,</em> and $15 million net operating loss carryforwards have <em style="font: inherit;">no</em> expiration date. These net operating loss carryforwards are subject to the limitations under Section <em style="font: inherit;">382</em> of the Internal Revenue Code due to changes in the equity ownership of the Company.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">A reconciliation of the effective income tax rate on operations reflected in the Statements of Operations to the US Federal statutory income tax rate is presented below.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal statutory income tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Permanent differences</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effect of net operating loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(12</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effective tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company has <em style="font: inherit;">not</em> been audited by the Internal Revenue Service (“IRS”) or any states in connection with income taxes. The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The periods from 2018 through <em style="font: inherit;">2021</em> remain open to examination by the IRS and state jurisdictions. The Company believes it is <em style="font: inherit;">not</em> subject to any tax audit risk beyond those periods. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company does <span style="-sec-ix-hidden:c82798167"><span style="-sec-ix-hidden:c82798172">not</span></span> have any accrued interest or penalties associated with any unrecognized tax benefits, nor was any interest expense incurred during the years ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020.</em></p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">135,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">81,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accounts receivable allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">75,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">474,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,149,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,073,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Basis differences in fixed assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(10,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(14,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Basis differences in intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">75,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">65,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net operating loss and credit carryforwards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">14,467,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">13,337,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowances</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15,891,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15,016,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> 135000 81000 75000 474000 1149000 1073000 10000 14000 75000 65000 14467000 13337000 15891000 15016000 61000000 46000000 15000000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal statutory income tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Permanent differences</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effect of net operating loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(12</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effective tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> </tbody></table> 0.21 0.21 0 -0.09 -0.21 -0.12 0 0 2018 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>NOTE U</b>—<b>PROFIT SHARING PLAN</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company has established a savings plan under section <em style="font: inherit;">401</em>(k) of the Internal Revenue Code. All employees of the Company, after completing <em style="font: inherit;">one</em> day of service, are eligible to enroll in the <em style="font: inherit;">401</em>(k) plan. Participating employees <em style="font: inherit;"> may </em>elect to defer a portion of their salary on a pre-tax basis up to the limits as provided by the IRS Code. The Company is <em style="font: inherit;">not</em> required to match employee contributions but <em style="font: inherit;"> may </em>do so at its discretion. The Company made <span style="-sec-ix-hidden:c82798199"><span style="-sec-ix-hidden:c82798203">no</span></span> contributions during the years ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>NOTE V</b>—<b>EARNINGS PER SHARE (EPS)</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company’s basic EPS is calculated using net income (loss) available to common shareholders and the weighted-average number of shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuance of common stock, such as stock issuable pursuant to the exercise of stock options and warrants and the assumed conversion of preferred stock.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The reconciliation of the numerator of the basic and diluted EPS calculations for the following fiscal years ended <em style="font: inherit;"> December </em><em style="font: inherit;">31:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Basic Numerator:</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net Loss</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(5,065,781</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(9,673,987</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deemed dividend from trigger of anti-dilution provision feature</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(112,686</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss available to common stockholders (basic and diluted EPS)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(5,065,781</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(9,786,673</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The following table summarizes the weighted average securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive due to net losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Years ended December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock options</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,002</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted stock</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,098</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Potentially dilutive securities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,100</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Items excluded from the diluted per share calculation because the exercise price was greater than the average market price of the common shares:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Years ended December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock options</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">212,461</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">223,899</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Warrants</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,689,387</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,689,387</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,901,848</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,913,286</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Basic Numerator:</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net Loss</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(5,065,781</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(9,673,987</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deemed dividend from trigger of anti-dilution provision feature</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(112,686</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss available to common stockholders (basic and diluted EPS)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(5,065,781</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(9,786,673</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> </tbody> </table> -5065781 -9673987 -0 112686 -5065781 -9786673 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Years ended December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock options</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,002</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted stock</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,098</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Potentially dilutive securities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,100</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Years ended December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock options</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">212,461</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">223,899</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Warrants</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,689,387</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,689,387</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,901,848</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,913,286</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 0 1002 0 3098 0 4100 212461 223899 4689387 4689387 4901848 4913286 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>NOTE W</b>—<b>SUBSEQUENT EVENTS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 5pt; text-indent: 32pt;">On <em style="font: inherit;"> March 8, 2022, </em>the Company completed the acquisition of 100% of the issued and outstanding capital stock of Swivel Secure Europe, SA pursuant to the terms of a stock purchase agreement. The aggregate purchase price consisted of a base purchase price of $1.75 million, subject to closing adjustments based on the closing date working capital, indebtedness and unpaid transaction expenses, and an earn-out of up to $500,000. At the closing, the Company made a cash payment of $1.27 million and issued 269,060 shares of common stock of which 89,687 shares were held back by the Company to secure certain indemnification obligations under the stock purchase agreement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:32pt;">On <em style="font: inherit;"> March 10, 2022, </em>the Company issued 6,360 shares of common stock to its directors in payment of board fees. Additionally, the Company issued an aggregate of 848 shares of common stock to its directors in payment of board committee fees. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 5pt; text-indent: 32pt;">On <em style="font: inherit;"> March 11, 2022, </em>the Company issued 932 shares of common stock to its directors in payment of board committee fees. The Company issued an aggregate of 274,250 shares of restricted common stock to employees and the board of directors which vest in equal annual installments over a <span style="-sec-ix-hidden:c82798235">three</span>-year period from the date of grant.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 5pt; text-indent: 32pt;">The Company has reviewed subsequent events through the date of this filing. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 1 1750000 500000 1270000 269060 89687 6360 848 932 274250 EMEA - Europe, Middle East, Africa EXCEL 104 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
38UKG?)J-SX_5;Y+'TA6 Y 9)E*KZN(YE0,G^B?31 M=QSL/]Z$5#"A3]9]A9H;JHW"?P(D*V[1'*CQZ'"L_H?C%->] AP/"KL/(7BL M>:".1L?C?B@;.^APM S6>++K;S6AF] $$$.0WLX!HN8QIDASAY[?]6.) 4;# MT!9D)@+(GG9XQ-1#)2+4[AH*2C&?N-^DB!H5\4:T*C1%1*$H8)*=?#23( M++!"N.6;MI_3-XR\[_7@# EF15@MI>ON 2L?7G*8@#G2'4@\X9;%GQTP]/R1 M_)%OEZ]+!)>#.UU1HS,TS+TD?XQQC1H=!ZP,C2_,#IC*MPH_-URK?52/UI1< M^[@CW0F.*KU?!XZ)H/PM#+Y>!C=">+L6[YS<+]E0,WHH!,*['5'^V]@[L;QW M2<7VFF^=5O['*'&Y@:>F6 _M0=AMFR[>S:+:P;!1M%F0_;6#$DS'D].,_X=F MXL/)6!V=C=49M#0^E M2:G),-[,XM'TFK,+RCDZ2N)#1Q@&W4'#)!G?0^A@4 MNR+R7"Z,Q>(R0R-I?Z.*/VVHN%]2GT_K%W[VB+A-RYBPL:H6!'*F!2Q M*6?.DGHHU?#CTH9=(D$[.Z=;K%+"F0GL"4G--TZL>_YP8; /$4GUC'&=H[AJ MW9)0(,$(V0RI%\GZ*S7R.:\/M_I.C\8K]>.)! MW82;%-01E@+(P,-UE?VSD\ZS+Q$/LM#00XX=XY+N',6[W:%NQ>OV*7%*4.R+ MV@IQ[V$K2T*VK1)'[!C!'NP5=3 UU)6IWD?[17Y(ZT,GTF'XS M0 ]%&0:M.>&Y;38BR*>/7X8FXLN^PZZ0%UQT1"(C?P7 ;8G;?75,W "'X]QZ M=.1]2_)K*5!2RH&'5QSI,!=5A &U7"\N4D5QPT[[DW@VO(1A^A/WQ<3$B2]4?]X%-]'F#PY9I@\C6_Z7U']JJN.XJ 'TDSB.9Q4_!#PE/^Z\R]1D#:[ MTKO5VW[\^"+Y_>G*- O^E2W) GR4GZ+&I_&'O!?R^]5^N/P*^+UN%N0I2C/' MU/'H]'A/S#A\:>LU_YIU5K=MO>*/2[YK2@/P?EXC"_9?:(/X\^97_P502P,$ M% @ +*9_5&P8:"B4! B0D !@ !X;"]W;W)KJ%0U^62I=>J.Z&K(@2(8UE\W@_-2OW>GS4[6QE6S$G0:S MJ6NNGR]$I;9G SK8+TSE:FW=PO#\M.4K,1/VOKW3.!OV**6L16.D:D"+Y=E@ M1$\N(K??;_@AQ=8XH2KCG[#M M]D;Y (J-L:K>&2.#6C;=FS_M=#@PR((W#-C.@'G>G2//\BNW_/Q4JRUHMQO1 MW,"'ZJV1G&SSYC;("+N S3,6C:#8"+K6J8:P:JU$P P_2KF'L M>0AM3H<6?3K+8;'#O^CPV1OXE,$U@JT-3)I2E+\##)%LSYCM&5^P=Q&_BN(8 M0DJ !8R^@Q?V"H0>+WQ' 0-6P:5L>%-(7L',2@LGO*!KO#G7#Q9N*A4\?.OUS1^W\/-[7R"9SB=_)C/;F_ET M-)[/X.';_ K&][/Y[?5D.H.OTO#52HL5][="+?N3GZ^1I*KPFLIF!98O*K&[ MJ_(?5$@?QE'T">(#*?8)@@ :+ (]"XXSX$99$P)*8Y'D"$2,1I0C- M,H1AR=%,Z$=T:W"))@C$_)X@" !]YS0#&N(K\X,40(:XSAB"6',L:=A0/(T=7$02B,29?G_UR?XKSX9$@T#A_K9>4M( MSIB3A3DI<) [)F%V($J2>A$^ XU0NR@%EI,L#2%"I)C^)@;+$Y(XP2(?0Y(1 MBC,6$AJ@)B0*F5M_*0;J&R"3W!'8V>)BG),T<9I0%I,T#_S&+$Q(FC'XU(4- M'S]DC-(O,-EH;$L$KF598I9.N+$$9MAS?LFUSVHM"K5J,(-+*#?:9_8N/=_, MSA>R0J/L&UE,8*YY8WC78^[0M8 1WJ$"*TCIJHKS-A6N/3K?=T+[1MK@MMM% M);M;:& T&T,2)*\[.C[Z^"%/TOR+OZ+M 83J(4 ::+FV[D+S_GJB=VYAS0UP MO.I:KK#$52">6NR)G2!]%5"-\ PPD6/,Y>@8>2R%UKA-]U)BWS>N+/JHQJIN M>?/LSR3]X@K$/LK7*;H=U5X61&JY++' M"VF.?(KP9E;X8HP'BVO*D=KNY;% MV@77DT;CQ6_'Z@N2H[_$_OY:P1X>M$?,CI7_"3 HTJ:Q7:?L5_O_C%'77G]M M[WY2KKE�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end XML 105 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 106 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 107 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 263 452 1 true 95 0 false 8 false false R1.htm 000 - Document - Document And Entity Information Sheet http://bio-key.com/20211231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://bio-key.com/20211231/role/statement-consolidated-balance-sheets Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://bio-key.com/20211231/role/statement-consolidated-balance-sheets-parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations Sheet http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations Consolidated Statements of Operations Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) Sheet http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit Consolidated Statements of Stockholders' Equity (Deficit) Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flows Sheet http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 006 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies Sheet http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies Note A - The Company and Summary of Significant Accounting Policies Notes 7 false false R8.htm 007 - Disclosure - Note B - Revenue From Contracts With Customers Sheet http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers Note B - Revenue From Contracts With Customers Notes 8 false false R9.htm 008 - Disclosure - Note C - PistolStar, Inc. Acquisition Sheet http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition- Note C - PistolStar, Inc. Acquisition Notes 9 false false R10.htm 009 - Disclosure - Note D - Factoring Sheet http://bio-key.com/20211231/role/statement-note-d-factoring Note D - Factoring Notes 10 false false R11.htm 010 - Disclosure - Note E - Fair Values of Financial Instruments Sheet http://bio-key.com/20211231/role/statement-note-e-fair-values-of-financial-instruments Note E - Fair Values of Financial Instruments Notes 11 false false R12.htm 011 - Disclosure - Note F - Concentration of Risk Sheet http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk Note F - Concentration of Risk Notes 12 false false R13.htm 012 - Disclosure - Note G - Note Receivable Sheet http://bio-key.com/20211231/role/statement-note-g-note-receivable Note G - Note Receivable Notes 13 false false R14.htm 013 - Disclosure - Note H - Inventory Sheet http://bio-key.com/20211231/role/statement-note-h-inventory- Note H - Inventory Notes 14 false false R15.htm 014 - Disclosure - Note I - Resalable Software Licenses Rights Sheet http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights Note I - Resalable Software Licenses Rights Notes 15 false false R16.htm 015 - Disclosure - Note J - Investment in Debt Security Sheet http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security- Note J - Investment in Debt Security Notes 16 false false R17.htm 016 - Disclosure - Note K - Equipment and Leasehold Improvements Sheet http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements Note K - Equipment and Leasehold Improvements Notes 17 false false R18.htm 017 - Disclosure - Note L - Intangible Assets Sheet http://bio-key.com/20211231/role/statement-note-l-intangible-assets Note L - Intangible Assets Notes 18 false false R19.htm 018 - Disclosure - Note M - Accrued Liabilities Sheet http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities Note M - Accrued Liabilities Notes 19 false false R20.htm 019 - Disclosure - Note N - Related Party Transactions Sheet http://bio-key.com/20211231/role/statement-note-n-related-party-transactions Note N - Related Party Transactions Notes 20 false false R21.htm 020 - Disclosure - Note O - Convertible Notes Payable Notes http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable Note O - Convertible Notes Payable Notes 21 false false R22.htm 021 - Disclosure - Note P - Leases Sheet http://bio-key.com/20211231/role/statement-note-p-leases Note P - Leases Notes 22 false false R23.htm 022 - Disclosure - Note Q - Commitments and Contingencies Sheet http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies- Note Q - Commitments and Contingencies Notes 23 false false R24.htm 023 - Disclosure - Note R - Equity Sheet http://bio-key.com/20211231/role/statement-note-r-equity Note R - Equity Notes 24 false false R25.htm 024 - Disclosure - Note S - Stock Options Sheet http://bio-key.com/20211231/role/statement-note-s-stock-options Note S - Stock Options Notes 25 false false R26.htm 025 - Disclosure - Note T - Income Taxes Sheet http://bio-key.com/20211231/role/statement-note-t-income-taxes Note T - Income Taxes Notes 26 false false R27.htm 026 - Disclosure - Note U - Profit Sharing Plan Sheet http://bio-key.com/20211231/role/statement-note-u-profit-sharing-plan Note U - Profit Sharing Plan Notes 27 false false R28.htm 027 - Disclosure - Note V - Earnings Per Share (EPS) Sheet http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps Note V - Earnings Per Share (EPS) Notes 28 false false R29.htm 028 - Disclosure - Note W - Subsequent Events Sheet http://bio-key.com/20211231/role/statement-note-w-subsequent-events Note W - Subsequent Events Notes 29 false false R30.htm 029 - Disclosure - Significant Accounting Policies (Policies) Sheet http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies 30 false false R31.htm 030 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies (Tables) Sheet http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables Note A - The Company and Summary of Significant Accounting Policies (Tables) Tables http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies 31 false false R32.htm 031 - Disclosure - Note B - Revenue From Contracts With Customers (Tables) Sheet http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-tables Note B - Revenue From Contracts With Customers (Tables) Tables http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers 32 false false R33.htm 032 - Disclosure - Note C - PistolStar, Inc. Acquisition (Tables) Sheet http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-tables Note C - PistolStar, Inc. Acquisition (Tables) Tables http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition- 33 false false R34.htm 033 - Disclosure - Note D - Factoring (Tables) Sheet http://bio-key.com/20211231/role/statement-note-d-factoring-tables Note D - Factoring (Tables) Tables http://bio-key.com/20211231/role/statement-note-d-factoring 34 false false R35.htm 034 - Disclosure - Note G - Note Receivable (Tables) Sheet http://bio-key.com/20211231/role/statement-note-g-note-receivable-tables Note G - Note Receivable (Tables) Tables http://bio-key.com/20211231/role/statement-note-g-note-receivable 35 false false R36.htm 035 - Disclosure - Note H - Inventory (Tables) Sheet http://bio-key.com/20211231/role/statement-note-h-inventory-tables Note H - Inventory (Tables) Tables http://bio-key.com/20211231/role/statement-note-h-inventory- 36 false false R37.htm 036 - Disclosure - Note I - Resalable Software Licenses Rights (Tables) Sheet http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-tables Note I - Resalable Software Licenses Rights (Tables) Tables http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights 37 false false R38.htm 037 - Disclosure - Note K - Equipment and Leasehold Improvements (Tables) Sheet http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-tables Note K - Equipment and Leasehold Improvements (Tables) Tables http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements 38 false false R39.htm 038 - Disclosure - Note L - Intangible Assets (Tables) Sheet http://bio-key.com/20211231/role/statement-note-l-intangible-assets-tables Note L - Intangible Assets (Tables) Tables http://bio-key.com/20211231/role/statement-note-l-intangible-assets 39 false false R40.htm 039 - Disclosure - Note M - Accrued Liabilities (Tables) Sheet http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-tables Note M - Accrued Liabilities (Tables) Tables http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities 40 false false R41.htm 040 - Disclosure - Note P - Leases (Tables) Sheet http://bio-key.com/20211231/role/statement-note-p-leases-tables Note P - Leases (Tables) Tables http://bio-key.com/20211231/role/statement-note-p-leases 41 false false R42.htm 041 - Disclosure - Note R - Equity (Tables) Sheet http://bio-key.com/20211231/role/statement-note-r-equity-tables Note R - Equity (Tables) Tables http://bio-key.com/20211231/role/statement-note-r-equity 42 false false R43.htm 042 - Disclosure - Note S - Stock Options (Tables) Sheet http://bio-key.com/20211231/role/statement-note-s-stock-options-tables Note S - Stock Options (Tables) Tables http://bio-key.com/20211231/role/statement-note-s-stock-options 43 false false R44.htm 043 - Disclosure - Note T - Income Taxes (Tables) Sheet http://bio-key.com/20211231/role/statement-note-t-income-taxes-tables Note T - Income Taxes (Tables) Tables http://bio-key.com/20211231/role/statement-note-t-income-taxes 44 false false R45.htm 044 - Disclosure - Note V - Earnings Per Share (EPS) (Tables) Sheet http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-tables Note V - Earnings Per Share (EPS) (Tables) Tables http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps 45 false false R46.htm 045 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies (Details Textual) Sheet http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual Note A - The Company and Summary of Significant Accounting Policies (Details Textual) Details http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables 46 false false R47.htm 046 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Summary of Accounts Receivable (Details) Sheet http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details Note A - The Company and Summary of Significant Accounting Policies - Summary of Accounts Receivable (Details) Details 47 false false R48.htm 047 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Estimated Useful Lives for Depreciation and Amortization (Details) Sheet http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details Note A - The Company and Summary of Significant Accounting Policies - Estimated Useful Lives for Depreciation and Amortization (Details) Details 48 false false R49.htm 048 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Share-based Compensation Expenses for Continuing Operations (Details) Sheet http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details Note A - The Company and Summary of Significant Accounting Policies - Share-based Compensation Expenses for Continuing Operations (Details) Details 49 false false R50.htm 049 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Valuation Assumptions for Stock Options (Details) Sheet http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-valuation-assumptions-for-stock-options-details Note A - The Company and Summary of Significant Accounting Policies - Valuation Assumptions for Stock Options (Details) Details 50 false false R51.htm 050 - Disclosure - Note B - Revenue From Contracts With Customers (Details Textual) Sheet http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-details-textual Note B - Revenue From Contracts With Customers (Details Textual) Details http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-tables 51 false false R52.htm 051 - Disclosure - Note B - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) Sheet http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details Note B - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) Details 52 false false R53.htm 052 - Disclosure - Note C - PistolStar, Inc. Acquisition (Details Textual) Sheet http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-details-textual Note C - PistolStar, Inc. Acquisition (Details Textual) Details http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-tables 53 false false R54.htm 053 - Disclosure - Note C - PistolStar, Inc. Acquisition - Assets Acquired and Liabilities Assumed (Details) Sheet http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details Note C - PistolStar, Inc. Acquisition - Assets Acquired and Liabilities Assumed (Details) Details 54 false false R55.htm 054 - Disclosure - Note C - PistolStar, Inc. Acquisition - Assets Acquired and Liabilities Assumed (Details) (Parentheticals) Sheet http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details-parentheticals Note C - PistolStar, Inc. Acquisition - Assets Acquired and Liabilities Assumed (Details) (Parentheticals) Details 55 false false R56.htm 055 - Disclosure - Note C - PistolStar, Inc. Acquisition - Intangible Assets Acquired (Details) Sheet http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-intangible-assets-acquired-details Note C - PistolStar, Inc. Acquisition - Intangible Assets Acquired (Details) Details 56 false false R57.htm 056 - Disclosure - Note D - Factoring (Details Textual) Sheet http://bio-key.com/20211231/role/statement-note-d-factoring-details-textual Note D - Factoring (Details Textual) Details http://bio-key.com/20211231/role/statement-note-d-factoring-tables 57 false false R58.htm 057 - Disclosure - Note D - Factoring - Due From Factor (Details) Sheet http://bio-key.com/20211231/role/statement-note-d-factoring-due-from-factor-details Note D - Factoring - Due From Factor (Details) Details 58 false false R59.htm 058 - Disclosure - Note D - Factoring - Fees (Details) Sheet http://bio-key.com/20211231/role/statement-note-d-factoring-fees-details Note D - Factoring - Fees (Details) Details 59 false false R60.htm 059 - Disclosure - Note F - Concentration of Risk (Details Textual) Sheet http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk-details-textual Note F - Concentration of Risk (Details Textual) Details http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk 60 false false R61.htm 060 - Disclosure - Note G - Note Receivable (Details Textual) Sheet http://bio-key.com/20211231/role/statement-note-g-note-receivable-details-textual Note G - Note Receivable (Details Textual) Details http://bio-key.com/20211231/role/statement-note-g-note-receivable-tables 61 false false R62.htm 061 - Disclosure - Note G - Note Receivable - Summary of Note Receivable (Details) Sheet http://bio-key.com/20211231/role/statement-note-g-note-receivable-summary-of-note-receivable-details Note G - Note Receivable - Summary of Note Receivable (Details) Details 62 false false R63.htm 062 - Disclosure - Note H - Inventory - Components of Inventory (Details) Sheet http://bio-key.com/20211231/role/statement-note-h-inventory-components-of-inventory-details Note H - Inventory - Components of Inventory (Details) Details 63 false false R64.htm 063 - Disclosure - Note I - Resalable Software Licenses Rights (Details Textual) Sheet http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-details-textual Note I - Resalable Software Licenses Rights (Details Textual) Details http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-tables 64 false false R65.htm 064 - Disclosure - Note I - Resalable Software Licenses Rights - Amortization Expense (Details) Sheet http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-amortization-expense-details Note I - Resalable Software Licenses Rights - Amortization Expense (Details) Details 65 false false R66.htm 065 - Disclosure - Note J - Investment in Debt Security (Details Textual) Sheet http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-details-textual Note J - Investment in Debt Security (Details Textual) Details http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security- 66 false false R67.htm 066 - Disclosure - Note K - Equipment and Leasehold Improvements (Details Textual) Sheet http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-details-textual Note K - Equipment and Leasehold Improvements (Details Textual) Details http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-tables 67 false false R68.htm 067 - Disclosure - Note K - Equipment and Leasehold Improvements - Summary of Equipment and Leasehold Improvements (Details) Sheet http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details Note K - Equipment and Leasehold Improvements - Summary of Equipment and Leasehold Improvements (Details) Details 68 false false R69.htm 068 - Disclosure - Note L - Intangible Assets (Details Textual) Sheet http://bio-key.com/20211231/role/statement-note-l-intangible-assets-details-textual Note L - Intangible Assets (Details Textual) Details http://bio-key.com/20211231/role/statement-note-l-intangible-assets-tables 69 false false R70.htm 069 - Disclosure - Note L - Intangible Assets - Summary of Intangible Assets (Details) Sheet http://bio-key.com/20211231/role/statement-note-l-intangible-assets-summary-of-intangible-assets-details Note L - Intangible Assets - Summary of Intangible Assets (Details) Details 70 false false R71.htm 070 - Disclosure - Note L - Intangible Assets - Amortization Expense (Details) Sheet http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details Note L - Intangible Assets - Amortization Expense (Details) Details 71 false false R72.htm 071 - Disclosure - Note M - Accrued Liabilities - Summary of Accrued Liabilities (Details) Sheet http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details Note M - Accrued Liabilities - Summary of Accrued Liabilities (Details) Details 72 false false R73.htm 072 - Disclosure - Note N - Related Party Transactions (Details Textual) Sheet http://bio-key.com/20211231/role/statement-note-n-related-party-transactions-details-textual Note N - Related Party Transactions (Details Textual) Details http://bio-key.com/20211231/role/statement-note-n-related-party-transactions 73 false false R74.htm 073 - Disclosure - Note O - Convertible Notes Payable (Details Textual) Notes http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual Note O - Convertible Notes Payable (Details Textual) Details http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable 74 false false R75.htm 074 - Disclosure - Note P - Leases - Operating Lease Balance Sheet Information (Details) Sheet http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details Note P - Leases - Operating Lease Balance Sheet Information (Details) Details 75 false false R76.htm 075 - Disclosure - Note Q - Commitments and Contingencies (Details Textual) Sheet http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual Note Q - Commitments and Contingencies (Details Textual) Details http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies- 76 false false R77.htm 076 - Disclosure - Note R - Equity (Details Textual) Sheet http://bio-key.com/20211231/role/statement-note-r-equity-details-textual Note R - Equity (Details Textual) Details http://bio-key.com/20211231/role/statement-note-r-equity-tables 77 false false R78.htm 077 - Disclosure - Note R - Equity - Valuation Assumptions for Warrants (Details) Sheet http://bio-key.com/20211231/role/statement-note-r-equity-valuation-assumptions-for-warrants-details Note R - Equity - Valuation Assumptions for Warrants (Details) Details 78 false false R79.htm 078 - Disclosure - Note R - Equity - Summary of Warrant Activity (Details) Sheet http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details Note R - Equity - Summary of Warrant Activity (Details) Details 79 false false R80.htm 079 - Disclosure - Note S - Stock Options (Details Textual) Sheet http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual Note S - Stock Options (Details Textual) Details http://bio-key.com/20211231/role/statement-note-s-stock-options-tables 80 false false R81.htm 080 - Disclosure - Note S - Stock Options - Option Activity (Details) Sheet http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details Note S - Stock Options - Option Activity (Details) Details 81 false false R82.htm 081 - Disclosure - Note S - Stock Options - Options Outstanding and Exercisable (Details) Sheet http://bio-key.com/20211231/role/statement-note-s-stock-options-options-outstanding-and-exercisable-details Note S - Stock Options - Options Outstanding and Exercisable (Details) Details 82 false false R83.htm 082 - Disclosure - Note T - Income Taxes (Details Textual) Sheet http://bio-key.com/20211231/role/statement-note-t-income-taxes-details-textual Note T - Income Taxes (Details Textual) Details http://bio-key.com/20211231/role/statement-note-t-income-taxes-tables 83 false false R84.htm 083 - Disclosure - Note T - Income Taxes - Components of Deferred Taxes (Details) Sheet http://bio-key.com/20211231/role/statement-note-t-income-taxes-components-of-deferred-taxes-details Note T - Income Taxes - Components of Deferred Taxes (Details) Details 84 false false R85.htm 084 - Disclosure - Note T - Income Taxes - Reconciliation of the Effective Income Tax Rate to US Federal Statutory Income Tax Rate (Details) Sheet http://bio-key.com/20211231/role/statement-note-t-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details Note T - Income Taxes - Reconciliation of the Effective Income Tax Rate to US Federal Statutory Income Tax Rate (Details) Details 85 false false R86.htm 085 - Disclosure - Note U - Profit Sharing Plan (Details Textual) Sheet http://bio-key.com/20211231/role/statement-note-u-profit-sharing-plan-details-textual Note U - Profit Sharing Plan (Details Textual) Details http://bio-key.com/20211231/role/statement-note-u-profit-sharing-plan 86 false false R87.htm 086 - Disclosure - Note V - Earnings Per Share (EPS) - Reconciliation of Numerator of Basic and Diluted EPS Calculations (Details) Sheet http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-reconciliation-of-numerator-of-basic-and-diluted-eps-calculations-details Note V - Earnings Per Share (EPS) - Reconciliation of Numerator of Basic and Diluted EPS Calculations (Details) Details http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-tables 87 false false R88.htm 087 - Disclosure - Note V - Earnings Per Share (EPS) - Securities Excluded from the Diluted Per Share Calculation (Details) Sheet http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-details Note V - Earnings Per Share (EPS) - Securities Excluded from the Diluted Per Share Calculation (Details) Details http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-tables 88 false false R89.htm 088 - Disclosure - Note W - Subsequent Events (Details Textual) Sheet http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual Note W - Subsequent Events (Details Textual) Details http://bio-key.com/20211231/role/statement-note-w-subsequent-events 89 false false All Reports Book All Reports bkyi20211231_10k.htm bkyi-20211231.xsd bkyi-20211231_cal.xml bkyi-20211231_def.xml bkyi-20211231_lab.xml bkyi-20211231_pre.xml ex_351264.htm ex_351265.htm ex_351266.htm ex_351267.htm ex_351268.htm ex_351269.htm ex_353505.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 110 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bkyi20211231_10k.htm": { "axisCustom": 0, "axisStandard": 34, "contextCount": 263, "dts": { "calculationLink": { "local": [ "bkyi-20211231_cal.xml" ] }, "definitionLink": { "local": [ "bkyi-20211231_def.xml" ] }, "inline": { "local": [ "bkyi20211231_10k.htm" ] }, "labelLink": { "local": [ "bkyi-20211231_lab.xml" ] }, "presentationLink": { "local": [ "bkyi-20211231_pre.xml" ] }, "schema": { "local": [ "bkyi-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 688, "entityCount": 1, "hidden": { "http://bio-key.com/20211231": 7, "http://fasb.org/us-gaap/2021-01-31": 44, "http://xbrl.sec.gov/dei/2021q4": 6, "total": 57 }, "keyCustom": 104, "keyStandard": 348, "memberCustom": 50, "memberStandard": 43, "nsprefix": "bkyi", "nsuri": "http://bio-key.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://bio-key.com/20211231/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "bkyi:FactoringTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note D - Factoring", "role": "http://bio-key.com/20211231/role/statement-note-d-factoring", "shortName": "Note D - Factoring", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "bkyi:FactoringTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note E - Fair Values of Financial Instruments", "role": "http://bio-key.com/20211231/role/statement-note-e-fair-values-of-financial-instruments", "shortName": "Note E - Fair Values of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note F - Concentration of Risk", "role": "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk", "shortName": "Note F - Concentration of Risk", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "bkyi:NotesReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note G - Note Receivable", "role": "http://bio-key.com/20211231/role/statement-note-g-note-receivable", "shortName": "Note G - Note Receivable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "bkyi:NotesReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note H - Inventory", "role": "http://bio-key.com/20211231/role/statement-note-h-inventory-", "shortName": "Note H - Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note I - Resalable Software Licenses Rights", "role": "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights", "shortName": "Note I - Resalable Software Licenses Rights", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note J - Investment in Debt Security", "role": "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-", "shortName": "Note J - Investment in Debt Security", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note K - Equipment and Leasehold Improvements", "role": "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements", "shortName": "Note K - Equipment and Leasehold Improvements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note L - Intangible Assets", "role": "http://bio-key.com/20211231/role/statement-note-l-intangible-assets", "shortName": "Note L - Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note M - Accrued Liabilities", "role": "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities", "shortName": "Note M - Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets", "role": "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:OtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note N - Related Party Transactions", "role": "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions", "shortName": "Note N - Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note O - Convertible Notes Payable", "role": "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "shortName": "Note O - Convertible Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note P - Leases", "role": "http://bio-key.com/20211231/role/statement-note-p-leases", "shortName": "Note P - Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note Q - Commitments and Contingencies", "role": "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-", "shortName": "Note Q - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note R - Equity", "role": "http://bio-key.com/20211231/role/statement-note-r-equity", "shortName": "Note R - Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note S - Stock Options", "role": "http://bio-key.com/20211231/role/statement-note-s-stock-options", "shortName": "Note S - Stock Options", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note T - Income Taxes", "role": "http://bio-key.com/20211231/role/statement-note-t-income-taxes", "shortName": "Note T - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note U - Profit Sharing Plan", "role": "http://bio-key.com/20211231/role/statement-note-u-profit-sharing-plan", "shortName": "Note U - Profit Sharing Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note V - Earnings Per Share (EPS)", "role": "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps", "shortName": "Note V - Earnings Per Share (EPS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note W - Subsequent Events", "role": "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "shortName": "Note W - Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "role": "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:ReceivablesPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies (Tables)", "role": "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables", "shortName": "Note A - The Company and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "lang": "en-US", "name": "bkyi:UsefulLivesOfPropertyPlanAndEquipmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note B - Revenue From Contracts With Customers (Tables)", "role": "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-tables", "shortName": "Note B - Revenue From Contracts With Customers (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note C - PistolStar, Inc. Acquisition (Tables)", "role": "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-tables", "shortName": "Note C - PistolStar, Inc. Acquisition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:ReceivablesPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note D - Factoring (Tables)", "role": "http://bio-key.com/20211231/role/statement-note-d-factoring-tables", "shortName": "Note D - Factoring (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "bkyi:FactoringTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "lang": "en-US", "name": "bkyi:FactoringFeesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:ReceivablesPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note G - Note Receivable (Tables)", "role": "http://bio-key.com/20211231/role/statement-note-g-note-receivable-tables", "shortName": "Note G - Note Receivable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "bkyi:NotesReceivableTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-NotesReceivableMember", "decimals": null, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note H - Inventory (Tables)", "role": "http://bio-key.com/20211231/role/statement-note-h-inventory-tables", "shortName": "Note H - Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note I - Resalable Software Licenses Rights (Tables)", "role": "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-tables", "shortName": "Note I - Resalable Software Licenses Rights (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-SoftwareLicenseRightsMember", "decimals": null, "lang": "en-US", "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note K - Equipment and Leasehold Improvements (Tables)", "role": "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-tables", "shortName": "Note K - Equipment and Leasehold Improvements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note L - Intangible Assets (Tables)", "role": "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-tables", "shortName": "Note L - Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations", "role": "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note M - Accrued Liabilities (Tables)", "role": "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-tables", "shortName": "Note M - Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "bkyi:LesseeOperatingLeaseCostsAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note P - Leases (Tables)", "role": "http://bio-key.com/20211231/role/statement-note-p-leases-tables", "shortName": "Note P - Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "bkyi:LesseeOperatingLeaseCostsAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "bkyi:ScheduleOfWarrantsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note R - Equity (Tables)", "role": "http://bio-key.com/20211231/role/statement-note-r-equity-tables", "shortName": "Note R - Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "bkyi:ScheduleOfWarrantsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note S - Stock Options (Tables)", "role": "http://bio-key.com/20211231/role/statement-note-s-stock-options-tables", "shortName": "Note S - Stock Options (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note T - Income Taxes (Tables)", "role": "http://bio-key.com/20211231/role/statement-note-t-income-taxes-tables", "shortName": "Note T - Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note V - Earnings Per Share (EPS) (Tables)", "role": "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-tables", "shortName": "Note V - Earnings Per Share (EPS) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "bkyi:OperationalCostsPerMonth", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies (Details Textual)", "role": "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "shortName": "Note A - The Company and Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "bkyi:OperationalCostsPerMonth", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:ReceivablesPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Summary of Accounts Receivable (Details)", "role": "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details", "shortName": "Note A - The Company and Summary of Significant Accounting Policies - Summary of Accounts Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:ReceivablesPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "bkyi:UsefulLivesOfPropertyPlanAndEquipmentTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentMember_RangeAxis-MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Estimated Useful Lives for Depreciation and Amortization (Details)", "role": "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "shortName": "Note A - The Company and Summary of Significant Accounting Policies - Estimated Useful Lives for Depreciation and Amortization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "bkyi:UsefulLivesOfPropertyPlanAndEquipmentTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentMember_RangeAxis-MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Share-based Compensation Expenses for Continuing Operations (Details)", "role": "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details", "shortName": "Note A - The Company and Summary of Significant Accounting Policies - Share-based Compensation Expenses for Continuing Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember", "decimals": "INF", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "b", "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)", "role": "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit", "shortName": "Consolidated Statements of Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Valuation Assumptions for Stock Options (Details)", "role": "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-valuation-assumptions-for-stock-options-details", "shortName": "Note A - The Company and Summary of Significant Accounting Policies - Valuation Assumptions for Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Note B - Revenue From Contracts With Customers (Details Textual)", "role": "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-details-textual", "shortName": "Note B - Revenue From Contracts With Customers (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Note B - Revenue From Contracts With Customers - Disaggregation of Revenue (Details)", "role": "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details", "shortName": "Note B - Revenue From Contracts With Customers - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_StatementGeographicalAxis-NorthAmericaMember", "decimals": "INF", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfNotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Note C - PistolStar, Inc. Acquisition (Details Textual)", "role": "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-details-textual", "shortName": "Note C - PistolStar, Inc. Acquisition (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2020-06-30_2020-06-30_BusinessAcquisitionAxis-PistolstarMember_DebtInstrumentAxis-PromissoryNoteMember", "decimals": null, "lang": "en-US", "name": "us-gaap:DebtInstrumentTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Note C - PistolStar, Inc. Acquisition - Assets Acquired and Liabilities Assumed (Details)", "role": "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details", "shortName": "Note C - PistolStar, Inc. Acquisition - Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2020-06-30_BusinessAcquisitionAxis-PistolstarMember", "decimals": "INF", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Note C - PistolStar, Inc. Acquisition - Assets Acquired and Liabilities Assumed (Details) (Parentheticals)", "role": "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details-parentheticals", "shortName": "Note C - PistolStar, Inc. Acquisition - Assets Acquired and Liabilities Assumed (Details) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R56": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2020-06-30_2020-06-30_BusinessAcquisitionAxis-PistolstarMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Note C - PistolStar, Inc. Acquisition - Intangible Assets Acquired (Details)", "role": "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-intangible-assets-acquired-details", "shortName": "Note C - PistolStar, Inc. Acquisition - Intangible Assets Acquired (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2020-06-30_2020-06-30_BusinessAcquisitionAxis-PistolstarMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "bkyi:FactoringTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "bkyi:FactoringArrangementMinimumAmountOfAccountsReceivablePerQuarter", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Note D - Factoring (Details Textual)", "role": "http://bio-key.com/20211231/role/statement-note-d-factoring-details-textual", "shortName": "Note D - Factoring (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "bkyi:FactoringTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "bkyi:FactoringArrangementMinimumAmountOfAccountsReceivablePerQuarter", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "bkyi:FactoringTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "bkyi:FactoredAccountsReceivableOriginalInvoiceValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "057 - Disclosure - Note D - Factoring - Due From Factor (Details)", "role": "http://bio-key.com/20211231/role/statement-note-d-factoring-due-from-factor-details", "shortName": "Note D - Factoring - Due From Factor (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "bkyi:FactoringTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "bkyi:FactoredAccountsReceivableOriginalInvoiceValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "bkyi:FactoringFeesTableTextBlock", "bkyi:FactoringTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "bkyi:FactoringFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "058 - Disclosure - Note D - Factoring - Fees (Details)", "role": "http://bio-key.com/20211231/role/statement-note-d-factoring-fees-details", "shortName": "Note D - Factoring - Fees (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "bkyi:FactoringFeesTableTextBlock", "bkyi:FactoringTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "bkyi:FactoringFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Cash Flows", "role": "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashUninsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "059 - Disclosure - Note F - Concentration of Risk (Details Textual)", "role": "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk-details-textual", "shortName": "Note F - Concentration of Risk (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashUninsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NotesAndLoansReceivableNetCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060 - Disclosure - Note G - Note Receivable (Details Textual)", "role": "http://bio-key.com/20211231/role/statement-note-g-note-receivable-details-textual", "shortName": "Note G - Note Receivable (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "bkyi:NotesReceivableTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": "2", "lang": null, "name": "us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "bkyi:NotesReceivableTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NotesReceivableGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061 - Disclosure - Note G - Note Receivable - Summary of Note Receivable (Details)", "role": "http://bio-key.com/20211231/role/statement-note-g-note-receivable-summary-of-note-receivable-details", "shortName": "Note G - Note Receivable - Summary of Note Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "bkyi:NotesReceivableTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NotesReceivableGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "062 - Disclosure - Note H - Inventory - Components of Inventory (Details)", "role": "http://bio-key.com/20211231/role/statement-note-h-inventory-components-of-inventory-details", "shortName": "Note H - Inventory - Components of Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "063 - Disclosure - Note I - Resalable Software Licenses Rights (Details Textual)", "role": "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-details-textual", "shortName": "Note I - Resalable Software Licenses Rights (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2015-12-31_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-SoftwareLicenseRightsMember", "decimals": "INF", "lang": null, "name": "us-gaap:PaymentsToAcquireSoftware", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "064 - Disclosure - Note I - Resalable Software Licenses Rights - Amortization Expense (Details)", "role": "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-amortization-expense-details", "shortName": "Note I - Resalable Software Licenses Rights - Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-SoftwareLicenseRightsMember", "decimals": "INF", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:HeldToMaturitySecuritiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "065 - Disclosure - Note J - Investment in Debt Security (Details Textual)", "role": "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-details-textual", "shortName": "Note J - Investment in Debt Security (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2019-12-31_FinancialInstrumentAxis-ForeignCorporateDebtSecuritiesMember", "decimals": "INF", "lang": null, "name": "us-gaap:HeldToMaturitySecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "066 - Disclosure - Note K - Equipment and Leasehold Improvements (Details Textual)", "role": "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-details-textual", "shortName": "Note K - Equipment and Leasehold Improvements (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "067 - Disclosure - Note K - Equipment and Leasehold Improvements - Summary of Equipment and Leasehold Improvements (Details)", "role": "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details", "shortName": "Note K - Equipment and Leasehold Improvements - Summary of Equipment and Leasehold Improvements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "068 - Disclosure - Note L - Intangible Assets (Details Textual)", "role": "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-details-textual", "shortName": "Note L - Intangible Assets (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-ResearchDevelopmentAndEngineeringExpenseMember", "decimals": "INF", "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies", "role": "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "shortName": "Note A - The Company and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "069 - Disclosure - Note L - Intangible Assets - Summary of Intangible Assets (Details)", "role": "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-summary-of-intangible-assets-details", "shortName": "Note L - Intangible Assets - Summary of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "070 - Disclosure - Note L - Intangible Assets - Amortization Expense (Details)", "role": "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details", "shortName": "Note L - Intangible Assets - Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember", "decimals": "INF", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AccruedSalariesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "071 - Disclosure - Note M - Accrued Liabilities - Summary of Accrued Liabilities (Details)", "role": "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details", "shortName": "Note M - Accrued Liabilities - Summary of Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AccruedSalariesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2019-12-31_BalanceSheetLocationAxis-AccountsPayableMember_RelatedPartyTransactionsByRelatedPartyAxis-MrWongKwokFongMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "072 - Disclosure - Note N - Related Party Transactions (Details Textual)", "role": "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions-details-textual", "shortName": "Note N - Related Party Transactions (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2019-12-31_BalanceSheetLocationAxis-AccountsPayableMember_RelatedPartyTransactionsByRelatedPartyAxis-MrWongKwokFongMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2015-09-23", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "073 - Disclosure - Note O - Convertible Notes Payable (Details Textual)", "role": "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual", "shortName": "Note O - Convertible Notes Payable (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2019-07-10_2019-07-10", "decimals": "INF", "lang": null, "name": "bkyi:PaymentsOfStockIssuanceCostsCommitmentFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "bkyi:LesseeOperatingLeaseCostsAssetsAndLiabilitiesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "074 - Disclosure - Note P - Leases - Operating Lease Balance Sheet Information (Details)", "role": "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details", "shortName": "Note P - Leases - Operating Lease Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "bkyi:LesseeOperatingLeaseCostsAssetsAndLiabilitiesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2015-09-23", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "075 - Disclosure - Note Q - Commitments and Contingencies (Details Textual)", "role": "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual", "shortName": "Note Q - Commitments and Contingencies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2020-03-25_RelatedPartyTransactionAxis-SalesIncentiveAgreementWithTTIMember_RelatedPartyTransactionsByRelatedPartyAxis-TechnologyTransferInstituteMember", "decimals": "INF", "lang": null, "name": "bkyi:RelatedPartyTransactionRevenueNeededToTriggerPaymentOfSalesIncentiveFee", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "076 - Disclosure - Note R - Equity (Details Textual)", "role": "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "shortName": "Note R - Equity (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "bkyi:ScheduleOfWarrantsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31_ClassOfWarrantOrRightAxis-ReferralFeeWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "077 - Disclosure - Note R - Equity - Valuation Assumptions for Warrants (Details)", "role": "http://bio-key.com/20211231/role/statement-note-r-equity-valuation-assumptions-for-warrants-details", "shortName": "Note R - Equity - Valuation Assumptions for Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "bkyi:ScheduleOfWarrantsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31_ClassOfWarrantOrRightAxis-ReferralFeeWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "078 - Disclosure - Note R - Equity - Summary of Warrant Activity (Details)", "role": "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details", "shortName": "Note R - Equity - Summary of Warrant Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "lang": "en-US", "name": "bkyi:WarrantsOutstandingWeightedAverageRemainingLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Note B - Revenue From Contracts With Customers", "role": "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers", "shortName": "Note B - Revenue From Contracts With Customers", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "b", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "079 - Disclosure - Note S - Stock Options (Details Textual)", "role": "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual", "shortName": "Note S - Stock Options (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "b", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080 - Disclosure - Note S - Stock Options - Option Activity (Details)", "role": "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details", "shortName": "Note S - Stock Options - Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2019-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "081 - Disclosure - Note S - Stock Options - Options Outstanding and Exercisable (Details)", "role": "http://bio-key.com/20211231/role/statement-note-s-stock-options-options-outstanding-and-exercisable-details", "shortName": "Note S - Stock Options - Options Outstanding and Exercisable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "082 - Disclosure - Note T - Income Taxes (Details Textual)", "role": "http://bio-key.com/20211231/role/statement-note-t-income-taxes-details-textual", "shortName": "Note T - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "083 - Disclosure - Note T - Income Taxes - Components of Deferred Taxes (Details)", "role": "http://bio-key.com/20211231/role/statement-note-t-income-taxes-components-of-deferred-taxes-details", "shortName": "Note T - Income Taxes - Components of Deferred Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "084 - Disclosure - Note T - Income Taxes - Reconciliation of the Effective Income Tax Rate to US Federal Statutory Income Tax Rate (Details)", "role": "http://bio-key.com/20211231/role/statement-note-t-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details", "shortName": "Note T - Income Taxes - Reconciliation of the Effective Income Tax Rate to US Federal Statutory Income Tax Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R86": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "085 - Disclosure - Note U - Profit Sharing Plan (Details Textual)", "role": "http://bio-key.com/20211231/role/statement-note-u-profit-sharing-plan-details-textual", "shortName": "Note U - Profit Sharing Plan (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R87": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "086 - Disclosure - Note V - Earnings Per Share (EPS) - Reconciliation of Numerator of Basic and Diluted EPS Calculations (Details)", "role": "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-reconciliation-of-numerator-of-basic-and-diluted-eps-calculations-details", "shortName": "Note V - Earnings Per Share (EPS) - Reconciliation of Numerator of Basic and Diluted EPS Calculations (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R88": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceLessThanAverageMarketPriceOfCommonSharesMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "087 - Disclosure - Note V - Earnings Per Share (EPS) - Securities Excluded from the Diluted Per Share Calculation (Details)", "role": "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-details", "shortName": "Note V - Earnings Per Share (EPS) - Securities Excluded from the Diluted Per Share Calculation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceLessThanAverageMarketPriceOfCommonSharesMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "088 - Disclosure - Note W - Subsequent Events (Details Textual)", "role": "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual", "shortName": "Note W - Subsequent Events (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2022-03-11_2022-03-11_AwardTypeAxis-RestrictedStockMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_SubsequentEventTypeAxis-SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note C - PistolStar, Inc. Acquisition", "role": "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-", "shortName": "Note C - PistolStar, Inc. Acquisition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 95, "tag": { "bkyi_AccruedEmployeeExpensesReimbursementCurrent": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents accrued employee expenses reimbursement, current.", "label": "Employee expenses reimbursement" } } }, "localname": "AccruedEmployeeExpensesReimbursementCurrent", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "bkyi_AccruedFactoringFeesCurrent": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of factoring fees incurred but not yet paid, due within one year or the normal operating cycle, if longer.", "label": "Factoring fees" } } }, "localname": "AccruedFactoringFeesCurrent", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "bkyi_AccruedFranchiseTaxesCurrent": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents current portion of accrued franchise taxes.", "label": "Franchise taxes" } } }, "localname": "AccruedFranchiseTaxesCurrent", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "bkyi_AccruedLiabilitiesOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to accrued liabilities (other).", "label": "Accrued Liabilities (Other) [Member]" } } }, "localname": "AccruedLiabilitiesOtherMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions", "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_AdditionalIncomeOfCashFlow": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents additional income of cash flow.", "label": "bkyi_AdditionalIncomeOfCashFlow", "terseLabel": "Additional Income of Cash Flow" } } }, "localname": "AdditionalIncomeOfCashFlow", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_AdjustmentsToAdditionalPaidInCapitalLegalAndCommitmentFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of decrease to additional paid in capital during the period resulting from legal and commitment fees.", "label": "bkyi_AdjustmentsToAdditionalPaidInCapitalLegalAndCommitmentFees", "negatedLabel": "Legal and commitment fees" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalLegalAndCommitmentFees", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" ], "xbrltype": "monetaryItemType" }, "bkyi_AdjustmentsToAdditionalPaidInCapitalLegalFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of decrease to additional paid in capital during the period resulting from legal fees.", "label": "bkyi_AdjustmentsToAdditionalPaidInCapitalLegalFees", "negatedLabel": "Legal fees" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalLegalFees", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" ], "xbrltype": "monetaryItemType" }, "bkyi_AllowanceForDoubtfulAccounts": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "bkyi_AllowanceForDoubtfulAccounts", "negatedLabel": "Allowance for doubtful account" } } }, "localname": "AllowanceForDoubtfulAccounts", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_AmendedNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Amended Note.", "label": "Amended Note [Member]" } } }, "localname": "AmendedNoteMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_AmortizationOfBeneficialConversionFeature": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to beneficial conversion feature.", "label": "Amortization of beneficial conversion feature" } } }, "localname": "AmortizationOfBeneficialConversionFeature", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_AmortizationOfSoftwareLicenseRights": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of amortization charged against earnings during the period for software license rights.", "label": "Amortization of resalable software license rights" } } }, "localname": "AmortizationOfSoftwareLicenseRights", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_BeneficialConversionFeature": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of beneficial conversion feature.", "label": "bkyi_BeneficialConversionFeature", "terseLabel": "Beneficial conversion feature" } } }, "localname": "BeneficialConversionFeature", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_BusinessCombinationAccountsReceivableAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of accounts receivable acquired.", "label": "Accounts receivable acquired from PistolStar" } } }, "localname": "BusinessCombinationAccountsReceivableAcquired", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_BusinessCombinationAccruedExpensesAcquired": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents amount of accrued expenses acquired.", "label": "Accrued expenses acquired from PistolStar" } } }, "localname": "BusinessCombinationAccruedExpensesAcquired", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_BusinessCombinationDeferredRevenueAcquired": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents amount of deferred revenue acquired.", "label": "Deferred revenue acquired from PistolStar" } } }, "localname": "BusinessCombinationDeferredRevenueAcquired", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_BusinessCombinationEquipmentAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of equipment acquired.", "label": "Equipment acquired from PistolStar" } } }, "localname": "BusinessCombinationEquipmentAcquired", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_BusinessCombinationIntangibleAssetsAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents intangible assets acquired.", "label": "Intangible assets acquired from PistolStar" } } }, "localname": "BusinessCombinationIntangibleAssetsAcquired", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_BusinessCombinationIssuanceOfNotesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents issuance of notes payable in businesses combination.", "label": "Issuance of note payable for PistolStar acquisition, net of discount" } } }, "localname": "BusinessCombinationIssuanceOfNotesPayable", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_BusinessCombinationPrepaidExpensesAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents prepaid expenses acquired.", "label": "Prepaid expenses acquired from PistolStar" } } }, "localname": "BusinessCombinationPrepaidExpensesAcquired", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPayrolAccountsPayable": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued payroll liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Accrued payroll" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPayrolAccountsPayable", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodWillTotal": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets including goodwill acquired at the acquisition date.", "label": "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodWillTotal", "totalLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodWillTotal", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOther": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 0.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued expenses and other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Accrued expenses and other current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOther", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFixedAssets": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 2.0, "parentTag": "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodWillTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of fixed assets recognized as of the acquisition date.", "label": "Fixed assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFixedAssets", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "bkyi_ClassOfWarrantOrRightExercisedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the class of warrant or right, exercised during period.", "label": "bkyi_ClassOfWarrantOrRightExercisedDuringPeriod", "terseLabel": "Class of Warrant or Right, Exercised During Period (in shares)" } } }, "localname": "ClassOfWarrantOrRightExercisedDuringPeriod", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "sharesItemType" }, "bkyi_ClassOfWarrantOrRightGrantsInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of warrants granted during the period.", "label": "Granted, warrants (in shares)", "terseLabel": "Granted, warrants (in shares)" } } }, "localname": "ClassOfWarrantOrRightGrantsInPeriod", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details" ], "xbrltype": "sharesItemType" }, "bkyi_ClassOfWarrantOrRightIncreaseDueToTriggerOfAntidilutionProvisionFuture": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents increase in class of warrants or rights due to trigger of anti-dilution provision feature.", "label": "Increase due to trigger of anti-dilution provision feature, warrants (in shares)" } } }, "localname": "ClassOfWarrantOrRightIncreaseDueToTriggerOfAntidilutionProvisionFuture", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details" ], "xbrltype": "sharesItemType" }, "bkyi_ClassOfWarrantOrRightIssuedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The class of warrant or right issued during the period.", "label": "bkyi_ClassOfWarrantOrRightIssuedDuringPeriod", "terseLabel": "Class of Warrant or Right, Issued During Period (in shares)" } } }, "localname": "ClassOfWarrantOrRightIssuedDuringPeriod", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "sharesItemType" }, "bkyi_ClassOfWarrantOrRightRecordedAsDebtDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of warrant or right recorded as a debt discount to be amortized over the life of the related debt.", "label": "bkyi_ClassOfWarrantOrRightRecordedAsDebtDiscount", "terseLabel": "Class of Warrant or Right, Recorded as Debt Discount" } } }, "localname": "ClassOfWarrantOrRightRecordedAsDebtDiscount", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_ConcentrationRiskNumberOfMajorCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of external customers that accounts for 10 percent or more of an entity's revenues or accounts receivable.", "label": "bkyi_ConcentrationRiskNumberOfMajorCustomers", "terseLabel": "Concentration Risk, Number of Major Customers" } } }, "localname": "ConcentrationRiskNumberOfMajorCustomers", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk-details-textual" ], "xbrltype": "integerItemType" }, "bkyi_ConversionOfSeniorSecuredConvertibleNoteToCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents conversion of senior secured convertible note to common stock.", "label": "Conversion of Senior Secured Convertible Note to Common Stock [Member]" } } }, "localname": "ConversionOfSeniorSecuredConvertibleNoteToCommonStockMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_CumulativeAmountOfAmortizationExpenseNetOfCredits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents cumulative amount of amortization expense net of credit expense.", "label": "bkyi_CumulativeAmountOfAmortizationExpenseNetOfCredits", "terseLabel": "Cumulative Amount of Amortization Expense, Net of Credits" } } }, "localname": "CumulativeAmountOfAmortizationExpenseNetOfCredits", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_DebtInstrumentConvertibleBeneficialConversionFeaturePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount per share of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.", "label": "bkyi_DebtInstrumentConvertibleBeneficialConversionFeaturePerShare", "terseLabel": "Debt Instrument, Convertible, Beneficial Conversion Feature, Per Share (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleBeneficialConversionFeaturePerShare", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "perShareItemType" }, "bkyi_DebtInstrumentConvertiblePremiumPaymentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage premium on principal of convertible debt instrument paid at time of redemption.", "label": "bkyi_DebtInstrumentConvertiblePremiumPaymentPercentage", "terseLabel": "Debt Instrument, Convertible, Premium Payment Percentage" } } }, "localname": "DebtInstrumentConvertiblePremiumPaymentPercentage", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "percentItemType" }, "bkyi_DebtInstrumentCovenantSharesToBePaidCommitmentFeeRepaidPriorToMaturity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares to be paid in lieu of commitment fee on debt instrument if repaid prior to maturity date.", "label": "bkyi_DebtInstrumentCovenantSharesToBePaidCommitmentFeeRepaidPriorToMaturity", "terseLabel": "Debt Instrument, Covenant, Shares to be Paid, Commitment Fee, Repaid Prior to Maturity (in shares)" } } }, "localname": "DebtInstrumentCovenantSharesToBePaidCommitmentFeeRepaidPriorToMaturity", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "sharesItemType" }, "bkyi_DebtInstrumentDeemedDividendExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deemed dividend expense of debt instrument.", "label": "bkyi_DebtInstrumentDeemedDividendExpense", "terseLabel": "Debt Instrument, Deemed Dividend Expense" } } }, "localname": "DebtInstrumentDeemedDividendExpense", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_DebtInstrumentNumberOfInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents number of installments in debt instrument.", "label": "bkyi_DebtInstrumentNumberOfInstallments", "terseLabel": "Debt Instrument, Number of Installments" } } }, "localname": "DebtInstrumentNumberOfInstallments", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-details-textual" ], "xbrltype": "integerItemType" }, "bkyi_DebtInstrumentPeriodicPaymentPrincipalDueIn180Days": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal due in 180 days.", "label": "bkyi_DebtInstrumentPeriodicPaymentPrincipalDueIn180Days", "terseLabel": "Debt Instrument, Periodic Payment, Principal due in 180 Days" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipalDueIn180Days", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_DebtInstrumentPeriodicPaymentPrincipalDueIn270Days": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal due in 270 days.", "label": "bkyi_DebtInstrumentPeriodicPaymentPrincipalDueIn270Days", "terseLabel": "Debt Instrument, Periodic Payment, Principal due in 270 Days" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipalDueIn270Days", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_DeemedDividendRelatedToDownRoundFeatures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of (increase) decrease in equity for deemed dividend related to down-round features.", "label": "Deemed dividends related to down-round features" } } }, "localname": "DeemedDividendRelatedToDownRoundFeatures", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" ], "xbrltype": "monetaryItemType" }, "bkyi_EffectiveIncomeTaxReconciliationEffectOfNetOperatingLoss": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-note-t-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details": { "order": 0.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective income tax reconciliation effect of net operating loss.", "label": "Effect of net operating loss" } } }, "localname": "EffectiveIncomeTaxReconciliationEffectOfNetOperatingLoss", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details" ], "xbrltype": "percentItemType" }, "bkyi_EffectiveIncomeTaxReconciliationPermanentDifferences": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-note-t-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective income tax reconciliation permanent differences.", "label": "Permanent differences" } } }, "localname": "EffectiveIncomeTaxReconciliationPermanentDifferences", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details" ], "xbrltype": "percentItemType" }, "bkyi_EmployeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about an employee.", "label": "Employee [Member]" } } }, "localname": "EmployeeMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information regarding employee stock purchase plan.", "label": "Employee Stock Purchase Plan [Member]" } } }, "localname": "EmployeeStockPurchasePlanMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_EquityWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the equity warrants.", "label": "Equity Warrants [Member]" } } }, "localname": "EquityWarrantsMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price greater than average market price of common shares member.", "label": "Exercise Price Greater Than Average Market Price Of Common Shares [Member]" } } }, "localname": "ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-details" ], "xbrltype": "domainItemType" }, "bkyi_ExercisePriceLessThanAverageMarketPriceOfCommonSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price less than average market price of common shares member.", "label": "Exercise Price Less Than Average Market Price Of Common Shares [Member]" } } }, "localname": "ExercisePriceLessThanAverageMarketPriceOfCommonSharesMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-details" ], "xbrltype": "domainItemType" }, "bkyi_ExercisePriceRange1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The first exercise price range.", "label": "Exercise Price Range 1 [Member]" } } }, "localname": "ExercisePriceRange1Member", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-options-outstanding-and-exercisable-details" ], "xbrltype": "domainItemType" }, "bkyi_ExercisePriceRange2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The second exercise price range.", "label": "Exercise Price Range 2 [Member]" } } }, "localname": "ExercisePriceRange2Member", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-options-outstanding-and-exercisable-details" ], "xbrltype": "domainItemType" }, "bkyi_ExercisePriceRange3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The third exercise price range.", "label": "Exercise Price Range 3 [Member]" } } }, "localname": "ExercisePriceRange3Member", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-options-outstanding-and-exercisable-details" ], "xbrltype": "domainItemType" }, "bkyi_FactoredAccountsReceivableFactoredAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Factored accounts receivable factored amount.", "label": "Factored amount" } } }, "localname": "FactoredAccountsReceivableFactoredAmount", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-d-factoring-due-from-factor-details" ], "xbrltype": "monetaryItemType" }, "bkyi_FactoredAccountsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Factored accounts receivable member.", "label": "Factored Accounts Receivable [Member]" } } }, "localname": "FactoredAccountsReceivableMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-d-factoring-tables" ], "xbrltype": "domainItemType" }, "bkyi_FactoredAccountsReceivableOriginalInvoiceValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Factored accounts receivable original invoice value.", "label": "Original Invoice Value" } } }, "localname": "FactoredAccountsReceivableOriginalInvoiceValue", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-d-factoring-due-from-factor-details" ], "xbrltype": "monetaryItemType" }, "bkyi_FactoringArrangementMinimumAmountOfAccountsReceivablePerQuarter": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of certain accounts receivable balances which must be sold to the Factor pursuant to the factoring arrangement.", "label": "bkyi_FactoringArrangementMinimumAmountOfAccountsReceivablePerQuarter", "terseLabel": "Factoring Arrangement, Minimum Amount of Accounts Receivable Per Quarter" } } }, "localname": "FactoringArrangementMinimumAmountOfAccountsReceivablePerQuarter", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-d-factoring-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_FactoringFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cost of factoring related to accounts receivable.", "label": "bkyi_FactoringFees", "terseLabel": "Factoring fees" } } }, "localname": "FactoringFees", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-d-factoring-fees-details" ], "xbrltype": "monetaryItemType" }, "bkyi_FactoringFeesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Factoring fees percent.", "label": "bkyi_FactoringFeesPercent", "terseLabel": "Factoring Fees Percent" } } }, "localname": "FactoringFeesPercent", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-d-factoring-details-textual" ], "xbrltype": "percentItemType" }, "bkyi_FactoringFeesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of factoring fees related to trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date.", "label": "Factoring Fees [Table Text Block]" } } }, "localname": "FactoringFeesTableTextBlock", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-d-factoring-tables" ], "xbrltype": "textBlockItemType" }, "bkyi_FactoringTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Factoring text block.", "label": "Factoring [Text Block]" } } }, "localname": "FactoringTextBlock", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-d-factoring" ], "xbrltype": "textBlockItemType" }, "bkyi_February2020NoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the February 2020 note.", "label": "February 2020 Note [Member]" } } }, "localname": "February2020NoteMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details": { "order": 0.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "bkyi_FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour", "terseLabel": "Thereafter" } } }, "localname": "FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details" ], "xbrltype": "monetaryItemType" }, "bkyi_GovernmentGrantIncome": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents income recognized from government grant under the CARES Act.", "label": "Government grant \u2013 Paycheck Protection Program" } } }, "localname": "GovernmentGrantIncome", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "bkyi_HardwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to hardware.", "label": "Hardware [Member]" } } }, "localname": "HardwareMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "bkyi_InTheMoneyOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents in-the-money options exercisable.", "label": "In The Money Options [Member]" } } }, "localname": "InTheMoneyOptionsMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options", "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_IncreaseDecreaseInCapitalizedContractCosts": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in capitalized contract costs.", "label": "bkyi_IncreaseDecreaseInCapitalizedContractCosts", "negatedTerseLabel": "Capitalized contract costs" } } }, "localname": "IncreaseDecreaseInCapitalizedContractCosts", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_IncreaseDecreaseInSoftwareLicenseRights": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying value of software license rights associated with underlying transactions that are classified as operating activities.", "label": "bkyi_IncreaseDecreaseInSoftwareLicenseRights", "negatedLabel": "Resalable software license rights" } } }, "localname": "IncreaseDecreaseInSoftwareLicenseRights", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_InvestmentInHeldToMaturityDebtSecuritiesTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the term of an investment in held-to-maturity debt securities.", "label": "bkyi_InvestmentInHeldToMaturityDebtSecuritiesTerm", "terseLabel": "Investment in Held-to-maturity Debt Securities, Term (Year)" } } }, "localname": "InvestmentInHeldToMaturityDebtSecuritiesTerm", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-details-textual" ], "xbrltype": "durationItemType" }, "bkyi_InvestmentInHeldtomaturityDebtSecuritiesInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the interest rate of an investment in held-to-maturity debt securities.", "label": "bkyi_InvestmentInHeldtomaturityDebtSecuritiesInterestRate", "terseLabel": "Investment in Held-to-maturity Debt Securities, Interest Rate" } } }, "localname": "InvestmentInHeldtomaturityDebtSecuritiesInterestRate", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-details-textual" ], "xbrltype": "percentItemType" }, "bkyi_InvestmentIncomeDebtSecurityReserveExpense": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses related to debt security reserve.", "label": "bkyi_InvestmentIncomeDebtSecurityReserveExpense", "negatedLabel": "Investment-debt security reserve" } } }, "localname": "InvestmentIncomeDebtSecurityReserveExpense", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "bkyi_InvestorWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to investor warrant.", "label": "Investor Warrant [Member]" } } }, "localname": "InvestorWarrantMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_January2020NoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the January 2020 note.", "label": "January 2020 Note [Member]" } } }, "localname": "January2020NoteMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_June2020NoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the June 2020 note.", "label": "June 2020 Note [Member]" } } }, "localname": "June2020NoteMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_LesseeOperatingLeaseCostsAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of costs, assets, and liabilities subject to operating lease by lessee.", "label": "Lessee, Operating Lease, Costs, Assets and Liabilities [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseCostsAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-p-leases-tables" ], "xbrltype": "textBlockItemType" }, "bkyi_LimitOfBond": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the limit of a bond held for investment.", "label": "bkyi_LimitOfBond", "terseLabel": "Limit of Bond" } } }, "localname": "LimitOfBond", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_May2020NoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the May 2020 note.", "label": "May 2020 Note [Member]" } } }, "localname": "May2020NoteMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_MrMichaelDepasqualeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Mr. Michael DePasquale.", "label": "Mr. Michael DePasquale [Member]" } } }, "localname": "MrMichaelDepasqualeMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions", "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_MrWongKwokFongMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Mr. Wong Kwok Fong.", "label": "Mr. Wong Kwok Fong [Member]" } } }, "localname": "MrWongKwokFongMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions", "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_NonPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non plan member.", "label": "Non Plan [Member]" } } }, "localname": "NonPlanMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "domainItemType" }, "bkyi_NonstatutoryStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nonstatutory stock member.", "label": "Nonstatutory Stock [Member]" } } }, "localname": "NonstatutoryStockMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options", "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_NotesReceivableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for notes receivable.", "label": "Notes Receivable [Text Block]" } } }, "localname": "NotesReceivableTextBlock", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-g-note-receivable" ], "xbrltype": "textBlockItemType" }, "bkyi_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_OneCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to one customer.", "label": "One Customer [Member]" } } }, "localname": "OneCustomerMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk", "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_OperatingLeaseLiabilityAssumedUnderAsc842": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash operating lease liability incurred because of adoption of ASC 842.", "label": "Operating lease liabilities under ASC 842" } } }, "localname": "OperatingLeaseLiabilityAssumedUnderAsc842", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_OperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward not subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "bkyi_OperatingLossCarryforwardsNotSubjectToExpiration", "terseLabel": "Operating Loss Carryforwards, Not Subject to Expiration" } } }, "localname": "OperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_OperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "bkyi_OperatingLossCarryforwardsSubjectToExpiration", "terseLabel": "Operating Loss Carryforwards, Subject to Expiration" } } }, "localname": "OperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_OperationalCostsPerMonth": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of funds required to conduct operations on a monthly basis.", "label": "bkyi_OperationalCostsPerMonth", "terseLabel": "Operational Costs Per Month" } } }, "localname": "OperationalCostsPerMonth", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_OtherWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to other warrants.", "label": "Other Warrants [Member]" } } }, "localname": "OtherWarrantsMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details" ], "xbrltype": "domainItemType" }, "bkyi_PaymentsForLegalFees": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash outflow for legal fees.", "label": "bkyi_PaymentsForLegalFees", "negatedLabel": "Legal fees" } } }, "localname": "PaymentsForLegalFees", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_PaymentsOfStockIssuanceCostsBankerFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for banker fee cost incurred directly with the issuance of an equity security.", "label": "bkyi_PaymentsOfStockIssuanceCostsBankerFees", "terseLabel": "Payments of Stock Issuance Costs, Banker Fees" } } }, "localname": "PaymentsOfStockIssuanceCostsBankerFees", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_PaymentsOfStockIssuanceCostsCommitmentFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for commitment fee cost incurred directly with the issuance of an equity security.", "label": "bkyi_PaymentsOfStockIssuanceCostsCommitmentFees", "terseLabel": "Payments of Stock Issuance Costs, Commitment Fees" } } }, "localname": "PaymentsOfStockIssuanceCostsCommitmentFees", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_PaymentsOfStockIssuanceCostsLegalFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for legal fee cost incurred directly with the issuance of an equity security.", "label": "bkyi_PaymentsOfStockIssuanceCostsLegalFees", "terseLabel": "Payments of Stock Issuance Costs, Legal Fees" } } }, "localname": "PaymentsOfStockIssuanceCostsLegalFees", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_PercentageOfAccountsReceivableRemittedByFactor": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of accounts receivable remitted by factor.", "label": "bkyi_PercentageOfAccountsReceivableRemittedByFactor", "terseLabel": "Percentage Of Accounts Receivable Remitted By Factor" } } }, "localname": "PercentageOfAccountsReceivableRemittedByFactor", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-d-factoring-details-textual" ], "xbrltype": "percentItemType" }, "bkyi_PercentageOfSupportAndMaintenanceRevenueToLicenseCost": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of support and maintenance revenue for SaaS license to total license cost.", "label": "bkyi_PercentageOfSupportAndMaintenanceRevenueToLicenseCost", "terseLabel": "Percentage of Support and Maintenance Revenue to License Cost" } } }, "localname": "PercentageOfSupportAndMaintenanceRevenueToLicenseCost", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "percentItemType" }, "bkyi_PistolstarMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents acquisition of PistolStar, Inc.(\"PistolStar\").", "label": "PistolStar [Member]" } } }, "localname": "PistolstarMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details-parentheticals", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-details-textual", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-intangible-assets-acquired-details" ], "xbrltype": "domainItemType" }, "bkyi_PlacementFeePercentOfAggregateGrossProceeds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the placement fee as a percentage of gross proceeds.", "label": "bkyi_PlacementFeePercentOfAggregateGrossProceeds", "terseLabel": "Placement Fee, Percent of Aggregate Gross Proceeds" } } }, "localname": "PlacementFeePercentOfAggregateGrossProceeds", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "percentItemType" }, "bkyi_PrefundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the pre-funded warrants.", "label": "Pre-Funded Warrants [Member]" } } }, "localname": "PrefundedWarrantsMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details" ], "xbrltype": "domainItemType" }, "bkyi_ProceedsFromEmployeeStockPurchasePlan": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents proceeds from employee stock purchase plan.", "label": "Proceeds from Employee Stock Purchase Plan" } } }, "localname": "ProceedsFromEmployeeStockPurchasePlan", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note issued to an investor pursuant to a Security Purchase Agreement.", "label": "Promissory Note [Member]" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details-parentheticals", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_ProprietarySoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to proprietary software.", "label": "Proprietary Software [Member]" } } }, "localname": "ProprietarySoftwareMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-intangible-assets-acquired-details", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "bkyi_PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to a public offering.", "label": "Public Offering [Member]" } } }, "localname": "PublicOfferingMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit", "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_PublicOfferingWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to the public offering warrants.", "label": "Public Offering Warrants [Member]" } } }, "localname": "PublicOfferingWarrantsMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details" ], "xbrltype": "domainItemType" }, "bkyi_ReferralFeeWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to referral fee warrants.", "label": "Referral Fee Warrants [Member]" } } }, "localname": "ReferralFeeWarrantsMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity-valuation-assumptions-for-warrants-details" ], "xbrltype": "domainItemType" }, "bkyi_RelatedPartyAgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The length of time of the agreement between two or more related parties.", "label": "bkyi_RelatedPartyAgreementTerm", "terseLabel": "Related Party Agreement, Term (Year)" } } }, "localname": "RelatedPartyAgreementTerm", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual" ], "xbrltype": "durationItemType" }, "bkyi_RelatedPartyTransactionMaximumRevenueToTriggerPaymentOfSalesIncentiveFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The maximum agreed upon revenue generated under the related party agreement which may trigger the payment of a sales incentive fee.", "label": "bkyi_RelatedPartyTransactionMaximumRevenueToTriggerPaymentOfSalesIncentiveFee", "terseLabel": "Related Party Transaction, Maximum Revenue to Trigger Payment of Sales Incentive Fee" } } }, "localname": "RelatedPartyTransactionMaximumRevenueToTriggerPaymentOfSalesIncentiveFee", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_RelatedPartyTransactionMaximumRevenueWarrantsIssuable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The maximum revenue for warrant issuable to a related party pursuant to the agreement.", "label": "bkyi_RelatedPartyTransactionMaximumRevenueWarrantsIssuable", "terseLabel": "Related Party Transaction, Maximum Revenue, Warrants Issuable" } } }, "localname": "RelatedPartyTransactionMaximumRevenueWarrantsIssuable", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_RelatedPartyTransactionRevenueNeededToTriggerPaymentOfSalesIncentiveFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of revenue which much be generated to trigger the payment of a sales incentive fee under the related party agreement.", "label": "bkyi_RelatedPartyTransactionRevenueNeededToTriggerPaymentOfSalesIncentiveFee", "terseLabel": "Related Party Transaction, Revenue Needed to Trigger Payment of Sales Incentive Fee" } } }, "localname": "RelatedPartyTransactionRevenueNeededToTriggerPaymentOfSalesIncentiveFee", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_RelatedPartyTransactionRevenueToTriggerPaymentOfSalesIncentiveFeePercentOfNetIncome": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum percent of net income which the revenue generated under the related party agreement must amount to.", "label": "bkyi_RelatedPartyTransactionRevenueToTriggerPaymentOfSalesIncentiveFeePercentOfNetIncome", "terseLabel": "Related Party Transaction, Revenue to Trigger Payment of Sales Incentive Fee, Percent of Net Income, Minimum" } } }, "localname": "RelatedPartyTransactionRevenueToTriggerPaymentOfSalesIncentiveFeePercentOfNetIncome", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual" ], "xbrltype": "percentItemType" }, "bkyi_RelatedPartyTransactionRevenueToTriggerPaymentOfSalesIncentiveFeePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of revenue to trigger payment of sales incentive fee under related party transaction.", "label": "bkyi_RelatedPartyTransactionRevenueToTriggerPaymentOfSalesIncentiveFeePeriod", "terseLabel": "Related Party Transaction, Revenue to Trigger Payment of Sales Incentive Fee, Period (Month)" } } }, "localname": "RelatedPartyTransactionRevenueToTriggerPaymentOfSalesIncentiveFeePeriod", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual" ], "xbrltype": "durationItemType" }, "bkyi_RelatedPartyTransactionSalesIncentiveFeeForEach5MillionRevenue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of sales incentive fee for each 5 million revenue pursuant to the agreement.", "label": "bkyi_RelatedPartyTransactionSalesIncentiveFeeForEach5MillionRevenue", "terseLabel": "Related Party Transaction, Sales Incentive Fee For Each 5 Million Revenue" } } }, "localname": "RelatedPartyTransactionSalesIncentiveFeeForEach5MillionRevenue", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_ResearchDevelopmentAndEngineeringExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research, development and engineering expense have been included.", "label": "Research, Development, and Engineering Expense [Member]" } } }, "localname": "ResearchDevelopmentAndEngineeringExpenseMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-l-intangible-assets", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_ReserveForInvestmentSecurity": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of reserve for investment security.", "label": "bkyi_ReserveForInvestmentSecurity", "negatedLabel": "Reserve for investment security" } } }, "localname": "ReserveForInvestmentSecurity", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_ReserveForNoteReceivable": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of reserve for note receivable.", "label": "bkyi_ReserveForNoteReceivable", "negatedLabel": "Allowance for note receivable" } } }, "localname": "ReserveForNoteReceivable", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_ReverseStockSplitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The conversion of a reverse stock split where there is a reduction in the shares outstanding.", "label": "Reverse Stock Split [Member]" } } }, "localname": "ReverseStockSplitMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_RightofuseAssetAdditionUnderAsc842": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of noncash right of use asset added because of adoption of ASC 842.", "label": "Right-of-use asset addition under ASC 842" } } }, "localname": "RightofuseAssetAdditionUnderAsc842", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_SalesIncentiveAgreementWithTTIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the Sales Incentive Agreement with Technology Transfer Institute (\"TTI\").", "label": "Sales Incentive Agreement With TTI [Member]" } } }, "localname": "SalesIncentiveAgreementWithTTIMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_ScheduleOfWarrantsValuationAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants.", "label": "Schedule of Warrants Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfWarrantsValuationAssumptionsTableTextBlock", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-tables" ], "xbrltype": "textBlockItemType" }, "bkyi_SecuredRedeemableConvertibleNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents secured redeemable convertible note.", "label": "Secured Redeemable Convertible Note [Member]" } } }, "localname": "SecuredRedeemableConvertibleNoteMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_SeniorSecuredConvertibleNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to senior secured convertible note.", "label": "Senior Secured Convertible Note [Member]" } } }, "localname": "SeniorSecuredConvertibleNoteMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_September2015WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The warrants issued in September 2015 warrants issuance.", "label": "September 2015 Warrants [Member]" } } }, "localname": "September2015WarrantsMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_ShareBasedCompensationExcludingDirectorsFees": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement, excluding directors fees.", "label": "Share based and warrant compensation for employees and consultants" } } }, "localname": "ShareBasedCompensationExcludingDirectorsFees", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_SharebasedCommitmentFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of share based commitment fees.", "label": "bkyi_SharebasedCommitmentFees", "terseLabel": "Issuance of common stock pursuant to securities purchase agreements" } } }, "localname": "SharebasedCommitmentFees", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options granted during the period.", "label": "bkyi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_SoftwareLicenseRights": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of current and noncurrent software license rights as of the balance sheet date.", "label": "bkyi_SoftwareLicenseRights", "terseLabel": "Software License Rights" } } }, "localname": "SoftwareLicenseRights", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_SoftwareLicenseRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The software license rights, generally of limited duration, for internal use.", "label": "Software License Rights [Member]" } } }, "localname": "SoftwareLicenseRightsMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-amortization-expense-details", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-details-textual", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-tables" ], "xbrltype": "domainItemType" }, "bkyi_SoftwareLicenseRightsNoncurrent": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amounts as of the balance sheet date of software license rights classified as non-current.", "label": "Resalable software license rights" } } }, "localname": "SoftwareLicenseRightsNoncurrent", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "bkyi_StockBasedFeesToDirectorsAndConsultants": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs and payments related to stock-based fees to directors and consultants.", "label": "Stock based fees to directors" } } }, "localname": "StockBasedFeesToDirectorsAndConsultants", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_StockIssuableForSalesIncentiveAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issuable pursuant to the sales incentive agreement.", "label": "bkyi_StockIssuableForSalesIncentiveAgreement", "terseLabel": "Stock Issuable for Sales Incentive Agreement (in shares)" } } }, "localname": "StockIssuableForSalesIncentiveAgreement", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual" ], "xbrltype": "sharesItemType" }, "bkyi_StockIssuableForSalesIncentiveFeePerEach5MillionRevenue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common shares issuable for sales incentive fee per each 5 million revenue.", "label": "bkyi_StockIssuableForSalesIncentiveFeePerEach5MillionRevenue", "terseLabel": "Stock Issuable for Sales Incentive Fee Per Each 5 Million Revenue (in shares)" } } }, "localname": "StockIssuableForSalesIncentiveFeePerEach5MillionRevenue", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual" ], "xbrltype": "sharesItemType" }, "bkyi_StockIssuedDuringPeriodSharesCommitmentFees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period for commitment fees.", "label": "bkyi_StockIssuedDuringPeriodSharesCommitmentFees", "terseLabel": "Stock Issued During Period, Shares, Commitment Fees (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesCommitmentFees", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "sharesItemType" }, "bkyi_StockIssuedDuringPeriodSharesConversionOfWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period upon the conversion of warrant.", "label": "Issuance of common stock pursuant to warrant exercises (in shares)", "terseLabel": "Stock Issued During Period, Shares, Conversion of Warrant (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfWarrant", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "sharesItemType" }, "bkyi_StockIssuedDuringPeriodSharesIssuedForDueDiligenceFee": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for due diligence fee.", "label": "bkyi_StockIssuedDuringPeriodSharesIssuedForDueDiligenceFee", "terseLabel": "Stock Issued During Period, Shares, Issued for Due Diligence Fee (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForDueDiligenceFee", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "sharesItemType" }, "bkyi_StockIssuedDuringPeriodSharesWarrantsExercises": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period for warrant exercises.", "label": "bkyi_StockIssuedDuringPeriodSharesWarrantsExercises", "terseLabel": "Stock Issued During Period, Shares, Warrants Exercises (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercises", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "sharesItemType" }, "bkyi_StockIssuedDuringPeriodValueConversionOfWarrant": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period upon the conversion of warrant.", "label": "Issuance of common stock pursuant to warrant exercises" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfWarrant", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" ], "xbrltype": "monetaryItemType" }, "bkyi_StockIssuedDuringPeriodValueIssuedForDueDiligenceFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued for due diligence fee.", "label": "bkyi_StockIssuedDuringPeriodValueIssuedForDueDiligenceFee", "terseLabel": "Stock Issued During Period, Value, Issued for Due Diligence Fee" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForDueDiligenceFee", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_StockIssuedInLieuOfBoardCommitteeFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "refers to stock issued in lieu of board committee fees.", "label": "Stock Issued in Lieu of Board Committee Fees [Member]" } } }, "localname": "StockIssuedInLieuOfBoardCommitteeFeesMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_StockIssuedInLieuOfBoardFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to stock issued in lieu of board fees.", "label": "Stock Issued in Lieu of Board Fees [Member]" } } }, "localname": "StockIssuedInLieuOfBoardFeesMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_SwivelSecureEuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information regarding the business acquisition of Swivel Secure Europe.", "label": "Swivel Secure Europe [Member]" } } }, "localname": "SwivelSecureEuropeMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_TechnologyTransferInstituteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the related party Technology Transfer Institute (\"TTI\").", "label": "Technology Transfer Institute [Member]" } } }, "localname": "TechnologyTransferInstituteMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_The2004StockOptionPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The2004 stock option plan member.", "label": "The2004 Stock Option Plan [Member]" } } }, "localname": "The2004StockOptionPlanMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options", "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "domainItemType" }, "bkyi_The2015EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to information regarding the 2015 Equity Incentive plan.", "label": "The 2015 Equity Incentive Plan [Member]" } } }, "localname": "The2015EquityIncentivePlanMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options", "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "domainItemType" }, "bkyi_The2015SoftwareLicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about the 2015 Software License.", "label": "The 2015 Software License [Member]" } } }, "localname": "The2015SoftwareLicenseMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_TheNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to The Note.", "label": "The Note [Member]" } } }, "localname": "TheNoteMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_ThreeCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to three customers.", "label": "Three Customers [Member]" } } }, "localname": "ThreeCustomersMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk", "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_TotalWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants exercised during period.", "label": "Exercised, warrants (in shares)", "negatedTerseLabel": "Exercised, warrants (in shares)" } } }, "localname": "TotalWarrantsExercised", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details" ], "xbrltype": "sharesItemType" }, "bkyi_TotalWarrantsExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants expired during period.", "label": "bkyi_TotalWarrantsExpired", "negatedTerseLabel": "Expired, warrants (in shares)" } } }, "localname": "TotalWarrantsExpired", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details" ], "xbrltype": "sharesItemType" }, "bkyi_TotalWarrantsForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants forfeited during period.", "label": "bkyi_TotalWarrantsForfeited", "negatedTerseLabel": "Forfeited, warrants (in shares)" } } }, "localname": "TotalWarrantsForfeited", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details" ], "xbrltype": "sharesItemType" }, "bkyi_UsefulLivesOfPropertyPlanAndEquipmentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Useful Lives of Property Plan and Equipment [Table Text Block]" } } }, "localname": "UsefulLivesOfPropertyPlanAndEquipmentTableTextBlock", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "bkyi_WarrantsIssuableForEach1MillionRevenueInExcessOf20MilllionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the warrants issuable for each 1 million revenue in excess of 20 million.", "label": "Warrants Issuable for Each 1 Million Revenue in Excess of 20 Million [Member]" } } }, "localname": "WarrantsIssuableForEach1MillionRevenueInExcessOf20MilllionMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_WarrantsIssuedInConnectionWithConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents warrants issued in connection with convertible notes.", "label": "Warrants Issued in Connection with Convertible Notes [Member]" } } }, "localname": "WarrantsIssuedInConnectionWithConvertibleNotesMember", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" ], "xbrltype": "domainItemType" }, "bkyi_WarrantsIssuedWithConvertibleNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents amount of warrants issued with convertible notes.", "label": "bkyi_WarrantsIssuedWithConvertibleNotes", "terseLabel": "Warrants issued with convertible notes" } } }, "localname": "WarrantsIssuedWithConvertibleNotes", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_WarrantsOutstandingExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants outstanding exercise price.", "label": "bkyi_WarrantsOutstandingExercisePrice", "periodEndLabel": "Outstanding, weighted average exercise price, warrants (in dollars per share)", "periodStartLabel": "Outstanding, weighted average exercise price, warrants (in dollars per share)" } } }, "localname": "WarrantsOutstandingExercisePrice", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details" ], "xbrltype": "perShareItemType" }, "bkyi_WarrantsOutstandingWeightedAverageRemainingLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants outstanding weighted average remaining life.", "label": "bkyi_WarrantsOutstandingWeightedAverageRemainingLife", "verboseLabel": "Outstanding, weighted average remaining contractual life, warrants (Year)" } } }, "localname": "WarrantsOutstandingWeightedAverageRemainingLife", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details" ], "xbrltype": "durationItemType" }, "bkyi_WeightedAverageExercisePriceWarrantIncreaseDueToTriggerOfAntidilutionProvisionFeature": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents weighted average exercise price of warrants increase due to trigger of anti-dilution provision feature.", "label": "Increase due to trigger of anti-dilution provision feature, weighted average exercise price, warrants (in dollars per share)" } } }, "localname": "WeightedAverageExercisePriceWarrantIncreaseDueToTriggerOfAntidilutionProvisionFeature", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details" ], "xbrltype": "perShareItemType" }, "bkyi_WeightedAverageExercisePriceWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of the warrants exercised in the period.", "label": "Exercised, weighted average exercise price, warrants (in dollars per share)", "verboseLabel": "Exercised, weighted average exercise price, warrants (in dollars per share)" } } }, "localname": "WeightedAverageExercisePriceWarrantsExercised", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details" ], "xbrltype": "perShareItemType" }, "bkyi_WeightedAverageExercisePriceWarrantsExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of the warrants expired during period.", "label": "bkyi_WeightedAverageExercisePriceWarrantsExpired", "verboseLabel": "Expired, weighted average exercise price, warrants (in dollars per share)" } } }, "localname": "WeightedAverageExercisePriceWarrantsExpired", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details" ], "xbrltype": "perShareItemType" }, "bkyi_WeightedAverageExercisePriceWarrantsForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of the warrants forfeited.", "label": "bkyi_WeightedAverageExercisePriceWarrantsForfeited", "verboseLabel": "Forfeited, weighted average exercise price, warrants (in dollars per share)" } } }, "localname": "WeightedAverageExercisePriceWarrantsForfeited", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details" ], "xbrltype": "perShareItemType" }, "bkyi_WeightedAverageExercisePriceWarrantsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of warrants granted during period.", "label": "Granted, weighted average exercise price, warrants (in dollars per share)", "verboseLabel": "Granted, weighted average exercise price, warrants (in dollars per share)" } } }, "localname": "WeightedAverageExercisePriceWarrantsGranted", "nsuri": "http://bio-key.com/20211231", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details" ], "xbrltype": "perShareItemType" }, "bkyi_statement-statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note A - The Company and Summary of Significant Accounting Policies - Estimated Useful Lives for Depreciation and Amortization (Details)" } } }, "localname": "statement-statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note A - The Company and Summary of Significant Accounting Policies - Share-based Compensation Expenses for Continuing Operations (Details)" } } }, "localname": "statement-statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note A - The Company and Summary of Significant Accounting Policies - Summary of Accounts Receivable (Details)" } } }, "localname": "statement-statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note A - The Company and Summary of Significant Accounting Policies" } } }, "localname": "statement-statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-a-the-company-and-summary-of-significant-accounting-policies-valuation-assumptions-for-stock-options-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note A - The Company and Summary of Significant Accounting Policies - Valuation Assumptions for Stock Options (Details)" } } }, "localname": "statement-statement-note-a-the-company-and-summary-of-significant-accounting-policies-valuation-assumptions-for-stock-options-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note B - Revenue From Contracts With Customers - Disaggregation of Revenue (Details)" } } }, "localname": "statement-statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-b-revenue-from-contracts-with-customers-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note B - Revenue From Contracts With Customers" } } }, "localname": "statement-statement-note-b-revenue-from-contracts-with-customers-tables", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note C - PistolStar, Inc. Acquisition - Assets Acquired and Liabilities Assumed (Details)" } } }, "localname": "statement-statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details-parentheticals": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note C - PistolStar, Inc. Acquisition - Assets Acquired and Liabilities Assumed (Details) (Parentheticals)" } } }, "localname": "statement-statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details-parentheticals", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-c-pistolstar-inc-acquisition-intangible-assets-acquired-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note C - PistolStar, Inc. Acquisition - Intangible Assets Acquired (Details)" } } }, "localname": "statement-statement-note-c-pistolstar-inc-acquisition-intangible-assets-acquired-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-c-pistolstar-inc-acquisition-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note C - PistolStar, Inc. Acquisition" } } }, "localname": "statement-statement-note-c-pistolstar-inc-acquisition-tables", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-d-factoring-due-from-factor-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note D - Factoring - Due From Factor (Details)" } } }, "localname": "statement-statement-note-d-factoring-due-from-factor-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-d-factoring-fees-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note D - Factoring - Fees (Details)" } } }, "localname": "statement-statement-note-d-factoring-fees-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-d-factoring-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note D - Factoring" } } }, "localname": "statement-statement-note-d-factoring-tables", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-g-note-receivable-summary-of-note-receivable-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note G - Note Receivable - Summary of Note Receivable (Details)" } } }, "localname": "statement-statement-note-g-note-receivable-summary-of-note-receivable-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-g-note-receivable-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note G - Note Receivable" } } }, "localname": "statement-statement-note-g-note-receivable-tables", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-h-inventory-components-of-inventory-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note H - Inventory - Components of Inventory (Details)" } } }, "localname": "statement-statement-note-h-inventory-components-of-inventory-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-h-inventory-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note H - Inventory" } } }, "localname": "statement-statement-note-h-inventory-tables", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-i-resalable-software-licenses-rights-amortization-expense-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note I - Resalable Software Licenses Rights - Amortization Expense (Details)" } } }, "localname": "statement-statement-note-i-resalable-software-licenses-rights-amortization-expense-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-i-resalable-software-licenses-rights-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note I - Resalable Software Licenses Rights" } } }, "localname": "statement-statement-note-i-resalable-software-licenses-rights-tables", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-k-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note K - Equipment and Leasehold Improvements - Summary of Equipment and Leasehold Improvements (Details)" } } }, "localname": "statement-statement-note-k-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-k-equipment-and-leasehold-improvements-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note K - Equipment and Leasehold Improvements" } } }, "localname": "statement-statement-note-k-equipment-and-leasehold-improvements-tables", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-l-intangible-assets-amortization-expense-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note L - Intangible Assets - Amortization Expense (Details)" } } }, "localname": "statement-statement-note-l-intangible-assets-amortization-expense-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-l-intangible-assets-summary-of-intangible-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note L - Intangible Assets - Summary of Intangible Assets (Details)" } } }, "localname": "statement-statement-note-l-intangible-assets-summary-of-intangible-assets-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-l-intangible-assets-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note L - Intangible Assets" } } }, "localname": "statement-statement-note-l-intangible-assets-tables", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note M - Accrued Liabilities - Summary of Accrued Liabilities (Details)" } } }, "localname": "statement-statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-m-accrued-liabilities-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note M - Accrued Liabilities" } } }, "localname": "statement-statement-note-m-accrued-liabilities-tables", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-p-leases-operating-lease-balance-sheet-information-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note P - Leases - Operating Lease Balance Sheet Information (Details)" } } }, "localname": "statement-statement-note-p-leases-operating-lease-balance-sheet-information-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-p-leases-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note P - Leases" } } }, "localname": "statement-statement-note-p-leases-tables", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-r-equity-summary-of-warrant-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note R - Equity - Summary of Warrant Activity (Details)" } } }, "localname": "statement-statement-note-r-equity-summary-of-warrant-activity-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-r-equity-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note R - Equity" } } }, "localname": "statement-statement-note-r-equity-tables", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-r-equity-valuation-assumptions-for-warrants-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note R - Equity - Valuation Assumptions for Warrants (Details)" } } }, "localname": "statement-statement-note-r-equity-valuation-assumptions-for-warrants-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-s-stock-options-option-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note S - Stock Options - Option Activity (Details)" } } }, "localname": "statement-statement-note-s-stock-options-option-activity-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-s-stock-options-options-outstanding-and-exercisable-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note S - Stock Options - Options Outstanding and Exercisable (Details)" } } }, "localname": "statement-statement-note-s-stock-options-options-outstanding-and-exercisable-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-s-stock-options-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note S - Stock Options" } } }, "localname": "statement-statement-note-s-stock-options-tables", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-t-income-taxes-components-of-deferred-taxes-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note T - Income Taxes - Components of Deferred Taxes (Details)" } } }, "localname": "statement-statement-note-t-income-taxes-components-of-deferred-taxes-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-t-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note T - Income Taxes - Reconciliation of the Effective Income Tax Rate to US Federal Statutory Income Tax Rate (Details)" } } }, "localname": "statement-statement-note-t-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-t-income-taxes-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note T - Income Taxes" } } }, "localname": "statement-statement-note-t-income-taxes-tables", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-v-earnings-per-share-eps-reconciliation-of-numerator-of-basic-and-diluted-eps-calculations-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note V - Earnings Per Share (EPS) - Reconciliation of Numerator of Basic and Diluted EPS Calculations (Details)" } } }, "localname": "statement-statement-note-v-earnings-per-share-eps-reconciliation-of-numerator-of-basic-and-diluted-eps-calculations-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-v-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note V - Earnings Per Share (EPS) - Securities Excluded from the Diluted Per Share Calculation (Details)" } } }, "localname": "statement-statement-note-v-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-details", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-v-earnings-per-share-eps-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note V - Earnings Per Share (EPS)" } } }, "localname": "statement-statement-note-v-earnings-per-share-eps-tables", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://bio-key.com/20211231", "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r706", "r707", "r708" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r706", "r707", "r708" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r706", "r707", "r708" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r706", "r707", "r708" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r709" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations", "http://bio-key.com/20211231/role/statement-document-and-entity-information", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-valuation-assumptions-for-stock-options-details", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-details-textual", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-tables", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details-parentheticals", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-details-textual", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-intangible-assets-acquired-details", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-tables", "http://bio-key.com/20211231/role/statement-note-d-factoring", "http://bio-key.com/20211231/role/statement-note-d-factoring-details-textual", "http://bio-key.com/20211231/role/statement-note-d-factoring-due-from-factor-details", "http://bio-key.com/20211231/role/statement-note-d-factoring-fees-details", "http://bio-key.com/20211231/role/statement-note-d-factoring-tables", "http://bio-key.com/20211231/role/statement-note-e-fair-values-of-financial-instruments", "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk", "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk-details-textual", "http://bio-key.com/20211231/role/statement-note-g-note-receivable", "http://bio-key.com/20211231/role/statement-note-g-note-receivable-details-textual", "http://bio-key.com/20211231/role/statement-note-g-note-receivable-summary-of-note-receivable-details", "http://bio-key.com/20211231/role/statement-note-g-note-receivable-tables", "http://bio-key.com/20211231/role/statement-note-h-inventory-", "http://bio-key.com/20211231/role/statement-note-h-inventory-components-of-inventory-details", "http://bio-key.com/20211231/role/statement-note-h-inventory-tables", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-amortization-expense-details", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-details-textual", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-tables", "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-", "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-details-textual", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-details-textual", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-tables", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-details-textual", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-summary-of-intangible-assets-details", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-tables", "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities", "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details", "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-tables", "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions", "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions-details-textual", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual", "http://bio-key.com/20211231/role/statement-note-p-leases", "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details", "http://bio-key.com/20211231/role/statement-note-p-leases-tables", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details", "http://bio-key.com/20211231/role/statement-note-r-equity-tables", "http://bio-key.com/20211231/role/statement-note-r-equity-valuation-assumptions-for-warrants-details", "http://bio-key.com/20211231/role/statement-note-s-stock-options", "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details", "http://bio-key.com/20211231/role/statement-note-s-stock-options-options-outstanding-and-exercisable-details", "http://bio-key.com/20211231/role/statement-note-s-stock-options-tables", "http://bio-key.com/20211231/role/statement-note-t-income-taxes", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-components-of-deferred-taxes-details", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-details-textual", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-tables", "http://bio-key.com/20211231/role/statement-note-u-profit-sharing-plan", "http://bio-key.com/20211231/role/statement-note-u-profit-sharing-plan-details-textual", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-reconciliation-of-numerator-of-basic-and-diluted-eps-calculations-details", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-details", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-tables", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual", "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r734" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r735" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r706", "r707", "r708" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations", "http://bio-key.com/20211231/role/statement-document-and-entity-information", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-valuation-assumptions-for-stock-options-details", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-details-textual", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-tables", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details-parentheticals", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-details-textual", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-intangible-assets-acquired-details", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-tables", "http://bio-key.com/20211231/role/statement-note-d-factoring", "http://bio-key.com/20211231/role/statement-note-d-factoring-details-textual", "http://bio-key.com/20211231/role/statement-note-d-factoring-due-from-factor-details", "http://bio-key.com/20211231/role/statement-note-d-factoring-fees-details", "http://bio-key.com/20211231/role/statement-note-d-factoring-tables", "http://bio-key.com/20211231/role/statement-note-e-fair-values-of-financial-instruments", "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk", "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk-details-textual", "http://bio-key.com/20211231/role/statement-note-g-note-receivable", "http://bio-key.com/20211231/role/statement-note-g-note-receivable-details-textual", "http://bio-key.com/20211231/role/statement-note-g-note-receivable-summary-of-note-receivable-details", "http://bio-key.com/20211231/role/statement-note-g-note-receivable-tables", "http://bio-key.com/20211231/role/statement-note-h-inventory-", "http://bio-key.com/20211231/role/statement-note-h-inventory-components-of-inventory-details", "http://bio-key.com/20211231/role/statement-note-h-inventory-tables", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-amortization-expense-details", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-details-textual", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-tables", "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-", "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-details-textual", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-details-textual", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-tables", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-details-textual", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-summary-of-intangible-assets-details", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-tables", "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities", "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details", "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-tables", "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions", "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions-details-textual", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual", "http://bio-key.com/20211231/role/statement-note-p-leases", "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details", "http://bio-key.com/20211231/role/statement-note-p-leases-tables", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details", "http://bio-key.com/20211231/role/statement-note-r-equity-tables", "http://bio-key.com/20211231/role/statement-note-r-equity-valuation-assumptions-for-warrants-details", "http://bio-key.com/20211231/role/statement-note-s-stock-options", "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details", "http://bio-key.com/20211231/role/statement-note-s-stock-options-options-outstanding-and-exercisable-details", "http://bio-key.com/20211231/role/statement-note-s-stock-options-tables", "http://bio-key.com/20211231/role/statement-note-t-income-taxes", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-components-of-deferred-taxes-details", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-details-textual", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-tables", "http://bio-key.com/20211231/role/statement-note-u-profit-sharing-plan", "http://bio-key.com/20211231/role/statement-note-u-profit-sharing-plan-details-textual", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-reconciliation-of-numerator-of-basic-and-diluted-eps-calculations-details", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-details", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-tables", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual", "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r703" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bio-key.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "srt_AsiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia [Member]" } } }, "localname": "AsiaMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r183", "r359", "r365", "r668" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk", "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk-details-textual" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r283", "r320", "r384", "r386", "r594", "r595", "r596", "r597", "r598", "r599", "r618", "r665", "r669", "r699", "r700" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-intangible-assets-acquired-details", "http://bio-key.com/20211231/role/statement-note-d-factoring", "http://bio-key.com/20211231/role/statement-note-d-factoring-details-textual", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options", "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r283", "r320", "r384", "r386", "r594", "r595", "r596", "r597", "r598", "r599", "r618", "r665", "r669", "r699", "r700" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-intangible-assets-acquired-details", "http://bio-key.com/20211231/role/statement-note-d-factoring", "http://bio-key.com/20211231/role/statement-note-d-factoring-details-textual", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options", "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r183", "r359", "r365", "r668" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk", "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk-details-textual" ], "xbrltype": "domainItemType" }, "srt_NorthAmericaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "North America [Member]" } } }, "localname": "NorthAmericaMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r180", "r359", "r363", "r620", "r664", "r666" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r180", "r359", "r363", "r620", "r664", "r666" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r283", "r320", "r368", "r384", "r386", "r594", "r595", "r596", "r597", "r598", "r599", "r618", "r665", "r669", "r699", "r700" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-intangible-assets-acquired-details", "http://bio-key.com/20211231/role/statement-note-d-factoring", "http://bio-key.com/20211231/role/statement-note-d-factoring-details-textual", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options", "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r283", "r320", "r368", "r384", "r386", "r594", "r595", "r596", "r597", "r598", "r599", "r618", "r665", "r669", "r699", "r700" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-intangible-assets-acquired-details", "http://bio-key.com/20211231/role/statement-note-d-factoring", "http://bio-key.com/20211231/role/statement-note-d-factoring-details-textual", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options", "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r181", "r182", "r359", "r364", "r667", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "srt_SouthAmericaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "South America [Member]" } } }, "localname": "SouthAmericaMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r181", "r182", "r359", "r364", "r667", "r685", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r184", "r578" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.", "label": "Balance due from factor" } } }, "localname": "AccountsAndOtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-d-factoring-due-from-factor-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Information by type of receivable.", "label": "Receivable Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-d-factoring-tables", "http://bio-key.com/20211231/role/statement-note-g-note-receivable-tables" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r57", "r584" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableMember": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Obligations incurred and payable to vendors for goods and services received.", "label": "Accounts Payable [Member]" } } }, "localname": "AccountsPayableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions", "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r185", "r186" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "us-gaap_AccountsReceivableGrossCurrent", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r686" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk", "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r8", "r37", "r185", "r186" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net of allowances for doubtful accounts", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r61" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued liabilities", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r12", "r13", "r61" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued legal and accounting fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r12", "r13", "r61" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Compensation" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r55", "r258" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Less accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r38", "r432", "r584" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r127", "r128", "r129", "r429", "r430", "r431", "r515" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r130", "r131", "r132", "r133", "r141", "r195", "r196", "r208", "r209", "r210", "r211", "r212", "r213", "r265", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r459", "r460", "r461", "r462", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r573", "r622", "r623", "r624", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r736", "r737", "r738", "r739", "r740" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": { "auth_ref": [ "r333", "r335", "r458" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.", "label": "Beneficial conversion feature" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.", "label": "Share based compensation for employee stock purchase plan" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r389", "r392", "r435", "r436" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r279", "r333", "r335" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Warrants issued" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to cash used for operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r439" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "us-gaap_AdvertisingExpense", "terseLabel": "Advertising Expense" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r392", "r422", "r434" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based compensation expense", "terseLabel": "Share-based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r189", "r214", "r216", "r217" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable", "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-g-note-receivable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r43", "r189", "r214" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent", "negatedLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r90", "r106", "r303", "r545" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r82", "r106", "r303", "r547" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r106", "r303", "r313", "r314", "r547" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "us-gaap_AmortizationOfFinancingCostsAndDiscounts", "terseLabel": "Amortization of Debt Issuance Costs and Discounts, Total" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r106", "r244", "r252" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of intangible assets and write-off", "terseLabel": "Amortization of Intangible Assets, Total" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-details-textual", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive securities (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-details" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-details" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-details" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r120", "r169", "r172", "r178", "r207", "r266", "r267", "r268", "r270", "r271", "r272", "r273", "r274", "r275", "r277", "r278", "r494", "r497", "r523", "r582", "r584", "r640", "r655" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r10", "r11", "r73", "r120", "r207", "r266", "r267", "r268", "r270", "r271", "r272", "r273", "r274", "r275", "r277", "r278", "r494", "r497", "r523", "r582", "r584" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r21", "r22", "r23", "r24", "r25", "r26", "r27", "r28", "r120", "r207", "r266", "r267", "r268", "r270", "r271", "r272", "r273", "r274", "r275", "r277", "r278", "r494", "r497", "r523", "r582" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "us-gaap_AssetsNoncurrent", "totalLabel": "Total non-current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r394", "r424" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options", "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions", "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r503", "r504" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions", "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r383", "r385" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details-parentheticals", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-details-textual", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-intangible-assets-acquired-details", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r383", "r385", "r473", "r474" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details-parentheticals", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-details-textual", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-intangible-assets-acquired-details", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "terseLabel": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired", "terseLabel": "Business Acquisition, Percentage of Voting Interests Acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r485", "r486", "r488" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "us-gaap_BusinessCombinationConsiderationTransferred1", "terseLabel": "Business Combination, Consideration Transferred, Total", "totalLabel": "Total purchase price consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-details-textual", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r483", "r485", "r486", "r490" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 0.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Present value of 4% Promissory note", "terseLabel": "Business Combination, Consideration Transferred, Liabilities Incurred" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r484", "r487", "r492" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "us-gaap_BusinessCombinationContingentConsiderationLiability", "terseLabel": "Business Combination, Contingent Consideration, Liability, Total" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate": { "auth_ref": [ "r476" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of indemnification assets (amounts to be reimbursed if and when certain assumed liabilities are paid) recognized at the acquisition date of a business combination.", "label": "us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate", "terseLabel": "Business Combination, Indemnification Assets, Amount as of Acquisition Date" } } }, "localname": "BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r477" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 5.0, "parentTag": "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodWillTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r477" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 3.0, "parentTag": "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodWillTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Prepaid expenses and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r477" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 4.0, "parentTag": "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodWillTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "auth_ref": [ "r477" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Deferred revenue" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r475", "r477" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 1.0, "parentTag": "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodWillTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r475", "r477" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "totalLabel": "Total fair value of assets acquired and liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair value of assets acquired and liabilities assumed:" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r126", "r163" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Business Description and Accounting Policies [Text Block]" } } }, "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalizedContractCostAmortization": { "auth_ref": [ "r235" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Amortization of capitalized contract costs" } } }, "localname": "CapitalizedContractCostAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostAmortizationPeriod": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_CapitalizedContractCostAmortizationPeriod", "terseLabel": "Capitalized Contract Cost, Amortization Period (Year)" } } }, "localname": "CapitalizedContractCostAmortizationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r91" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash acquired from purchase of PistolStar" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r6", "r52", "r108" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "terseLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r20", "r109" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r101", "r108", "r114" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF YEAR", "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r101", "r536" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "us-gaap_CashUninsuredAmount", "terseLabel": "Cash, Uninsured Amount" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r337", "r391" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details", "http://bio-key.com/20211231/role/statement-note-r-equity-valuation-assumptions-for-warrants-details" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details", "http://bio-key.com/20211231/role/statement-note-r-equity-valuation-assumptions-for-warrants-details" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "us-gaap_ClassOfWarrantOrRightOutstanding", "periodEndLabel": "Outstanding, warrants (in shares)", "periodStartLabel": "Outstanding, warrants (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r66", "r264", "r646", "r661" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments Disclosure [Text Block]" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r127", "r128", "r515" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit", "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r35", "r333" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r35", "r584" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock \u2014 authorized, 170,000,000 shares; issued and outstanding; 7,853,759 and 7,814,572 of $.0001 par value at December 31, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensatedAbsencesLiability": { "auth_ref": [ "r367" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability accrued for the employer's obligation related to an employee's right to receive compensation for future absences that have been earned by employee.", "label": "Compensated absences" } } }, "localname": "CompensatedAbsencesLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r158", "r159", "r183", "r521", "r522", "r686" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk", "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r158", "r159", "r183", "r521", "r522", "r682", "r686" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk", "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r158", "r159", "r183", "r521", "r522", "r682", "r686" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk", "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r163" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r158", "r159", "r183", "r521", "r522" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r158", "r159", "r183", "r521", "r522", "r686" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk", "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r115", "r496" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNetNoncurrent": { "auth_ref": [ "r339", "r341", "r360" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.", "label": "Capitalized contract costs, net" } } }, "localname": "ContractWithCustomerAssetNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r339", "r340", "r360" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "us-gaap_ContractWithCustomerLiability", "terseLabel": "Contract with Customer, Liability, Total" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r339", "r340", "r360" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred revenue - current" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r339", "r340", "r360" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred revenue, net of current portion" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r361" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "us-gaap_ContractWithCustomerLiabilityRevenueRecognized", "terseLabel": "Contract with Customer, Liability, Revenue Recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r85", "r620" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "us-gaap_CostOfGoodsAndServicesSold", "terseLabel": "Costs and other expenses" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and other expenses" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "stringItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r157", "r183" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk", "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-intangible-assets-acquired-details", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "auth_ref": [ "r111", "r113" ], "lang": { "en-us": { "role": { "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.", "label": "Debt Conversion Description [Axis]" } } }, "localname": "DebtConversionByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r111", "r113" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "us-gaap_DebtConversionConvertedInstrumentSharesIssued1", "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionNameDomain": { "auth_ref": [ "r111", "r113" ], "lang": { "en-us": { "role": { "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Name [Domain]" } } }, "localname": "DebtConversionNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r111", "r113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "us-gaap_DebtConversionOriginalDebtAmount1", "terseLabel": "Debt Conversion, Original Debt, Amount" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r117", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r297", "r304", "r305", "r307", "r317" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r30", "r31", "r32", "r119", "r125", "r280", "r281", "r282", "r283", "r284", "r285", "r287", "r293", "r294", "r295", "r296", "r298", "r299", "r300", "r301", "r302", "r303", "r311", "r312", "r313", "r314", "r548", "r641", "r642", "r654" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details-parentheticals", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-details-textual", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r282", "r309" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "us-gaap_DebtInstrumentConvertibleConversionPrice1", "terseLabel": "Debt Instrument, Convertible, Conversion Price (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r280", "r311", "r312", "r546", "r548", "r549" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFeeAmount": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.", "label": "us-gaap_DebtInstrumentFeeAmount", "terseLabel": "Debt Instrument, Fee Amount" } } }, "localname": "DebtInstrumentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r63", "r281" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details-parentheticals", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-details-textual", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r65", "r119", "r125", "r280", "r281", "r282", "r283", "r284", "r285", "r287", "r293", "r294", "r295", "r296", "r298", "r299", "r300", "r301", "r302", "r303", "r311", "r312", "r313", "r314", "r548" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details-parentheticals", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-details-textual", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r65" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "us-gaap_DebtInstrumentPeriodicPaymentPrincipal", "terseLabel": "Debt Instrument, Periodic Payment, Principal" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_DebtInstrumentTerm", "terseLabel": "Debt Instrument, Term (Month)" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r293", "r545", "r549" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "us-gaap_DebtInstrumentUnamortizedDiscount", "terseLabel": "Debt Instrument, Unamortized Discount, Total" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossNoncurrent": { "auth_ref": [ "r214" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss for debt security measured at amortized cost (held-to-maturity), classified as noncurrent.", "label": "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossNoncurrent", "terseLabel": "Debt Securities, Held-to-maturity, Allowance for Credit Loss, Noncurrent" } } }, "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Basis differences in intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes-components-of-deferred-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r455", "r456" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss and credit carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes-components-of-deferred-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "auth_ref": [ "r455", "r456" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.", "label": "Accrued compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes-components-of-deferred-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r455", "r456" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes-components-of-deferred-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "auth_ref": [ "r455", "r456" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.", "label": "Accounts receivable allowance" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes-components-of-deferred-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r450" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedLabel": "Valuation allowances" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes-components-of-deferred-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r455", "r456" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment", "negatedLabel": "Basis differences in fixed assets" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes-components-of-deferred-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount", "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-u-profit-sharing-plan-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r56" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 8.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits and other assets" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r106", "r256" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "us-gaap_Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r106", "r256" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "us-gaap_DepreciationAndAmortization", "terseLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r124", "r499", "r500", "r501", "r502", "r505" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-", "http://bio-key.com/20211231/role/statement-note-d-factoring", "http://bio-key.com/20211231/role/statement-note-e-fair-values-of-financial-instruments", "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk", "http://bio-key.com/20211231/role/statement-note-g-note-receivable", "http://bio-key.com/20211231/role/statement-note-h-inventory-", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights", "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets", "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities", "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-p-leases", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-", "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-s-stock-options", "http://bio-key.com/20211231/role/statement-note-t-income-taxes", "http://bio-key.com/20211231/role/statement-note-u-profit-sharing-plan", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsPaidinkind": { "auth_ref": [ "r335", "r653" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid paid-in-kind dividends (PIK) declared for classes of stock, for example, but not limited to, common and preferred.", "label": "us-gaap_DividendsPaidinkind", "negatedLabel": "Deemed dividend from trigger of anti-dilution provision feature", "terseLabel": "Dividends, Paid-in-kind, Total", "verboseLabel": "Deemed dividends related to down-round features" } } }, "localname": "DividendsPaidinkind", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-reconciliation-of-numerator-of-basic-and-diluted-eps-calculations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r57", "r123", "r269", "r271", "r272", "r276", "r277", "r278", "r577" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_DueToRelatedPartiesCurrent", "terseLabel": "Due to Related Parties, Current, Total" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "EMEA [Member]" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Basic and Diluted Loss per Common Share (in dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r148", "r149" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r148", "r149", "r150", "r151" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r444" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-t-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "totalLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r121", "r444", "r465" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-t-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Federal statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r423" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-details" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r77", "r78", "r79", "r127", "r128", "r129", "r131", "r138", "r140", "r152", "r211", "r333", "r335", "r429", "r430", "r431", "r461", "r462", "r515", "r537", "r538", "r539", "r540", "r541", "r542", "r672", "r673", "r674", "r740" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit", "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-e-fair-values-of-financial-instruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r201", "r202", "r204", "r205", "r206", "r215", "r218", "r219", "r220", "r222", "r228", "r229", "r230", "r231", "r306", "r331", "r506", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r710", "r711", "r712", "r713", "r718", "r719", "r720" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-", "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivableAllowanceForCreditLosses": { "auth_ref": [ "r187", "r214", "r216", "r217", "r644", "r724", "r726", "r727" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-g-note-receivable-summary-of-note-receivable-details": { "order": 0.0, "parentTag": "us-gaap_NotesReceivableNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.", "label": "us-gaap_FinancingReceivableAllowanceForCreditLosses", "negatedLabel": "Allowance for doubtful account" } } }, "localname": "FinancingReceivableAllowanceForCreditLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-g-note-receivable-summary-of-note-receivable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.", "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-lived Intangible Assets Acquired (Year)", "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-intangible-assets-acquired-details", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r251" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "negatedLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-summary-of-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r253" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-amortization-expense-details": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 }, "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-amortization-expense-details", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r253" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r253" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r253" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-amortization-expense-details": { "order": 0.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 }, "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-amortization-expense-details", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r253" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-amortization-expense-details": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 }, "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-amortization-expense-details", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r245", "r247", "r251", "r254", "r621", "r625" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-intangible-assets-acquired-details", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-amortization-expense-details", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-details-textual", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-tables", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-summary-of-intangible-assets-details" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r251", "r625" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Gross carrying amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-summary-of-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r245", "r250" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-intangible-assets-acquired-details", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-amortization-expense-details", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-details-textual", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-tables", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r251", "r621" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-amortization-expense-details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Net carrying amount", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-amortization-expense-details", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-summary-of-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r246" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-intangible-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCorporateDebtSecuritiesMember": { "auth_ref": [ "r199", "r369" ], "lang": { "en-us": { "role": { "documentation": "Debt security issued by corporation not domiciled in United States of America (US).", "label": "Debt Security, Corporate, Non-US [Member]" } } }, "localname": "ForeignCorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-", "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r532", "r533", "r534", "r535" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign currency loss", "negatedLabel": "Loss on foreign currency" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r106", "r315", "r316" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Loss on extinguishment of debt", "negatedLabel": "Loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicDistributionAxis": { "auth_ref": [ "r223", "r649", "r650", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r728", "r729", "r730", "r731", "r732", "r733" ], "lang": { "en-us": { "role": { "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Axis]" } } }, "localname": "GeographicDistributionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-d-factoring", "http://bio-key.com/20211231/role/statement-note-d-factoring-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_GeographicDistributionDomain": { "auth_ref": [ "r649", "r650", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r728", "r729", "r730", "r731", "r732", "r733" ], "lang": { "en-us": { "role": { "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Domain]" } } }, "localname": "GeographicDistributionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-d-factoring", "http://bio-key.com/20211231/role/statement-note-d-factoring-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicDistributionDomesticMember": { "auth_ref": [ "r224", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r728", "r729", "r730", "r731", "r732", "r733" ], "lang": { "en-us": { "role": { "documentation": "Allocation of business activity identified as domestic.", "label": "Geographic Distribution, Domestic [Member]" } } }, "localname": "GeographicDistributionDomesticMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-d-factoring", "http://bio-key.com/20211231/role/statement-note-d-factoring-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicDistributionForeignMember": { "auth_ref": [ "r225", "r649", "r650", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r728", "r729", "r730", "r731", "r732", "r733" ], "lang": { "en-us": { "role": { "documentation": "Allocation of business activity identified as foreign.", "label": "Geographic Distribution, Foreign [Member]" } } }, "localname": "GeographicDistributionForeignMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-d-factoring", "http://bio-key.com/20211231/role/statement-note-d-factoring-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r236", "r238", "r584", "r639" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 }, "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 0.0, "parentTag": "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodWillTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r239" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill related to PistolStar acquisition" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r241", "r248" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r106", "r237", "r240", "r242" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "us-gaap_GoodwillImpairmentLoss", "terseLabel": "Goodwill, Impairment Loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_GranteeStatusAxis": { "auth_ref": [ "r388", "r390", "r420" ], "lang": { "en-us": { "role": { "documentation": "Information by status of recipient to whom award is granted.", "label": "Grantee Status [Axis]" } } }, "localname": "GranteeStatusAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Status of recipient to whom award is granted.", "label": "Grantee Status [Domain]" } } }, "localname": "GranteeStatusDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r84", "r120", "r169", "r171", "r174", "r177", "r179", "r207", "r266", "r267", "r268", "r271", "r272", "r273", "r274", "r275", "r277", "r278", "r523" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "us-gaap_GrossProfit", "totalLabel": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesCurrent": { "auth_ref": [ "r198", "r200", "r214" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.", "label": "Investment \u2013 debt security", "terseLabel": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current" } } }, "localname": "HeldToMaturitySecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesNoncurrent": { "auth_ref": [ "r198", "r200", "r214" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.", "label": "Investment - debt security, noncurrent" } } }, "localname": "HeldToMaturitySecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r260", "r262" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-details-textual", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-details-textual", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r121", "r445", "r448", "r453", "r463", "r466", "r468", "r469", "r470" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r122", "r139", "r140", "r168", "r443", "r464", "r467", "r663" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_IncomeTaxExpenseBenefit", "terseLabel": "Income Tax Expense (Benefit), Total" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r76", "r441", "r442", "r448", "r449", "r452", "r457" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r103", "r110" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r105" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r105" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r105" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r105" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "us-gaap_IncreaseDecreaseInDeferredRevenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r105" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "us-gaap_IncreaseDecreaseInInventories", "negatedTerseLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r105", "r556" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "auth_ref": [ "r105" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in receivables classified as other.", "label": "us-gaap_IncreaseDecreaseInOtherReceivables", "negatedLabel": "Due from factor" } } }, "localname": "IncreaseDecreaseInOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r105" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedTerseLabel": "Prepaid expenses and other" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-l-intangible-assets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r243", "r249" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r80", "r167", "r544", "r547", "r648" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "us-gaap_InterestExpense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r90", "r301", "r310", "r313", "r314" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "us-gaap_InterestExpenseDebt", "terseLabel": "Interest Expense, Debt, Total" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash paid for:" } } }, "localname": "InterestPaidAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r100", "r102", "r110" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-h-inventory-" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r44", "r232" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-h-inventory-components-of-inventory-details": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-h-inventory-components-of-inventory-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r7", "r71", "r584" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://bio-key.com/20211231/role/statement-note-h-inventory-components-of-inventory-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory", "totalLabel": "Total inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20211231/role/statement-note-h-inventory-components-of-inventory-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": { "auth_ref": [ "r45", "r46", "r232" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-h-inventory-components-of-inventory-details": { "order": 0.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.", "label": "Fabricated assemblies" } } }, "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-h-inventory-components-of-inventory-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r88", "r166" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Interest income", "terseLabel": "Investment Income, Interest" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations", "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r203", "r638", "r651", "r684", "r722" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestorMember": { "auth_ref": [ "r576", "r577" ], "lang": { "en-us": { "role": { "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.", "label": "Investor [Member]" } } }, "localname": "InvestorMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r559", "r561" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details" ], "xbrltype": "domainItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "us-gaap_LegalFees", "terseLabel": "Legal Fees" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r560" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total future lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r560" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r560" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r560" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-p-leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r60", "r120", "r173", "r207", "r266", "r267", "r268", "r271", "r272", "r273", "r274", "r275", "r277", "r278", "r495", "r497", "r498", "r523", "r582", "r583" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r42", "r120", "r207", "r523", "r584", "r643", "r659" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r62", "r120", "r207", "r266", "r267", "r268", "r271", "r272", "r273", "r274", "r275", "r277", "r278", "r495", "r497", "r498", "r523", "r582", "r583", "r584" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r17", "r18", "r19", "r32", "r33", "r120", "r207", "r266", "r267", "r268", "r271", "r272", "r273", "r274", "r275", "r277", "r278", "r495", "r497", "r498", "r523", "r582", "r583" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "us-gaap_LiabilitiesNoncurrent", "totalLabel": "Total non-current liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r32", "r294", "r308", "r311", "r312", "r642", "r657" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "us-gaap_LongTermDebt", "terseLabel": "Long-term Debt, Total" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-valuation-assumptions-for-warrants-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-valuation-assumptions-for-warrants-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-valuation-assumptions-for-warrants-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-valuation-assumptions-for-warrants-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-valuation-assumptions-for-warrants-details" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-valuation-assumptions-for-warrants-details" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r101" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "terseLabel": "Net Cash Provided by (Used in) Financing Activities, Total", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r101" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used for investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r101", "r104", "r107" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used for operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOW FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r74", "r75", "r79", "r81", "r107", "r120", "r130", "r134", "r135", "r136", "r137", "r139", "r140", "r144", "r169", "r171", "r174", "r177", "r179", "r207", "r266", "r267", "r268", "r271", "r272", "r273", "r274", "r275", "r277", "r278", "r517", "r523", "r647", "r662" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 25.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 }, "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-reconciliation-of-numerator-of-basic-and-diluted-eps-calculations-details": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Loss", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations", "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-reconciliation-of-numerator-of-basic-and-diluted-eps-calculations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r134", "r135", "r136", "r137", "r142", "r143", "r145", "r147", "r169", "r171", "r174", "r177", "r179" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-reconciliation-of-numerator-of-basic-and-diluted-eps-calculations-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net loss available to common stockholders (basic and diluted EPS)", "totalLabel": "Net loss available to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-reconciliation-of-numerator-of-basic-and-diluted-eps-calculations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NonmonetaryTransactionTypeAxis": { "auth_ref": [ "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572" ], "lang": { "en-us": { "role": { "documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange.", "label": "Nonmonetary Transaction Type [Axis]" } } }, "localname": "NonmonetaryTransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_NonmonetaryTransactionTypeDomain": { "auth_ref": [ "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572" ], "lang": { "en-us": { "role": { "documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange.", "label": "Nonmonetary Transaction Type [Domain]" } } }, "localname": "NonmonetaryTransactionTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r89" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "auth_ref": [ "r8", "r9", "r36", "r185", "r186", "r645" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.", "label": "Current portion, net of allowance", "terseLabel": "Financing Receivable, after Allowance for Credit Loss, Current, Total" } } }, "localname": "NotesAndLoansReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20211231/role/statement-note-g-note-receivable-details-textual", "http://bio-key.com/20211231/role/statement-note-g-note-receivable-summary-of-note-receivable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansReceivableNetNoncurrent": { "auth_ref": [ "r37" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 7.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.", "label": "Note receivable, net of allowance" } } }, "localname": "NotesAndLoansReceivableNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20211231/role/statement-note-g-note-receivable-summary-of-note-receivable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r32", "r642", "r657" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "us-gaap_NotesPayable", "terseLabel": "Notes Payable, Total" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableGross": { "auth_ref": [ "r190", "r214", "r219", "r221", "r226", "r227", "r723", "r724", "r725" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-g-note-receivable-summary-of-note-receivable-details": { "order": 1.0, "parentTag": "us-gaap_NotesReceivableNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of financing receivable.", "label": "Note receivable" } } }, "localname": "NotesReceivableGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-g-note-receivable-summary-of-note-receivable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.", "label": "Notes Receivable [Member]" } } }, "localname": "NotesReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-g-note-receivable-tables" ], "xbrltype": "domainItemType" }, "us-gaap_NotesReceivableNet": { "auth_ref": [ "r37", "r185", "r221" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-g-note-receivable-summary-of-note-receivable-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.", "label": "us-gaap_NotesReceivableNet", "totalLabel": "Note receivable, net of allowance" } } }, "localname": "NotesReceivableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-g-note-receivable-summary-of-note-receivable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OpenTaxYear": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.", "label": "us-gaap_OpenTaxYear", "terseLabel": "Open Tax Year" } } }, "localname": "OpenTaxYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes-details-textual" ], "xbrltype": "gYearListItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r169", "r171", "r174", "r177", "r179" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r555", "r561" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r552" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "us-gaap_OperatingLeaseLiability", "totalLabel": "Total operating lease liabilities", "verboseLabel": "Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r552" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liabilities, current portion", "terseLabel": "Operating lease liabilities, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r552" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 }, "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details": { "order": 0.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liabilities, net of current portion", "terseLabel": "Operating lease liabilities, non-current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r553", "r556" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Cash paid for amounts included in the measurement of operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r551" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 6.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r106" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Amortization of operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r558", "r561" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted average discount rate \u2013 operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r557", "r561" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining lease term (in years) \u2013 operating leases (Year)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r454" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards, Total" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r12", "r13", "r14", "r61" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r72", "r584" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "us-gaap_OtherAssetsCurrent", "terseLabel": "Due from factor" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r98" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "us-gaap_PaymentsOfDebtIssuanceCosts", "terseLabel": "Payments of Debt Issuance Costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r99" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "us-gaap_PaymentsOfStockIssuanceCosts", "negatedLabel": "Costs to issue notes and common stock" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r93", "r489" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "us-gaap_PaymentsToAcquireBusinessesGross", "negatedLabel": "Purchase of PistolStar", "terseLabel": "Payments to Acquire Businesses, Gross" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r93" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Total cash paid, net of acquired cash", "terseLabel": "Payments to Acquire Businesses, Net of Cash Acquired, Total" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": { "auth_ref": [ "r92", "r197" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities.", "label": "us-gaap_PaymentsToAcquireHeldToMaturitySecurities", "negatedLabel": "Purchase of debt security" } } }, "localname": "PaymentsToAcquireHeldToMaturitySecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireLoansReceivable": { "auth_ref": [ "r92" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the purchase of loan receivable arising from the financing of goods and services.", "label": "us-gaap_PaymentsToAcquireLoansReceivable", "negatedLabel": "Issuance of note receivable" } } }, "localname": "PaymentsToAcquireLoansReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r94" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireSoftware": { "auth_ref": [ "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition from vendors of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "us-gaap_PaymentsToAcquireSoftware", "terseLabel": "Payments to Acquire Software" } } }, "localname": "PaymentsToAcquireSoftware", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r368", "r370", "r371", "r372", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r387" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-u-profit-sharing-plan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r394", "r424" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options", "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options", "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r34", "r318" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "us-gaap_PreferredStockParOrStatedValuePerShare", "terseLabel": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "us-gaap_PreferredStockSharesAuthorized", "terseLabel": "Preferred Stock, Shares Authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r10", "r50", "r51" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r96" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from issuance of convertible notes" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "auth_ref": [ "r96" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "label": "us-gaap_ProceedsFromDebtNetOfIssuanceCosts", "terseLabel": "Proceeds from Debt, Net of Issuance Costs" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r95" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from public offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r95" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity", "terseLabel": "Proceeds from Issuance or Sale of Equity, Total" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from maturity of debt security" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r95" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from the exercise of warrants", "terseLabel": "Proceeds from Warrant Exercises" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r55", "r259" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r261", "r687", "r688", "r689" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r54", "r257" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, plant, and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r24", "r25", "r259", "r584", "r652", "r660" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 }, "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Equipment and leasehold improvements, net", "totalLabel": "Total" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r53", "r259", "r687", "r688" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r24", "r259" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r24", "r257" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant, and Equipment (Year)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivableTypeDomain": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.", "label": "Receivable [Domain]" } } }, "localname": "ReceivableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-d-factoring-tables", "http://bio-key.com/20211231/role/statement-note-g-note-receivable-tables" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate": { "auth_ref": [ "r546", "r548" ], "lang": { "en-us": { "role": { "documentation": "Yield on the receivable, on which interest has been imputed, as calculated from its issuance value or purchase price. The calculated effective interest rate considers factors such as the issued face value or price paid for the receivable, the time period between payments, and the time until maturity [full receipt] of the receivable.", "label": "us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate", "terseLabel": "Receivable with Imputed Interest, Effective Yield (Interest Rate)" } } }, "localname": "ReceivableWithImputedInterestEffectiveYieldInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-g-note-receivable-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r188", "r192", "r193", "r194" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r373", "r576", "r577" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions", "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions-details-textual", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r373", "r576", "r577", "r579" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r373", "r576", "r579", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions", "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions-details-textual", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r574", "r575", "r577", "r580", "r581" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfConvertibleDebt": { "auth_ref": [ "r97" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "us-gaap_RepaymentsOfConvertibleDebt", "negatedLabel": "Repayment of convertible notes", "terseLabel": "Repayments of Convertible Debt" } } }, "localname": "RepaymentsOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r97" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "us-gaap_RepaymentsOfNotesPayable", "negatedLabel": "Repayment of note payable - PistolStar", "terseLabel": "Repayments of Notes Payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r97" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "us-gaap_RepaymentsOfRelatedPartyDebt", "negatedLabel": "Net repayments of loans payable to related parties" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r440", "r619", "r701" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research, development and engineering" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "auth_ref": [ "r702" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.", "label": "Research, Development, and Computer Software Disclosure [Text Block]" } } }, "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-details", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r39", "r335", "r432", "r584", "r658", "r676", "r681" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r127", "r128", "r129", "r131", "r138", "r140", "r211", "r429", "r430", "r431", "r461", "r462", "r515", "r672", "r674" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r164", "r165", "r170", "r175", "r176", "r180", "r181", "r183", "r358", "r359", "r620" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax", "terseLabel": "Revenue from Contract with Customer, Including Assessed Tax" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r116", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r366" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r362", "r366" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r83", "r269", "r271", "r272", "r276", "r277", "r278", "r683" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "us-gaap_RevenueFromRelatedParties", "terseLabel": "Revenue from Related Parties" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit", "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SalesAndExciseTaxPayableCurrent": { "auth_ref": [ "r13", "r57" ], "calculation": { "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Sales tax payable" } } }, "localname": "SalesAndExciseTaxPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r158", "r183" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk", "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables", "http://bio-key.com/20211231/role/statement-note-d-factoring-tables", "http://bio-key.com/20211231/role/statement-note-g-note-receivable-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r392", "r421", "r434" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r245", "r250" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r15", "r47", "r48", "r49" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-h-inventory-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r400", "r409", "r412" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r337", "r391" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-tables", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r87" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "us-gaap_SellingGeneralAndAdministrativeExpense", "verboseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividends" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-valuation-assumptions-for-stock-options-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Weighted average Volatility of stock price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-valuation-assumptions-for-stock-options-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Weighted average Risk free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-valuation-assumptions-for-stock-options-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Exercisable (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Options exercisable, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details", "http://bio-key.com/20211231/role/statement-note-s-stock-options-options-outstanding-and-exercisable-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r411" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "negatedLabel": "Expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Granted (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r424" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Outstanding, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r402", "r424" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodEndLabel": "Outstanding (in shares)", "periodStartLabel": "Outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)", "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r412" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested or expected to vest, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested or expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested or expected, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r391", "r397" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options", "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Expired, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Forfeited, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Granted, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r394", "r398" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-options-outstanding-and-exercisable-details", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-details" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-options-outstanding-and-exercisable-details", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Range of exercise prices, lower range (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-options-outstanding-and-exercisable-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Options exercisable (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-options-outstanding-and-exercisable-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Options outstanding (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-options-outstanding-and-exercisable-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Range of exercise prices, upper range (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-options-outstanding-and-exercisable-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "auth_ref": [ "r390", "r420" ], "lang": { "en-us": { "role": { "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Share-based Payment Arrangement, Employee [Member]" } } }, "localname": "ShareBasedPaymentArrangementEmployeeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "us-gaap_SharePrice", "terseLabel": "Share Price (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r416", "r433" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life of options (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-valuation-assumptions-for-stock-options-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r424" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Exercisable, weighted average remaining life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding, weighted average remaining life (Year)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested or expected to vest, weighted average remaining life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r399" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Options outstanding, weighted average exercise price (in dollars per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-options-outstanding-and-exercisable-details" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Options outstanding, weighted average remaining remaining life (Year)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-s-stock-options-options-outstanding-and-exercisable-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "us-gaap_SharesIssuedPricePerShare", "terseLabel": "Shares Issued, Price Per Share (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r29", "r584", "r641", "r656" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Note payable \u2013 PistolStar acquisition, net of debt discount" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SoftwareDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internally developed software for sale, licensing or long-term internal use.", "label": "Software Development [Member]" } } }, "localname": "SoftwareDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r69", "r77", "r78", "r79", "r127", "r128", "r129", "r131", "r138", "r140", "r152", "r211", "r333", "r335", "r429", "r430", "r431", "r461", "r462", "r515", "r537", "r538", "r539", "r540", "r541", "r542", "r672", "r673", "r674", "r740" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit", "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations", "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-valuation-assumptions-for-stock-options-details", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-details-textual", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-tables", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details-parentheticals", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-details-textual", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-intangible-assets-acquired-details", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-tables", "http://bio-key.com/20211231/role/statement-note-d-factoring", "http://bio-key.com/20211231/role/statement-note-d-factoring-details-textual", "http://bio-key.com/20211231/role/statement-note-d-factoring-due-from-factor-details", "http://bio-key.com/20211231/role/statement-note-d-factoring-fees-details", "http://bio-key.com/20211231/role/statement-note-d-factoring-tables", "http://bio-key.com/20211231/role/statement-note-e-fair-values-of-financial-instruments", "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk", "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk-details-textual", "http://bio-key.com/20211231/role/statement-note-g-note-receivable", "http://bio-key.com/20211231/role/statement-note-g-note-receivable-details-textual", "http://bio-key.com/20211231/role/statement-note-g-note-receivable-summary-of-note-receivable-details", "http://bio-key.com/20211231/role/statement-note-g-note-receivable-tables", "http://bio-key.com/20211231/role/statement-note-h-inventory-", "http://bio-key.com/20211231/role/statement-note-h-inventory-components-of-inventory-details", "http://bio-key.com/20211231/role/statement-note-h-inventory-tables", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-amortization-expense-details", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-details-textual", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-tables", "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-", "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-details-textual", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-details-textual", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-tables", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-details-textual", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-summary-of-intangible-assets-details", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-tables", "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities", "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details", "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-tables", "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions", "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions-details-textual", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual", "http://bio-key.com/20211231/role/statement-note-p-leases", "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details", "http://bio-key.com/20211231/role/statement-note-p-leases-tables", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details", "http://bio-key.com/20211231/role/statement-note-r-equity-tables", "http://bio-key.com/20211231/role/statement-note-r-equity-valuation-assumptions-for-warrants-details", "http://bio-key.com/20211231/role/statement-note-s-stock-options", "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details", "http://bio-key.com/20211231/role/statement-note-s-stock-options-options-outstanding-and-exercisable-details", "http://bio-key.com/20211231/role/statement-note-s-stock-options-tables", "http://bio-key.com/20211231/role/statement-note-t-income-taxes", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-components-of-deferred-taxes-details", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-details-textual", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-tables", "http://bio-key.com/20211231/role/statement-note-u-profit-sharing-plan", "http://bio-key.com/20211231/role/statement-note-u-profit-sharing-plan-details-textual", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-reconciliation-of-numerator-of-basic-and-diluted-eps-calculations-details", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-details", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-tables", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual", "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r127", "r128", "r129", "r152", "r620" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations", "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables", "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-valuation-assumptions-for-stock-options-details", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-details-textual", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-tables", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-assets-acquired-and-liabilities-assumed-details-parentheticals", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-details-textual", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-intangible-assets-acquired-details", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-tables", "http://bio-key.com/20211231/role/statement-note-d-factoring", "http://bio-key.com/20211231/role/statement-note-d-factoring-details-textual", "http://bio-key.com/20211231/role/statement-note-d-factoring-due-from-factor-details", "http://bio-key.com/20211231/role/statement-note-d-factoring-fees-details", "http://bio-key.com/20211231/role/statement-note-d-factoring-tables", "http://bio-key.com/20211231/role/statement-note-e-fair-values-of-financial-instruments", "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk", "http://bio-key.com/20211231/role/statement-note-f-concentration-of-risk-details-textual", "http://bio-key.com/20211231/role/statement-note-g-note-receivable", "http://bio-key.com/20211231/role/statement-note-g-note-receivable-details-textual", "http://bio-key.com/20211231/role/statement-note-g-note-receivable-summary-of-note-receivable-details", "http://bio-key.com/20211231/role/statement-note-g-note-receivable-tables", "http://bio-key.com/20211231/role/statement-note-h-inventory-", "http://bio-key.com/20211231/role/statement-note-h-inventory-components-of-inventory-details", "http://bio-key.com/20211231/role/statement-note-h-inventory-tables", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-amortization-expense-details", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-details-textual", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-tables", "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-", "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-details-textual", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-details-textual", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-tables", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-amortization-expense-details", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-details-textual", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-summary-of-intangible-assets-details", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-tables", "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities", "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-summary-of-accrued-liabilities-details", "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-tables", "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions", "http://bio-key.com/20211231/role/statement-note-n-related-party-transactions-details-textual", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable", "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual", "http://bio-key.com/20211231/role/statement-note-p-leases", "http://bio-key.com/20211231/role/statement-note-p-leases-operating-lease-balance-sheet-information-details", "http://bio-key.com/20211231/role/statement-note-p-leases-tables", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity-summary-of-warrant-activity-details", "http://bio-key.com/20211231/role/statement-note-r-equity-tables", "http://bio-key.com/20211231/role/statement-note-r-equity-valuation-assumptions-for-warrants-details", "http://bio-key.com/20211231/role/statement-note-s-stock-options", "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details", "http://bio-key.com/20211231/role/statement-note-s-stock-options-options-outstanding-and-exercisable-details", "http://bio-key.com/20211231/role/statement-note-s-stock-options-tables", "http://bio-key.com/20211231/role/statement-note-t-income-taxes", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-components-of-deferred-taxes-details", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-details-textual", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-tables", "http://bio-key.com/20211231/role/statement-note-u-profit-sharing-plan", "http://bio-key.com/20211231/role/statement-note-u-profit-sharing-plan-details-textual", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-reconciliation-of-numerator-of-basic-and-diluted-eps-calculations-details", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-details", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-tables", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual", "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r111", "r112", "r113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Issuance of common stock for conversion of note payable" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r68", "r298", "r333", "r334", "r335" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Issuance of common stock for conversion of convertible note payable (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r34", "r35", "r333", "r335" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Issuance of common stock for Employee stock purchase plan (in shares)", "terseLabel": "Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r34", "r35", "r333", "r335" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of common stock pursuant to securities purchase agreements (in shares)", "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r34", "r35", "r333", "r335" ], "lang": { "en-us": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "negatedLabel": "Forfeiture of restricted stock (in shares)", "terseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r34", "r35", "r333", "r335" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Issuance of restricted common stock to employees (in shares)", "terseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r34", "r35", "r333", "r335" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Issuance of common stock for directors\u2019 fees (in shares)", "terseLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Total (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross", "terseLabel": "Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r34", "r35", "r333", "r335", "r404" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised", "negatedLabel": "Exercised (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options-details-textual", "http://bio-key.com/20211231/role/statement-note-s-stock-options-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r69", "r333", "r335" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Issuance of common stock for conversion of convertible note payable" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r34", "r35", "r333", "r335" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Issuance of common stock for Employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r34", "r35", "r333", "r335" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of common stock pursuant to securities purchase agreements" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": { "auth_ref": [ "r34", "r35", "r333", "r335" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.", "label": "Forfeiture of restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r333", "r335" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Issuance of restricted common stock to employees" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r34", "r35", "r335", "r393", "r410" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Issuance of common stock for directors\u2019 fees", "terseLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r35", "r40", "r41", "r120", "r191", "r207", "r523", "r584" ], "calculation": { "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r118", "r319", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r332", "r335", "r338" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1", "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "pureItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r543", "r586" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r543", "r586" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r543", "r586" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r585", "r587" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-w-subsequent-events" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit", "http://bio-key.com/20211231/role/statement-note-r-equity", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events", "http://bio-key.com/20211231/role/statement-note-w-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables", "http://bio-key.com/20211231/role/statement-note-b-revenue-from-contracts-with-customers-tables", "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-tables", "http://bio-key.com/20211231/role/statement-note-d-factoring-tables", "http://bio-key.com/20211231/role/statement-note-g-note-receivable-tables", "http://bio-key.com/20211231/role/statement-note-h-inventory-tables", "http://bio-key.com/20211231/role/statement-note-i-resalable-software-licenses-rights-tables", "http://bio-key.com/20211231/role/statement-note-k-equipment-and-leasehold-improvements-tables", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-tables", "http://bio-key.com/20211231/role/statement-note-m-accrued-liabilities-tables", "http://bio-key.com/20211231/role/statement-note-p-leases-tables", "http://bio-key.com/20211231/role/statement-note-r-equity-tables", "http://bio-key.com/20211231/role/statement-note-s-stock-options-tables", "http://bio-key.com/20211231/role/statement-note-t-income-taxes-tables", "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-c-pistolstar-inc-acquisition-intangible-assets-acquired-details", "http://bio-key.com/20211231/role/statement-note-l-intangible-assets-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r201", "r202", "r204", "r205", "r206", "r306", "r331", "r506", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r710", "r711", "r712", "r713", "r718", "r719", "r720" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-", "http://bio-key.com/20211231/role/statement-note-j-investment-in-debt-security-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r130", "r131", "r132", "r133", "r141", "r195", "r196", "r208", "r209", "r210", "r211", "r212", "r213", "r265", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r459", "r460", "r461", "r462", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r573", "r622", "r623", "r624", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r736", "r737", "r738", "r739", "r740" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r446" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-t-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r153", "r154", "r155", "r156", "r160", "r161", "r162" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-v-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-details" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "us-gaap_WarrantsAndRightsOutstanding", "terseLabel": "Warrants and Rights Outstanding" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrant measurement input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-r-equity-valuation-assumptions-for-warrants-details" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_WarrantsAndRightsOutstandingTerm", "terseLabel": "Warrants and Rights Outstanding, Term (Year)" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-note-o-convertible-notes-payable-details-textual", "http://bio-key.com/20211231/role/statement-note-q-commitments-and-contingencies-details-textual", "http://bio-key.com/20211231/role/statement-note-r-equity-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Basic and Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Shares Outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bio-key.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "stringItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r126": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r151": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r163": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL6283291-111563" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "79", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "80", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131251-203054" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r255": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r263": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r317": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r338": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r366": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19366-108361" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r387": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r437": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "51", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e34017-109320" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r493": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r562": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "845", "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29470-108402" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "845", "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29470-108402" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "845", "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29470-108402" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "845", "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29470-108402" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "845", "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29502-108402" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "845", "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29515-108402" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "845", "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29515-108402" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "845", "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29515-108402" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "845", "URI": "http://asc.fasb.org/extlink&oid=123385986&loc=d3e32049-108421" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "845", "URI": "http://asc.fasb.org/extlink&oid=6457341&loc=d3e32102-108422" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r581": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r587": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r638": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r651": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r684": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r702": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "730", "Topic": "985", "URI": "http://asc.fasb.org/subtopic&trid=2197926" }, "r703": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r704": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r705": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r706": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r707": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r708": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r709": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r710": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r711": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r712": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r713": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r714": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(4)" }, "r715": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(5)" }, "r716": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)(i)" }, "r717": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)(ii)" }, "r718": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r719": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r720": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r721": { "Name": "Regulation S-K (SK)", "Number": "229", "Publisher": "SEC", "Section": "1402", "Subsection": "Instruction 5" }, "r722": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r723": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1404" }, "r724": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(1)" }, "r725": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(2)" }, "r726": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(3)" }, "r727": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1405" }, "r728": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(1)" }, "r729": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(2)" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r730": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(3)" }, "r731": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(4)" }, "r732": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(5)" }, "r733": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1406" }, "r734": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r735": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" } }, "version": "2.1" } ZIP 111 0001437749-22-007930-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-22-007930-xbrl.zip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�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end